INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Mellinghoff et al.
TRUE

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Schrag et al.
TRUE

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Herbst et al.
TRUE

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
Herrera et al.
TRUE

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Wakelee et al.
TRUE

Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
Ebrahimi et al.
TRUE

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
Dhakal et al.
TRUE

Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
Westin et al.
TRUE

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.
Slamon et al.
TRUE

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).
Cortes et al.
TRUE

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
Yeung et al.
TRUE

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky et al.
TRUE

Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.
Conte et al.
TRUE

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
Sonke et al.
TRUE

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).
Jiang et al.
TRUE

Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.
Kogawa et al.
TRUE

A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer.
Noronha et al.
TRUE

A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
Mulholland et al.
TRUE

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Meric-Bernstam et al.
TRUE

Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.
Jensen et al.
TRUE

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
Conroy et al.
TRUE

Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
Labori et al.
TRUE

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
Choueiri et al.
TRUE

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
Rini et al.
TRUE

Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
Pfister et al.
TRUE

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
Loriot et al.
TRUE

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
Bossi et al.
TRUE

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Harter et al.
TRUE

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Moore et al.
TRUE

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
Plante et al.
TRUE

PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).
Ma et al.
TRUE

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).
Kothari et al.
TRUE

Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.
Zucca et al.
TRUE

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
Chu et al.
TRUE

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Yang et al.
TRUE

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
Leal et al.
TRUE

A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.
Kanda et al.
TRUE

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).
Dingemans et al.
TRUE

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
Carbone et al.
TRUE

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
Khattak et al.
TRUE

Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
Luke et al.
TRUE

Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).
Olofsson Bagge et al.
TRUE

Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.
Carlino et al.
TRUE

Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.
Van Tine et al.
TRUE

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
Reijers et al.
TRUE

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
Wolf et al.
TRUE

Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).
Derosa et al.
TRUE

Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.
Park et al.
TRUE

Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Hamilton et al.
TRUE

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.
Turner et al.
TRUE

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
Gray et al.
TRUE

Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.
Brown et al.
TRUE

Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).
Tesch et al.
TRUE

Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.
Stecklein et al.
TRUE

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
Hills et al.
TRUE

Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.
Bartlett et al.
TRUE

Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study.
Tarantino et al.
TRUE

Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.
Gill et al.
TRUE

A randomized controlled trial of a mobile app and tailored messages to improve outcomes among women with breast cancer receiving adjuvant endocrine therapy.
Graetz et al.
TRUE

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
Rugo et al.
TRUE

ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.
Can et al.
TRUE

AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.
Frey et al.
TRUE

Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.
Waks et al.
TRUE

Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial.
Graeser et al.
TRUE

MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
Beitsch et al.
TRUE

Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.
Agostinetto et al.
TRUE

A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.
Shien et al.
TRUE

Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.
Mailhot Vega et al.
TRUE

Long-term oncologic outcomes after omitting axillary surgery in older women with early stage, node-negative breast cancer: A systematic review and meta-analysis.
Rana et al.
TRUE

Differences of prediction performances by multigene assays in patients with breast cancer with distinct genetic backgrounds.
Xing et al.
TRUE

Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.
Audi Blotta et al.
TRUE

Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.
Li et al.
TRUE

Assessing the marginal costs of radiation therapy and antiestrogen therapy for post-lumpectomy, early-stage breast cancer across Medicaid and Medicare plans.
Wu et al.
TRUE

Association between patient-reported outcomes and therapeutic outcomes in patients with breast cancer: A pooled individual-participant data analysis.
Modi et al.
TRUE

The impact of the 4R Oncology model on OncotypeDx turnaround time.
Wei et al.
TRUE

A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.
Han et al.
TRUE

Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.
Beltran-Bless et al.
TRUE

Real-world impact of TAILORx on chemotherapy use and SOFT/TEXT on ovarian function suppression uptake in a population based-cohort of women 40 years and under with HR-positive, HER2-negative, axillary lymph node negative breast cancer.
Hannouf et al.
TRUE

Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.
Untch et al.
TRUE

Image-only deep learning risk model performance in patients with known germline mutations.
Sodagari et al.
TRUE

Effect of astragalus polysaccharides (PG2) treatment of adjuvant chemotherapy-induced fatigue in premenopausal patients with breast cancer.
Rau et al.
TRUE

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
Takahashi et al.
TRUE

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon et al.
TRUE

Pulsed electrical fields in combination with anti-PD1 and survival of mice with TNBC (EMT6) murine breast tumor.
Nafie et al.
TRUE

Impact of endocrine therapy adherence on racial disparities in breast cancer survival.
Lee et al.
TRUE

Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
Graff et al.
TRUE

The worldwide impact of HER2-targeted treatments in women with breast cancer: An epidemiological modeling study.
Press et al.
TRUE

Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.
Myers et al.
TRUE

Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer.
Coombes et al.
TRUE

Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
Giacchetti et al.
TRUE

Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study.
Musolino et al.
TRUE

Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.
Ahn et al.
TRUE

An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
Siu-Li et al.
TRUE

Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.
Tang et al.
TRUE

Influence of adherence to adjuvant endocrine therapy in early breast cancer: Results from a large German real-world claims data analysis.
Dannehl et al.
TRUE

Beneficial effect of repeated participation in breast cancer screening upon survival.
Smith et al.
TRUE

State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
Becker et al.
TRUE

SEER analysis of 9-year breast cancer specific mortality (BCSM) in patients (pts) with invasive lobular breast cancer (ILC) assessed by the 21-gene Breast Recurrence Score assay.
Geyer et al.
TRUE

Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer.
Myers et al.
TRUE

Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer.
Barbacioru et al.
TRUE

Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis.
Yu et al.
TRUE

Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.
Lin et al.
TRUE

Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).
Patel et al.
TRUE

Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.
Dedic Plavetic et al.
TRUE

Prognosis of squamous cell carcinoma of the breast by biological subtypes and the efficacy of radiotherapy: The Japanese Breast Cancer Registry analysis.
Ogita et al.
TRUE

Survival outcomes of young patients under 40 with breast cancer in Asian countries according to subtype: An international multicenter cohort study.
Kim et al.
TRUE

Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor–positive breast cancer.
Ma et al.
TRUE

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer.
Reid et al.
TRUE

Lipidomic signature from plasma to detect localised breast cancer.
Lamoury et al.
TRUE

Correlation of gene signatures of Kaiso and LC3A/B protein expression with distinct tumor ecosystems and to predict response to breast cancer therapy.
Singhal et al.
TRUE

Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.
Serrano Domingo et al.
TRUE

Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency.
Lim et al.
TRUE

ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
Liu et al.
TRUE

Do HER2 low tumors have a distinct clinicopathologic phenotype?
Polidorio et al.
TRUE

Outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis based on the 21-gene recurrence score.
Bilani et al.
TRUE

Clinical meaning of stromal tumor infiltrating lymphocytes (sTIL) in luminal early breast cancer.
García-Torralba et al.
TRUE

Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.
Spears et al.
TRUE

Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.
Vannier et al.
TRUE

Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.
Munoz-Arcos et al.
TRUE

Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history.
Rozenblit et al.
TRUE

Exploring HER2-low disease: Does it impact breast cancer survival?
López-Paradís et al.
TRUE

Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).
Stecklein et al.
TRUE

Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.
Mouabbi et al.
TRUE

Assessment of the differential profile of breast intratumoral bacteria in treatment responders and nonresponders.
Basgaran et al.
TRUE

Characteristics associated with spatially resolved immune landscapes in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.
Chumsri et al.
TRUE

The somatic mutation profile of breast cancer in Uganda.
Menon et al.
TRUE

Phase II study on feasibility of sentinel lymph node biopsy for ycN0 patients treated with primary chemotherapy in cT1-3N1M0 breast cancer (SHARE study).
Nakamura et al.
TRUE

10-year mastectomy trends among breast cancer phenotypes: A national cohort study.
Pierotti et al.
TRUE

Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed surgical treatment: Mediating impact on mortality.
Bangolo et al.
TRUE

Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.
Kantor et al.
TRUE

Association of minimizing the false negative rate of axillary staging surgery in patients with cN1 breast cancer after neoadjuvant chemotherapy with surgical overtreatment.
Laws et al.
TRUE

A phase II randomized clinical trial to assess toxicity and quality of life of patients with breast cancer with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation.
Gil et al.
TRUE

Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.
Chew et al.
TRUE

Effect of tumor microenvironment on chemotherapy response of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy.
Kim et al.
TRUE

Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.
Park et al.
TRUE

Use of machine learning to predict pathological complete response using multi-modal data from I-SPY2 clinical trials.
Ahmed
TRUE

Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
Wang et al.
TRUE

Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.
Wang et al.
TRUE

Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.
Erber et al.
TRUE

Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.
Han et al.
TRUE

Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
Mastrantoni et al.
TRUE

Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
Soliman et al.
TRUE

Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.
Wang et al.
TRUE

Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
Singer et al.
TRUE

Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study.
Stanciu et al.
TRUE

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.
Jiang et al.
TRUE

Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
Force et al.
TRUE

NeoIRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC).
Page et al.
TRUE

Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy.
Garrone et al.
TRUE

Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.
Abuhadra et al.
TRUE

A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.
Chen et al.
TRUE

Association of biophysics-based biomarker with tumor volumetric response in breast cancer treated with immunotherapy.
Cook et al.
TRUE

Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
Kim et al.
TRUE

Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting.
Danso et al.
TRUE

Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.
Jacob et al.
TRUE

The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
Abdel-Fatah et al.
TRUE

LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis.
Deluche et al.
TRUE

lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
Geyer et al.
TRUE

Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.
Patel et al.
TRUE

Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25).
Ahn et al.
TRUE

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.
Tolaney et al.
TRUE

A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).
Elliott et al.
TRUE

FLEX, a real-world evidence full transcriptome study of 30,000 patients with early-stage breast cancer.
Brown et al.
TRUE

MRD assay to evaluate recurrence and response via a tumor-informed assessment: MARIA-Breast observational trial.
Esplin et al.
TRUE

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.
White et al.
TRUE

Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
Ryu et al.
TRUE

SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial.
McIntosh et al.
TRUE

MELODY (Methods for Localization of Different Types of Breast Lesions): A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).
Banys-Paluchowski et al.
TRUE

Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).
Jung et al.
TRUE

Tailored axillary surgery (TAS) in patients with clinically node-positive breast cancer in the upfront surgery setting: A prospective, single-arm, multicenter trial.
Terata et al.
TRUE

Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial.
Costa et al.
TRUE

DIRECT2: A randomized phase III trial with a fasting mimicking diet program to improve chemotherapy in patients with hormone receptor positive, HER2-negative breast cancer—A Dutch Breast Cancer Research Group study (BOOG).
de Gruil et al.
TRUE

Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).
B M et al.
TRUE

ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.
Chen et al.
TRUE

A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
Goetz et al.
TRUE

Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
McArthur et al.
TRUE

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
McArthur et al.
TRUE

A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.
Gwin et al.
TRUE

Evolution of breast cancer management in the Dominican Republic in the 21st century.
Molaire et al.
FALSE

Correlation of breast arterial calcification with overall survival in patients with breast cancer.
Dusi et al.
FALSE

Management of adjuvant endocrine therapy (AET) side effects in patients with breast cancer: A single cancer center experience.
Kuhn et al.
FALSE

Possible advantage of granulocyte colony-stimulating factor in breast cancer chemotherapy during COVID-19 pandemic: A single center experience in Japan.
Yokoyama
FALSE

Re-referral for post-op radiation in elderly breast cancer patients who initially omit RT but are unable to tolerate endocrine therapy.
Kaleem et al.
FALSE

Systematic review of breast implant associated squamous cell carcinoma.
Niraula et al.
FALSE

Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2- breast cancer.
Edwards et al.
FALSE

Treatment pattern of early-stage premenopausal breast cancer patients with low Oncotype DX score: Single center experience.
Al Saheli et al.
FALSE

The safety of breast reconstruction: The impact of breast reconstruction surgery on postoperative adjuvant therapy for breast cancer.
Nagura et al.
FALSE

Clinical utility of sentinel lymph node biopsy in women ≥ 70 years with early breast cancer.
Merh et al.
FALSE

An analysis of National Cancer Data Base: Male breast cancer and overall survival.
Albagoush et al.
FALSE

Role of chemotherapy in early-stage hormone receptor positive HER2-negative (HR+) breast cancer patients with variant histology.
Roy et al.
FALSE

Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
Lin et al.
FALSE

Accelerated partial breast irradiation (APBI) for ductal carcinoma in situ.
Roth O'Brien et al.
FALSE

Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden.
Khandare et al.
FALSE

Exosome-based delivery of microRNAs to confer adriamycin-resistance to sensitive cells through modulating the immune- and metabolism-related gene PTEN in HER2-negative breast cancer.
Yang et al.
FALSE

Amelioration of acute radiation dermatitis in patients with breast cancer by a bioadhesive barrier-forming oral gel (Episil): A single-center, open, parallel, randomized controlled trial.
Li et al.
FALSE

Therapy decision-making after pre-operative endocrine therapy in HR+ HER2- early breast cancer.
Sorokina et al.
FALSE

The use of minimal residual disease in patients with high-risk breast cancer.
Kameoka et al.
FALSE

HR+/HER2- Breast cancer: The effect of online education on clinician knowledge, competence, and confidence in monitoring, mitigating toxicities, and developing patient-centric plans using a team-based approach.
Patel et al.
FALSE

ctDNA detection before and during systemic therapy for inflammatory breast cancer.
Alexander et al.
FALSE

Overall breast cancer survival and prognostic factors.
Benzebda et al.
FALSE

Use of AI-based second harmonic generation digital pathology for predicting patient survival for triple negative breast cancer patients.
Tai et al.
FALSE

Subcutaneous versus endovenous trastuzumab: Real world data from a reference cancer center in Peru.
Otoya et al.
FALSE

Nomograms for predicting survival in patients with HER2 negative breast cancer.
Xu et al.
FALSE

Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh.
Ahmed et al.
FALSE

Clinical-pathological characterization of patients with HER2 negative breast cancer submitted to adjuvant docetaxel/cyclophosphamide (TC), TC4 versus TC6.
Kraychete et al.
FALSE

Longitudinal trends in serum calcium, parathormone and bone mineral density in breast cancer survivors on aromatase inhibitor therapy: A single institutional cohort study.
Sorathia et al.
FALSE

A prospective real-world study to assess the effectiveness and safety of trastuzumab biosimilar in the adjuvant treatment of HER2-positive breast cancer: Preliminary safety results.
Cardoso et al.
FALSE

Early taxane-induced neurotoxicity and quality of life in patients with breast cancer: A single center, retrospective study.
Cimbro et al.
FALSE

Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2-positive breast cancers.
Godbole et al.
FALSE

Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology setting: A retrospective observational study.
Andersen et al.
FALSE

Symptom burden of patients with breast cancer on adjuvant hormone therapy: A preliminary report.
Gomaa et al.
FALSE

Factors associated with oncotype and recurrence among a diverse breast cancer population seeking care at an urban safety-net hospital.
Wang et al.
FALSE

FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients.
Perez et al.
FALSE

Simultaneous expression of androgen receptor and tumor-associated neutrophil in breast cancer subtypes.
Moghimi et al.
FALSE

Association of quantitative MRI features of DCIS with surgical upstaging and recurrence after treatment.
Kim et al.
FALSE

Relation assessment between TAN and AR with the survival of breast cancer patients.
Moghimi et al.
FALSE

Prevalence of low HER2 expression in breast cancer patients: An Indian experience.
Gogia et al.
FALSE

BMI and mortality in hormone-negative breast cancer: A PLCO trial subgroup analysis.
Chamseddine et al.
FALSE

Clinicopathologic features of early stage HER2-low breast cancer.
Nashed et al.
FALSE

Genomic and transcriptomic profiling of inflammatory breast cancers and non-inflammatory breast cancers in Asian women.
Zhou et al.
FALSE

The race, staging and clinical correlations with genetic mutations detected in breast cancer patients.
Kyaw et al.
FALSE

Neutrophil/lymphocyte ratio (NLR) and albumin-globulin ratio (AGR): Correlations with outcomes in patients with stage I-III breast cancer.
Tey et al.
FALSE

Characterizing the mental health of South African women living with comorbid HIV and breast cancer.
O'Neil et al.
FALSE

Estrogen receptor positive breast cancer in an Afro-Caribbean cohort.
Cimpeanu et al.
FALSE

Fatty acid desaturase activity and single nucleotide polymorphism of fatty acid desaturase gene and breast cancer risk in estrogen receptor subtype.
Sonkusare
FALSE

Incidental discovery of second primary malignancies in patients diagnosed with breast cancer: An institutional case series.
Iancu et al.
FALSE

Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort.
Huang et al.
FALSE

Identification of intraductal component by core-biopsy in invasive breast cancer and its impact on pCR achievement.
Krivorotko et al.
FALSE

Correlation between Magee score and recurrence score in Indian patients with breast cancer.
Davis et al.
FALSE

The polymorphic markers of the XRCC1, ERCC5, TP53, CDKN1A1 genes and the survival of triple negative breast cancer patients after platinum-based chemotherapy.
Kolyadina et al.
FALSE

Correlation of neutrophil-to-lymphocyte ratio and stromal tumor infiltrating lymphocytes across early breast cancer subtypes.
García-Torralba et al.
FALSE

In search for new targets: Differences of HER2 receptor expression between CNB and synchronous axillary lymph node metastases in 205 patients.
Weydandt et al.
FALSE

Prevalence and patterns of breast white adipose tissue inflammation among American Black women and indigenous Nigerian women with early-stage breast cancer.
Liu et al.
FALSE

Use of the genetic signature of 70-genes MammaPrint in comparision with the immunohistochemical profile to de-escalate systemic treatment in the elderly population: Real-world study (AGEMA-BR).
Mansani et al.
FALSE

Demographic characteristics of encapsulated papillary carcinoma.
Luker et al.
FALSE

Clustering whole-exome sequences of breast cancer and associations with staging and molecular subtype.
Man et al.
FALSE

Clinical subtypes and survival outcomes in invasive breast cancer with Paget’s disease: A SEER population-based study.
Bae et al.
FALSE

Clinical and biological heterogeneity in triple-negative breast cancer and HER2-low.
Hu et al.
FALSE

Use of tumoral LDH to predict residual tumor burden after neoadjuvant chemotherapy in breast cancer.
Lee et al.
FALSE

Are we using the right cut-offs to obtain maximum information from Ki-67 in patients with early breast cancer?
Trifanescu et al.
FALSE

Clinicopathological characteristics and outcome of very young breast cancer patients at a referral center in Iran.
Malekzadeh Moghani et al.
FALSE

Incidence of hypomagnesemia in patients with HER2+ breast cancer treated with pertuzumab.
Shah et al.
FALSE

Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer.
Kinoshita et al.
FALSE

Oncologic outcomes for different axillary staging techniques in nodal positive breast cancer undergoing neoadjuvant systematic treatment: A cancer registry study.
Pfob et al.
FALSE

Are preoperative sexual well-being and breast satisfaction associated with the decision making in patients with early-stage breast cancer undergoing oncologic surgery?
Lee et al.
FALSE

Long term survival in patients with bony oligometastatic breast cancer treated with curative intent: An institutional case series.
Iancu et al.
FALSE

Ozone-loaded Pt(IV) prodrug self-assembled micelles with high bioavailability, low toxicity as a novel irradiation-controlled release treatment and the immune microenvironment editor for triple-negative breast cancer.
Zheng et al.
FALSE

From the lab to the clinic: Lessons learned from a translational working group.
Lynch et al.
FALSE

Treatment patterns and clinical outcomes of newly diagnosed early-stage and locally advanced triple negative breast cancer (TNBC): A retrospective cohort analysis of national real-world data in England.
Barham et al.
FALSE

Comparison of conventional clinical models and a multigene assay to assess DCIS risk in a prospective single center study.
Wairiri et al.
FALSE

Impact of distance between tumor and nipple on survival outcomes in breast cancer.
Cheun et al.
FALSE

Assessment of cardiorespiratory dysfunction in patients with breast carcinoma receiving neo-adjuvant chemotherapy using cardiopulmonary exercise testing, and to evaluate their early post-operative trajectory with patients with breast carcinoma posted for upfront surgery: A prospective observational study.
Gupta et al.
FALSE

Reflex MammaPrint testing on breast core biopsies: A single center experience.
Kerrigan et al.
FALSE

Neoadjuvant therapy (NAT) in early breast cancer (EBC): Results from a prospective observational multicenter BRIDE study.
Gori et al.
FALSE

A meta-analysis of cardiac toxicity of concurrent epirubicin and trastuzumab in early breast cancer.
Yang et al.
FALSE

Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction measurement by ultrasound.
Chen et al.
FALSE

Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer.
Zhukova et al.
FALSE

Association of circulating tumor DNA with survival in neoadjuvant-treated triple negative breast cancer independent of pathological complete response.
Li et al.
FALSE

Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patients.
Vaid et al.
FALSE

Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer.
Gasol Cudos et al.
FALSE

Role of plasma circulating HER2/EFTUD2 ratio in predicting pathological complete response (pCR) after neoadjuvant dual anti-HER2 therapy in HER2-positive breast cancer (HER2+ BC).
Chan et al.
FALSE

Factors associated with response to neoadjuvant chemotherapy and immune checkpoint inhibition in triple-negative breast cancer.
LeVee et al.
FALSE

Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).
Iwamoto et al.
FALSE

Informative tools to optimize neoadjuvant therapy in ER positive, HER2 negative breast cancers.
Luzhna et al.
FALSE

The impact of exercise training on the pathologic response and tumor immune microenvironment in breast cancer after neoadjuvant chemotherapy: An exploratory study.
Guedes et al.
FALSE

Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.
Chai et al.
FALSE

National trends in neoadjuvant chemotherapy utilization for cT1-2 N0 triple negative breast cancer: Did the CREATE-X trial impact treatment patterns?
Rogers et al.
FALSE

Multi-omic subtyping and molecular determinants of neoadjuvant therapeutic regimen for locally advanced HER2-positive and triple-negative breast cancer: Implications of novel therapy.
Ji et al.
FALSE

Magnetic resonance imaging tumor regression shrinkage patterns during neoadjuvant chemotherapy versus neoadjuvant immunochemotherapy in triple-negative breast cancer (NeoMDSS-TN-SP): A nonrandomized, prospective cohort study.
Zhang et al.
FALSE

Racial disparity in the clinical outcomes of HER2-low and HER2-zero early-stage breast cancer.
Gandhi et al.
FALSE

Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.
Xue et al.
FALSE

Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.
Niu et al.
FALSE

Homologous recombination deficiency (HRD) status to predict the efficacy and prognosis of platinum-based neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Jin et al.
FALSE

INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results.
Zhukova et al.
FALSE

Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).
Miras et al.
FALSE

Practice patterns in ongoing neoadjuvant ATNEC trial for patients with cT1-3N1M0 breast cancer: Response to neoadjuvant chemotherapy (NACT), targeted axillary dissection and breast conservation rates.
Goyal et al.
FALSE

Retrospective analysis of Ki-67 as a predictive and prognostic marker for pathological complete response to neoadjuvant chemotherapy in breast cancer.
Randhawa et al.
FALSE

Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.
Dacoregio et al.
FALSE

Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer.
Rodriguez Garcés et al.
FALSE

Combined role of the neutrophil/lymphocyte ratio and Neo-Bioscore in neoadjuvant therapy in HER2-positive early breast cancer.
Sánchez Escudero et al.
FALSE

DCE-MRI-derived microvasculature mapping and outcome prediction in patients with breast cancer.
Stefka et al.
FALSE

Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer.
Niu et al.
FALSE

Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.
White et al.
FALSE

Comparing time to treatment for neoadjuvant chemotherapy for breast cancer across the urban-rural continuum.
Kasper et al.
FALSE

Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).
Abdullaeva et al.
FALSE

Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer.
Paredes Mogica et al.
FALSE

Identifying determinants of pathologic complete response in patients with breast cancer after receiving neoadjuvant systemic therapy.
Chan et al.
FALSE

A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer.
Vosoughi et al.
FALSE

Can axillary lymph node dissection (ALND) be omitted in patients with breast cancer with persistent axillary disease after neoadjuvant chemotherapy?
Hlavin et al.
FALSE

Neoadjuvant endocrine therapy for early-stage breast cancer: An institutional experience during the COVID19 pandemic.
Buteau et al.
FALSE

De-escalating therapy dilemma in small HER2 positive node negative breast cancer.
Hajjaji
FALSE

Analysis of pathological complete response (PCR) and impact of modifiable risk factors on the premature discontinuation of pertuzumab use in early stage HER-2 breast cancer: A retrospective single-institutional study.
Anwar et al.
FALSE

Pathologic complete response in germline mutation carriers by mutation type and biomarkers in a safety-net population.
Shah et al.
FALSE

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.
Llombart-Cussac et al.
TRUE

Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.
Cabel et al.
TRUE

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
Tolaney et al.
TRUE

A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).
Hamilton et al.
TRUE

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.
Bar et al.
TRUE

An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
Krop et al.
TRUE

Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
Khan et al.
TRUE

CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.
Harbeck et al.
TRUE

Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01.
Hilbers et al.
TRUE

Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).
Stover et al.
TRUE

RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.
Huebner et al.
TRUE

BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.
Clark et al.
TRUE

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.
Frenel et al.
TRUE

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
Yamamoto et al.
TRUE

The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.
Andrieu et al.
TRUE

LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
Xu et al.
TRUE

First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
Carola et al.
TRUE

Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
Agostinetto et al.
TRUE

Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.
Modi et al.
TRUE

HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.
Lin et al.
TRUE

Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
Abelman et al.
TRUE

Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study.
Guerrero et al.
TRUE

Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
Gennari et al.
TRUE

Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study.
Nader Marta et al.
TRUE

Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.
Juan et al.
TRUE

Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer.
Lohmann et al.
TRUE

Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).
Ko et al.
TRUE

Comparison of immune microenvironment between primary and metastatic breast tumors.
Ko et al.
TRUE

Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).
Yuan et al.
TRUE

Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.
Griguolo et al.
TRUE

UGT1A1 *28/*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy.
Wong et al.
TRUE

Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
Wang et al.
TRUE

Comprehensive characterization of androgen receptor expression in breast cancer.
Jayachandran et al.
TRUE

Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci et al.
TRUE

Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).
Byron et al.
TRUE

Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).
Zhang et al.
TRUE

Genomic characterization of the GATA3 mutational landscape in breast cancer.
Mouabbi et al.
TRUE

Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
Ma et al.
TRUE

Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.
Anders et al.
TRUE

Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.
Lv et al.
TRUE

Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer.
Bao et al.
TRUE

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.
Wang et al.
TRUE

Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).
Yan et al.
TRUE

PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).
Zhang et al.
TRUE

Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort.
Lee et al.
TRUE

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.
Yan et al.
TRUE

Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
Shin et al.
TRUE

Secondary primary malignancy risk by ER, PR, and HER-2 status in post-menopausal women with breast cancer: A population-based analysis.
Khan et al.
TRUE

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer.
Anders et al.
TRUE

HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
Drago et al.
TRUE

Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer.
Bourdon et al.
TRUE

First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
Sommerhalder et al.
TRUE

Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).
Ivory et al.
TRUE

Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Kappel et al.
TRUE

Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.
Damodaran et al.
TRUE

Prognostic factors in hormone receptor positive oligometastatic breast cancer.
Jean Louis et al.
TRUE

Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
Gerratana et al.
TRUE

ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.
Guerrero et al.
TRUE

Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC).
Oliveira et al.
TRUE

Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
Jeselsohn et al.
TRUE

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
El Saghir et al.
TRUE

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.
Makharadze et al.
TRUE

Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.
Tolosa Ortega et al.
TRUE

Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
Oliveira et al.
TRUE

Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.
Rugo et al.
TRUE

Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).
Collier et al.
TRUE

Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
Kaklamani et al.
TRUE

Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
Zhao et al.
TRUE

A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.
Wang et al.
TRUE

Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer.
Cescon et al.
TRUE

ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
Medford et al.
TRUE

Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
Fuentes Antrás et al.
TRUE

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
Cobain et al.
TRUE

Relation between circulating biomarkers at diagnosis of early luminal-like breast cancer and subsequent risk of distant metastases.
Lambrechts et al.
TRUE

Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.
Chia et al.
TRUE

A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
Mainor et al.
TRUE

Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.
Rosen et al.
TRUE

Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
Wander et al.
TRUE

Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.
Bardia et al.
TRUE

Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.
Majeski et al.
TRUE

Targeting squalene epoxidase in breast-to-brain metastasis: A new therapeutic target for brain extravasation and colonization using animal models.
Lee et al.
TRUE

Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.
Wang et al.
TRUE

The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.
Chen et al.
TRUE

Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.
Lukashchuk et al.
TRUE

ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
Chen et al.
TRUE

The case for acceleration of prospective multi- stakeholder led community-based research in young Black women with triple negative breast cancer (TNBC).
Regnante et al.
TRUE

Sociodemographic and clinicopathologic factors of triple negative breast cancer at an academic urban safety-net hospital.
Wang et al.
TRUE

Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).
Huppert et al.
TRUE

Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
Rimawi et al.
TRUE

Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).
De La Haba et al.
TRUE

The impact of social determinants of health (SDOH) on use of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Reid et al.
TRUE

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
Chen et al.
TRUE

Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.
Zhao et al.
TRUE

High dose alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Results from the randomized phase 3 OLIGO study.
Van Ommen-Nijhof et al.
TRUE

Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC.
Nicolò et al.
TRUE

Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.
Lim et al.
TRUE

Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.
Ma et al.
TRUE

Actionability of comprehensive genomic profiling compared to the tissue-based and plasma-based assay in patients with metastatic breast cancer: A real-world study.
Tada et al.
TRUE

Social determinants of health factors and palliative care services use among patients with metastatic breast cancer in Florida.
Giap et al.
TRUE

Association between baseline radiological tumor burden and outcomes in patients with metastatic breast cancer treated with an immune checkpoint inhibitor.
Brown et al.
TRUE

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.
Molinelli et al.
TRUE

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer.
Iwase et al.
TRUE

Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.
Abelman et al.
TRUE

Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).
Graham et al.
TRUE

Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study.
Huppert et al.
TRUE

Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.
Zagami et al.
TRUE

Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.
Tamimi et al.
TRUE

Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
Okines et al.
TRUE

Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.
Gandhi et al.
TRUE

Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
Han et al.
TRUE

A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
Hurvitz et al.
TRUE

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.
Hamilton et al.
TRUE

UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.
McAndrew et al.
TRUE

EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan.
Iwata et al.
TRUE

A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
Hurvitz et al.
TRUE

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
Mayer et al.
TRUE

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.
Ibrahim et al.
TRUE

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
Layman et al.
TRUE

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
Campone et al.
TRUE

INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
Juric et al.
TRUE

CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
Fasching et al.
TRUE

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
Pascual et al.
TRUE

Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).
Torres et al.
TRUE

A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
Borges et al.
TRUE

The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.
Cornelius et al.
TRUE

A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
Rainey et al.
TRUE

The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.
Shen et al.
TRUE

A randomized phase II clinical trial of talazoparib maintenance therapy in patients with triple-negative breast cancer who showed platinum-sensitivity on first- or second-line platinum-based chemotherapy: KCSG BR21-10.
Sohn et al.
TRUE

Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.
Shen et al.
TRUE

Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).
Vidula et al.
TRUE

D-dimer as a predictive biomarker of response to chemotherapy in patients with metastatic breast cancer.
Alkhoder et al.
FALSE

Serial multiomic analysis in advanced breast cancer: A novel platform to inform therapeutic decisions.
Kong et al.
FALSE

Bioequivalence study of BH009 and Winthrop (docetaxel) injection (an authorized generic drug of Taxotere) in patients with advanced solid tumor: An open-label, randomized, single-dose, two-way crossover evaluation.
Sun
FALSE

Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.
Batalini et al.
FALSE

Prevalence of BRCA1 and BRCA2 mutations in an unselected cohort of Indian women with breast cancer.
Gogia et al.
FALSE

PI3KCA mutation prevalence and outcome among patients with metastatic breast cancer in Bulgaria treated with first-line endocrine therapy.
Gencheva et al.
FALSE

A combination of circulating tumor cell (CTC) and cancer stem cell (CSC) markers to predict the prognosis of breast cancer.
Sun et al.
FALSE

Body composition measures as predictors of toxicity in patients with metastatic breast cancer receiving PARP inhibitors.
Etan et al.
FALSE

Risk factors of early liver metastasis in patients with breast cancer.
Zhu et al.
FALSE

Characterization of patients with recurrent breast cancer submitted to neoadjuvant therapy in a Brazilian cancer center.
Rossato de Almeida et al.
FALSE

HER2-low expression as a prognostic factor in patients treated with CDK4/6 inhibitors: A retrospective analysis.
Cejuela Solís et al.
FALSE

The mechanism of exosome delivered circ-PDE7B promoting liver metastasis of breast cancer.
Dandan et al.
FALSE

Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.
Amoako et al.
FALSE

Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor.
Tao et al.
FALSE

The role of ct-DNA in breast cancer surveillance assessing treatment response and recurrence: A community center experience.
Khalid et al.
FALSE

Androgen receptor expression in female patients with triple-negative breast cancer: Relation to clinical, pathological, and ethnical data and comparison with non–triple-negative breast cancer.
Zidan
FALSE

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: A systematic review and network meta-analysis.
Wang et al.
FALSE

Radiotherapy combined with pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases: A single-arm, exploratory trial.
Wang et al.
FALSE

Real-world safety and effectiveness of CT-P6 (biosimilar trastuzumab): A post-marketing surveillance study in Korea.
Park et al.
FALSE

Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).
Wang et al.
FALSE

Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia.
Chavarría Piudo et al.
FALSE

Effect of suppressing the p38 pathway through upregulation of Wip1 on Her2 early dissemination of breast cancer.
Wang et al.
FALSE

Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.
Chen et al.
FALSE

Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03.
Yamashita et al.
FALSE

Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a multicenter, prospective study in China.
Hong et al.
FALSE

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab-deruxtecan in patients with breast cancer: A systematic review and single-arm meta-analysis.
Soares et al.
FALSE

Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer.
Audi Blotta et al.
FALSE

Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study.
Vosoughi et al.
FALSE

ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.
Bian et al.
FALSE

Shifting trends in the usage of trastuzumab with its biosimilar inception in India.
Ramanjinappa et al.
FALSE

Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial.
Li et al.
FALSE

A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924).
Harper-Wynne et al.
FALSE

Real world clinical outcomes of patients with HER2 positive metastatic breast cancer with central nervous system involvement treated with modern regimens.
Siegelmann-Danieli et al.
FALSE

Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study.
Wu et al.
FALSE

Comparing digital and glass slide methods for determining the HER2-low and negative categories in breast cancer.
Xue et al.
FALSE

Use of PARPi among patients with HER2+ve MBC: Results from a real world dataset.
Dawood et al.
FALSE

De novo metastatic Her2+ breast cancer in a diverse population of women under age 40.
Chung et al.
FALSE

Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset.
Dawood et al.
FALSE

ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer.
Yeung et al.
FALSE

Time to treatment failure (TTF) and overall survival (OS) with palbociclib (PAL) plus endocrine therapy (ET) versus ET in HR+/HER2- advanced breast cancer (ABC) patients: A real-world multicenter study from China.
Zhang et al.
FALSE

Prognostic significance of estrogen receptor status in de novo metastatic breast cancer.
Chongxi et al.
FALSE

Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.
Decker et al.
FALSE

BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.
Zhang et al.
FALSE

Open-label phase II study of everolimus plus endocrine therapy in postmenopausal women with ER+, HER2- metastatic breast cancer (Chloe trial).
Shien et al.
FALSE

Outcome of second-line treatment after CDK4/6 inhibitors in hormonal-positive HER-2 negative metastatic breast cancer: Single institution experience.
Alghanmi et al.
FALSE

Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.
Lok et al.
FALSE

Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.
Yuan et al.
FALSE

Comparative effectiveness of palbociclib plus aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: A real-world study.
Yue et al.
FALSE

Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis.
Wang et al.
FALSE

The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer.
Godina et al.
FALSE

Gene expression comparison between primary aggressive luminal breast cancer and paired axillary and sentinel lymph node metastasis.
Li et al.
FALSE

Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study.
Zhao et al.
FALSE

Effect of high immune-related gene expression on resistance to CDK4/6 inhibitors in advanced breast cancer.
Chekhun et al.
FALSE

First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.
Piazza et al.
FALSE

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
Zurcher et al.
FALSE

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.
Dempsey et al.
FALSE

Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study.
Mehta et al.
FALSE

The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2− metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3.
Pilehvari et al.
FALSE

A quality improvement initiative on the utility of the Oncotype DX breast cancer assay in a community hospital.
Iqbal et al.
FALSE

Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
Garcés et al.
FALSE

Sustained prognostic impact of primary tumor characteristics on long-term (overall) survival after distant metastasis in young ER+ HER2- breast cancer.
Lee et al.
FALSE

Integrating radiation therapy with CDK4/6 inhibitors for breast cancer: A systematic review and meta-analysis of toxicity.
Becherini et al.
FALSE

Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer.
Gunuganti et al.
FALSE

Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i): Real world data.
Dedic Plavetic et al.
FALSE

Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2- metastatic breast cancer (mBC).
Avesani et al.
FALSE

Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.
Rohatgi et al.
FALSE

Differences in treatment outcomes in relation to level of human epidermal growth factor receptor-2 (HER2) expression, HER2-low vs HER2-zero, in patients with hormone receptor-positive metastatic breast cancer treated with cyclin dependent kinase CDK4/6 inhibitors: A systematic review and meta-analysis.
Sharaf et al.
FALSE

Commercial next generation sequencing in a real-world cohort of patients with metastatic breast cancer.
Taneja et al.
FALSE

Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta et al.
FALSE

Exploring the effects of inhibiting miR-10b on breast cancer stemness and metastasis.
Al-Qadi et al.
FALSE

Reliance of agency-approved and guideline-recommended therapies on surrogate endpoints in triple-negative breast cancer (TNBC).
Gala et al.
FALSE

Extracellular mechanical forces and ferroptosis in triple negative breast cancer (TNBC): Targeting of aurora kinase A (AURKA).
Wang et al.
FALSE

CCT6A and triple-negative breast cancer metastasis: Activating the AKT/MDM2/P53 pathway.
Yang et al.
FALSE

Identifying the education, information and support needs of Canadians diagnosed with breast cancer: A Canadian Breast Cancer Network (CBCN) assessment project.
Ammendolea et al.
FALSE

Correlation analysis to assess surrogate endpoints for overall survival (OS) in triple-negative breast cancer (TNBC).
Pérez-Granado et al.
FALSE

A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer.
Zhao et al.
FALSE

A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer.
Wu et al.
FALSE

Lactate-induced lactylation circularly regulates glucose metabolism enzymes in breast cancer.
Xu et al.
FALSE

Recurrent versus non-recurrent triple negative breast cancer: An institutional study.
Akpoviroro et al.
FALSE

Effect of doxorubicin on efficacy of immune checkpoint inhibitors through increasing infiltration of CD8-positive T cells and activating STAT1-IRF1-CXCL10 axis.
Xiaosu et al.
FALSE

Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins.
Jin et al.
FALSE

Shugoshin as a key mediator in the metastasis of triple negative breast cancer.
Hernandez et al.
FALSE

Prognostic value of TP53 mutation status in metastatic triple-negative and hormone receptor-positive breast cancer using cell-free DNA genomic profiling.
Seriak et al.
FALSE

Effect of DUAL pharmacological blockade of AURKA and PD-L1 pathways on plasticity and metastasis for triple negative breast cancer.
Takchi et al.
FALSE

Identification of a novel squalene epoxidase function in breast cancer brain metastasis.
Wang et al.
FALSE

Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study.
Peng et al.
FALSE

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
Chen et al.
FALSE

Survival outcomes and clinicopathological factors analysis of breast cancer patients. A single-institution cohort from 2012 to 2020 in a Mexican population.
Grajales et al.
FALSE

Circulating methylated-HOXA9 tumor DNA as a biomarker for mortality in recurrent breast cancer.
Hansen et al.
FALSE

A pilot study of the combination of entinostat with capecitabine in high-risk breast cancer after neoadjuvant therapy.
Humphrey et al.
FALSE

Incidence and outcomes of cardiac tamponade in patients with breast cancer.
Ilerhunmwuwa et al.
FALSE

Prognosis of patients with HER2-low breast cancer brain metastasis: A single-institution experience.
Xu et al.
FALSE

Cancer recurrence: Detection and diagnostic intervals in Danish primary care.
Grooss et al.
FALSE

B-TREUH results: A single-arm phase II pilot study of euthyroid hypothyroxinemia in metastatic breast carcinoma.
Trehan et al.
FALSE

Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.
Xu et al.
FALSE

Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Ali et al.
FALSE

A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2–negative advanced breast cancer.
Zhang et al.
FALSE

The mutational landscape of Chinese breast cancer by liquid biopsy.
Fan et al.
FALSE

Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study.
Yang et al.
FALSE

Optimization of protein extraction for proteomic analysis of formalin-fixed and paraffin-embedding (FFPE) biopsy specimens from males with breast cancer.
Bezerra et al.
FALSE

Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer.
El Kaddissi et al.
FALSE

Clinical and molecular characterization of a cohort with breast cancer brain metastases.
Oyogoa et al.
FALSE

Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan et al.
FALSE

Development and validation of a NCC-BC-A scale to assess patient-reported outcomes for advanced breast cancer patients in China.
Guan et al.
FALSE

Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.
Yan et al.
FALSE

Efficacy and safety of eribulin as a front-line treatment in patients with advanced breast cancer: The first large scale prospective real-world study in China.
Zhao et al.
FALSE

Therapeutic strategies for metaplastic breast cancer: A clinicopathologic analysis of a single institution cohort.
Batra-Sharma et al.
FALSE

Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers.
Bieth et al.
FALSE

Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.
Blankfard et al.
FALSE

A novel pan-RAS inhibitor for luminal B breast cancer.
Arshad et al.
FALSE

In-hospital outcomes of patients with breast cancer and venous thromboembolism.
Sanghvi et al.
FALSE

AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 individuals.
Wong et al.
TRUE

Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation.
Nicholson et al.
TRUE

Childhood leukemia survival in the US-Mexico border: Building sustainable leukemia care using health systems strengthening models.
Aristizabal et al.
TRUE

Analysis of patient-physician portal secure message content and the associated cost savings in oncology practice.
Anderson et al.
TRUE

Prior authorizations for oral anticancer drugs and delayed prescription fills.
Kyle et al.
TRUE

SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.
Jefford et al.
TRUE

Observational prospective study of physical activity in patients with cancer to define an objective performance status (OPS).
Ruiz-Hispán et al.
TRUE

A cognitive behavioral digital therapeutic for anxiety and depression in patients with cancer: A decentralized randomized controlled trial.
Zion et al.
TRUE

Remote symptom-monitoring of patients with advanced lung cancer: A Danish national randomized controlled trial—The ProWide study.
Friis et al.
TRUE

Association of Medicaid expansion with treatment receipt, delays in treatment initiation, and survival among young adult women with breast cancer.
Han et al.
TRUE

Association between state Medicaid policies and accrual of Black and Hispanic patients to cancer clinical trials.
Takvorian et al.
TRUE

State mandatory paid medical leave policies and survival among adults with cancer in the US.
Barnes et al.
TRUE

Impact of the oncology care model (OCM) on Medicare payments, utilization, and care delivery: Update through year 5.
Brooks et al.
TRUE

Engagement of Patients with Advanced Cancer (EPAC) randomized clinical trial: Long-term effects on survival and healthcare use.
Patel et al.
TRUE

Patient- and clinician-directed implementation strategies to improve serious illness communication for high-risk patients with cancer: A cluster-randomized pragmatic trial.
Takvorian et al.
TRUE

Identifying clinical trial candidates using AI predictions of treatment change: A pilot implementation study.
Kehl et al.
TRUE

Developing machine learning algorithms incorporating patient reported outcome measures to predict acute care events among patients with cancer.
Roberts et al.
TRUE

AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.
Simon et al.
TRUE

Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe.
Ferreira et al.
TRUE

Expanding veteran treatment access points through Close To Me (CTM) infusion service.
Shields et al.
TRUE

Improving cancer care in underserved regions through technology-enabled patient-reported outcomes.
Ndoh et al.
TRUE

Multidisciplinary prostate cancer consultation at home: Does the virtual visit platform adversely affect care for elderly patients or impact treatment recommendations?
Dorin et al.
TRUE

Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD).
Park et al.
TRUE

The impact of the 4R Oncology model of team-based care delivery on timing and sequence of guideline recommended interdependent care in breast and lung cancers.
Liu et al.
TRUE

English- and Spanish-preferring patient perspectives on managing acute care needs at two disparate health systems.
Kyalwazi et al.
TRUE

Assessing mail-in cryopreservation for fertility preservation.
Belarmino et al.
TRUE

Implementation of a multi-cancer early detection (MCED) test using a centralized model within (w/i) a multi-state health system.
Agarwal et al.
TRUE

Differential responses to systemic therapy among patients who are financially fragile and receiving Medicaid: Results from ePRO and biometric monitoring study.
Ramsey et al.
TRUE

Team-based versus technology-based supportive cancer care (SCC): Assessment of implementation across 24 different clinical settings.
Moufarrej et al.
TRUE

Dose rounding bevacizumab and its biosimilars to reduce drug waste in the oncology care model in a community oncology network.
Indurlal et al.
TRUE

Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer.
Yee et al.
TRUE

Implementation of a streamlined prior authorization process to improve cancer care delivery.
Bhardwaj et al.
TRUE

Best practices study to enhance the quality of multi-disciplinary teams in lung cancer care.
Gallego Llorente et al.
TRUE

Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.
Bansal et al.
TRUE

Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
Patel et al.
TRUE

Decreasing the burden of febrile neutropenia through dynamic remote patient monitoring: The DEFeNDER program.
Pritchett et al.
TRUE

Outcomes on the hematology malignancy hospitalist service: A model for inpatient care.
Kessler et al.
TRUE

Are we ready to mitigate time toxicity of cancer care? Oncologists’ perceptions on digital interventions to fast-track cancer care.
Bange et al.
TRUE

Overcoming barriers and improving genetic testing completion rate for hereditary cancer in an underserved population at a large safety net hospital.
Vara et al.
TRUE

Antineoplastic and immunomodulating agent effects on immunization outcomes.
New et al.
TRUE

Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.
Lin et al.
TRUE

Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD).
Chang et al.
TRUE

Distribution of alternate site infusion providers in the US.
Revol et al.
TRUE

National lung cancer screening rates among women veterans within the Veterans’ Health Administration.
Bail et al.
TRUE

Association between inpatient clinical nursing acuity and 30-day rehospitalization among hospitalized patients with advanced cancer.
Lage et al.
TRUE

Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.
Polcari et al.
TRUE

Effect of an oncology care management program on unplanned hospital admissions in a commercially insured population.
French et al.
TRUE

An AI tool for chest X-ray interpretation and lung cancer pre-screening in developing countries.
González Espinoza et al.
TRUE

Deep learning-based approach to predict multiple genetic mutations in colorectal and lung cancer tissues using hematoxylin and eosin-stained whole-slide images.
Konishi et al.
TRUE

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.
Zhang et al.
TRUE

Prediction of cancer treatment response from histopathology images through imputed transcriptomics.
Hoang et al.
TRUE

Utilizing predictive modeling to identify patients at high risk of death from immune checkpoint inhibitor therapy-related pneumonitis.
Hazim et al.
TRUE

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.
Aharonov et al.
TRUE

Can synthetic data accurately mimic oncology clinical trials?
El Kababji et al.
TRUE

Relevance and accuracy of ChatGPT-generated NGS reports with treatment recommendations for oncogene-driven NSCLC.
Hamilton et al.
TRUE

Identification of genes encoding targets associated with adverse events in multiple myeloma.
Xu et al.
TRUE

An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE.
Grant et al.
TRUE

Lost in translation? Information exchange during breast cancer care and implications for technology design.
Salwei et al.
TRUE

Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer.
Mukherjee et al.
TRUE

Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States.
Aran et al.
TRUE

Natural language processing identification of documented mental health symptoms associated with risk of mental health disorders in patients with cancer.
Friesner et al.
TRUE

Accuracy of a clinical decision support system in identifying patients at risk of cancer in primary care.
Bakshi et al.
TRUE

ALAN as an omic tool to build gene signatures and to stratify patients.
Bergom et al.
TRUE

Deep learning to estimate RECIST in patients with cancer treated in real-world settings.
Riaz et al.
TRUE

Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.
Unger et al.
TRUE

Trial eligibility criteria (EC) and diversity among patients with advanced non small cell lung cancer (advNSCLC).
Kaur et al.
TRUE

Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.
Yu et al.
TRUE

Technology-enabled clinical trials: Intentional capture of source data (IDC) in the electronic-health record (EHR) and direct transfer to trial database (electronic data capture [EDC]) in a phase II multicenter trial.
Royce et al.
TRUE

The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
Ojo et al.
TRUE

Endpoints reported in phase 3 randomized clinical trials at ASCO 2022.
Teuwen et al.
TRUE

Utilizing Drug Combo to improve the design of phase 1 trials for anticancer drugs.
Wang et al.
TRUE

Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.
Colley et al.
TRUE

Survival-inferred fragility index of FDA-approved cancer drugs using surrogate endpoints.
Ofer et al.
TRUE

Use of gender-neutral language in clinical trial protocols in select cancers.
Gupta et al.
TRUE

Trends in U.S and global patient enrollment from 2014 to 2022 in lung cancer clinical trials supporting marketing applications: An FDA analysis.
Akinboro et al.
TRUE

Quantifying the growth of clinical actionability in precision oncology using OncoKB.
Suehnholz et al.
TRUE

Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health.
Davella et al.
TRUE

Completion rates and trends of the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) across 14 oncology clinical trials.
Emerson et al.
TRUE

Association of remote, longitudinal patient-reported outcomes (PROs) and step counts with hospitalization or death among patients with advanced cancer undergoing chemotherapy: Secondary analysis of the PROStep randomized trial.
Parikh et al.
TRUE

Differences in perceptions and use of remote patient monitoring technology in rural cancer programs.
Penberthy et al.
TRUE

The Tempus TIME trial portal and clinical trial enrollment.
Rao et al.
TRUE

Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.
Daly et al.
TRUE

Longitudinal changes in patient reported outcome measures in patients with cancer six months prior to death: A case-control study.
Tam et al.
TRUE

Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapy.
Blinder et al.
TRUE

Acceptability and effectiveness of digital prehabilitation and personalised support for patients with cancer in the UK National Health Service.
Wynter-Blyth et al.
TRUE

Comparison of publications between cancer sites in high impact factor journals.
Sinha et al.
TRUE

Association of state policies regulating short-term limited-duration insurance plans and cancer stage at diagnosis.
Barnes et al.
TRUE

Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.
Mooghali et al.
TRUE

“It was so many hoops to jump through”: Patient-reported administrative burden from disability, Family and Medical Leave Act (FMLA), and insurance appeals.
Chino et al.
TRUE

Trends in new and persistent opioid use in older adults with cancer.
Baum et al.
TRUE

Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.
Dickerson et al.
TRUE

Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.
Liu et al.
TRUE

Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.
Taparra et al.
TRUE

Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis.
Mullangi et al.
TRUE

Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?
Patel et al.
TRUE

Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.
Heiss et al.
TRUE

Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study.
Cliff et al.
TRUE

System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.
Limvorasak et al.
TRUE

Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
Campoverde et al.
TRUE

Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service.
Lin et al.
TRUE

Use and value of self-management (SM) recommendations in a real-world evidence study evaluating digital patient monitoring (DPM) of patients (pts) receiving cancer care.
Eicher et al.
TRUE

SpotCheck: A skin cancer diagnostic clinical trial comparing dermoscopy-enhanced telemedicine to in-person evaluation.
Ingrassia et al.
TRUE

A study to assess the diagnostic performance of a digital remote monitoring tool for patients with cancer: The POSITEA-VA study.
Parnot et al.
TRUE

Trends and disparities in oncology telehealth after the initial pandemic era.
Lee et al.
TRUE

Impact of state policies on telehealth use among the privately insured with newly diagnosed cancer.
Shih et al.
TRUE

Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).
Kim et al.
TRUE

Open label single arm study to assess the implementation of home based daratumumab administration in patients being treated for multiple myeloma.
Binder et al.
TRUE

Screening for high frequency malignant disease (SHIELD).
NGUYEN et al.
TRUE

Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.
Ando et al.
TRUE

Infrastructure for rare cancer in the Netherlands: Towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE).
Pieterman et al.
TRUE

The PLATON Network: An interactive platform for precision oncology.
Al-Batran et al.
TRUE

Electronic collection of cancer patient-reported outcomes using a novel digital oncology platform: A multi-site randomized controlled trial.
Fidyk et al.
TRUE

Mixed-methods clinical trial to evaluate the feasibility of the CURATE.AI optimised digital cognitive rehabilitation therapeutic (COR-Tx) in patients post brain radiotherapy.
Raczkowska et al.
TRUE

Liquid biopsy-informed precision oncology study to evaluate utility of plasma genomic profiling for therapy selection.
Tao et al.
TRUE

An interventional study of the impact of digital patient monitoring (DPM) on health outcomes, healthcare resource utilization, and feasibility of a combination with at-home treatment (tx) for delivery of systemic anticancer tx in clinical practice.
Iivanainen et al.
TRUE

Evaluating the impact of a molecular tumor board in a community oncology center: Results from the Avera Cancer Institute's experience.
Elsey et al.
FALSE

Improving multidisciplinary patient-centered care for adolescents and young adults with cancer.
Elliott et al.
FALSE

Virtual nutrition services in oncology.
Lammersfeld et al.
FALSE

Clinical pathways utilization and characteristics of non-adherence at Sidney Kimmel Cancer Center.
Houtmann et al.
FALSE

Patient decision aid for chemotherapy or exclusion in cisplatin-intolerant patients with locally advanced cervical cancer (CECIL): Development, alpha testing, and peer-validation.
Bacorro et al.
FALSE

Network-enabled rapid growth of a US-based remote asynchronous oncology subspecialist case review service.
West et al.
FALSE

Improving compliance with post-hospitalization follow-up visits: A single community cancer center experience.
Venigalla et al.
FALSE

Carboplatin beyond 4 cycles during therapy with carboplatin, pemetrexed, and pembrolizumab for advanced non-small cell lung cancer (NSCLC).
Ahmad et al.
FALSE

Evaluating the impact of nurse navigation on high-risk breast clinic appointment uptake in a cancer risk assessment program.
Levin et al.
FALSE

Impact of centralization of initial breast cancer care on time to surgery.
Yen et al.
FALSE

Overcoming barriers to adoption of precision medicine in community oncology centers in the rural southeastern United States using novel informatics tools and academic collaborations.
Caughey et al.
FALSE

Implementation of an early-stage lung cancer survivorship clinic in a comprehensive cancer center.
Wentworth et al.
FALSE

Changes in time to treatment initiation for patients diagnosed with breast, lung, colon, or rectal cancer during the 2020 COVID-19 pandemic in the US.
Fan et al.
FALSE

The 2022 NCI Community Oncology Research Program (NCORP) Landscape Committee Assessment: Methods and participating practice group characteristics.
Nightingale et al.
FALSE

Disparate impact of healthcare access restrictions due to COVID-19 pandemic on breast cancer diagnosis and treatment.
Nair et al.
FALSE

Improvement of the timeliness to lung cancer diagnosis and treatment with the Rapid Access Lung Lesion Clinic in regional Australia.
Yeoh et al.
FALSE

Influence of personal and socioeconomic factors on patient’s perception and experience of clinical trial participation at rural NCI designated comprehensive cancer center.
Afzal et al.
FALSE

Evidence supporting innovative cancer care delivery model for overcoming health disparity.
Pendharkar et al.
FALSE

Time to initial review by oncology clinical pathways committees for new FDA approvals/label expansions.
Caranfa et al.
FALSE

Barriers in the identification and diagnosis of hereditary colon cancer.
Usry et al.
FALSE

International molecular tumour board: A transatlantic precision oncology collaboration.
Gallagher et al.
FALSE

Cancer co-rounds: A novel inpatient multidisciplinary oncology rounding model.
Ni et al.
FALSE

Identifying care fragmentation in the management of non-metastatic muscle-invasive bladder cancer.
Bhattacharya et al.
FALSE

Assessing the feasibility of recording smartphone-based patient-reported outcomes in patients with cancer: A pilot study.
Batra et al.
FALSE

The availability of comprehensive care of gastric cancer in developing countries: Georgian experience.
Esakia et al.
FALSE

Time to treatment in inflammatory breast cancer: Experience from a single institution.
Lopez-Aguiar et al.
FALSE

A comparison study of solid tumor, malignant hematology, and general medicine inpatient services.
Faieta et al.
FALSE

Delivery of precision oncology in advanced lung cancer: Gaps, barriers, and potential solutions.
Stein et al.
FALSE

Addressing suicidal ideation in oncology patients.
Sandow et al.
FALSE

Implementation of the novel use of an objective scoring rubric to reduce utilization of inpatient non-formulary chemotherapy.
Bhardwaj et al.
FALSE

A low-cost breast cancer prognosis tool for developing countries using AI.
González Espinoza et al.
FALSE

Guidance on modeling circulating miRNA to distinguish multiple cancer types by an observation of large-scale open data.
Hsieh et al.
FALSE

PGS-Explorer: A web-based meta-analysis tool for polygenic scores.
Lopez Pineda et al.
FALSE

A machine learning model to predict treatment initiation among new patients in a community oncology network.
He et al.
FALSE

Optimization of a deep convolution neural network (DCNN) for osteosarcoma necrosis quantification and outcome prediction.
Occidental et al.
FALSE

Intra- and peri-tumoral radiomics based on dynamic contrast-enhanced MRI for prediction of benign disease in BI-RADS 4 breast lesions: A multicentre study.
Hu et al.
FALSE

Clinicopathological characteristics, treatment patterns, and prognosis of male breast cancer: China versus the United States.
Gao et al.
FALSE

Predicting which cancer patients will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing.
Nunez et al.
FALSE

Toward automating RECIST 1.1: Improving AI new lesion detection with longitudinal image data.
Gong et al.
FALSE

Effect of an artificial intelligence–powered programmed death-ligand 1 combined positive score analyzer in urothelial cancer on inter-observer and inter-site variability.
Cho et al.
FALSE

Validating the use of machine-learning cancer staging algorithms for Medicare cost analyses.
Smith et al.
FALSE

Post-pandemic outlook of the oncology clinical trial landscape.
Pant et al.
FALSE

A comparison between a clinical decision support system and clinicians with guidelines in breast cancer.
Li et al.
FALSE

Using EHR data and machine learning approach to facilitate the identification of patients with lung cancer from a pan-cancer cohort.
Yu et al.
FALSE

Performance validation of an artificial intelligence-powered PD-L1 combined positive score analyzer in six cancer types.
Lee et al.
FALSE

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.
Sharma et al.
FALSE

Cost and time estimates for integrating a cardiovascular health application for cancer survivors in the electronic health record: Case studies from the NCORP network.
Foraker et al.
FALSE

Impact of breast density on classification of infrared spectroscopy for breath-based breast cancer screening.
Naz et al.
FALSE

Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer.
Varolgüneş et al.
FALSE

Advanced deep-learning algorithm for multi-cancer detection using cf-WGS.
Lee et al.
FALSE

HER2 in situ hybridization testing in breast cancer: Applying algorithm-assisted assessment to reduce interobserver variability in difficult cases.
Gough et al.
FALSE

Deep learning-based prediction model for predicting the tumor origin of cancers of unknown primary.
Lan et al.
FALSE

Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.
Lin et al.
FALSE

AI-driven real-time patient identification for randomized controlled trials.
Miyasato et al.
FALSE

Evaluating clinical trial inclusion/exclusion criteria from claims using generative artificial intelligence.
Mueller et al.
FALSE

Clinical factors associated with successful liquid tumor biopsy in men with prostate cancer.
Guo et al.
FALSE

Time savings from integrating discrete, genomic data into the electronic health record using the Epic Aura Network.
Posteraro et al.
FALSE

Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management.
Walsh et al.
FALSE

Morphomic phenotyping of oncologic populations.
Wang et al.
FALSE

Augmented curation of disease diagnoses and medications for patients with hepatocellular carcinoma.
Ip et al.
FALSE

Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2- advanced breast cancer (aBC).
Hathi et al.
FALSE

Exchanging genomics reports between pathology labs and medical centers using the Minimal Clinical Oncology Data Element (mCODE) FHIR implementation guide.
Terry et al.
FALSE

Analyzing free-text clinical narratives for veterans with lymphoid malignancies using natural language processing (NLP).
He et al.
FALSE

Explainable AI and machine learning algorithms to predict treatment failures for patients with cancer.
Farooq et al.
FALSE

Deep learning-based ensemble model using hematoxylin and eosin (H&E) whole slide images (WSIs) for the prediction of MET mutations in non-small cell lung cancer (NSCLC).
Choi et al.
FALSE

Performance analysis of four machine learning algorithms for the accurate prediction of metastatic disease in cutaneous squamous cell carcinoma.
Andrew et al.
FALSE

Use of an artificial intelligence (AI) –based pre-screening tool for patients with bladder cancer with fibroblast growth factor receptor (FGFR) alteration.
Shi et al.
FALSE

Association of presenting symptoms with COVID-19 disease severity and outcomes among hospitalized patients with cancer and COVID-19.
Ali et al.
FALSE

Application of natural language processing to assess the performance status documentation quality metric in patients with non–small-cell lung cancer.
Maghsoudi et al.
FALSE

Comparative assessment of manual chart review and patient-level adverse drug event identification using artificial intelligence in evaluating immunotherapy-related adverse events (irAEs).
Zitu et al.
FALSE

The identification of blood pattern for gastric cancer from routine blood tests in a territory-wide big clinical database.
Cheung et al.
FALSE

Deriving breast cancer chemotherapy patterns from real-world data.
London et al.
FALSE

Digital Trial Solutions eScreening: Software to rank patients by their predicted clinical trial eligibility using real-world data and machine learning.
Bhandari et al.
FALSE

Machine learning prediction of progression events in oncology RECIST 1.1 clinical trials.
Bowman et al.
FALSE

Impact of life-sustaining therapies on critically ill patients with cancer.
Shah et al.
FALSE

Sequential learning for pan-tumor detection of metastatic disease progression.
Green et al.
FALSE

Generating synthetic samples of chondrosarcoma histopathology with a denoising diffusion probabilistic model.
Nye et al.
FALSE

A bibliometric analysis of immuno-oncology research: Is a new global leader emerging?
Lythgoe et al.
FALSE

Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer.
Dantes et al.
FALSE

The association of sociodemographic variables with smoking prevalence in patients enrolled on clinical trials.
Presant et al.
FALSE

Growing wiser with age: Results from the ACCELERATE Fostering Age Inclusive Research Group clinical trial survey.
Williamson et al.
FALSE

Different efficacy of pembrolizumab in overall survival between Asians and non-Asians with advanced cancers: A systematic review and meta-regression analysis.
Peng et al.
FALSE

Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada.
Jafri et al.
FALSE

Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.
Espinoza Gutarra et al.
FALSE

Representativeness of patients with lung cancer in an integrated health care delivery system.
Yang et al.
FALSE

Exploring the most appropriate primary endpoint of immune checkpoint inhibitors for previously treated advanced solid cancers.
Zhu et al.
FALSE

FDA analysis of treatment-free survival in frontline advanced immuno-oncology–VEGF TKI renal cell carcinoma trials.
Chang et al.
FALSE

Phase I solid tumor trials (PHIstt) in the era of precision oncology (PO): A systematic survey.
Stockton et al.
FALSE

Standardizing the strategy in glioblastoma trials to promote success in cell and gene therapy clinical development.
Elorza et al.
FALSE

Imbalanced censoring as a bias in evaluation of randomized controlled trials: A simulation-based study.
Rumyantsev et al.
FALSE

Primary care provider perceptions of patient participation in a multi-cancer early detection trial.
Myers et al.
FALSE

Bridging the gap: FDA diversity-related postmarketing requirements.
Kormanik et al.
FALSE

Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials.
Shin et al.
FALSE

A smart clinical cohort selection system for clinical oncology research.
Basharat et al.
FALSE

Patients’ views on paying to participate in clinical trials.
Niyibizi et al.
FALSE

Design, reporting, and disparities of advanced non–small cell lung cancer phase 3 clinical trials in the era of immunotherapy.
Ayumi Miyawaki et al.
FALSE

Comparative effectiveness trial of two supportive cancer care (SCC) delivery models at 24 clinics: An ongoing cluster randomized trial.
Medrano et al.
FALSE

Use of secondary subgroup analysis of clinical trials across solid malignancies.
Alzubi et al.
FALSE

Using SMS technology to improve quality of life and symptom management in the breast cancer patient population: A feasibility study.
Fulton et al.
FALSE

The role of micro-CT for intraoperative margin assessment of breast cancer.
Vasigh et al.
FALSE

Remote evaluation of NAVIFY Oncology Hub using clinical simulation.
Halligan et al.
FALSE

Longitudinal MRI-based radiomic model to complement sentinel lymph node biopsy assessment after neoadjuvant chemotherapy in initially clinically node-positive breast cancer: A multicentre, diagnostic study.
Wang et al.
FALSE

Integrating technology to support data management abstraction of adverse events (AE) and concomitant medications (ConMed) from the electronic health record (EHR) to sponsor electronic data capture (EDC) systems using design thinking (DT) methodology.
Yuravlivker et al.
FALSE

Continuous temperature monitoring: A systematic review of literature findings.
Phillips et al.
FALSE

Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).
Rajeeve et al.
FALSE

The NETFIT trial: Smart wearable medical devices to assess the quality of life of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).
Molina Cerrillomd et al.
FALSE

A deep learning system to predict origins for cancers of unknown primary using cytological images from hydrothorax and ascites.
Tian et al.
FALSE

Decentralized elements within oncology trials: Labcorp experience.
Rami et al.
FALSE

Real-world study to evaluate the clinical performance of a computational method in precision oncology.
Dirner et al.
FALSE

Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy.
Alva Bianchi et al.
FALSE

Quality assessment of information on chimeric antigen receptor T-cell therapy on YouTube: An analysis.
Chahal et al.
FALSE

An ultra-sensitive amplicon-based NGS assay for MRD detection.
Li et al.
FALSE

Effect of a digital biopsychometric risk profile of patients with cancer on the delivery of risk-stratified personalised prehabilitation.
Halliday et al.
FALSE

CancerX: A national public-private partnership to boost innovation in the fight against cancer.
Goldsack et al.
FALSE

The CLARIFY digital decision support platform: An artificial intelligence tool for exploring multidimensional cancer data.
Torrente et al.
FALSE

Reveal irAE by analysis of 197,921 claim-based prescriptions.
Scholl et al.
FALSE

Altmetrics of breast cancer clinical trials’ subgroup analysis: A systematic review.
Odeh et al.
FALSE

Trends in Medicare utilization and reimbursement for hematology/oncology procedures.
Conic et al.
FALSE

Symptomatic adverse events in lung cancer clinical trials included in US drug labels from 2015 to 2021 to inform patient-reported outcomes.
Horodniceanu et al.
FALSE

Trends and characteristics of potentially preventable emergency department visits among patients with cancer in the US.
Alishahi Tabriz et al.
FALSE

Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions.
Strohbehn et al.
FALSE

Is there a harmonised standard to oncology trial data provision in data sharing initiatives?
Hopkins et al.
FALSE

Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.
Cimen et al.
FALSE

The evolving value assessment of cancer therapies: Principles from the cancer community.
Lee et al.
FALSE

Cancer research in vulnerable populations: A call for collaboration and sustainability from MENATC countries.
Tolba et al.
FALSE

Temporal trends of atypical drug access at an academic oncology unit: The Verona University Hospital experience.
Atsina et al.
FALSE

The impact of SARS-CoV2 Omicron variants epidemic on patients with cancer in China.
Xiao et al.
FALSE

Overall survival information and population correspondence for FDA cancer accelerated approval indications between 2006 and 2021.
Benedict et al.
FALSE

Increasing the study of novel anticancer therapies in adolescents: Facilitating adolescent inclusion in adult research.
Bucci-Rechtweg et al.
FALSE

Clinical evidence and benefit of special FDA designations in anti-cancer drugs.
Michaeli et al.
FALSE

Tumor marker testing among Medicare beneficiaries with cancer after changes in insurance coverage for testing.
Lu et al.
FALSE

Recent analysis of frequency of surrogate end points used in oncology clinical trials 2006-2022.
Chitkara et al.
FALSE

Trends in FDA approval of solid tumor therapies with analysis of single-agent vs. combination therapies.
Rai et al.
FALSE

Measuring time toxicity of systemic therapies for advanced esophageal and gastric cancers.
Agrawal et al.
FALSE

Inter-regional differences of authorship in secondary analyses of solid malignancies.
Hamadneh et al.
FALSE

Towards the improvement of breast cancer management based on EUSOMA quality indicators: Insights from a 15-year institutional experience.
Paulina et al.
FALSE

Pattern of molecular testing among US veterans with gastrointestinal cancers: A single center experience.
Shikdar et al.
FALSE

Better together: A team-based approach to improve prior authorization efficiencies and wellness in physicians and advanced care providers.
Pintova et al.
FALSE

Effect of national multidisciplinary tumor boards on diagnostic stratification and therapeutic management in cancers of unknown primary.
Jacquin et al.
FALSE

Use of adjuvant bisphosphonate therapy in breast cancer by Indian oncologists: An implementation science study.
Davis et al.
FALSE

Complicating breast cancer treatment: Reasons patients present to the ED.
Hsiung et al.
FALSE

Association of patient age and insurance status with in-hospital mortality for patients with lung cancer.
Hsiung et al.
FALSE

Effectiveness of a pharmaceutical consultation in the care of cancer patients receiving oral anti-cancer therapy: PHACON study.
Mohamed et al.
FALSE

Capability evaluation of a large regional clinical trials unit to assess growth over time.
Bell et al.
FALSE

Knowledge gaps and educational needs for common cancer therapy-related cardiovascular toxicities and related drug interactions.
Kaspari et al.
FALSE

Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.
Camejo et al.
FALSE

“You matter”: Patient reported outcomes on cancer disparities related to the COVID-19 pandemic.
Mohanna et al.
FALSE

Fertility preservation in women with cancer in Brazil: Infertility specialists' perceptions and attitudes.
Andrade et al.
FALSE

Telemedicine services in community oncology practices.
Loh et al.
FALSE

Telemedicine and cancer care in Syria: A promising initiative during the war and COVID-19 era.
Saifo et al.
FALSE

Tele-oncology implementation logic model.
Alishahi Tabriz et al.
FALSE

Cost of care associated with utilization of telehealth in clinical trials.
Gleason et al.
FALSE

Geographic disparities in Medicare telehealth utilization and access to specialized cancer care in the United States.
Goel et al.
FALSE

Barriers and facilitators to implementing the Veterans Health Administration National Teleoncology Service: A qualitative descriptive study.
King et al.
FALSE

Rural disparities in telemedicine use among cancer survivors during the COVID-19 pandemic.
Lee et al.
FALSE

Using telehealth to conduct serious illness conversations (SIC) for patients with metastatic lung cancer during the COVID-19 pandemic.
Dhawale et al.
FALSE

Current trends in oncology-related utilization of digital health (telemedicine, RPM, and asynchronous messaging).
Revol et al.
FALSE

Is the digital divide between older adults and other age groups closing? Impact of telemedicine and adherence with remote symptom monitoring in older adults compared to middle age and AYA patients with cancer.
Subbiah et al.
FALSE

Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Kotecha et al.
TRUE

Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.
Vora et al.
TRUE

PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study.
Bagley et al.
TRUE

Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.
Carpentier et al.
TRUE

Phase II trial of pembrolizumab in patients with brain metastases.
Brastianos et al.
TRUE

INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
Lobbous et al.
TRUE

Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.
Iliopoulos et al.
TRUE

Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.
Chen et al.
TRUE

Prognostic evaluation of surgical re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Karschnia et al.
TRUE

A genomic score to predict local control among patients with brain metastases managed with radiation.
Lamba et al.
TRUE

External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
Hasanov et al.
TRUE

Pretreatment clinical parameters associated with intracranial progression burden following an initial stereotactic radiosurgery course in a multi-institutional brain metastases cohort.
Huang et al.
TRUE

A radiomic-based predictive model of lung adenocarcinoma brain metastases and molecular subtypes.
Wu et al.
TRUE

Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).
Morad et al.
TRUE

Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419).
Weller et al.
TRUE

RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade gliomas in adults.
Wen et al.
TRUE

BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis.
Goplen et al.
TRUE

EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
Wick et al.
TRUE

Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.
Chen et al.
TRUE

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).
Goldlust et al.
TRUE

Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.
Tran et al.
TRUE

Short-length DNA fragments in plasma to predict clinical outcome in unresected glioblastoma patients.
Fontanilles et al.
TRUE

Association of CDK4 amplification with duration of response to bevacizumab in glioblastoma.
Villano et al.
TRUE

ctDNA detection in patients with brain metastases arising from solid tumors.
Alder et al.
TRUE

Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology.
Appel et al.
TRUE

Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: A real-world analysis of outcomes, clinical and pathologic characteristics.
Megid et al.
TRUE

A radiomics model developed from pre-metastatic brain magnetic resonance imaging to predict brain metastasis in non–small-cell lung cancer: Evidence to the seed-and-soil theory.
Chu et al.
TRUE

INTRAMET: Results of a prospective, single-arm, open-label phase II trial of intraoperative radiotherapy after resection of brain metastases.
Brehmer et al.
TRUE

Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment.
Zhou et al.
TRUE

The prognostic role of ventricular size and its dynamics in patients with leptomeningeal metastases from solid tumors.
Le Rhun et al.
TRUE

A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos et al.
TRUE

HER2-low breast cancer brain metastases: Incidence and treatment implications.
Chehade et al.
TRUE

Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC).
Honarvar et al.
TRUE

Large-scale clinicogenomic models of solid tumor CNS metastasis.
Jee et al.
TRUE

Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.
Ozair et al.
TRUE

Multi-cancer brain metastasis risk score development and validation using 220,246 whole transcriptomes and machine learning.
Abraham et al.
TRUE

Cerebrospinal fluid immunological cytokines to predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases: GASTO 1060.
Chen et al.
TRUE

Analysis of tumor progression among patients with glioma after COVID-19 infection.
Gregory et al.
TRUE

Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
Yao et al.
TRUE

An exploratory clinical trial on intra-lumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas.
Shang
TRUE

Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.
Lopez et al.
TRUE

A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.
Bagley et al.
TRUE

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
Stefan et al.
TRUE

Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
Bota et al.
TRUE

Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.
Giordano et al.
TRUE

Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011–2022.
Mrugala et al.
TRUE

Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF.
Kebir et al.
TRUE

A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.
Sanai et al.
TRUE

H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
Zhang et al.
TRUE

Phase 1 study of pritumumab in brain cancer.
Carrillo et al.
TRUE

Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
Le Rhun et al.
TRUE

New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
Mirallas et al.
TRUE

Distinct molecular features and potential therapeutic strategies for spinal cord gliomas.
Chow et al.
TRUE

Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.
Kesari et al.
TRUE

Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).
Holdhoff et al.
TRUE

Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review.
Ballo et al.
TRUE

Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
Ahluwalia et al.
TRUE

Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
Ryu et al.
TRUE

Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.
Webb et al.
TRUE

Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.
Ellingson et al.
TRUE

Ultrasensitive detection and monitoring of central nervous system tumors from plasma using personalized whole-genome ctDNA profiling.
Tran et al.
TRUE

Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).
Rhee et al.
TRUE

Vulnerability to immune therapy in BRAF- and MYB-altered pediatric gliomas.
DeCuypere et al.
TRUE

Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.
Ahluwalia et al.
TRUE

Interrogating drug action and immune response in organotypic glioma microenvironment.
Liang et al.
TRUE

A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.
Mehta et al.
TRUE

Investigation of leptomeningeal disease in high grade glioma and characterization of molecular alterations.
Shoaf et al.
TRUE

Intra-operative desorption-electrospray ionization mass-spectrometry for real-time diagnosis, margin assessment, and maximization of brain cancer resection.
Garcia et al.
TRUE

Intraoperative glioma characterization using time-resolved fluorescence spectroscopy.
Menaker et al.
TRUE

Detection of methylation-based prognostic signatures in liquid biopsy specimens from patients with meningiomas.
Herrgott et al.
TRUE

FOXC1 expression in meningiomas.
Wedemeyer et al.
TRUE

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
Tabouret et al.
TRUE

The ketogenic diet plus standard of care for adults with recently diagnosed glioblastoma: Results from a phase 1 trial.
Amaral et al.
TRUE

Osmotic blood-brain barrier disruption with mannitol followed by methotrexate, rituximab, and carboplatin in treating patients with newly diagnosed primary central nervous system lymphoma.
Ambady et al.
TRUE

Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.
Iliopoulos et al.
TRUE

MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma.
Karschnia et al.
TRUE

The clinical relevance of margins in frameless stereotactic radiosurgery for intact brain metastases: A randomized trial of 0 vs 2 mm margins.
Juloori et al.
TRUE

A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM).
Sarkaria et al.
TRUE

A first-in-human pharmacodynamic evaluation of dual polyamine depletion for patients with high-grade gliomas.
Riviere-Cazaux et al.
TRUE

Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma.
Shi et al.
TRUE

Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).
Ahluwalia et al.
TRUE

Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
Webb et al.
TRUE

Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.
Litten et al.
TRUE

Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.
Schaff et al.
TRUE

Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.
Wang et al.
FALSE

Relationship between efficacy of phase I/II drug ispinesib in medulloblastoma, molecular subtypes, and p53-mutant status.
Teo et al.
FALSE

A multicenter study of central nervous system (CNS) metastasis in EGFR-mutated advanced non–small-cell lung cancer in Thailand: CNS progression-free survival analysis.
Supavavej et al.
FALSE

Combination of regorafenib with BRAF-/MEK-inhibitors for the treatment of patients with refractory melanoma brain metastases.
Dirven et al.
FALSE

Baseline characteristics, hospital outcomes, and palliative care utilization in leptomeningeal disease: A nationwide analysis.
Turk et al.
FALSE

Impact of immunotherapy on intracranial progression-free survival in patients with advanced lung cancer and melanoma with brain metastasis: A single-center retrospective study and comparison of the pre- and post-immunotherapy era.
Kim et al.
FALSE

Outcomes with bevacizumab for radiation induced-brain necrosis.
Muminovic et al.
FALSE

Cytology-histology correlation, time to diagnosis and time to therapy when cytology is performed in addition to biopsies in malignant spinal lesions of previously unknown malignant disease.
Asemissen et al.
FALSE

A characteristic comparison of cell-free DNA isolated from plasma and cerebrospinal fluid in patients with cancer.
Zhang et al.
FALSE

Wolf in sheep’s clothing: Effect of primary lung tumor cells equipped with elevated neuron-like properties on brain metastases formation.
Xu et al.
FALSE

Pattern of failure and re-irradiation for stereotactic radiotherapy treated brain metastases from non-small cell lung cancer (NSCLC).
Xu et al.
FALSE

Predicting survival and prognosis of postoperative breast cancer brain metastasis: A population-based retrospective analysis.
Yan et al.
FALSE

Safety and efficacy of silibinin in patients with brain metastases after stereotactc radiosurgery: SUSTAIN trial.
Desideri et al.
FALSE

Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis.
Farhat et al.
FALSE

Rates of hematologic toxicity in WBRT vs SRS.
McCalla et al.
FALSE

Brain metastases and anticoagulant therapy: Safety and outcome in a real-world study.
Fancelli et al.
FALSE

Combination beta-adrenergic blockade and immunotherapy for the treatment of primary and metastatic brain cancer.
Lorrey et al.
FALSE

Survival in patients with brain metastasis secondary to breast cancer from Saudi Arabia.
Abusanad et al.
FALSE

A demographic and socioeconomic analysis of risk factors in meningeal melanomatosis.
Jacobs et al.
FALSE

Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
Mantica et al.
FALSE

Ivosidenib off-label use for IDH mutant gliomas: The MD Anderson Cancer Center real life experience.
Lam et al.
FALSE

Homologous recombination-related (HRR) gene mutations in patients with glioma and their relevance to genomic characteristics, tumor mutation burden (TMB), and prognosis.
Zheng et al.
FALSE

Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed and resected glioblastoma: Pazoglio trial.
Saada-Bouzid et al.
FALSE

Results from the first step of a phase II study of vaccination with autologous dendritic cells loaded with autologous tumour homogenate in glioblastoma.
Ridolfi et al.
FALSE

Prevalence and characteristics analysis of CDKN2A/B deletion in glioma.
Zhuang et al.
FALSE

Use of proton pump inhibitors (PPI) in glioblastoma (GBM) and relationship to overall survival in a national real-world evidence (RWE) database.
Castro et al.
FALSE

The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis.
Li et al.
FALSE

Feasibility and utility of the custom RNA-seq for the identification of therapeutic targets and diagnostic biomarkers in glioma.
Takahashi et al.
FALSE

Tumor treating fields (TTFields) therapy skin safety and prevention strategy using a fractionated schema protocol (3-days on/1-day off), effect on skin adverse events.
Gatson et al.
FALSE

The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study.
Sun et al.
FALSE

Incidence of non-canonical IDH mutations and IDH co-mutations in a multicenter prospective study of patients with glioma.
Cabezas-Camarero et al.
FALSE

A multicenter retrospective study of timing of chemoradiation in high-risk, grade 2, IDH-mutated astrocytoma.
McGranahan et al.
FALSE

When to treat: A multicenter retrospective study of timing of radiation therapy in 1p19q co-deleted, IDH mutated oligodendrogliomas.
Densmore et al.
FALSE

Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy.
Lai et al.
FALSE

Genomic landscape of CDK6 amplification and its potential prognostic value in adult-type diffuse gliomas.
Yuan et al.
FALSE

Anlotinib for patients with newly diagnosed glioblastoma with unmethylated MGMT promoter: An open-label, single-center, phase 2 clinical trial.
Yang et al.
FALSE

Modulating MDSCs by HF1K16: A mono-therapy phase Ia study examining safety and preliminary efficacy in patients with refractory and metastatic cancer.
Xu et al.
FALSE

Mutation profiling of gliomas based on sex, age, and family history.
Fan et al.
FALSE

Evolution of genomic profiles in primary and recurrent brain gliomas.
Lizcova et al.
FALSE

Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.
Wu et al.
FALSE

Incidence of thromboembolic events in glioblastoma multiforme: The first Middle Eastern study risk stratifying patients from this region.
Hassan et al.
FALSE

Overcoming temozolomide resistance in glioblastoma through selective inhibition of phosphoinositide 3-kinase catalytic subunit.
Hutchings et al.
FALSE

Identification of SNVs via targeted comprehensive genome profiling in patients with brain cancer.
Shafi et al.
FALSE

A multicenter retrospective study of the duration of adjuvant temozolomide in IDH-mutant gliomas.
Densmore et al.
FALSE

Engineering of mesenchymal stem cells to express cytosine deaminase gene with a selecable marker gene.
Suh-Kim et al.
FALSE

PIK3CB as a potential target to regulate chemosensitivity in glioblastoma.
Beck et al.
FALSE

Xenonucleic acid technology in high-sensitivity IDH1/2 mutation detection for glioma molecular profiling.
Yang et al.
FALSE

Concurrent chemoradiation and adjuvant chemotherapy in newly diagnosed glioblastoma multiforme: A retrospective analysis of single center.
Iruarrizaga et al.
FALSE

Glioblastoma in elderly patients: A retrospective analysis of survival and response based on molecular and clinical characteristics—Experience in our centre.
Iza et al.
FALSE

Difference in presentation of pediatric and adult ependymoma: An NCDB analysis.
Tuman et al.
FALSE

A preclinical study to evaluate the combination of azeliragon, an inhibitor of the receptor for advanced glycation endproducts (RAGE), with radiation therapy as a potential treatment of glioblastoma.
Ghosh et al.
FALSE

Overall survival in patients with recurrent glioblastomas with combination chemotherapy and tumor treating fields (TTF).
Nahm et al.
FALSE

Genomic analysis in NF2 meningiomas: Does co-mutation suggest new subgroups?
Xi et al.
FALSE

Hints for reclassification of meningiomas based on the fifth edition of WHO CNS.
Cheng et al.
FALSE

Mutational landscape of intracranial germ cell tumors.
Wang et al.
FALSE

Outcomes of stereotactic radiosurgery in central nervous system lymphoma: A single institution experience.
Azad et al.
FALSE

Ventriculoperitoneal shunt and performance status as prognostic factors of overall survival in a retrospective cohort of 78 adult patients with medulloblastoma.
Trejo-Rosales et al.
FALSE

Human epidermal growth factor receptor 2/3 (HER2/HER3) expression in higher-grade meningioma.
Mair et al.
FALSE

Medullomyoblastoma: A study of demographic and socioeconomic factors.
Patel et al.
FALSE

Real world data about stupp platform in the treatment of glioblastoma in a single center of Colombia.
Cantor Rizo et al.
FALSE

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).
Melero Bermejo et al.
TRUE

Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.
Dumbrava et al.
TRUE

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
Gandara et al.
TRUE

Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
Othus et al.
TRUE

Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.
Chmielowski et al.
TRUE

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.
Feng et al.
TRUE

Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
Safran et al.
TRUE

Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.
Ruiz-Esteves et al.
TRUE

First-line treatment of fecal microbiota transplantation for immune-mediated colitis.
Wang et al.
TRUE

Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.
Siddiqui et al.
TRUE

Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study.
Rodriguez-Abreu et al.
TRUE

Targeting CD47 in lymphoid malignancies with CAR T cells.
Boardman et al.
TRUE

Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.
Barnet et al.
TRUE

Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.
Spiliopoulou et al.
TRUE

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.
Dall'Olio et al.
TRUE

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
Locke et al.
TRUE

CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.
Mackensen et al.
TRUE

A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
Schlechter et al.
TRUE

A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.
Ji et al.
TRUE

Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
Montazeri et al.
TRUE

The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures.
Lucas et al.
TRUE

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).
Winer et al.
TRUE

A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
Barve et al.
TRUE

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
Daud et al.
TRUE

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
Shu et al.
TRUE

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.
Koshy et al.
TRUE

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.
O'Reilly et al.
TRUE

Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.
Carneiro et al.
TRUE

A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.
Xue et al.
TRUE

A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
Tolcher et al.
TRUE

A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
Wang et al.
TRUE

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.
El-Khoueiry et al.
TRUE

Clinical development of the bispecific PSMAxCD3 antibody CC-1.
Hackenbruch et al.
TRUE

Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors.
Cheng et al.
TRUE

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.
Guo et al.
TRUE

Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.
Sharma et al.
TRUE

A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.
Li et al.
TRUE

Peri Cruiser CAR-T: An innovative platform to reduce on-target off-tumor toxicity of CAR-T therapy.
zhang et al.
TRUE

Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy.
Haerizadeh et al.
TRUE

A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.
Gutierrez et al.
TRUE

Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype.
Yuhas et al.
TRUE

AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.
Hoffmann et al.
TRUE

A pilot study of lymphodepletion intensity for PBMC-derived, neoantigen-specific CD8+ T cells (Neo-Ts) therapy in patients with advanced solid tumors.
Li et al.
TRUE

A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood–derived natural killer cell immunotherapy for pediatric solid tumor malignancies.
Khazal et al.
TRUE

Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
Morelli et al.
TRUE

Effect of the killing style of individual CAR T cells on the clinicopathological behavior of therapeutic products in the clinic.
Gad et al.
TRUE

Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
Nadal et al.
TRUE

Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap.
Conley et al.
TRUE

Harnessing the power of tumor-infiltrating lymphocytes: A first-in-human study of GT201 as monotherapy in advanced solid tumors.
Liu et al.
TRUE

MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.
Barve et al.
TRUE

Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.
Kirkey et al.
TRUE

Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors.
Chattopadhyay et al.
TRUE

Preclinical testing of FOLR1-CAR T cells against osteosarcoma (OS).
Choe et al.
TRUE

A novel platform to enrich for tumor-specific T cells in non–small-cell lung cancer.
Hachey et al.
TRUE

A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
Shaked et al.
TRUE

The exploratory case-control study on prediction of immune checkpoint inhibitor-induced thyroiditis by human leukocyte antigen types.
Natori et al.
TRUE

C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.
Karol et al.
TRUE

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).
Karlovich et al.
TRUE

Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.
Barnett et al.
TRUE

Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
Landre et al.
TRUE

Pan-cancer analysis of natural killer (NK) cell infiltration in human malignancies: Molecular features and clinical implications.
Zorko et al.
TRUE

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
Nardo et al.
TRUE

The prognostic ability of immune scoring system Immunoscore in patients with localized colon cancer: A systematic review and meta-analysis.
Padayao et al.
TRUE

Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding.
Ottensmeier et al.
TRUE

Investigation of synthetic lethality gene pairs in the DNA damage response pathway in response to immunotherapy in pan-cancer.
Huang et al.
TRUE

VirMAP for cancer: Characterization of the intratumoral virome in virally associated cancers and a resource for investigators.
Seo et al.
TRUE

A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).
Saltos et al.
TRUE

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.
Zhou et al.
TRUE

Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy.
Zhou et al.
TRUE

Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).
Patel et al.
TRUE

T cell engager (TCE) score in patients treated with bispecific CD3 TCE in phase I clinical trials.
Herbel et al.
TRUE

A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.
Desai et al.
TRUE

IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
Coupe et al.
TRUE

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.
Mao et al.
TRUE

Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.
Liu et al.
TRUE

Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC).
Kim et al.
TRUE

Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.
Rajasekaran et al.
TRUE

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.
Fu et al.
TRUE

SpliceIO: A robust platform for the discovery and validation of splicing-derived neoantigens.
Arun et al.
TRUE

Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
Ahlstrom et al.
TRUE

Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists.
Wang et al.
TRUE

Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
Gomez-Roca et al.
TRUE

Relationship between tumor microenvironment (TME)-based histomic TGFβ signature (TGFBs), stromal fibroblast recruitment, and exclusion of immune cells as immunotherapy resistance mechanisms.
Park et al.
TRUE

Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease.
Soto et al.
TRUE

Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.
Chakraborty et al.
TRUE

Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.
Du et al.
TRUE

Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.
Geurts et al.
TRUE

Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.
De La Fouchardiere et al.
TRUE

Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network.
Natesan et al.
TRUE

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
Korpics et al.
TRUE

Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.
Kansara et al.
TRUE

Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety.
Alberti et al.
TRUE

Retrospective analysis on association of ABO blood type and immune checkpoint inhibitor response.
Batra et al.
TRUE

Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).
Le Tourneau et al.
TRUE

Phase 1B study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD) from epithelial carcinomas: Final results and molecular analyses with single cell RNA sequencing.
Pina et al.
TRUE

A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
Hamid et al.
TRUE

IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).
Song et al.
TRUE

A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.
Tan et al.
TRUE

Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).
Genta et al.
TRUE

PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) regimen in advanced refractory solid tumors: A prospective, multicenter, single-arm clinical trial.
Xing et al.
TRUE

Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.
De La Fouchardiere et al.
TRUE

The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.
Chiang et al.
TRUE

Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.
Yuan et al.
TRUE

Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with early-stage, triple-negative breast cancer.
Venkatesh et al.
TRUE

The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer.
Gandini et al.
TRUE

A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.
Fojo et al.
TRUE

DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC).
Keilholz et al.
TRUE

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
Spigel et al.
TRUE

High transferrin receptor expression marks tumors with increased immune-effector infiltration and expression of targetable checkpoint molecules: Results of a multi-cancer analysis in solid tumors.
Trabolsi et al.
TRUE

Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
Fujiwara et al.
TRUE

Distributional range of tumor mutational burden (TMB) across multiple cancer types emphasizing the importance of different cutoff values in different tumor types for clinical interpretation: A consensus statement from the SEQUOIA consortium.
Swat et al.
TRUE

Quantitative 3D assessment of the lung cancer microenvironment using multi-resolution open-top light-sheet microscopy.
Stoltzfus et al.
TRUE

Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.
Wang et al.
TRUE

Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).
Wang et al.
TRUE

STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations.
Iglesia et al.
TRUE

The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.
Khushman et al.
TRUE

Artificial intelligence (AI) –powered spatial analysis of macrophages in tumor microenvironment and its association with interferon-gamma (IFNG) signature and immune phenotype (IP) in pan-cancer dataset.
Oum et al.
TRUE

Spatial distribution of B cells and lymphocyte clusters for the treatment of non-small cell lung cancer.
Ramos et al.
TRUE

Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer.
Costantini et al.
TRUE

Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies.
Hwang et al.
TRUE

Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.
Brockstedt et al.
TRUE

Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.
Kaufman et al.
TRUE

Tracking plasticity along with proliferation and immune evasion using FOXC1, MKI67 and PDL1 for prediction of therapeutic response and risk for hyperprogressive disease with PD1/PDL1 inhibitors in advanced/metastatic cancers: Pan-tumor validation in clinical trial and real-world cohorts.
Ray et al.
TRUE

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).
Floudas et al.
TRUE

Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
Perales et al.
TRUE

Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.
Le Tourneau et al.
TRUE

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
Saeed et al.
TRUE

A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
Lee et al.
TRUE

Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers.
Charifa et al.
TRUE

Multisystem immune-related adverse events from dual agent immunotherapy use.
Li et al.
TRUE

Cardiotoxicity surveillance among patients with cancer treated with immunotherapy.
Fagundes et al.
TRUE

Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.
Syed et al.
TRUE

A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Barker et al.
TRUE

A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.
Li et al.
TRUE

The incidence of thyroid-related adverse events in solid tumors receiving immune checkpoint blockade with curative intent: A meta-analysis.
Zhou et al.
TRUE

The study of immune-related adverse events in a community-based centre.
Cautha et al.
TRUE

Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition.
Verheijden et al.
TRUE

Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).
Kapiris et al.
TRUE

Effect of fecal transplantation on patients’ reported outcome after immune checkpoint inhibitor colitis.
Wang et al.
TRUE

Sex differences in burden of adverse events in patients receiving immunotherapy.
Miceli et al.
TRUE

Timing of immunotherapy-induced pneumonitis in patients with primary lung malignancy.
Winter et al.
TRUE

Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
Grover et al.
TRUE

Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.
Elias et al.
TRUE

Immune related adverse events (irAEs) in patients with solid tumors and advanced chronic kidney disease (CKD) receiving checkpoint inhibitors (CPIs).
Kaakour et al.
TRUE

Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration.
Alkadimi et al.
TRUE

Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).
Durbin et al.
TRUE

Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.
Nassar et al.
TRUE

Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.
Phan et al.
TRUE

Incidence and characterization of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors.
Hunting et al.
TRUE

A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
Lu et al.
TRUE

Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.
Elkrief et al.
TRUE

Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.
Abu-Sbeih et al.
TRUE

Immune-related adrenal insufficiency: A single center retrospective analysis.
Polshina et al.
TRUE

Impact of obesity on the risk of immune-related adverse events (irAEs) among patients receiving immune-checkpoint inhibitors (ICI) treatment: A retrospective cohort study.
Elsaid et al.
TRUE

Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors.
Cascetta et al.
TRUE

Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.
Balaji et al.
TRUE

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.
Liu
TRUE

A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
Rodon Ahnert et al.
TRUE

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
Villalona-Calero et al.
TRUE

A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
Abdou et al.
TRUE

Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors.
Weinberg et al.
TRUE

GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
Wang et al.
TRUE

A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors.
Yap et al.
TRUE

A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors.
Papadopoulos et al.
TRUE

Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.
Sullivan et al.
TRUE

A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors.
Knecht et al.
TRUE

A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).
Ellis et al.
TRUE

High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.
Sartore-Bianchi et al.
TRUE

Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.
Powderly et al.
TRUE

Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
Jain et al.
TRUE

A phase I trial of diphencyprone for cutaneous neurofibromas in adult patients with neurofibromatosis type 1.
Poplausky et al.
TRUE

A prospective observational study investigating the impact of immune checkpoint inhibitors for cancer on fertility in males and females of child-bearing age (immuno-fertility).
Keogh et al.
TRUE

Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.
Reynolds et al.
TRUE

Pharmacokinetics and pharmacodynamics of proposed denosumab biosimilar and reference denosumab in healthy male subjects.
Vogg et al.
FALSE

Characterizing the tumor selectivity of oncolytic adenovirus ICVB-1042: Analysis of S-phase induction, viral replication, and cytolytic activity in human primary normal cell types.
Pokrass et al.
FALSE

First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.
Qin et al.
FALSE

Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers.
Fan et al.
FALSE

A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results.
Frentzas et al.
FALSE

Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.
Cervantes et al.
FALSE

Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer.
Cheng et al.
FALSE

Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors.
Xue et al.
FALSE

A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas.
Zhang et al.
FALSE

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.
Mark-Adjeli et al.
FALSE

Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer.
Kim et al.
FALSE

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling.
Park et al.
FALSE

Pre-clinical efficacy of the first glyco-humanized oncolytic polyclonal antibody (XON7) in onco-hematology.
Ciron et al.
FALSE

In vivo anti-tumor effects of XON7 in association with ICIs.
Ciron et al.
FALSE

An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers.
O et al.
FALSE

Preclinical characterization of a novel anti-CD39/TGFβ-trap bispecific antibody that aims to modulate tumor microenvironment.
Lu et al.
FALSE

Hypophosphatemia and thrombocytopenia: A retrospective chart review to identify markers for prediction of CRS and ICANS in CAR T-cell therapy.
Barker et al.
FALSE

Investigator-initiated phase 1 clinical trial of synthetic TIL: Autologous peripheral T cells engineered with polyclonal TIL-derived TCRs.
Cheng et al.
FALSE

Tolerability and response of palliative radiotherapy in patients receiving tumor-infiltrating lymphocyte therapy.
Rogers et al.
FALSE

Weight loss (WL) as a predictive factor for immune oncology (IO).
Fugere et al.
FALSE

WTX212, an erythrocyte-anti-PD1 antibody conjugate, to demonstrate anti-tumor activities in tumor models and patients with cancer with acquired resistance to immunotherapy.
Xiaoqian et al.
FALSE

"Armed" CEA CAR-T with a SIRPγ-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer.
Zhao et al.
FALSE

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.
D'Angelo et al.
FALSE

Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials.
Nardo et al.
FALSE

Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Xu et al.
FALSE

The practice of thyroid monitoring in patients treated with lenalidomide for hematological malignancies: A single-center retrospective analysis.
lakra et al.
FALSE

Innovative platforms for development of TCR-T cell therapies against novel tumor targets: Triple negative breast cancer.
Abbott et al.
FALSE

Pressurized intra-peritoneal aerosol as a delivery system for macrophage reprogramming cellular therapy in conjunction with chemotherapy for the treatment of advanced peritoneal malignancies.
Ben-Yaacov et al.
FALSE

Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer.
Roy et al.
FALSE

VHH-based chimeric antigen receptor T cells against CD70 to eliminate primary and re-challenge renal cell carcinoma tumors in preclinical study.
Jiang et al.
FALSE

Serum vitamin B12 levels and response to immunotherapy.
Turgeman et al.
FALSE

Safety and efficacy of loading-dose thymosin α1 in patients with advanced and refractory solid tumors with lower absolute T lymphocyte.
Xu et al.
FALSE

Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple negative breast cancer (TNBC) and non-TNBC.
Smit et al.
FALSE

Extracellular vesicles budding from stromal macrophages from the blood circulating in patients with metastatic non-small cell lung cancer to predict clinical outcomes.
Moran et al.
FALSE

Correlation of micronuclei formation in circulating stromal cells with their PD-L1 expression and predicts for poorer clinical outcomes in metastatic breast cancer.
Kasabwala et al.
FALSE

Relationship of platelet-to-lymphocyte ratio with tumor immune microenvironment and efficacy of anti-PD-1 combined with neoadjuvant chemotherapy in muscle invasive bladder cancer.
Hu et al.
FALSE

Dynamic monitoring of ctDNA to predict response to immunotherapy plus chemotherapy in BTC.
Liu et al.
FALSE

Prognostic impact of baseline circulating extracellular vesicles (BCEVs) in the setting of patients with advanced non-small cell lung cancer (ANSCLC) eligible for first line treatment with osimertinib.
Gristina et al.
FALSE

Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Weiskittel et al.
FALSE

The clinical impact of soluble natural killer cell group 2-member D (NKG2D) receptor ligands on tumor tumorigenicity and anti-tumor immunity.
Serritella et al.
FALSE

Correlation between MSI, TMB, and TGFBR2 gene mutation in solid tumors.
Fan et al.
FALSE

Find: Immunomodulation after a fasting mimicking diet analyzed by Nanostring and multispectral flowcytometry in healthy volunteers: A pilot study.
de Gruil et al.
FALSE

Implications of GITR expression profile for precision immunotherapeutics.
Moussa et al.
FALSE

Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer.
Ovcaricek et al.
FALSE

PD-L1 in head and neck cancers: Audit for tertiary care centre in India.
Peelay et al.
FALSE

Upgrading the non-gene-editing, allogeneic ThisCART platform for extending persistence in vivo.
Liu et al.
FALSE

Efficacy and safety study of a novel alpha-fetoprotein (AFP)-maytansine conjugate in an ovarian xenograft model.
Sherman et al.
FALSE

A multi-targeted T-cell engagement of PD1-resistant colorectal cancer cells via delivery of glycopeptide conjugates.
Adesokan et al.
FALSE

Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours.
Krell et al.
FALSE

Outcomes of peritoneal metastases in mismatch repair deficient (dMMR) cancers treated with immune checkpoint inhibitors and variables associated with response.
Mosalem et al.
FALSE

A study to evaluate the safety, tolerability, and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1–selected non–small-cell lung cancer (NSCLC): Updated efficacy and safety results.
Wu et al.
FALSE

Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.
Liu et al.
FALSE

A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.
Becerra et al.
FALSE

Effect of machine learning-based integration develops M2 macrophage-activation genes signature on outcomes in nasopharyngeal carcinoma.
Huang et al.
FALSE

Immunomodulatory AVM0703 enhances R-CHOP anti-lymphoma effect with reduced toxicity: Immune-resistant, aggressive A20 lymphoma model.
Deisher et al.
FALSE

First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.
Nelson et al.
FALSE

Immunomodulatory AVM0703 lacks the association between anti-cancer activity and immune-mediated side-effects of the checkpoint Inhibitors.
Mittal et al.
FALSE

Pharmacokinetics (PK) of epacadostat in combination with sirolimus in advanced malignancy.
Huang et al.
FALSE

T cell redirecting and TLR7/8 agonist encapsulated liposomes targeting HER2+ tumors: Preclinical efficacy, pharmacokinetics and safety evaluations.
Zheng et al.
FALSE

A phase I/II trial of NOX66 in combination with nivolumab in patients (pts) with advanced cancer.
de Souza et al.
FALSE

A functional immuno-oncology (IO) assay to assess patient response to immunotherapeutics in metastatic disease.
Hsu et al.
FALSE

Extracorporeal removal of soluble tumor necrosis factor receptors for the treatment of advanced refractory solid tumors.
Manax et al.
FALSE

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.
Peng et al.
FALSE

The first cold atmospheric plasma phase I clinical trial for the treatment of advanced solid tumors: A novel 4th treatment arm for cancer.
Canady et al.
FALSE

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.
Starodub et al.
FALSE

COVID-19 induced remission of biliary and renal cell carcinomas.
Tan
FALSE

Are severe immune-related adverse events more likely in patients with pre-existing autoimmune disease?
Isaacs et al.
FALSE

Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.
Pinato et al.
FALSE

Safety and clinical efficacy of sintilimab in pediatric patients with advanced or recurrent malignancies in a phase I study.
Que et al.
FALSE

The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments.
De Giglio et al.
FALSE

Role of immune checkpoint inhibitors in PDL1-negative, low TMB, stable MSI metastatic solid tumours: Single centre study.
Moorthy et al.
FALSE

The association between body mass index and immune checkpoint inhibitors outcomes in melanoma: Results from real-world data.
Elantably et al.
FALSE

Evaluation of immune related adverse events following extended interval dosing of immune checkpoint inhibitors.
Deviley et al.
FALSE

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.
Han et al.
FALSE

Association of neutrophil/lymphocyte ratio and IFN-γ with clinical response and survival in patients with MSS/pMMR mCRC treated with anti-PD-1 and VEGF inhibitors.
Liu et al.
FALSE

Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma.
Pan et al.
FALSE

Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela.
Borga et al.
FALSE

A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.
Xu et al.
FALSE

Effect of FAPα-expressing tumor cell vaccine with PD-1 mAb on its efficacy in mice colorectal cancer model.
Jia et al.
FALSE

Doxorubicin to enhance the abscopal effect depending on tumor cell mitochondrial DNA and cGAS/STING.
Wang et al.
FALSE

Atezolizumab plus bevacizumab combined with transarterial embolization plus hepatic arterial infusion-chemotherapy for unresectable hepatocellular carcinoma with a diameter larger than 8 cm: A retrospective study.
Guo et al.
FALSE

Immune checkpoint inhibitors-associated periodontitis: A propensity score-matched retrospective cohort study.
Hsia et al.
FALSE

Outcomes for immuno-chemotherapy based treatment in patients with poorly differentiated extrapulmonary neuroendocrine carcinoma.
Kumar et al.
FALSE

Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.
Fu et al.
FALSE

Peripheral immunological response to treatment with a novel bifunctional anti-PD-L1/TGFβRII agent in recurrent/metastatic nasopharyngeal carcinoma.
Kam et al.
FALSE

Neoadjuvant tislelizumab, a PD-1 mAb plus nab-paclitaxel (nab-P) followed by tislelizumab plus epirubicin/cyclophosphamide (EC) for triple-negative breast cancers (TNBC): Interim analysis of clinical response in a phase 2 TREND trial.
Xu et al.
FALSE

Effect of immunotherapy combined with chemotherapy with or without thoracic radiotherapy on markers of myocardial injury in patients with thoracic tumors.
Zhu et al.
FALSE

Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma.
Jiang et al.
FALSE

A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).
Somaiah et al.
FALSE

TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study.
Mu et al.
FALSE

Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer.
Niu et al.
FALSE

Atypical response patterns in Chinese patients with cancer with immune checkpoint blockade.
Cui et al.
FALSE

Clinical and pathological description of patients with triple negative breast cancer undergoing neoadjuvant chemotherapy and pembrolizumab in a Brazilian cancer center.
Sousa et al.
FALSE

Effect of trametinib and anti-PD-1 combo on tumor growth and survival of KRAS-mutant lung cancer by ID1 downregulation.
Puyalto Calvo et al.
FALSE

Meta-analysis of gastrointestinal adverse effects in patients with non-small cell lung cancer treated with a combination therapy of pembrolizumab and chemotherapy versus chemotherapy alone.
Khosla et al.
FALSE

TIGIT transcriptomic expression and high levels of multiple checkpoints across diverse cancers.
Adashek et al.
FALSE

Correlation between biomarkers and treatment outcomes in diverse cancers: A meta-analysis of phase I and II immunotherapy clinical trials.
Fountzilas et al.
FALSE

Prognostic value of human leukocyte antigen G (HLA-G) expression in solid tumors: A systematic review and meta-analysis.
Bartolome et al.
FALSE

PD-L1 expression in Chinese patients with solid tumor and its correlation with gene alternations.
Zhang et al.
FALSE

BTLA transcriptomic expression correlates with high levels of PD-1, PD-L2, and CTLA-4 checkpoints and with its ligand, HVEM, across diverse solid cancers.
Choi et al.
FALSE

Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathologic study.
Shold et al.
FALSE

Evaluation of immunotherapy response score (IRS) for predicting pembrolizumab (pembro) clinical benefit in patients (pts) with advanced solid tumors.
Thomas et al.
FALSE

Quantitative analysis of MMR deficiency in dMMR/MSI high CRC and levels of instability: Implications for ICI therapy of dMMR tumors.
Staninova Stojovska et al.
FALSE

Tissue cadherin 17 (CDH17): A favorable prognostic determinant of colorectal cancer using digital image analysis.
Ng et al.
FALSE

Artificial intelligence–based biomarkers of response to immunotherapy in patients with non–small-cell lung cancer considering previous lines of treatment.
Iriso et al.
FALSE

Precision immuno-oncology (IO) ISH/IF multiplex panel: Spatial detection of cytokines and IO biomarkers.
Patel et al.
FALSE

Quantitation of the PD-1/PD-L1 axis in non-small cell lung cancer by immuno-multiple reaction monitoring.
Lacasse et al.
FALSE

Correlation of fragmented pattern of tumor mass captured by artificial intelligence (AI)-powered whole-slide image (WSI) analysis with biased fibroblast expansion over tumor growth and distinct mutational signatures.
Kim et al.
FALSE

A pilot trial of personalized neoantigen pulsed autologous dendritic cell vaccine as adjuvant treatment in hepatocellular carcinoma.
Wu et al.
FALSE

A first-in-human phase I trial of a novel peptide vaccine LabVax 3(22)-23 and adjuvant GM-CSF sargramostim in patients with refractory labyrinthin-expressing adenocarcinomas.
Li et al.
FALSE

Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models.
You et al.
FALSE

Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.
Overman et al.
FALSE

An exploratory trial of a novel R-ISV-RO technique in the treatment of advanced solid tumors.
Li et al.
FALSE

Adverse events (AEs) of immune checkpoint therapy (ICT) combined with vascular endothelial growth factor inhibitors (VEGFi) vs. ICT alone: A pooled meta-analysis of 1735 patients.
Kovalenko et al.
FALSE

SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study.
Wang et al.
FALSE

Relationship between ICOS and ICOS ligand RNA expression patterns with tumor type, tumor mutational burden, and clinically relevant immune checkpoints.
Nikanjam et al.
FALSE

IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study.
Wang et al.
FALSE

Safety, tolerability, and pharmacokinetics of HLX26 (an anti-LAG3 antibody) in patients with advanced or metastatic solid tumors or lymphomas.
Liu et al.
FALSE

The timing of statin initiation on survival outcomes of cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study.
See et al.
FALSE

A phase Ia trial to evaluate the safety and efficacy of HB0030, an anti-TIGIT antibody, in patients with advanced solid tumors: Preliminary results.
Zhou et al.
FALSE

Factors associated with myocarditis in patients with cancer treated with immune checkpoint inhibitors.
Izadi et al.
FALSE

Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.
Olusoji et al.
FALSE

Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.
Valerin et al.
FALSE

Preliminary efficacy and safety of camrelizumab plus metronomic oral vinorelbine as first-line therapy for people aged 70 and above with advanced non-small cell lung cancer (NSCLC) from a phase II trial.
Li et al.
FALSE

Association of immune checkpoint inhibitors (ICI) and venous thromboembolism (VTE) in non–small-cell lung cancer (NSCLC): A single healthcare system experience.
Arivazhagan et al.
FALSE

Incidence of venous thromboembolism with immune checkpoint inhibitors in a community setting: A single-center retrospective study.
Kumar et al.
FALSE

Clostridium difficile infection and immune mediated diarrhea and colitis in patients with cancer on immune checkpoint inhibitors.
Khalid et al.
FALSE

Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: A pharmacovigilance study from FDA Database.
Neupane et al.
FALSE

Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
Davar et al.
FALSE

Efficacy of checkpoint inhibitors in hospitalized patients with cancer.
Medik et al.
FALSE

Real-time customized precision combination therapies based on potential actionability and coalterations to provide therapeutic opportunities for hyperprogressive disease after immune checkpoint inhibitor therapy.
Wang et al.
FALSE

Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study.
Niu et al.
FALSE

Chronic opioid use and effects on survival in patients with advanced stage malignancies treated with immunotherapy.
Weinfeld et al.
FALSE

Tumor immunity portrait: An AI-driven molecular predictor combining tumor microenvironment and tumor mutational burden for immune checkpoint inhibitor response prediction.
Shilo et al.
FALSE

Do corticosteroids affect immunotherapy efficacy in malignancy? A systematic review.
Byron et al.
FALSE

Development of a novel ddPCR assay for nonclinical and clinical pharmacokinetic characterization of ICVB-1042.
Rice et al.
FALSE

Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration.
Merkin et al.
FALSE

Integrated survival analysis.
Chiu et al.
FALSE

Clinical outcomes in patients with metastatic non-small cell lung cancer and head and neck squamous cell cancer treated with immune checkpoint inhibitors according to COVID-19 vaccination status.
Khaddour et al.
FALSE

Immune-mediated adverse event management at a tertiary care cancer center.
Shatila et al.
FALSE

Plasma proteomics approach to distinguishing PD-1 inhibitor-associated myocarditis from acute myocardial infarction in patients receiving PD-1 inhibitors treatment: A clinical and preclinical study.
Luo et al.
FALSE

Influence of CD47 on CD8+ T-cell and tumor prognosis based on pan-cancer analysis.
Liang et al.
FALSE

Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.
Zhou et al.
FALSE

Replacement of anti-PD-1 drugs with prolgolimab during treatment, safety and efficacy.
Andabekov et al.
FALSE

Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).
Maier et al.
FALSE

Immune-related hypophysitis: An analysis of a heterogeneous entity.
Nanah et al.
FALSE

A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.
Thomsen et al.
FALSE

Importance of patient related outcomes in diagnosing fatigue related to immunotherapy treatment in patients with lung cancer: A real life study.
Almodovar et al.
FALSE

Microbiome, socioeconomic status (SES), fiber intake, and response to checkpoint inhibitor therapy in patients with non-small cell lung cancer (NSCLC): A pilot study.
Patel et al.
FALSE

Management of immune related adverse events through electronic multidisciplinary consultation: Five years of experience from Peking Union Medical College Hospital.
Liu et al.
FALSE

Retrospective analysis of digital biomarker predictability of immune checkpoint inhibitor therapy outcomes in patients with NSCLC.
Abousaud et al.
FALSE

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
Zhang et al.
TRUE

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.
Morgensztern et al.
TRUE

Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.
Wagner et al.
TRUE

Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.
Patel et al.
TRUE

Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.
Cousin et al.
TRUE

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
De La Fuente et al.
TRUE

A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.
Zhou et al.
TRUE

A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).
Monga et al.
TRUE

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
Yap et al.
TRUE

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
Yap et al.
TRUE

FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
Zhimin et al.
TRUE

Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
Gelderblom et al.
TRUE

Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
Taniguchi et al.
TRUE

Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.
Sharma et al.
TRUE

First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.
Wang et al.
TRUE

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.
Wang et al.
TRUE

Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
Tsimberidou et al.
TRUE

Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
Piha-Paul et al.
TRUE

A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
Drilon et al.
TRUE

A phase II study of tinostamustine in patients (pts) with advanced solid tumours.
Tinker et al.
TRUE

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
Ko et al.
TRUE

Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
Moore et al.
TRUE

SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
Hollebecque et al.
TRUE

Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Liu et al.
TRUE

A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.
Thomas et al.
TRUE

Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.
Carneiro et al.
TRUE

A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.
Palles et al.
TRUE

A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.
Ma et al.
TRUE

Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials.
Stires et al.
TRUE

Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.
Yeung et al.
TRUE

First report of ELUCIDATOR study: A prospective observational multicenter study on resistance mechanisms in patients with early disease progression during osimertinib.
Mizumori et al.
TRUE

Diagnostic value of hPG80, as a new multi-cancer blood biomarker, in 16 different cancers: Results of the ONCOPRO prospective study.
You et al.
TRUE

First report of tumor-informed circulating tumor DNA in fibrolamellar carcinoma in adolescents and young adults: 51 patients.
McKenna et al.
TRUE

Early detection of lung cancer using small RNAs.
Sharma et al.
TRUE

Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.
Peltzer et al.
TRUE

Long-term clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.
Buchanan et al.
TRUE

A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection.
Tcherkassova et al.
TRUE

Outcomes in participants with a false positive multi-cancer early detection (MCED) test: Results from >4 years follow-up from DETECT-A, the first large, prospective, interventional MCED study.
Lennon et al.
TRUE

The detection of multiple cancer types with an extended set of methylation and protein markers.
Katerov et al.
TRUE

Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.
Takei et al.
TRUE

A 5-hydroxymethylcytosine-based noninvasive model for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma: The METHOD-2 study.
Xu et al.
TRUE

Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model.
Albitar et al.
TRUE

FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.
Li et al.
TRUE

RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
Rachiglio et al.
TRUE

Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).
LoCoco et al.
TRUE

Construction of DNA methylation-based biomarkers for diagnosis of hepatocellular carcinoma.
Xu et al.
TRUE

ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.
Severson et al.
TRUE

Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.
Kommalapati et al.
TRUE

Detection of early-stage cancers using circulating orphan non-coding RNAs in blood.
Karimzadeh et al.
TRUE

Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia.
Pek et al.
TRUE

CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.
Yablonovitch et al.
TRUE

Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value.
Gardner et al.
TRUE

Pan-cancer detection and tissue-of-origin identification by whole-genome sequencing of plasma cell-free DNA.
Guo et al.
TRUE

Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.
Rodriguez et al.
TRUE

NMR metabolomics in bladder cancer: Identification and monitoring of serum biomarkers during Pt-based treatment.
Giorgione et al.
TRUE

Diagnostic application of circulating CDH17 biomarker for screening GI malignancies.
Ng et al.
TRUE

Concordance of circulating and solid tumor DNA through comprehensive genomic profiling in a large integrated cancer network.
LaFramboise et al.
TRUE

Preclinical circulating tumor DNA (ctDNA) shedding duration and prognostic implications of modeling 3669 participants from American Cancer Society Cancer Prevention Study-3 (CPS-3) and Circulating Cell-free Genome Atlas substudy 3 (CCGA3).
Patel et al.
TRUE

Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.
Di Caro et al.
TRUE

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.
Sivaprakasam et al.
TRUE

Potential improvement in the diagnostic accuracy in detecting the estrogen receptor status in metastatic and recurrent breast cancer using 18F-FES PET/CT in the US.
Fuentes-Alburo et al.
TRUE

68Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.
Fendler et al.
TRUE

Utility of artificial intelligence-based genomic classification of occult malignancies in clinical practice.
Darabi et al.
TRUE

Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.
Rieke et al.
TRUE

A panel of seven protein tumor markers for multi-cancer early detection by artificial intelligence.
Tu et al.
TRUE

Deep neural networks to predict pathological invasiveness through surgical resection images: A computer vision based prospective clinical trial in pulmonary nodules.
Yao et al.
TRUE

Systematic review and meta-analysis of the accuracy and applicability of blood-based multi-cancer early detection (MCED) in the general population.
Park et al.
TRUE

A machine learning–based multidimensional model integrating clinical, radiomics, and cell-free DNA methylation biomarkers for the classification of pulmonary nodules.
Liang et al.
TRUE

Large retrospective validation study of metabolomic biomarkers for resectable lung cancer detection and risk assessment.
Joubert et al.
TRUE

Liquid biopsy in combination with PET/CT versus PET/CT alone in diagnosis of lung cancer in small nodules.
Shah et al.
TRUE

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort.
Repetto et al.
TRUE

Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository.
Choudhury et al.
TRUE

Detecting early stage breast cancer using low-depth cell-free DNA fragmentomics: A multi-center cohort study.
Liu et al.
TRUE

Aggregated analysis of 1,000 patients with cancer to assess the benefits of integrated whole exome and whole transcriptome sequencing.
Chernyshov et al.
TRUE

Alternative allele frequency recallibration after NGS data analysis.
Ivanov et al.
TRUE

Multimodal machine learning analysis of more than 220,000 tumor profiles to diagnose molecular and morphological subtypes of cancer.
Abraham et al.
TRUE

In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.
McDermott et al.
TRUE

Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
Bashir et al.
TRUE

Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
Juric et al.
TRUE

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
Konecny et al.
TRUE

A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.
Sommerhalder et al.
TRUE

First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer.
Tolcher et al.
TRUE

Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes.
Mittal et al.
TRUE

Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers.
Gouda et al.
TRUE

CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.
Rodriguez Rivera et al.
TRUE

Comprehensive CRISPR-enabled functional genomics profiling to identify targetable cancer genes in primary acute myeloid leukemia (AML).
Corbel et al.
TRUE

Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
Meric-Bernstam et al.
TRUE

Pan-cancer landscape of FOXA1 alterations: Insights and clinical implications.
Dee et al.
TRUE

Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
Geraud et al.
TRUE

Hypersensitivity reaction to taxanes following COVID-19 vaccination.
Osantowski et al.
TRUE

Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer.
Michels et al.
TRUE

EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results.
Drescher et al.
TRUE

BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
Patel et al.
TRUE

Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).
Tahara et al.
TRUE

Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.
Wysocki et al.
TRUE

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.
Piha-Paul et al.
TRUE

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
Lynch et al.
TRUE

First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
Falchook et al.
TRUE

Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Zeverijn et al.
TRUE

Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.
Jogo et al.
TRUE

A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
Hu et al.
TRUE

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.
Maldonado et al.
TRUE

RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study.
Nelson et al.
TRUE

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results.
Sherman et al.
TRUE

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Ulahannan et al.
TRUE

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
Coleman et al.
TRUE

First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.
Kizilbash et al.
TRUE

First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).
Di Giacomo et al.
TRUE

Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.
Matsubara et al.
TRUE

Discovery of gene fusions in driver-negative NCI-MATCH screening samples.
Kaluziak et al.
TRUE

Impact of patient travel time on disparities in precision oncology clinical trials.
Uehara et al.
TRUE

The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.
Bilici et al.
TRUE

Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Srkalovic et al.
TRUE

Molecular classification of cancer site of origin and lineage.
Rydzewski et al.
TRUE

Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Calfa et al.
TRUE

The genomic, transcriptomic, and immunological landscape of TROP2 in solid tumors.
Trabolsi et al.
TRUE

Novel deep learning–based prognostic prediction model for colorectal cancer using hematoxylin and eosin–stained whole slide images.
Konishi et al.
TRUE

Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples.
Boys et al.
TRUE

Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
Pant et al.
TRUE

Characterizing telomerase reverse transcriptase (TERT) promoter mutations (mut) across sex, race, and cancer types.
El Zarif et al.
TRUE

Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.
Thiede et al.
TRUE

Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
Fox
TRUE

Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis.
Dankner et al.
TRUE

Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines.
Shaw et al.
TRUE

Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.
Thavaneswaran et al.
TRUE

Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.
Warnecke et al.
TRUE

A 19-protein signature to predict outcomes in a cohort of stage II and III CRC.
Habib et al.
TRUE

Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.
Nielsen et al.
TRUE

Patient access to precision medicine: Identifying barriers to biomarker testing in non-small cell lung cancer.
Levent et al.
TRUE

NRG1 fusions in solid tumors.
Gupta et al.
TRUE

The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).
Jones et al.
TRUE

Characterizing the landscape of RING-type E3 ubiquitin transferase-altered (RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC.
Naqash et al.
TRUE

Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.
Shin et al.
TRUE

Use of a systems-biology informed machine learning model to predict drug response using clinically available NGS data.
Baron et al.
TRUE

Impact of HER2 assay sensitivity on the ability to detect tumors with low to ultra-low HER2 expression: A TMA study on more than 10,000 tumors from more than 100 tumor entities.
Lennartz et al.
TRUE

Pathway enrichment analysis in tumors with high mutation burdens and interferon-γ signature expression: A pancancer analysis.
Li et al.
TRUE

Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.
Chong et al.
TRUE

A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
Ou et al.
TRUE

Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
Hong et al.
TRUE

Treatment of chronic hepatitis C virus infection to increase access to cancer clinical trials in patients with hematologic malignancies: A prospective observational study.
Mustafayev et al.
TRUE

Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors.
Gu et al.
TRUE

Novel LTK fusions based on NGS sequencing data in Chinese patients with solid tumors.
Chen et al.
TRUE

Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naïve patients with cancer: Updated safety data.
Lythgoe et al.
TRUE

Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions.
Chen et al.
TRUE

Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
Lin et al.
TRUE

Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
Rami et al.
TRUE

The characteristics of metabolic related pathways under different anoikis activities revealed by pan-cancer analyses.
Xiao et al.
TRUE

Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.
Begovich et al.
TRUE

A powerful drug combination strategy targeting BRAF-mutant melanoma.
Rothermel et al.
TRUE

TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.
Janjigian et al.
TRUE

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.
Hamilton et al.
TRUE

EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
Aggarwal et al.
TRUE

Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors.
Call et al.
TRUE

TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).
Borghaei et al.
TRUE

Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).
Ma et al.
TRUE

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.
Feldman et al.
TRUE

FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
Bodei et al.
TRUE

Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.
Owonikoko et al.
TRUE

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.
McKean et al.
TRUE

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.
Beck et al.
TRUE

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
Rodon Ahnert et al.
TRUE

SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.
Ricciuti et al.
TRUE

BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).
El-Deiry et al.
TRUE

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
Iyer et al.
TRUE

First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.
Li et al.
FALSE

Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors.
Li et al.
FALSE

Pan-cancer analysis to identify molecules interacting with CasL-Like 2 to promote angiogenesis via mTOR/HIF1A/VEGFA pathway in hypoxia tumor environment.
Song et al.
FALSE

Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.
Gazzah et al.
FALSE

The impact of clinical equations on carboplatin dosing: A systematic review to determine appropriate dosing of carboplatin in adult cancer patients.
Leiva et al.
FALSE

A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors.
Li et al.
FALSE

Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.
Shen et al.
FALSE

Tolerability and toxicity profiles of antibody-drug conjugates for the treatment of malignant neoplasms: A meta-analysis of randomized clinical trials.
Zhou et al.
FALSE

Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer.
Gough et al.
FALSE

Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor.
Zhong et al.
FALSE

No checkmate in metastatic setting: Navigating real world patients applying personalized therapy based on extensive tumor profiling.
Schaffrin-Nabe et al.
FALSE

A study of antibody conjugates for the treatment of inflammatory breast cancer.
Yang et al.
FALSE

Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.
Skorupan et al.
FALSE

Relationship between EGFR inhibition in lung adenocarcinoma, cell surface expression of the placental antigen ALPP, and efficacy of ALPP-ADC therapy.
Katayama et al.
FALSE

Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer.
Lee et al.
FALSE

Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.
Ye et al.
FALSE

A next-generation sequencing methylation assay for sub-typing small cell lung cancer in cell-free DNA.
Huang et al.
FALSE

Impact of panel size on minimum residual disease (MRD) assay performance.
Battey et al.
FALSE

Candidates for early detection: Effect of pluripotent very small embryonic-like stem cells (VSELs) to transform into cancer stem cells (CSCs) and candidacy for early detection of cancer in a liquid biopsy.
Tripathi et al.
FALSE

An in-house testing for detection of homologous recombination repair deficiency (HRD) in patients with solid tumors.
Tan et al.
FALSE

Comparison of cfDNA content in different cancer types with different extraction methods.
Zhang et al.
FALSE

Detecting variation of clonal hematopoiesis using machine-learning in liquid biopsy.
Zhang et al.
FALSE

Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes.
Schuurbiers et al.
FALSE

Bi-directional interaction and predictive potential of inflammatory and oxidative stress-related biomarkers in patients with non-small cell lung cancer.
Nikolovski et al.
FALSE

Large healthy donor dataset demonstrates high analytical specificity and repeatability for the NeXT Personal molecular residual disease assay.
Navarro et al.
FALSE

Epigenetic profile of elevated cell free circulating nucleosomes in non-Hodgkin lymphoma.
Van den Ackerveken et al.
FALSE

Novel blood-based assay for detection of early stage multi-cancer.
Gregg et al.
FALSE

C-reactive protein in solid tumors: Clinically meaningful change and prognosis.
Lasheen et al.
FALSE

Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?
Desai et al.
FALSE

Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients.
Kelley et al.
FALSE

Implementing liquid biopsy in rural cancer care when tissue is insufficient for molecular testing: Retrospective review.
Singh et al.
FALSE

Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentomic patterns for multi-cancer early detection.
Kim et al.
FALSE

Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoimmunotherapy.
Kim et al.
FALSE

Somatic hereditary gene panel analysis: A pilot study from Uzbekistan.
Olimova
FALSE

Comprehensive multi-omic testing from a single laboratory to provide information in ovarian cancer.
Mancini-Dinardo et al.
FALSE

An electrochemical molecular assay for the detection of cancer-associated Thomsen-Friedenreich glycans.
Moraes Silva et al.
FALSE

Landscape of FGFR2/3 alterations in genitourinary cancer.
Che et al.
FALSE

Validation of a whole exome/whole transcriptome liquid biopsy assay with correction for clonal hematopoiesis.
Perdigones Borderias et al.
FALSE

Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India.
Sirohi et al.
FALSE

Health equity challenges facing testing, evaluation, and implementation of multi-cancer early detection tests.
LeBeau et al.
FALSE

An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.
Okuma et al.
FALSE

Systematic review and meta-analysis of accuracy of tumor origin detection in blood cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) assays in the general population.
Park et al.
FALSE

Utilize protein markers and genomic features for minimal residual disease detection in hepatocellular carcinoma.
Tu et al.
FALSE

Feasibility and clinical utility of cancer whole-genome sequencing in adult solid tumors.
Kwon et al.
FALSE

MATRIX plasma-in-plasma contrived samples assessment and detection of MRD using the Personalis NeXT Personal assay.
Labrousse
FALSE

Generalizable FGFR prediction across tumor types using self supervised learning.
Parmar et al.
FALSE

RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.
Kasi et al.
FALSE

Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.
Thacker et al.
FALSE

Diagnostic utility of next generation sequencing for somatic variants in cancer: A seven year cumulative cohort.
Boga et al.
FALSE

Expanding the spectrum of neoplasms harboring EWSR1:CREM fusion as detected by a real-world clinical genomics platform.
Campoverde et al.
FALSE

Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.
Yan et al.
FALSE

Physician-reported barriers and strategies to using tumor mutational burden (TMB) testing in oncology care: An interview based study.
Jones et al.
FALSE

The role of MIBG scan in the diagnosis of pheochromocytoma.
Ghomari et al.
FALSE

From seed to harvest: 18-month experience of molecular tumor board (MTB)-based precision oncology practice at the Verona University Hospital.
Rossi et al.
FALSE

Comprehensive clinical tumor RNA sequencing for children with cancer.
Vaske et al.
FALSE

Interim analysis examining the feasibility of incorporating laser microdissection enrichment of tumor specimens and reverse phase protein array analysis with next generation sequencing into a molecular tumor board.
Cannon et al.
FALSE

Approaches and data needed for real-world evaluation of multicancer early detection tests.
Tunis et al.
FALSE

Molecular characteristics of KRAS mutations in Chinese patients with cancer.
Yan et al.
FALSE

The analysis of BRAF fusions characteristics in Chinese solid tumor patients.
Ma et al.
FALSE

CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence.
Fiste et al.
FALSE

MOSAIC: Multi-Omic Spatial Atlas in Cancer, effect on precision oncology.
Lehar et al.
FALSE

Association of encapsulation of CDK12 inhibitor with anti-tumour activity in colon cancer cell lines.
Pérez-Segura et al.
FALSE

Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial.
Sjoquist et al.
FALSE

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).
Berz et al.
FALSE

Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.
Gordon et al.
FALSE

Transformation of tissue-resident, very small embryonic-like stem cells (VSELs) into cancer stem cells (CSCs) and its role in cancer initiation via epigenetic changes.
Bhartiya et al.
FALSE

Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members.
Okimoto et al.
FALSE

Safety and feasibility of the addition of a radiosensitizing methionine-restricted diet to radiation therapy.
Mattes et al.
FALSE

A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.
Taza et al.
FALSE

Capturing age-related changes in the tumor microenvironment of luminal breast cancer using the multiplex immunohistochemistry technique, MILAN.
Lambrechts et al.
FALSE

The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg et al.
FALSE

GLS in Philadelphia-negative and JAK2 V617F-driven myeloproliferative neoplasms (MPNs).
Ciboddo et al.
FALSE

Genomics-based screening of novel therapeutic targets and biomarkers for lung cancer.
Daigo et al.
FALSE

A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.
Sangha et al.
FALSE

PUF: A potential repressor of oncogenes.
Aslam et al.
FALSE

Single-stranded linear amplification library preparation method for highly sensitive and low input amount ctDNA detection.
Hu et al.
FALSE

The Platon Network: One step closer to improved personalized medicine.
Vogel et al.
FALSE

A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ⅰa/Ⅰb, first-in-human, open-label, single-center study.
Song et al.
FALSE

Association of cachexia with loss of function mutations in STK11/LKB1 for NSCLC.
Infante et al.
FALSE

MELK and Del-1 as druggable targets in TNBC.
Lee et al.
FALSE

Cure-PROs: Next-generation targeted protein degraders.
Giardina et al.
FALSE

RGX-019-MMAE, a novel MERTK-targeting antibody-drug conjugate (ADC) with robust anti-tumor efficacy in both solid and liquid tumors.
Takeda et al.
FALSE

Base-edited live microbiome therapeutics with target-aid -live biotherapeutic products (LBPS) with synergistic effects of anti-PD-1 antibodies in a syngeneic model of mice.
Okumura et al.
FALSE

Identification of a novel class of early exon ALK rearrangements across two pan tumor sequencing databases.
Leong et al.
FALSE

Heterofunctional polymeric degrading chimeras (HYDRAC) for targeted protein degradation.
Wang et al.
FALSE

Droplet digital PCR as an alternative method for detecting MET amplification in patients with non-small cell lung cancer.
Su et al.
FALSE

Retrospective evaluation of erlotinib and gefitinib used in the military health system from the perspective of drug-drug interactions.
Shou et al.
FALSE

Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.
Proskuriakova et al.
FALSE

Characterization of drug and non-drug interactions in patients treated in medical oncology.
Ghomari et al.
FALSE

The antinociceptive effects of selective TRPV1 antagonist RCI002 against chemotherapy-induced peripheral neuropathy.
Kim et al.
FALSE

Continuous dosing of AUM001 with cyclical gemcitabine/nab-paclitaxel to maintain the tumor growth kinetics in KPC xenograft model.
Chowbay et al.
FALSE

Novel peptide binder for EphA2-targeted radiopharmaceutical therapy for multiple solid tumors.
Clift et al.
FALSE

Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers.
Beckford Vera et al.
FALSE

A novel 89Zr-a-PD-1 immuno-PET-CT may improve pseudoprogression detection in a lung cancer murine model receiving immunotherapy.
Puyalto Calvo et al.
FALSE

GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: Final results of the phase I study.
Guo et al.
FALSE

Novel multitarget small molecule inhibitor LCI133 and synthetic lethality in endometrial carcinoma via CDK9/PI3K axis.
Delara et al.
FALSE

Examination of in vitro and in vivo antitumor activity of Menin-MLL inhibitor, D0060-319.
Xu et al.
FALSE

Antitumor activity of AX-0085, a novel AXL kinase inhibitor: Analysis of apoptotic cell death in triple-negative breast cancer cells.
Choi et al.
FALSE

AX-0085, a novel AXL kinase inhibitor, and effects on osimertinib-resistance in non–small-cell lung cancer.
Choi et al.
FALSE

Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.
Weyer et al.
FALSE

Tumor sensitization to PARP inhibitors by DNA damaging synthetically lethal acylfulvenes.
Kulkarni et al.
FALSE

Portal hemodynamic effects of different TKIs in patients with advanced hepatocellular carcinoma: A prospective cohort study.
Li et al.
FALSE

First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.
Liu et al.
FALSE

The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.
Burns et al.
FALSE

Penpulimab combined with anlotinib therapy in patients with advanced refractory solid tumors: A single-center, observational, prospective study.
Zhou et al.
FALSE

A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
Ortiz et al.
FALSE

Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models.
Dash et al.
FALSE

Effects of namodenoson on pancreatic carcinoma: Preclinical evidence.
Fishman et al.
FALSE

A novel orally bioavailable small molecular ENPP1 inhibitor (OC-1) for cancer immunotherapy.
Chen et al.
FALSE

Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors.
Lin et al.
FALSE

GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.
El-Deiry et al.
FALSE

Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer.
Li et al.
FALSE

Clinical characterization of MYC family proto-oncogene amplification in solid tumors from Chinese patients.
Liu et al.
FALSE

Programmed cell death ligand 1 (PD-L1) expression landscape and its relationship with tumor mutational burden (TMB) in a community-based cancer center patient population in rural central Nebraska.
Copur et al.
FALSE

Prognostic relevance of 3q amplification (AMP) in a racially diverse patient population with advanced squamous cell carcinoma of the lung.
Abu Rous et al.
FALSE

Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).
Gérus-Durand et al.
FALSE

Copy number variation (CNV) calling of MET, MYC, and ERBB2 using PiVAT bioinformatic platform.
Yu et al.
FALSE

The landscape of ATM alteration in Chinese solid tumor patients.
Li et al.
FALSE

Frequency of somatic mutations in solid tumor malignancies from inner city minorities: A single center study.
Cuartas Mesa et al.
FALSE

Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity.
Elsey et al.
FALSE

The clinical and genomic characteristics of KRAS G12D mutated cancers.
Lin et al.
FALSE

PD-L1 expression in patients with multiple tumors and their correlation with genomic mutations.
Lin et al.
FALSE

Multi-omics study of the genomic features and clinical characteristics of hepatic sarcomatoid carcinoma located at different sites.
Li et al.
FALSE

Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC).
Sarker et al.
FALSE

Identifying anatomopathological factors associated with a Oncotype DX 21-gene recurrence score higher than 25 in menopaused women.
Guerif et al.
FALSE

Trends in the needs and clinical utility of comprehensive genomic profiling test in rare cancers before and after the National Health Insurance coverage in Japan.
Sanomachi et al.
FALSE

Pattern of CD8+ tissue resident memory T cells between local recurrence and distant metastasis in nasopharyngeal carcinoma.
Kam et al.
FALSE

Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: The experience of an academic hospital.
Teuwen et al.
FALSE

Comprehensive multigene profiling impact on clinical decisions in patients with advanced cancers: A multicenter, retrospective analysis.
Kuznetsova et al.
FALSE

Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade.
Randon et al.
FALSE

m6A mediated upregulation of lncRNA CASC9 in head and neck squamous cell carcinoma.
Karuvantevida et al.
FALSE

Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.
Ghosh et al.
FALSE

The prognostic effect of ADH1B and ALDH2in lung adenocarcinoma.
Zhang et al.
FALSE

Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.
Jung et al.
FALSE

The application of a multigene NGS assay in homologous recombination deficiency tracking.
Tsoulos et al.
FALSE

Circulating tumor DNA methylation marker-based minimal residual diseases detection and recurrence monitoring of cancer.
Wang et al.
FALSE

Whole genome sequencing for more accurate TMB and mutational signatures in common cancers.
Lee et al.
FALSE

Pan-cancer analysis and KNSTRN as a potential prognosis biomarker.
Xiao et al.
FALSE

Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors.
Jansen et al.
FALSE

Dissecting the tumor microenvironment of papillary thyroid carcinomas in primary tumor and metastatic lymph nodes at single-cell resolution.
Nguyen et al.
FALSE

Effects of oncolytic bacteria, SGN1, against a broad spectrum of malignancies in pre-clinical and clinical studies.
Zhao et al.
FALSE

Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors.
Meng et al.
FALSE

Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical prostate cancer models.
Currie et al.
FALSE

Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.
Verco et al.
FALSE

IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.
Helland et al.
FALSE

Marketing approvals for cell and gene therapy products in oncology: Current review of EMA and FDA approvals.
Chandaria et al.
FALSE

Building liquid-liquid perfusion interface (LLPI) –based patient-derived tumoroids (PDTs) model system as clinical research tools for testing cancer therapeutics.
Giri et al.
FALSE

Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.
Vieito et al.
FALSE

Aluminium phthalocyanine–mediated photodynamic therapy promotes antitumour activity in oesophageal cancer stem cells.
Didamson et al.
FALSE

Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects.
Qi et al.
FALSE

Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in rats.
Zhu et al.
FALSE

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
Antoniotti et al.
TRUE

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
Raghav et al.
TRUE

Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.
Zhang et al.
TRUE

NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
Osumi et al.
TRUE

Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
Stintzing et al.
TRUE

Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
Yamazaki et al.
TRUE

Transcriptional metabolic profiling young onset colorectal cancer (CRC) patients.
Vadehra et al.
TRUE

Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma.
Jayakrishnan et al.
TRUE

Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer.
Lander et al.
TRUE

Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.
Andre et al.
TRUE

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
Hong et al.
TRUE

Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.
Giannakis et al.
TRUE

Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).
Gelli et al.
TRUE

Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controlled trial.
Li et al.
TRUE

Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).
Koopman et al.
TRUE

15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.
Larsen et al.
TRUE

Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.
Tsukada et al.
TRUE

Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial.
Verheij et al.
TRUE

Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.
Oki et al.
TRUE

Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
Dasari et al.
TRUE

Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.
Gallois et al.
TRUE

Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.
Alvarez et al.
TRUE

HPV integration as a prognostic biomarker for metastatic anal cancer: A next-generation sequencing ctDNA-based approach.
Johnson et al.
TRUE

Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.
Carlsen et al.
TRUE

Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas.
Sinicrope et al.
TRUE

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
Strickler et al.
TRUE

A prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT in vitro diagnostic for the detection of biomarkers associated with colorectal cancer.
He et al.
TRUE

Comprehensive study of the intratumoral microbiome in early- vs. late-onset colorectal cancer: Final analysis of COSMO CRC.
Weinberg et al.
TRUE

Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.
Walden et al.
TRUE

Circulating tumor DNA in plasma as an early predictor for pathological lymph node involvement and (neo-)adjuvant chemotherapy in patients with colon cancer.
Raunkilde et al.
TRUE

Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B), ± atezolizumab (A).
Mettu et al.
TRUE

Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.
Marmorino et al.
TRUE

Consensus molecular subtyping of colorectal cancer to demonstrate cetuximab benefit in right-sided CMS2 tumors, and pembrolizumab benefit in MSS CMS1 tumors.
Shen et al.
TRUE

Genomic landscapes of early-onset versus average-onset colorectal cancer populations.
Storandt et al.
TRUE

Deep learning tumor heterogeneity metric from histopathology images vs next generation sequencing-derived scores for colon cancer prognostication.
Amiji et al.
TRUE

Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.
Balogun et al.
TRUE

Prognostic and predictive significance of pre- and post-operative plasma tumor markers in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery: Insights from a single-center study.
Yousef et al.
TRUE

Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?
Loree et al.
TRUE

Racial and genetic ancestry associations with gene expression patterns in a real-world cohort of colorectal cancer patients.
Hein et al.
TRUE

Artificial intelligence–derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer (NCCTG N0147; Alliance).
Saberzadeh Ardestani et al.
TRUE

A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.
Xu et al.
TRUE

Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study).
Normanno et al.
TRUE

Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
Ma et al.
TRUE

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.
Xiao et al.
TRUE

A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study.
Satake et al.
TRUE

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
Lenz et al.
TRUE

Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).
Sommerhäuser et al.
TRUE

Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.
Ree et al.
TRUE

Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions.
Sommerhäuser et al.
TRUE

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Cohen et al.
TRUE

A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
Li et al.
TRUE

Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study.
Karthaus et al.
TRUE

Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).
Lee et al.
TRUE

Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).
Ulahannan et al.
TRUE

Novel GUCY2C targeting CAR-T therapy: Efficacy in advanced colorectal cancer.
Zhang et al.
TRUE

Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Price et al.
TRUE

Determinants of permanent liver limited disease (pLLD) in metastatic colorectal cancer (mCRC).
Salva et al.
TRUE

A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).
Liu et al.
TRUE

Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
Ruan et al.
TRUE

Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
Heinrich et al.
TRUE

A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
Bando et al.
TRUE

Associations between early tumor shrinkage (ETS)/depth of response (DpR) and overall and post-progression survivals (OS/PPS) from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Bando et al.
TRUE

Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial.
Wu et al.
TRUE

Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment.
Vetere et al.
TRUE

Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT).
Germani et al.
TRUE

Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.
Gallois et al.
TRUE

Intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study.
Avallone et al.
TRUE

Impact of WNT/B-catenin alterations and metastasis location among patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) combinations.
Ros Montañá et al.
TRUE

Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).
Chapin et al.
TRUE

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.
Conca et al.
TRUE

Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).
Carullo et al.
TRUE

Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.
Pugh et al.
TRUE

Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.
Mittal et al.
TRUE

Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
Alese et al.
TRUE

OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.
Alese et al.
TRUE

Deep learning-derived spatial organization features on histopathology images to predict prognosis in patients with colorectal liver metastasis, after hepatectomy.
Wang et al.
TRUE

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.
Zhao et al.
TRUE

The impact of sodium-glucose cotransporter-2 inhibitors on the outcome of patients with colorectal adenocarcinoma.
Chiang et al.
TRUE

A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.
Koenig et al.
TRUE

Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.
Feng et al.
TRUE

Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.
Yuan et al.
TRUE

Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.
Bergamo et al.
TRUE

Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Yamazaki et al.
TRUE

Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands.
van Nassau et al.
TRUE

Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).
Boland et al.
TRUE

Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.
Trunk et al.
TRUE

MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.
Dayanidhi et al.
TRUE

Management of Early-onset Metastatic Colorectal Cancer (ERMIONE): A single institution analysis.
Valente et al.
TRUE

Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial.
Taieb et al.
TRUE

PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).
Hubbard et al.
TRUE

VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.
Chen et al.
TRUE

Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.
Maurel et al.
TRUE

Preoperative assessment in lung-limited metastatic patients with colorectal cancer: The Meta-Lung Score.
Ziranu et al.
TRUE

Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study.
Palmieri et al.
TRUE

Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer.
Johnson et al.
TRUE

Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.
Eng et al.
TRUE

Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA’s National Precision Oncology Program (NPOP).
Nono Djotsa et al.
TRUE

Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study.
Orlandi et al.
TRUE

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
Dasari et al.
TRUE

Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.
Obeng-Kusi et al.
TRUE

Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.
Shah et al.
TRUE

Impact of vitamin d on the colon tumor immune microenvironment: Results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.
Dias Costa et al.
TRUE

Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).
Imai et al.
TRUE

Combined associations of a healthy lifestyle and body mass index on colorectal cancer recurrence and survival: A cohort study.
Barot et al.
TRUE

Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response.
Fox et al.
TRUE

The role of image-guided volume-adapted high-dose-rate endorectal brachytherapy boost in total neoadjuvant treatment of distal locally advanced rectal cancer.
Jiang et al.
TRUE

The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery.
JEON et al.
TRUE

Efficacy and safety of mFOLFOX6 with apatinib as postoperative adjuvant chemotherapy in stage IIIB or IIIC colorectal cancer.
Gu et al.
TRUE

The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy.
Judge et al.
TRUE

Mismatch Repair system protein deficiency as a factor of resistance to chemo-radiotherapy treatment in patients with locally advanced rectal adenocarcinoma and its influence on disease-free survival.
Pretta et al.
TRUE

The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.
Michael et al.
TRUE

Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy.
Romesser et al.
TRUE

A prospective evaluation of pelvic radiation vs. no radiation among patients with young-onset rectal cancer: Impact on patient-reported outcomes.
Corrigan et al.
TRUE

Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis?
Sun et al.
TRUE

Treatments and clinical outcomes in stage II colon cancer (CC) patients (pts) with 12-gene Oncotype DX Colon Recurrence Score assay-guided therapy: Real-world data.
Brenner et al.
TRUE

Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.
Gong et al.
TRUE

Molecular profiling and characterization of the tumor immune microenvironment (TME) in appendiceal carcinoma (AC).
Rehman et al.
TRUE

Comparison of synchronous neoplasms at colonoscopic diagnosis of early-onset versus average-onset colorectal cancer.
Emiloju et al.
TRUE

Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
Capdevila et al.
TRUE

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Morris et al.
TRUE

The Ohio State University Guardant Shield Colorectal Cancer Screening Project.
Stanich et al.
TRUE

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Kopetz et al.
TRUE

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Shepard et al.
TRUE

Alliance A022101: A pragmatic, randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating Radiation, Ablation, and Surgery (ERASur).
Hitchcock et al.
TRUE

STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.
Hecht et al.
TRUE

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.
Bekaii-Saab et al.
TRUE

A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
Desai et al.
TRUE

Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).
Siena et al.
TRUE

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
Dasari et al.
TRUE

The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.
Tarazona et al.
TRUE

The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.
Williams et al.
TRUE

PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.
Hou et al.
TRUE

Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).
Lin et al.
TRUE

Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.
Cercek et al.
TRUE

Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
Smith et al.
TRUE

A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.
Yaeger et al.
TRUE

Carboplatin and paclitaxel chemoradiation for localized anal cancer in patients not eligible for mitomycin and 5-fluorouracil.
DeZeeuw et al.
FALSE

Prognostic factors of long-term outcomes after primary chemo-radiotherapy in non-metastatic anal squamous cell carcinoma: An international bicentric cohort.
Iseas et al.
FALSE

Anal carcinoma: A retrospective analysis in a Mexican cohort.
Reyna de la Garza et al.
FALSE

20-year incidence trends of anal squamous cell carcinoma.
Jhaveri et al.
FALSE

The long journey of patients with anal carcinoma in a Mexican cohort.
Martinez Moyano et al.
FALSE

Influence of intestinal microbiota on autophagy in colorectal cancer.
Nawfal et al.
FALSE

Study on the mechanism of CXCR3 expression in paracancer and tumor tissues of colon cancer patients.
Wang et al.
FALSE

Genomic characterization in gastrointestinal cancer patients based on cfDNA sequencing.
Wang et al.
FALSE

The impact of COVID-19 on mortality, length of stay, and cost of care among patients with gastrointestinal malignancies: A propensity score-matched analysis.
Ulanja et al.
FALSE

Early gastrointestinal tumour detection using cfDNA fragmentomes based on low-pass whole-genome sequencing (lp-WGS).
Zhang et al.
FALSE

Socioeconomic and demographic disparities in rectal cancer treatment.
Wu et al.
FALSE

Translationally controlled tumor protein as a prognostic marker in metastatic colon cancer.
Stoyanov et al.
FALSE

The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer.
Nederby et al.
FALSE

Prevalence of hypertension, hyperlipidemia and diabetes in colon cancer patients and its impact on physical health and quality of life reported in the All of Us research program.
Osei et al.
FALSE

The risk of cerebrovascular accidents in colon cancer in the United States: A population-based national study.
Alkrekshi et al.
FALSE

The risk of myocardial infarction and heart failure in colon cancer in the United States: A population-based national study.
Brell et al.
FALSE

Microscopic residual disease (MRD) monitoring and time to disease recurrence across gastrointestinal (GI) malignancies: A single-institution, real-world study.
Winters et al.
FALSE

Identification and evaluation of a reliable, non-invasive diagnostic method using serum microRNA expression to diagnose high-risk colorectal cancer candidates.
Foo et al.
FALSE

Efficacy of PD-1 inhibitors for colorectal cancer and polyps in patients with Lynch syndrome.
Yu et al.
FALSE

Colorectal cancer screening and treatment before and during the COVID-19 pandemic at a Southeast Texas community hospital.
Abdelhakeem et al.
FALSE

Integrated analysis of colorectal neoplasia tissue and gut microbiome associated serum metabolites for diagnosis of early-stage CRC and advanced adenoma.
Gu et al.
FALSE

Genomic characterization of MSI-H and TMB in gastrointestinal cancer.
Zheng et al.
FALSE

Cost-effectiveness of ColoSTAT for primary colorectal cancer screening in the United States.
He et al.
FALSE

A novel liquid biopsy methylation-based technology and early detection of colorectal cancer in patients.
Bocanegra et al.
FALSE

Preliminary study of microRNA expression profiling in non-metastatic colorectal cancer.
Kluz et al.
FALSE

Oncologic outcomes in patients with radiation associated rectal adenocarcinoma.
Omer et al.
FALSE

Colorectal cancer mortality in young adults in the United States.
Didier et al.
FALSE

Tumor immune environment in colitis-associated colorectal cancers: Comparison with sporadic colorectal cancers.
Li et al.
FALSE

Determining MSI status by a one-step PCR melting curve analysis of Chinese-specific mononucleotide repeats.
Chen et al.
FALSE

Is there an increase in elective utilization of non-operative management for rectal cancer?
Manisundaram et al.
FALSE

Immune activation-related risk score: A new tool to predict prognosis and immunotherapy applicability in colorectal cancer.
Zhu et al.
FALSE

Comprehensive analysis of the mutational status of early colon cancer: Real world data from the AIO ColoPredict registry study.
Gisder et al.
FALSE

Tumor immune environment in multiple primary malignancies involving colorectal cancers: Comparison with single primary colorectal cancers.
Chen
FALSE

Use of circulating tumor DNA analysis to predict recurrence and need for adjuvant chemotherapy in stage I-IV colorectal cancer.
Li et al.
FALSE

Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.
Cosgrove et al.
FALSE

Italian real world artificial intelligence (AI) based analysis of early-onset colorectal cancer: The ERCOLE study.
Calegari et al.
FALSE

Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.
Patell et al.
FALSE

Plasma cfDNA role in detecting cardiovascular, metabolic and other diseases in a FIT+ population enrolled for a colorectal cancer screening program.
Scimia et al.
FALSE

Analysis of patients at the Memphis VA Medical Center with positive FIT testing and incomplete GI evaluation during the COVID-19 pandemic.
Mitchell et al.
FALSE

High rates of detection of metastatic/recurrent colorectal cancer on clinical imaging at the time of molecular residual disease testing following operative management.
Trotier et al.
FALSE

Genomic analysis of RAS and BRAF mutation in an oncology reference hospital in Brazil.
Amorim et al.
FALSE

Mutational and DNA fragment analysis may help in the triage of FIT+ patients enrolled in colorectal cancer screening programs.
Scimia et al.
FALSE

ScRNA-seq to examine heterogeneity of transcriptional regulation of CAFs between left-sided and right-sided CRC.
Fan et al.
FALSE

Does severity of periodontal disease influence the risk of developing gastrointestinal malignancies?
Iqbal et al.
FALSE

Single cell transcriptomics to identify immunological ACKR1+ DCs and their effect on clinical outcomes in left-sided CRC.
Wang et al.
FALSE

Trends and disparities in incidence and mortality of early-onset colorectal cancer (EOCRC) in the United States (1999-2019).
Grewal et al.
FALSE

Trends of colorectal cancer and associated factors in the United States: A SEER registry analysis.
Fatima et al.
FALSE

Disparities in presentation, treatment, and overall survival for South Asian American patients with colorectal cancer.
Ahmed et al.
FALSE

Real-world safety and effectiveness of MVASI in metastatic colorectal cancer patients in Canada.
Cheung et al.
FALSE

Quality of life, effectiveness, and compliance of fruquintinib in the treatment of metastatic colorectal cancer: Results from a prospective real-world study.
Zhang et al.
FALSE

A phase Ⅰ/Ⅱa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.
Li et al.
FALSE

Efficacy and safety of radiation therapy combined with anti-angiogenic agentsand immunotherapy for MSS/pMMR metastatic colorectal cancer: A real-world study.
Lin et al.
FALSE

Survival trends for left and right sided colon cancer using the population-based SEER database: A 45-year analysis from 1975 to 2019.
Ulanja et al.
FALSE

Results of a retrospective multicenter study comparing the effectiveness of regorafenib and the rechallenge of chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
Kuzmina et al.
FALSE

Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study.
Li et al.
FALSE

Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.
Fumet et al.
FALSE

Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials.
Aiman et al.
FALSE

Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial.
Wang et al.
FALSE

A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.
Li et al.
FALSE

Chemotherapy and radiofrequency hyperthermia (oncothermia) in the treatment of metastatic colorectal cancer.
Deniz et al.
FALSE

Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.
Qu et al.
FALSE

Clinical and molecular characterization of HER2-low metastatic colorectal cancer.
Babkoff et al.
FALSE

Refractory colorectal cancer patient derived MicroOrganoSpheres (MOS) to enable correlation of targeted therapy combination response with clinical outcomes.
Ding et al.
FALSE

Association of intermediates of bioenergetic pathways and plasma metabolomics with colorectal cancer (CRC): Diagnosis, stage, and survival.
Gangi et al.
FALSE

The preventive effect of celecoxib on regorafenib-associated hand-foot syndrome in patients with liver metastasis from colorectal cancer: A single-center, retrospective, real-world study.
Wang et al.
FALSE

ALBI and APRI score as prognostic factors for predicting the FABIB complications after liver resection in metastatic colorectal cancer.
Napolskaia et al.
FALSE

The multi-omics signature to predict sensitive to anti-epidermal growth factor receptor therapy in RAS wild-type colorectal cancer liver metastases.
Chang et al.
FALSE

Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).
Benson et al.
FALSE

ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
Goetze et al.
TRUE

Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
Sohal et al.
TRUE

An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.
Gbolahan et al.
TRUE

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
Rogers et al.
TRUE

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.
Del Rivero et al.
TRUE

LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).
Sharma et al.
TRUE

Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
Gebauer et al.
TRUE

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC).
Weinberg et al.
TRUE

Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.
Ruffolo et al.
TRUE

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.
Liu et al.
TRUE

ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
Dean et al.
TRUE

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
Chung et al.
TRUE

Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.
Babiker et al.
TRUE

CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.
Manji et al.
TRUE

A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.
O'Hara et al.
TRUE

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
Reiss et al.
TRUE

ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients.
Dhani et al.
TRUE

Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.
Chawla et al.
TRUE

Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).
Kasi et al.
TRUE

STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Klempner et al.
TRUE

Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with esophageal and gastric cancer.
Wang et al.
FALSE

Clinicogenomic analysis of rare histologic variants of pancreatic carcinoma: Undifferentiated carcinomas with and without osteoclast-like giant cells.
Mills et al.
FALSE

Association of enhanced epithelial-mesenchymal transition signature with tumor microenvironment, angiogenesis, and survival in gastric cancer.
Oshi et al.
FALSE

Effect of hypoxic status on survival and therapeutic responses in gastric cancer.
Dai et al.
FALSE

Liquid biopsy effectiveness of esophageal cancer-related genes and their correlation in clinical research.
Jiang et al.
FALSE

Effect of system analysis of reactive oxygen species on prognosis and treatment decisions for patients with esophageal squamous carcinoma.
Lu et al.
FALSE

Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer.
Raut et al.
FALSE

Expression profiles of MUC5AC glycoforms in neoplastic and non-neoplastic pancreatic tissue.
Manne et al.
FALSE

KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.
Zhang et al.
FALSE

The prognostic value of degree of pre- and post-treatment anemia in patients with advanced gastroesophageal cancers.
Hu et al.
FALSE

Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.
Liu et al.
FALSE

Efficacy and safety of first-line immunotherapy for advanced gastric or gastroesophageal cancer: System review network meta-analysis.
Qin et al.
FALSE

Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort.
Cui et al.
FALSE

Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).
Huang et al.
FALSE

Efficacy and safety of second-line treatment for advanced gastric cancer: A network meta-analysis of randomized controlled trials.
Ma et al.
FALSE

High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.
Khan et al.
FALSE

Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer.
Chen et al.
FALSE

Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.
Lee et al.
FALSE

Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).
Tsai et al.
FALSE

The prognostic value of metastasectomy among patients with gastric, pancreatic, and colorectal cancer accompanied by isolated liver metastasis: A SEER analysis.
Fahmawi et al.
FALSE

Multi-hospital retrospective study comparing gastric adenocarcinoma in Hispanic versus non-Hispanic patients.
Zarrinkhoo et al.
FALSE

First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial.
Liangjun
FALSE

Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.
Wang et al.
FALSE

Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI).
Min et al.
FALSE

TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.
Wang et al.
FALSE

Efficacy and safety of camrelizumab combined with apatinib in the treatment of advanced gastric cancer: Preliminary results from a multicenter, prospective study.
He et al.
FALSE

18F-FDG PET and CT identifiers of high-risk lesions in the stomach and esophagus.
EighaeiSedeh et al.
FALSE

Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models.
Qian et al.
FALSE

Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.
Paydary et al.
FALSE

Assessing the real-world experience of treating gastric cancer in Armenia: A retrospective-study.
Sargsyan et al.
FALSE

Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO.
Scheck et al.
FALSE

Co-occurrence of mutations and related signal pathway analysis of CCND1 amplification in esophageal squamous cell cancer.
Pang et al.
FALSE

Genetic alteration and ctDNA mutation profiling of esophageal cancer in Chinese patients.
Qingxin et al.
FALSE

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06).
Lim et al.
FALSE

A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.
Hou et al.
FALSE

Clinical analysis of immunotherapy rechallenge in advanced gastric cancer.
Zhang et al.
FALSE

The safety and efficacy of cadonilimab in combination with AK117 (anti-CD47 antibody) plus chemotherapy as first-line treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.
Xia et al.
FALSE

Effect of overexpression of ERK1/2 and MDR1 on chemoresistance in advanced gastric cancer patients.
Ghosh et al.
FALSE

Immunotherapy with or without radiotherapy in late-line treatment for metastatic esophageal cancer: A real-world study.
Chen et al.
FALSE

The mutational landscape of circulating cell free DNA in patients with gastric cancer.
Qian et al.
FALSE

Identification of FEN1 as a prognostic marker and novel therapeutic target in gastric cancer harboring TP53 mutations.
Deng
FALSE

A risk-scoring prognostic model of gastric cancer based on angiogenesis.
Wu et al.
FALSE

Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced esophageal cancer.
Chen et al.
FALSE

Association of PIWI-interacting RNA-23210 with tumor metastasis in esophageal squamous cell carcinoma.
Peng et al.
FALSE

Phase I clinical trial using a unique immunotherapeutic combination of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of patients with advanced esophageal cancer.
Chen et al.
FALSE

Personalized circulating tumor DNA (ctDNA) analysis in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).
Liu et al.
FALSE

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric adenocarcinoma (FRUTINEOGA): A multicenter, phase II study.
Wu et al.
FALSE

Phase I/II study of nab-paclitaxel combined with S-1 as adjuvant chemotherapy in diffuse type of stage III gastric or gastroesophageal junction adenocarcinoma.
Cui et al.
FALSE

Short-term locally advanced gastric cancer management: A cost-effectiveness analysis.
Prasath et al.
FALSE

Comparison of multi-omics biomarkers via liquid biopsy in early detection of gastric cancer.
Wang et al.
FALSE

Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial.
Peng et al.
FALSE

Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase 2 trial.
Cheng et al.
FALSE

Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 in patients with gastric cancer after gastrectomy based on the registry data base on the National Health Insurance Service (NHIS) database in Korea.
Maeng et al.
FALSE

Co-mutation-based subtyping of Chinese patients with gastric cancer.
Huang et al.
FALSE

A propensity score–matched analysis to evaluate the benefit of adjuvant therapy on disease progression of esophageal squamous cell carcinoma after R0 esophagectomy.
Cao et al.
FALSE

Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial.
Kennedy et al.
FALSE

Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.
Zhao et al.
FALSE

A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.
Qi et al.
FALSE

Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma.
Huang et al.
FALSE

A prospective analysis of robotic three-stage esophagectomy for carcinoma of the esophagus in a tertiary care cancer centre.
Bathala
FALSE

Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.
Vikash et al.
FALSE

A phase 2 study of modified chemotherapy plus pembrolizumab as perioperative therapy for stage II/IIIA esophageal squamous cell carcinoma.
Yang et al.
FALSE

Anlotinib hydrochloride combined with tislelizumab, paclitaxel liposome, and nedaplatin regimen for preoperative neoadjuvant therapy of esophageal cancer: A single-arm, single-center, phase II exploratory clinical study.
Ma et al.
FALSE

Circulating tumor DNA in individuals with stomach adenocarcinoma (STAD) to detect MMR-related gene alterations.
Zhang et al.
FALSE

Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial.
Zhao et al.
FALSE

Effect of multi-omics analysis on tumor ecosystem during neoadjuvant dose-limiting chemotherapy combination with sequential PD-1 blockade for patients with esophageal cancer.
Song et al.
FALSE

Phase II trial of terelizumab combined with radiotherapy of locally advanced unresectable esophageal squamous cell carcinoma: TREC trial.
Liu et al.
FALSE

Neoadjuvant tislelizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis of a phase 2 study.
Zhuo et al.
FALSE

A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection.
Ni et al.
FALSE

Toripalimab combined with fluorouracil, leucovorin calcium, oxaliplatin and irinotecan (FOLFIRINOX) regimen or combined with oxaliplatin and tegafur (SOX) regimen in perioperative treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma (G/GEJ): An open-label, randomized, phase II study.
Liu et al.
FALSE

The effect of inflammatory-nutri̇tional prognosti̇c scori̇ng (INPS) system on treatment response and prognosi̇s i̇n pati̇ents wi̇th locally advanced gastroesophageal juncti̇on and gastri̇c cancer wi̇th neoadjuvant systemi̇c treatment.
Keskinkilic et al.
FALSE

Variation of body composition and its impact on survival in a global population of patients receiving multimodal treatment for esophageal cancer.
Boshier et al.
FALSE

Outcomes of patients with oesophageal and gastric cancer in relation to their age and metropolitan residential status: A South Australian audit.
Kalapurackal Mathai et al.
FALSE

The impact of cancer prehabilitation on psychological outcomes and quality of life in patients with gastro-oesophageal cancer.
Halliday et al.
FALSE

Survival analysis comparing neoadjuvant chemoradiotherapy versus perioperative chemotherapy for locoregional gastric cancer.
Sabbagh et al.
FALSE

Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis.
Wang et al.
FALSE

Development of a postoperative nomogram to predict disease-specific mortality in gastric cancer: A competing risk analysis using variables the AJCC recommends be collected and registered.
Bando et al.
FALSE

Eligibility of patients with esophageal and gastroesophageal cancer for biology-guided radiotherapy in a retrospective cohort.
Olaechea et al.
FALSE

Development of a plasma biomarker panel for gastric cancer detection based on an autoimmune response signature.
Dou et al.
FALSE

A national analysis evaluating the role of neoadjuvant chemoradiotherapy in upper esophageal cancer.
Sabbagh et al.
FALSE

Early onset gastric cancer: An analysis of epidemiological and environmental risk factors.
Zarrinkhoo et al.
FALSE

Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.
Li et al.
FALSE

A phase Ib study of porustobart (HBM4003), an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with hepatocellular carcinoma.
Zhang et al.
FALSE

Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable/advanced hepatocellular carcinoma (HCC).
Zhou et al.
FALSE

The impact of anti-EGFR therapy when added to first-line standard platinum-gemcitabine chemotherapy in advanced biliary tract cancers: A meta-analysis of randomized studies.
Findakly et al.
FALSE

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.
Coffman et al.
FALSE

Examining the treatment journey of patients diagnosed with hepatocellular carcinoma (HCC) using retrospective real-world data in British Columbia, Canada.
Seung et al.
FALSE

Costs and health care resource utilization (HCRU) for patients with advanced biliary tract (aBTC) cancer using administrative databases in Ontario, 2010 to 2020.
Seung et al.
FALSE

PVR expression in tumor microenvironment of advanced hepatocellular carcinoma.
Lu et al.
FALSE

Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study.
Kaseb et al.
FALSE

Diagnostic and prognostic biomarker value of blood circulating inflammatory cytokines in hepatocellular carcinoma.
Chamseddine et al.
FALSE

Clinical characteristics and initial treatment patterns of patients with HCC in Korea: A multi-center real-world database analysis from the LINK research network.
Kim et al.
FALSE

Efficacy of low dose sorafenib and capecitabine in the management of hepatocellular cancer.
Mateen et al.
FALSE

A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.
Xu et al.
FALSE

Clinical efficacy and safety of regorafenib for patients with recurrent hepatocellular carcinoma after hepatectomy: A real-world study in China.
Ni et al.
FALSE

Efficacy and safety of donafenib combined with transcatheter arterial chemoembolization (TACE) and anti-PD1 antibody for the treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective study.
Ge et al.
FALSE

A retrospective study of the efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with high-risk recurrence factors after hepatocellular carcinoma surgery.
Zou et al.
FALSE

Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma.
Ruan et al.
FALSE

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.
Pan et al.
FALSE

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.
Cheng et al.
FALSE

Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.
Chen et al.
FALSE

Regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma efficacy and safety of patients: A real-world study.
Bai et al.
FALSE

Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).
Chen et al.
FALSE

The impact of previous local therapy (LT) on overall survival (OS) in patients with advanced hepatocellular carcinoma (aHCC) treated with atezolizumab/bevacizumab (A+B) as first line systemic therapy.
Fierro et al.
FALSE

Anti–PD-1 combination regimen as first-line therapy in advanced biliary tract cancer and biomarker exploration: A retrospective study.
Guo et al.
FALSE

Novel peptide binder to Glypican-3 for targeted radiopharmaceutical therapy of hepatocellular carcinoma.
Li et al.
FALSE

Immunotherapy versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma in first-line setting: A systematic review and meta-analysis of randomized controlled trials.
Marin Comini et al.
FALSE

TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study.
Mu et al.
FALSE

Hepatic artery infusion chemotherapy combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma presenting portal vein tumor thrombus: A prospective, single-arm study.
He et al.
FALSE

Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinoma.
Wen et al.
FALSE

Gaps in care planning and delivery for patients with liver cancer: Baseline assessment for implementation of 4R Oncology model.
Therapondos et al.
FALSE

Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.
Tan et al.
FALSE

Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: A retrospective controlled study.
Guo et al.
FALSE

Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study.
Hong et al.
FALSE

Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors.
Guo et al.
FALSE

Efficacy and safety of radiotherapy combined with regorafenib for advanced hepatocellular carcinoma: A real-world study from a single center.
Xin et al.
FALSE

OS analysis of patients with different short-term response and progression patterns of donafenib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: An exploratory subgroup analysis of ZGDH3.
Qin et al.
FALSE

A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma.
Liu et al.
FALSE

Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.
Xu et al.
FALSE

Efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) for treating intermediate/advanced-stage hepatocellular carcinoma (HCC): A retrospective real-world study.
Wei et al.
FALSE

Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study.
Chen et al.
FALSE

Comparative efficacy and safety of anti-PD-1/L1 antibody plus anti-VEGF antibody and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A systematic review and network meta-analysis.
Jieer et al.
FALSE

Transarterial chemoembolization combined with camrelizumab and apatinib in the treatment of advanced hepatocellular carcinoma: Preoperative or postoperative combination? A prospective clinical study.
Xie et al.
FALSE

Efficacy and safety of regorafenib and PD-1 combined with cryoablation in the treatment of advanced hepatocellular carcinoma after second-line targeted therapy.
Chen et al.
FALSE

Landscape of FGFR2/3 alterations in hepatobiliary malignancies.
Liu et al.
FALSE

HER3 expression status following systemic chemotherapy treatment in biliary tract cancers.
Nishioka et al.
FALSE

A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC).
Qi et al.
FALSE

Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).
Paul et al.
FALSE

Efficacy and safety in unresectable hepatocellular carcinoma with VP4 tumor embolus using sinilimab plus bevacizumab: A retrospective analysis of real-world evidence.
Cheng et al.
FALSE

Locoregional plus systemic therapy for unresectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Qiu et al.
FALSE

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
Monge B. et al.
FALSE

Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.
Fu et al.
FALSE

Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.
Dong et al.
FALSE

Phase II study of fruquintinib as second or further-line therapy for patients with advanced biliary tract cancer.
Zhang et al.
FALSE

Effect on in-hospital outcomes of patients with hepatocellular carcinoma on aspirin.
Dhaliwal et al.
FALSE

Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis.
Yin et al.
FALSE

Regorafenib second-line therapy for surgical recurrent hepatocellular carcinoma: An exploration of continuing regorafenib therapy after tumor progression—A single-center retrospective analysis of 90 cases.
Wu et al.
FALSE

Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study).
Zhang et al.
FALSE

Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
Peng et al.
FALSE

Atezolizumab and bevacizumab in advanced hepatocellular carcinoma: Real-world data.
Bezalel et al.
FALSE

Gemcitabine, cisplatin, nab-paclitaxel: The effectiveness of this regimen for gall bladder cancer.
Chaugule et al.
FALSE

Real-world efficacy and safety of donafenib-based therapies in patients with unresectable hepatocellular carcinoma: A retrospective study.
Shang et al.
FALSE

The clinical efficacy and safety of sintilimab plus anlotinib for unresectable intrahepatic cholangiocarcinoma (ICC): A prospective, single-arm phase II study.
Cheng et al.
FALSE

Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.
Zhang et al.
FALSE

Efficacy and safety in unresectable hepatocellular carcinoma using atezolizumab plus bevacizumab in later-line: A retrospective analysis of real-world evidence.
Cheng et al.
FALSE

Comparison of Child-Turcotte-Pugh score and albumin bilirubin index score for advanced hepatocellular carcinoma at an LMIC tertiary cancer facility.
Sinha et al.
FALSE

Genomic profiling of biliary tract carcinomas by their location.
Gatalica et al.
FALSE

A retrospective study on the efficacy and safety of regorafenib alone or in combination in advanced hepatocellular carcinoma.
Fu et al.
FALSE

Cholangiocarcinoma: A nationwide trend analysis from 2016 to 2020.
Ishaya et al.
FALSE

A survey on the detection of hepatitis B virus (HBV) in blood samples of patients with hepatocellular carcinoma (HCC) in China.
Gao et al.
FALSE

Trends in hepatocellular carcinoma rates by age, region, race, and ethnicity: A SEER database population study 2000-2019.
Schodowski et al.
FALSE

Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).
Zhao et al.
FALSE

Genomic profiles of chromosome remodeling pathway and their correlation with TMB, MSI, PD-L1, and immune microenvironment in biliary tract tumors.
Shen et al.
FALSE

Changing survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results Database (2000–2018).
Wang et al.
FALSE

Therapeutic outcomes of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Naz et al.
FALSE

The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
Yang et al.
FALSE

Molecular profiling of Chinese patients with advanced hepatocellular carcinoma using circulating tumor DNA.
Zhu et al.
FALSE

Liver directed therapies in primary and metastatic liver cancer: A rural academic institution experience.
Saeed et al.
FALSE

Real-world experience with atezolizumab plus bevacizumab in the management of non-resectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.
Devarkonda et al.
FALSE

The impact of DNA damage repair gene mutations on therapeutic response among Chinese patients diagnosed with advanced biliary tract cancer.
Gou
FALSE

Incidence of synchronous and metachronous peritoneal metastases for gallblader cancer: A single-center cohort analysis.
Gül-Klein et al.
FALSE

Prevalence of next generation sequencing testing and targetable mutations in cholangiocarcinoma.
Shah et al.
FALSE

Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.
Aldawoodi et al.
FALSE

Translational analysis of combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer.
Lee et al.
FALSE

Incidence of metachronous peritoneal metastases for intrahepatic cholangiocarcinoma after curative resection: A single center cohort analysis.
Gül-Klein et al.
FALSE

A multicenter study on adjuvant chemotherapy of S-1 versus observation for resected perihilar cholangiocarcinoma.
Hosokawa et al.
FALSE

The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.
Chen et al.
FALSE

Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
Cao et al.
FALSE

Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.
Duan et al.
FALSE

Association between autologous transfusion and recurrence-free survival in patients with hepatocellular carcinoma after resection: A prospective nonrandomized controlled trial.
Zhong et al.
FALSE

EGFR/ERBB2 aberrations in Chinese biliary tract carcinomas.
Wu et al.
FALSE

Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis.
Li et al.
FALSE

Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study.
Tu et al.
FALSE

Anticoagulation for portal vein thrombosis in patients with hepatocellular carcinoma: A retrospective observational study.
Antonios et al.
FALSE

The efficacy and safety of donafenib-containing regimens as postoperative adjuvant therapy for hepatocellular carcinoma (HCC): A multicenter retrospective study.
Rao et al.
FALSE

Safety and efficacy exploration of intraperitoneal perfusion of PD-1 monoclonal antibody for patients with primary liver cancer with malignant ascites: A prospective, single-arm, phase Ib clinical trial.
Chen et al.
FALSE

Real world impact of hepatocellular carcinoma stage and hepatic function on health-related quality of life.
Gupta et al.
FALSE

Huaier granules for hepatocellular carcinoma recurrence after ablation: A multicenter prospective cohort study.
Han et al.
FALSE

A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.
Baretti et al.
FALSE

A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.
Song
FALSE

A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma.
Zhong et al.
FALSE

Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase II trial.
Sun et al.
FALSE

Adjuvant therapy in localized vs regional biliary tract cancers: A SEER analysis.
Wei et al.
FALSE

Updated results from ALTER-H004 trial: Anlotinib combined with TACE as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.
Wu et al.
FALSE

Real-world (RW) treatment and surveillance patterns in patients with hepatocellular carcinoma (HCC) after resection (R) or ablation (A): Evidence from commercial and Medicare populations.
Tan et al.
FALSE

Impact of surgical treatment on overall survival in cholangiocarcinoma of the gallbladder: An NCDB study.
Al Kurnas et al.
FALSE

Recurrence rate-based strategy to tailor surveillance scheduling in single hepatocellular carcinoma ≤2 cm after curative therapy: Analysis of 6,105 global patients.
Chen et al.
FALSE

Comparison of T cell infiltration in hepatocellular carcinoma between whole exome and transcriptome sequencing data.
Lv et al.
FALSE

An observational study of donafenib as adjuvant therapy to prevent hepatocellular carcinoma recurrence after curative surgery.
Shang et al.
FALSE

Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma.
Hu et al.
FALSE

Using machine learning-based boosting algorithm to predict hepatotoxicity after local therapy and association with survival in patients undergoing liver directed therapy.
Mo et al.
FALSE

Survival outcomes with observation or adjuvant therapy in elderly patients with biliary tract cancer.
Gbolahan et al.
FALSE

Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.
Yu et al.
FALSE

Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.
Parekh et al.
FALSE

Incidence of hepatocellular cancer in India: Analysis of population based cancer registry data.
Gopalakrishna et al.
FALSE

Trends in utilization of first-line palliative care in non-metastatic hepatocellular carcinoma.
Ozer et al.
FALSE

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study.
Su et al.
FALSE

Comprehensive analysis of molecular characteristics, TMB, and MSI in Chinese patients with neuroendocrine neoplasms.
Li et al.
FALSE

Real world sequence of peptide receptor radionucleotide therapy (PRRT) and chemotherapy in patients with metastatic pancreatic neuroendocrine tumors (pNETs).
Phillips et al.
FALSE

Pathologic exploration of neuroendocrine differentiation in carcinomas.
Wen et al.
FALSE

Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.
Wang et al.
FALSE

Association of guideline adherence in diagnosis and treatment of pancreatic neuroendocrine tumors with survival.
Overheu et al.
FALSE

Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR.
Meng et al.
FALSE

Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs).
Sim et al.
FALSE

Investigation into the immune microenvironment of gastroenteropancreatic high-grade neuroendocrine carcinoma.
McDonald et al.
FALSE

Clinical and radiological criteria for candidate patients with small bowel neuroendocrine neoplasms (SB-NEN) for minimally invasive surgery: A single-centre experience.
Guidi et al.
FALSE

Correlation of cancer testis antigen and interleukin expression with survival in small bowel neuroendocrine tumors.
Seo et al.
FALSE

Prognostic value of total tumor volume with 68Ga DOTATOC PET/CT in predicting response to 177-Lu-DOTATOC treatment in metastatic well-differentiated neuroendocrine tumors (NETs).
Vega-Zolano et al.
FALSE

177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting.
Sassic et al.
FALSE

Treatment and outcomes of pancreatic cancer in Armenia: Hospital-based study.
Bardakhchyan et al.
FALSE

Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with pancreatic cancer.
Wu et al.
FALSE

The efficacy of cationic amphiphilic antihistamines on outcomes of patients with pancreatic ductal adenocarcinoma.
Chiang et al.
FALSE

Effects of pancreatic enzyme replacement therapy (PERT) on overall survival (OS) in patients (pts) with advanced pancreatic ductal adenocarcinoma (APDAC) and evidence of pancreatic enzyme insufficiency (PEI): A single institution, retrospective, cohort study.
Picozzi et al.
FALSE

Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.
MacEwan et al.
FALSE

Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas.
Lee et al.
FALSE

Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).
Sahai et al.
FALSE

Molecular and clinical characteristics of patients with KRAS mutated pancreatic ductal adenocarcinoma.
Xiao et al.
FALSE

Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.
Gupta et al.
FALSE

Single-cell RNA sequencing and influences of necroptosis-associated myeloid lineages in immune microenvironment of PDAC.
Dong et al.
FALSE

NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials.
Nichetti et al.
FALSE

A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy.
Grierson et al.
FALSE

Impact of homelessness on outcomes among pancreatic cancer hospitalization: Insight from the 2016-2020 National Inpatient Sample.
Pagidipally et al.
FALSE

Effect of UBR7 deficiency on glycolysis and PDAC resistance to gemcitabine by promoting PRMT5 stability.
Bi et al.
FALSE

Outcomes among patients with pancreatic malignancy on long-term anticoagulation hospitalized for acute pulmonary embolism: A nationwide analysis.
Syal et al.
FALSE

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).
Zhou et al.
FALSE

Total pancreatectomy: Experience within an integrated health care system.
Chang et al.
FALSE

Effect of operative time and blood lost on overall survival after pancreaticoduodenectomy.
Kwak et al.
FALSE

A retrospective real-world study of nimotuzumab combined with chemotherapy for advanced pancreatic cancer.
Wu et al.
FALSE

Disparities in pancreatic cancer among Asian-Pacific Islander and American Indian-Alaskan Native populations.
Cullen et al.
FALSE

Genetic testing in patients with pancreatic cancer to reveal pathogenic variants in cancer susceptibility genes.
Tsoulos et al.
FALSE

Urine DNA model to predict response to neoadjuvant immune checkpoint inhibitors combined with chemotherapy in muscle-invasive bladder cancer.
Hu et al.
FALSE

Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection.
Yang et al.
FALSE

A novel approach to the treatment of high-risk non–muscle-invasive bladder cancer: Combining immune checkpoint inhibitor (ICI) and microtubule inhibitor (MTI).
Hu et al.
FALSE

Clinical performance of Bladder EpiCheck methylation test for active surveillance of non-muscle invasive bladder cancer: Systematic review and meta-analysis.
HSIA et al.
FALSE

Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.
Rose et al.
FALSE

Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer.
Yang et al.
FALSE

Neutrophil extracellular trap as a predictive marker to cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer.
Shang et al.
FALSE

A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).
Xu et al.
FALSE

Prediction of nonresponse and theranostic imaging in MIBC being resistant to NACT within the Bladder BRIDGister.
Kastner et al.
FALSE

Detection of bladder cancer relapse after TURBT through urinary tumor DNA analysis: A prospective real-world evidence study.
Zhang et al.
FALSE

A meta-analysis of local-regional therapy (LRT) in liver metastases from genitourinary cancers.
Behara et al.
FALSE

ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).
Galsky et al.
FALSE

Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.
Li et al.
FALSE

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with high-risk UTUC.
Niu et al.
FALSE

Preoperative oral antibiotic bowel preparation regimens in radical cystectomies with continent diversion.
Simhal et al.
FALSE

Monoamine oxidase as a potential target for the development of new therapeutic strategies for bladder cancer.
Camargo et al.
FALSE

Early postoperative outcomes in stent vs stent-less ileal conduits after radical cystectomies.
Shah et al.
FALSE

Phase Ib neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).
Li et al.
FALSE

A single institution experience of multimodality radiation therapy for muscle-invasive bladder cancer.
Nair et al.
FALSE

Prognostic value of DNA damage repair and tolerance factors in patients with muscle-infiltrating urothelial carcinoma.
Palacka et al.
FALSE

The efficacy and safety of antibody drug conjugate for high-risk non-muscle-invasive bladder cancer.
Li et al.
FALSE

Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI).
Nazha et al.
FALSE

Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV).
Jiang et al.
FALSE

Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced bladder cancer.
Chen et al.
FALSE

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer.
Jarvelainen et al.
FALSE

Incidence of other multiple primary malignancies in patients with adrenocortical carcinoma.
Koshiya et al.
FALSE

Differentiating bladder cancer (BLCA) tumor immune microenvironment (TME) profiles based on predicted intrinsic radiosensitivity (RS).
Vuong et al.
FALSE

Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.
Armstrong et al.
TRUE

Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
Ravi et al.
TRUE

Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status.
Olmos et al.
TRUE

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Fizazi et al.
TRUE

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).
Sandhu et al.
TRUE

Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.
Nappi et al.
TRUE

The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.
Bagrodia et al.
TRUE

Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.
Tandstad et al.
TRUE

PSMA PET guided salvage radiotherapy among patients with prostate cancer in the post-prostatectomy setting: A single center post-hoc analysis.
Smith et al.
TRUE

Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
Hadaschik et al.
TRUE

Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers.
Fendler et al.
TRUE

Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.
Thiery-Vuillemin et al.
TRUE

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).
Agarwal et al.
TRUE

Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
Sentana Lledo et al.
TRUE

A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
George et al.
TRUE

Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
Zhang et al.
TRUE

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.
Tagawa et al.
TRUE

Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
Dorff et al.
TRUE

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
Jensen et al.
TRUE

Association of adaptive immunity/inflammatory genes with survival in prostate cancer.
Hopper et al.
TRUE

Clinical analysis of optimized neural network risk models to predict clinically significant prostate cancer and avoid unnecessary prostate biopsies.
Wallis et al.
TRUE

Clinical implications of molecular alterations in intraductal carcinoma of the prostate.
Miron et al.
TRUE

Prostate cancer public health system database from Brazil: Racial disparities and heterogeneity of treatment interventions to understand evidence-based practice patterns in a large real-world database.
Herchenhorn et al.
TRUE

Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA).
Ross et al.
TRUE

AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
Mobadersany et al.
TRUE

Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.
Herrmann et al.
TRUE

The performance of prostate specific antigen (PSA) testing in the population based NPCC cohort.
Oldenburg et al.
TRUE

Predicting absolute benefit in risk of metastasis of androgen deprivation therapy added to radiation therapy in patients with newly diagnosed prostate cancer using Prolaris.
Tward et al.
TRUE

Prevalence of mismatch repair deficiency in a large prospective prostate cancer cohort.
McNevin et al.
TRUE

Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.
Carretero-González et al.
TRUE

Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.
Pouliot et al.
TRUE

Genetic ancestry associations with somatic mutations in a real-world cohort of over 3,000 patients with prostate cancer.
De La Vega et al.
TRUE

Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.
Feng et al.
TRUE

HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).
Bsteh et al.
TRUE

Association of plant-based diet index with quality of life in patients with prostate cancer.
Loeb et al.
TRUE

The impact of household income on prostate cancer diagnosis, treatment, and outcomes.
Panzone et al.
TRUE

64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.
Lengyelova et al.
TRUE

A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).
Funt et al.
TRUE

Prognostic factors for relapse in patients with clinical stage I testicular seminoma: A nationwide, population-based cohort study.
Wagner et al.
TRUE

Hospital Anxiety and Depression Scale (HADS) score trends among testicular cancer survivors: A longitudinal study.
Alkhatib et al.
TRUE

Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.
Garcia del Muro et al.
TRUE

Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.
Sager et al.
TRUE

Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.
Soon et al.
TRUE

Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.
Krause et al.
TRUE

Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
Sokolova et al.
TRUE

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.
Lara et al.
TRUE

Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).
Gebrael et al.
TRUE

Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.
Song et al.
TRUE

The effect of a reduced dose of enzalutamide on fatigue and cognition.
Overbeek et al.
TRUE

A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial.
Martinez et al.
TRUE

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.
Azad et al.
TRUE

Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
Raychaudhuri et al.
TRUE

PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
Raychaudhuri et al.
TRUE

Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Azad et al.
TRUE

Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.
Zhu et al.
TRUE

mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.
Isebia et al.
TRUE

Characterizing the molecular landscape of early onset and average onset prostate cancer.
Ogobuiro et al.
TRUE

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
Guo et al.
TRUE

Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.
Ledet et al.
TRUE

Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.
Desai et al.
TRUE

Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.
Unterrainer et al.
TRUE

Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.
Hamid et al.
TRUE

Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.
Ye et al.
TRUE

Enzalutamide vs abiraterone in patients with prostate cancer with and without type 2 diabetes mellitus.
Shaver et al.
TRUE

Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.
Dee et al.
TRUE

Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.
Zhang et al.
TRUE

Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.
Roy et al.
TRUE

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Halabi et al.
TRUE

Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
Ryan et al.
TRUE

Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
Burgess et al.
TRUE

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
Halabi et al.
TRUE

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
Parikh et al.
TRUE

Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC).
Mathew Thomas et al.
TRUE

Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (g-rate).
Leuva et al.
TRUE

Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).
Aggarwal et al.
TRUE

Assessing racial differences in time to treatment escalation following androgen-deprivation therapy among veterans with prostate cancer.
Friedrich et al.
TRUE

Treatment and survival of de novo metastatic hormone sensitive prostate cancer among African American US Veterans.
De Jesus Pizarro et al.
TRUE

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
Goldkorn et al.
TRUE

Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
Kohli et al.
TRUE

Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.
Hamid et al.
TRUE

Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).
Reig Torras et al.
TRUE

CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
Zaretsky et al.
TRUE

An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate cancer (mCSPC).
Zhou et al.
TRUE

Androgen-deprivation therapy and risk of dementia in patients with prostate cancer: Clinical outcomes from real-world data.
Elantably et al.
TRUE

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.
Marshall et al.
TRUE

The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Naqvi et al.
TRUE

Early findings from the GARUDA trial: The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making.
Weidhaas et al.
TRUE

Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
Djaileb et al.
TRUE

PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.
Armstrong et al.
TRUE

Socio-demographic, clinical, and genetic predictors of low versus high Gleason score among men with prostate cancer in the Detroit Research on Cancer Survivorship (ROCS) cohort.
Goodenow et al.
TRUE

Racial differences in the utilization of MRI-guided biopsy before prostate cancer diagnosis.
Lu-Yao et al.
TRUE

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
Phillips et al.
TRUE

Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.
McKay et al.
TRUE

Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): Updated individual patient data meta-analyses from the MARCAP consortium.
Ong et al.
TRUE

Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
Morgans et al.
TRUE

Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.
Jacobs et al.
TRUE

GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).
Conduit et al.
TRUE

CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906.
Conduit et al.
TRUE

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).
Atiq et al.
TRUE

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Zebic et al.
TRUE

SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.
Morin Coulombe et al.
TRUE

AGCT1531: Evaluating the utility of circulating microRNA in the management of children, adolescents, and adults with malignant germ cell tumors.
Shaikh et al.
TRUE

A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Guo et al.
TRUE

The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
McKay et al.
TRUE

A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.
Posadas et al.
TRUE

HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.
Chism et al.
TRUE

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.
Aggarwal et al.
TRUE

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
Jani et al.
TRUE

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.
Gao et al.
TRUE

Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
Shore et al.
TRUE

A feasibility study of 177Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligo-metastatic, hormone-sensitive prostate cancer after curative therapy: The DUET study.
Vis et al.
TRUE

ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.
Hackenbruch et al.
TRUE

APPROACH trial: Multimodal approach in patients with mHSPC: A pragmatic, randomized, phase 3 trial of androgen-deprivation therapy (ADT) plus apalutamide (APA) versus ADT plus apalutamide (APA) and local treatment—Meet-URO 29 study.
Guadalupi et al.
TRUE

PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.
Tagawa et al.
TRUE

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
Shore et al.
TRUE

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.
Vapiwala et al.
TRUE

Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer.
Stein et al.
TRUE

Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.
Kang et al.
TRUE

A multi-center natural history study of precision-based genomics in prostate cancer (PC).
Beltran et al.
TRUE

Circulating levels of PCSK9, ANGPTL3, and other lipid-related factors in men with high-grade prostate cancer.
Joncas et al.
FALSE

Genomic characterization of locally recurrent prostate cancer after radiation therapy.
Yang et al.
FALSE

Baseline endogenous serum testosterone levels and all-cause mortality in men with prostate cancer treated by radical radiotherapy: 11-year follow-up data.
Sundar et al.
FALSE

Comprehension characterization of prostate cancer cell lines identified JAK-STAT3 signaling in lineage-switched non-neuroendocrine cells.
Cheng et al.
FALSE

Real-world evidence analysis of early-stage prostate cancer using natural language processing.
Juárez et al.
FALSE

Hyperinsulinemia and risk of lethal prostate cancer.
Tanawattanacharoen et al.
FALSE

Circulating ether lipids in prostate cancer.
Horvath et al.
FALSE

Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET.
Maldonado et al.
FALSE

The clinical value of homologous recombination deficiency score in prostate cancer.
Wang et al.
FALSE

X-linked inhibitor of apoptosis protein (XIAP) expression level analyzed by immunohistochemistry (IHC) as it relates to clinical and pathologic characteristics in prostate cancer.
Beckerman et al.
FALSE

Patterns of recurrence post prostatectomy in the PSMA era: What lessons can we take to daily practice from a high-volume nuclear medicine center?
Lages et al.
FALSE

Assessing the discordance rate of HER2 expression by immunohistochemistry between primary and secondary prostate cancer biopsies.
Mabellos et al.
FALSE

Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer.
Song et al.
FALSE

Circulating chromatin conformation signatures to enhance PSA positive predictive value and overall accuracy for prostate cancer detection.
Akoulitchev et al.
FALSE

The association of HLA-DR and PD-L1 expression with clinical characteristics in prostate adenocarcinoma.
Tuerff et al.
FALSE

Do we need to redefine the phoenix criteria after the arrival of the new generation imaging techniques?
Muelas et al.
FALSE

Longitudinal variability in symptom burden for patients with prostate cancer (PC).
Wong et al.
FALSE

Development and initial clinical testing of a multiplex assay evaluating histone modifier p300 acetylation in prostate cancer circulating tumor cells.
Jarrard et al.
FALSE

Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer.
Barnett et al.
FALSE

Awareness of testicular cancer and testicular self-examination in young adults, and the efficacy of education-based media.
Walt et al.
FALSE

Germline thrombophilia gene alterations and thrombosis rates among patients with advanced germ cell tumors treated with chemotherapy.
Brown et al.
FALSE

Epidemiology and clinical trends of testicular cancer and secondary malignant tumors in a north Italian province.
Masini et al.
FALSE

Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma and non-testicular choriocarcinoma: A SEER database analysis.
Alshwayyat et al.
FALSE

Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT).
King et al.
FALSE

Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors.
Xiang et al.
FALSE

Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors.
Hassoun et al.
FALSE

Testicular GERM cell tumors treatment outcome in a national cancer institution in Peru.
Rioja et al.
FALSE

Chemotherapy induced peripheral neuropathy (CIPN) and biomarkers of gut microbial translocation in long-term survivors of testicular germ cell tumors.
Chovanec et al.
FALSE

Analysis of hospitalizations of patients with penile cancer: A national population-based study.
Kanemo et al.
FALSE

Luminal and basal subtyping of circulating tumor cells and influence on outcomes in patients with metastatic castration-resistant prostate cancer.
Wang et al.
FALSE

Retrospective review of 250 gallium-68 PSMA scans in prostate cancer patients in Health Canada Special Access Program.
Cohen et al.
FALSE

A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR).
Autio et al.
FALSE

Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).
Ganta et al.
FALSE

Therapy with metronomic cyclophosphamide (mCyc) in metastatic castrate resistant prostate cancer (mCRPC) and genomic correlates.
Mar et al.
FALSE

Dual inhibition of PARP and ATR induces homologous recombination repair deficiency and leads to synthetic lethality in prostate cancer with CDK12 alteration.
Akamatsu et al.
FALSE

Effect of SNPs in TMPRSS2 to severe COVID-19 in patients with prostate cancer.
Claps et al.
FALSE

Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.
Hassoun et al.
FALSE

Integration analysis of single-cell multi-omics in the prostate cancer ecosystem.
Bian et al.
FALSE

Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).
Sillah et al.
FALSE

Clonal hematopoiesis of indeterminate potential (CHIP) and association with response to bipolar androgen therapy (BAT).
Holler et al.
FALSE

Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.
Paller et al.
FALSE

Lu-PSMA-617 in combination with third-line therapy for castration-resistant prostate cancer: A systemic review and meta-analysis.
Akbar et al.
FALSE

Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect (IC) PrecisionQ.
Thomas et al.
FALSE

Use of poly (adp-ribose) polymerase inhibitors (PARPi) in metastatic castration resistant prostate cancer (mCRPC) patients stratified by homologous recombination repair mutations.
Thomas et al.
FALSE

The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Secondary analysis of two randomized clinical trials.
Ni et al.
FALSE

Real-world genetic testing patterns in metastatic prostate cancer in Latin American (LATAM) population.
Angel et al.
FALSE

Increasing targeted therapy options for mCRPC patients using multigene NGS panel.
Meintani et al.
FALSE

Tolerability of lutetium-177–PSMA-617 in men with prostate cancer and baseline cytopenia.
Abdelrazek et al.
FALSE

The expression of PKM1 and PKM2 in benign and cancerous prostatic tissues.
Li et al.
FALSE

Efficacy of PARP inhibitors in patients with metastatic castration resistant prostate carcinoma: A meta-analysis of phase III randomized controlled trials.
Patel et al.
FALSE

Accuracy of a simplified sequencing and bioinformatics platform on genetic variant detection in patients with prostate cancer.
Kapoor et al.
FALSE

Castration-resistant prostate cancer (CRPC) on PSMA-PET: Imaging features, disease distribution, and a comparison to castration-sensitive prostate cancer (CSPC).
Hsu et al.
FALSE

Platinum-based chemotherapy in patients with castration-resistant prostate cancer and hepatic metastases.
Von Amsberg et al.
FALSE

Racial and income characteristics and the burden of illness among metastatic prostate cancer patients.
Poolakkad Sankaran et al.
FALSE

Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177).
Nelson et al.
FALSE

Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro.
Schwermann et al.
FALSE

Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS.
Medley et al.
FALSE

Personalized precision combination therapies based on potential actionability and coalterations and therapeutic opportunities for CDK12-mutated prostate cancer.
Li et al.
FALSE

Androgen receptor–specific CD8+ T cells with tumor cell cytotoxicity in patients with prostate cancer in Taiwan.
Huang et al.
FALSE

Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
Lombana Quinonez et al.
FALSE

Head-to-head comparison of 68Ga-PSMA-11 PET with 99mTc-MDP bone scan for detection of bone disease in patients with prostate cancer with biochemical progression during ADT: A single center prospective study.
Gafita et al.
FALSE

Real world data of apalutamid in the treatment of prostate cancer: Data of the German multicenter AmPel trial.
Hegele et al.
FALSE

Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
Aydogdu et al.
FALSE

Darolutamide and time to pain progression by disease volume in ARASENS.
Smith et al.
FALSE

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.
Wang et al.
FALSE

The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.
Hoang et al.
FALSE

Prognosis stratification by a mutational signature in metastatic prostate cancer.
Zhang et al.
FALSE

Characterizing the role of PIM kinases in the prostate tumor immune microenvironment.
Clements et al.
FALSE

Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.
Freedland et al.
FALSE

Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Sutera et al.
FALSE

Relationship between androgen biosynthesis linked to 3βHSD1 and resistance to radiotherapy: A germline biomarker for combined androgen blockade with radiation in high-risk prostate cancer.
Ganguly et al.
FALSE

Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.
Shevrin et al.
FALSE

Impact of social determinants of health (SDOH) measures on prescribing advanced androgen blockade (AAB) in patients with metastatic hormone sensitive prostate cancer (mHSPC).
Ravilla et al.
FALSE

Biochemical recurrence after salvage prostate bed radiotherapy captured on PSMA-PET: Patient characteristics and distribution of recurrent disease.
Hsu et al.
FALSE

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.
Hawley et al.
FALSE

Replicating the timing of androgen deprivation therapy randomized trial (TROG 03.06 and VCOG PR 01-03 [TOAD]) for recurrent prostate cancer using real-world observational data.
Shin et al.
FALSE

Survival of de novo metastatic hormone sensitive prostate cancer in US Veterans based on treatment and PSA at diagnosis.
Babar et al.
FALSE

A brief mind-body intervention to reduce pain and anxiety during prostate needle biopsy: A randomized, controlled trial with two-staged consent.
Gaffney et al.
FALSE

Comparison of generic and specific anxiety in patients treated with apalutamide plus active surveillance vs active surveillance alone for low and intermediate risk prostate cancer.
Gravis et al.
FALSE

Maintenance of castration with concomitant relugolix and apalutamide (Apa) in patients with high-risk localized prostate cancer (HR-LPC): 1 year update.
Brown et al.
FALSE

Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.
Yu et al.
FALSE

Algorithm-based histologic grade and tumor ratio for radical prostatectomy: Comparison with pathology reports.
Kwak et al.
FALSE

A novel, AI-generated morphologic biomarker to predict prostate cancer recurrence in patients with intermediate risk of progression.
Nair et al.
FALSE

Machine learning to predict future PSA in patients with prostate cancer managed with active surveillance.
Ayed et al.
FALSE

Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.
Carletti et al.
FALSE

Ten-year outcomes of hypofractionated (45 Gy in 9 fractions) intensity-modulated radiotherapy for localized prostate cancer.
Zhong et al.
FALSE

Effect of the COVID-19 pandemic on radical prostatectomy: A Brazilian retrospective study.
Marangoni Roschel et al.
FALSE

EPIC-26 urinary incontinence score results and pad use 12 months after radical prostatectomy for localized or (locally) advanced prostate cancer: Results of a cohort of 14,920 patients from 118 certified centers in Germany, Switzerland, and Austria.
Hammerer et al.
FALSE

Results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.
Knipper et al.
FALSE

Validation of AI-based postoperative nomograms for biochemical recurrence in prostate adenocarcinoma.
Lee et al.
FALSE

Exploring the efficacy of a continuous form of the histologic grade in prostate cancer prognosis prediction.
Kwak et al.
FALSE

Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian public health system.
Carvalhal et al.
FALSE

Deep learning-based histomorphological pattern profiles for effective risk stratification in prostate cancer.
Lee et al.
FALSE

Perioperative safety and outcomes following radical prostatectomy in setting of locally advanced, node positive, and metastatic prostate cancer.
Wang et al.
FALSE

3D open-top light-sheet microscopy and 3D microdissection of neuoadjuvant-treated primary prostate cancer reveals latent subclonal mutations.
Reder et al.
FALSE

Impact of obesity on admissions for COVID-19 with concurrent prostate cancer.
Verma et al.
FALSE

Biochemical recurrence (BCR) among patients (pts) with prostate cancer (PC) after radiation therapy (RT).
Spratt et al.
FALSE

Biochemical recurrence (BCR) and outcomes in patients (pts) with prostate cancer (PC) following radical prostatectomy (RP).
Khan et al.
FALSE

Investigating the association (assoc) between mental health illness (MHI) and development of prostate cancer (PC) in a nationwide matched cohort of >5,000,000 US Veterans.
Klaassen et al.
FALSE

Late-stage prostate cancer and associated socioeconomic and demographic factors: A National Cancer Database Study.
Abodunrin et al.
FALSE

Difference in management of patients with prostate cancer and spinal cord compression in teaching vs non-teaching hospitals in the United States.
Yazdanpanah et al.
FALSE

Evaluating genetic screening/counseling for patients diagnosed with prostate cancer who meet hereditary risk assessment based on NCCN Guidelines.
Ruiz Vega et al.
FALSE

Fully automated prostate cancer identification using multiplex fluorescence immunohistochemistry to assess prognosis markers on a single tissue section.
Blessin et al.
FALSE

Bone health practices in metastatic prostate cancer (mPCA).
Eule et al.
FALSE

Treatment trends and prognostic factors related to histology of squamous cell carcinoma of the prostate: A SEER review.
Siripurapu et al.
FALSE

Update on the outcome of patients with metastatic prostate cancer in Kentucky: A Kentucky Cancer Registry (KCR) study.
Pandey et al.
FALSE

Socioeconomic and demographic patterns associated with treatment delay in prostate cancer: An analysis of the National Cancer Database.
Abodunrin et al.
FALSE

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Monk et al.
TRUE

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.
Ray-Coquard et al.
TRUE

Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Leath et al.
TRUE

Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell et al.
TRUE

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.
Mirza et al.
TRUE

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).
Arend et al.
TRUE

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
Oaknin et al.
TRUE

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.
Aronson et al.
TRUE

Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.
Classe et al.
TRUE

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
Konstantinopoulos et al.
TRUE

Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).
Liu et al.
TRUE

A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.
Damian et al.
TRUE

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Banerjee et al.
TRUE

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.
Wang et al.
TRUE

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.
Chae et al.
TRUE

Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.
Nakamura et al.
TRUE

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
Chen et al.
TRUE

Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.
Joly et al.
TRUE

The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.
Han et al.
TRUE

The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecologic malignancies in the United States.
Kohut et al.
TRUE

Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Wang et al.
TRUE

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.
Mackay et al.
TRUE

Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.
Kee et al.
TRUE

Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.
Pellegrino et al.
TRUE

Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool.
Prescott et al.
TRUE

SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
Liu et al.
TRUE

Efficacy and safety of combining PD-1 blockage and human papillomavirus vaccine for patients with relapsed/refractory advanced cervical cancer.
Wang et al.
TRUE

The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
Zhu et al.
TRUE

A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.
Arimoto et al.
TRUE

Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.
Corrigan et al.
TRUE

The value of progression-free survival at three years as a primary endpoint for studies on radiotherapy in patients with locally advanced cervical cancer: Individual patient data from Chinese National Cancer Center and validation from 27 global randomized trials.
Yang et al.
TRUE

A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed.
An et al.
TRUE

Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.
Fogt et al.
TRUE

Development of cervical cancer patient reported clinical outcome assessment scale (CC-PRO137): A dedicated tool for multidimensional evaluation of treatment outcomes.
Wu et al.
TRUE

A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Nakagawa et al.
TRUE

Surgical resection based on ontogenetic cancer field theory for cervical cancer: 10-year updated results of the MMR study.
Weydandt et al.
TRUE

Association between serum folate and vitamin B12 and cervical high-risk human papillomavirus (HPV) infection.
Peitz et al.
TRUE

Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.
Chen et al.
TRUE

The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
Ahsan et al.
TRUE

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
Lakhani et al.
TRUE

Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC).
Richardson et al.
TRUE

Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
Foster et al.
TRUE

The impact of adjuvant platinum-based chemotherapy in early adult granulosa cell tumor of the ovaries: A meta-analysis of comparative studies.
Keerty et al.
TRUE

Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Drescher et al.
TRUE

Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer.
Knisely et al.
TRUE

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
Harter et al.
TRUE

Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).
Zhao et al.
TRUE

Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
McLaughlin et al.
TRUE

Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).
Ananda et al.
TRUE

Safety and efficacy of PIPAC in patients with ovarian cancer with peritoneal metastases: A first-in-US phase I study.
Senguttuvan et al.
TRUE

Analyses of tumor microenvironment affecting the survival in patients with ovarian cancer receiving intraperitoneal chemotherapy: Translational research from the phase 3 trial of intraperitoneal therapy for ovarian cancer with carboplatin (TRiPocc).
Ogasawara et al.
TRUE

Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial.
Shen et al.
TRUE

The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.
Giudice et al.
TRUE

DNA methylation patterns between tissue and blood samples in ovarian cancer.
Wen et al.
TRUE

BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
Blons et al.
TRUE

Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.
Corr et al.
TRUE

Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Werner et al.
TRUE

Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.
Kong et al.
TRUE

Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.
Ottevanger et al.
TRUE

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.
Shin et al.
TRUE

Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.
Kahn et al.
TRUE

Anastomotic leakage following bowel resection in radical cytoreductive surgery for ovarian cancer: A subgroup analysis of the prospective AGO-OVAR.OP3/LION.
Czogalla et al.
TRUE

Proactive assessment of patient reported outcomes in patients with ovarian cancer.
Madariaga et al.
TRUE

The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
Barakzai et al.
TRUE

CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.
Leary et al.
TRUE

Trends in ovarian cancer incidence and incidence-based mortality: A 15-year population-based analysis.
Somasegar et al.
TRUE

Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer.
Barakzai et al.
TRUE

Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR).
Naidoo et al.
TRUE

Impact of cytoreductive surgery on survival outcomes for recurrent adult-type granulosa cell tumors of the ovary.
How et al.
TRUE

A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
Gaillard et al.
TRUE

Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).
Jiang et al.
TRUE

Understanding differences in the rates of BRCA/HRD testing and treatment in 1st line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ.
Kudrik et al.
TRUE

First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.
Gong et al.
TRUE

Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.
MacAulay Vacheresse et al.
TRUE

Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations.
Strickland et al.
TRUE

Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis.
Cunha et al.
TRUE

Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Silberman et al.
TRUE

Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?
Ahsan et al.
TRUE

Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
Richardson et al.
TRUE

Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
Kim et al.
TRUE

The diagnostic landscape of HRD testing based on cross-sectional survey of physicians and molecular biologists conducting testing (INDICATOR ONE).
Coleman et al.
TRUE

Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).
Leary et al.
TRUE

Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups.
Lindemann et al.
TRUE

Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.
Buisson et al.
TRUE

Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.
Graybill et al.
TRUE

Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
Liao et al.
TRUE

The role of Chemotherapy Response Score (CRS) in the decision making process for patients with advanced high grade serous ovarian cancer undergoing neoadjuvant chemotherapy.
Marchetti et al.
TRUE

Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.
Coleman et al.
TRUE

Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.
Danziger et al.
TRUE

Healthcare access dimensions and uterine cancer survival: A National Cancer Database study.
Anastasio et al.
TRUE

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.
Rasco et al.
TRUE

Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.
Liu et al.
TRUE

The effect of megestrol acetate ± pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial.
Senguttuvan et al.
TRUE

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.
Zeng et al.
TRUE

Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.
Santin et al.
TRUE

Racial and ethnic disparities in quality of diagnostic evaluation for uterine cancer among Medicare patients.
Xu et al.
TRUE

OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.
Schilder et al.
TRUE

Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes.
Depke et al.
TRUE

Association of the Duffy-null allele and endometrial cancer characteristics: An effort to explore racial disparity in Black women with endometrial cancer.
Webster et al.
TRUE

The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).
Buchanan et al.
TRUE

Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Reimer et al.
TRUE

Impact of best practice advisory on genetic counseling referral patterns for patients with endometrial cancer.
Nagle et al.
TRUE

Impact of surgical weight loss treatments on care burden among obese endometrial cancer survivors.
Noyes et al.
TRUE

Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.
Hong et al.
TRUE

A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.
Yuan et al.
TRUE

TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
Santin et al.
TRUE

Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers.
Son et al.
TRUE

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).
Herzog et al.
TRUE

UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC).
Hays et al.
TRUE

UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.
Richardson et al.
TRUE

A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
Mirza et al.
TRUE

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
Westin et al.
TRUE

CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC).
Mackay et al.
TRUE

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
Leary et al.
TRUE

Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.
How et al.
TRUE

First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).
Braicu et al.
TRUE

Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).
LEE et al.
TRUE

GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
O'Malley et al.
TRUE

Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.
Mackay et al.
TRUE

First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.
Moore et al.
TRUE

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.
Barroilhet et al.
TRUE

A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Corr et al.
TRUE

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.
Vergote et al.
TRUE

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
Lee et al.
TRUE

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.
Rimel et al.
TRUE

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
Joly et al.
TRUE

RT-PACE: Phase I/II study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.
Son et al.
TRUE

CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.
McAlpine et al.
TRUE

The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.
Kaya et al.
TRUE

AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.
Cantillo et al.
TRUE

GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients' expectations and assessment of care.
Lindemann et al.
TRUE

A cross-sectional study of 73,390 women without ovarian cancer and the effect of age and benign gynecological diseases on serum CA125 levels.
Zhu et al.
FALSE

The insights of mutations of gynecological oncology by liquid biopsy for Chinese patients.
Huang et al.
FALSE

AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines.
Perez-Fidalgo et al.
FALSE

Comprehensive ctDNA analysis to identify genome-instability and actionable mutation landscape in gynecologic cancers.
Bharde et al.
FALSE

The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.
Perez-Fidalgo et al.
FALSE

Predictive molecular markers of chemoradiation resistance in cervical cancer.
Kumar et al.
FALSE

Incidence of low volume metastases after retrospective ultrastaging of patients with early stage, node negative cervical cancer and receipt of post-operative adjuvant therapy.
Welp et al.
FALSE

Identifying small non-coding RNAs as biomarkers for cervical cancer.
Peitz et al.
FALSE

18F-FDG PET/CT parameters in precision treatment planning for locally advanced squamous cell carcinoma of the uterine cervix.
Lai et al.
FALSE

Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study.
Esin et al.
FALSE

Guideline adherent colposcopy completion following abnormal cervical cancer screening.
Patel et al.
FALSE

Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy.
Coutinho et al.
FALSE

Penpulimab plus platinum-based chemotherapy combined with anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, open-label phase Ⅱ study (ALTN-AK105-II-06).
Xu et al.
FALSE

Long-term survival outcomes and immune checkpoint inhibitor (ICI) retreatment in patients with advanced cervical cancer who received camrelizumab plus apatinib in the CLAP study.
Lan et al.
FALSE

Circulating exosomal PD-L1 to predict response with immunotherapy in patients with advanced cervical cancer.
Tang et al.
FALSE

The safety and efficacy of cadonilimab in the treatment of advanced and metastatic cervical cancer: A retrospective, real-world study.
Fan et al.
FALSE

Response and re-treatment response to immune checkpoint inhibitor treatment in advanced cervical cancer: A follow up study.
Wolf et al.
FALSE

Prognostic value of systemic immune-inflammation index in patients with locally advanced cervical cancer.
Torres-Cisneros et al.
FALSE

Maintenance therapy for patients with recurrent or metastatic cervical cancer: A multicentre, cohort study.
Peng et al.
FALSE

The perception of cervical cancer screening and prevention among Saudi women.
Abusanad et al.
FALSE

Ribosomal protein S26 (RPS26) expression of advanced cervical cancer (CC) to predict response to programmed death-1 inhibitor combination therapy: A secondary analysis of the CIBI308ALTER-C201 trial.
Liu et al.
FALSE

Tertiary lymphoid structure prevalence and prognostic value in cervical cancer.
Gorecki et al.
FALSE

Association between cervical immune markers and cervical high-risk HPV infections.
Adebamowo et al.
FALSE

Revealing a novel tumor immune escaping mechanism induced by macrophage-tumor fusion cells in HPV- cervical cancer through spatial SCRNA analysis.
Zhang et al.
FALSE

Trends in cervical cancer incidence rates among demographic groups: A SEER database analysis.
Thierheimer et al.
FALSE

Risk factors for lymph node metastasis and clinical outcomes in cervical cancer patients following primary radical hysterectomy: A single-center analysis of 1495 patients.
Qian et al.
FALSE

Evaluation of the prevalence of HPV from environmentally unfavorable districts of the Republic of Karakalpakistan.
Zakhirova et al.
FALSE

Impact of hospital volume and margin status on survival following radical hysterectomy: An expanded NCDB study.
Jhaveri et al.
FALSE

Single-cell and spatial transcriptomics to analyze radiation therapy-induced tumor microenvironment reshaping in HPV- cervical cancer.
Zhang et al.
FALSE

Impact of hemoglobin on survival of young women with cervical cancer treated with concurrent chemoradiotherapy.
Castro-Mollo et al.
FALSE

Single cell analysis to study the longitudinal changes in systemic tumor immune environment in cervical cancer after radiochemotherapy.
Zhao et al.
FALSE

Start so young? Defense of the primary HPV test as a screening test for cervical cancer in women aged 25 and over in Brazil.
Costa et al.
FALSE

A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer.
Li et al.
FALSE

Homologous recombination deficiency (HRD) status and response to platinum-based chemotherapy and PARP inhibitors in Chinese patients with ovarian cancer.
Yuan et al.
FALSE

Diagnostic model of low-grade serous ovarian cancer and borderline serous ovarian tumor: Model development and validation based on radiomics.
Song et al.
FALSE

Single cell multiomic profiling of high-grade serous carcinoma.
Assad Maia Sandoval et al.
FALSE

Different disease progression patterns based on RECIST and CA-125 criteria and the impact on prognosis in patients with ovarian cancer treated with PARP inhibitors.
Song et al.
FALSE

Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.
Khanmammadov et al.
FALSE

Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer.
Li et al.
FALSE

Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant ovarian cancer.
Shneider et al.
FALSE

Clinical remission rates in patients with epithelial ovarian cancer in the pandemic versus the pre-pandemic period.
Shammas et al.
FALSE

Circulating tumor DNA–based detection of molecular residual disease as a biomarker for recurrence monitoring predict disease recurrence in patients with ovarian cancer.
Lv et al.
FALSE

Spatial profiling of ovarian clear cell carcinoma (OCCC) and identification of immune-hot features.
Tai et al.
FALSE

Phase 1/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors.
Wang
FALSE

Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).
Hannaway et al.
FALSE

A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.
P B et al.
FALSE

Genetic counseling referral frequency and attrition for newly diagnosed epithelial ovarian cancer at Grady Memorial Hospital from 2012-2022.
Wood et al.
FALSE

Effect of multi-targeting bacterial gene therapy on tumour regression and survival in mouse models of ovarian and intraperitoneal cancer.
Samaranayake et al.
FALSE

A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study).
Lin et al.
FALSE

Clinical safety and efficacy observation of ex vivo-expanded peripheral blood-derived allogeneic NK cells in the treatment of refractory or recurrent ovarian cancer.
Zhu et al.
FALSE

Screening mitophagy-related lncRNAs based on WGCNA to identify and validate a prognostic signature for patients with ovarian cancer.
Zheng et al.
FALSE

Impact of postoperative residual disease in patients with primary epithelial ovarian cancer in the era of maintenance therapies with targeted agents: A systematic review and meta-analysis.
Kim et al.
FALSE

The peripheral TCR repertoire diversity indexes can be used as an independent indicator for long term survival rate of ovarian cancer patients.
Fu et al.
FALSE

Posterior reversible encephalopathy syndrome in malignancy: Hypercalcemic storm?
Dandwani et al.
FALSE

Is laparoscopic approach feasible in early-stage ovarian cancer? A retrospective study in single tertiary center.
Chang
FALSE

Proteomic profiling of peritoneal fluid-derived exosomes as a tool for the identification of prognostic markers in advanced ovarian carcinomas.
Quiralte et al.
FALSE

Can epigenetic treatments efficiently revoke the ability of 3D ovarian cancer cells to proliferate, migrate, and invade?
Kelly et al.
FALSE

Genetic counseling and testing for epithelial ovarian cancer in a diverse patient population.
Kim et al.
FALSE

Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.
Ngoi et al.
FALSE

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.
Hou et al.
FALSE

Comparison of BRCA genetic testing and subsequent treatment with PARP inhibitors (PARPi) for ederly vs non-elderly women with non-mucinous epithelial ovarian cancer (EOC): A large prospective cohort study from the Australian National Gynaecology Oncology Registry (NGOR).
Naidoo et al.
FALSE

Demographic and socioeconomic factors in poorly differentiated Sertoli-Leydig cell tumors: A National Cancer Database analysis.
Cogua
FALSE

Prognostic risk stratification of low-grade serous ovarian cancer: Model development and validation based on machine learning algorithm.
Chen et al.
FALSE

A web-based prediction model for overall survival of elderly patients with epithelial ovarian cancer: A population-based study.
Tang et al.
FALSE

Genomic and transcriptomic characterization of ovarian cancer under neoadjuvant and adjuvant chemotherapy.
Jin et al.
FALSE

The impact of lymphadenectomy on survival outcomes of ovarian clear cell carcinoma: A systematic review and meta-analysis.
Liu et al.
FALSE

The impact of homologous recombination deficiency on first-line adjuvant chemotherapy and first-line PARPi maintenance therapy in Chinese patients with epithelial ovarian cancer.
Li et al.
FALSE

Real world study on the effect of PARPi as maintenance therapy after first-line and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer.
Guo et al.
FALSE

Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.
Barretina-Ginesta et al.
FALSE

Effect of testing for BRCA1/2 on outcomes in patients with ovarian cancer treated with PARPi in 1st line maintenance (1LM).
Gordan et al.
FALSE

Prognostic value of insulin-like growth factor receptor 1 (IGF1R) expression in high-grade serous ovarian cancer (HGSOC) treated with first line platinum derivative based chemotherapy.
Szymanowski et al.
FALSE

Targeting regeneration capacity of stem cells to improve surgical wound healing outcomes in ovarian cancer patients.
Kelly et al.
FALSE

Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage ovarian cancer: A prospective multicentre study (SELLY).
Nero et al.
FALSE

Levels of ANGPTL3 and characterization of other circulating cholesterol-related factors in high-grade serous ovarian cancers.
Wong Chong et al.
FALSE

Investigating the association between BRCA1/2 copy number variation and homologous recombination deficiency score in ovarian cancer: A cross-sectional study.
Yang et al.
FALSE

Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer.
Park et al.
FALSE

Resistance mechanism and microenvironment changes after PARPi treatment: Paired analysis of ovarian cancer samples pre and post treatment.
Li et al.
FALSE

Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.
Stecca et al.
FALSE

A DMBA-induced ovarian cancer model: Could it be clinically useful to test OncoTherad and erythropoietin as anticancer approaches?
Ribeiro de Souza et al.
FALSE

Factors associated with platinum sensitivity (PST) and related outcomes in patients with ovarian cancer (OC) in a US community oncology setting: Looking beyond.
Chase et al.
FALSE

Comprehensive HRD testing in epithelial ovarian cancer: A further step toward personalized therapy decisions.
Reimer et al.
FALSE

Role of BRCA1 promotor methylation (BRCA1meth) in homologous recombination deficiency (HRD) in high-grade epithelial ovarian cancer.
Zeimet et al.
FALSE

Progression-free survival in patients receiving first-line platinum-based therapy in Argentina: OCEANIA study.
Abreu et al.
FALSE

Prognostic and predictive significance of CA-125 elimination rate constant K (KELIM) in ovarian cancer patients treated with neoadjuvant chemotherapy in a real-world setting.
Liontos et al.
FALSE

Overall survival in treated ovarian cancer patients in Argentina: OCEANIA study.
Abreu et al.
FALSE

Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.
Bisgin et al.
FALSE

Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.
Vasudevan et al.
FALSE

Does age matter? An ovarian cancer cohort from a single, urban, academic institution.
Holtzman et al.
FALSE

Circulating tumor DNA-based molecular residual disease detection for the monitoring of high-grade serous ovarian cancer.
Ying et al.
FALSE

PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer.
Kudrik et al.
FALSE

OncoTherad immunotherapy plus platelet rich plasma as potential therapeutic strategy for ovarian cancer: The role of toll-like receptors 2 and 4 signaling pathways.
Oliveira et al.
FALSE

TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors.
Falchook et al.
FALSE

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of ovarian cancer.
Jeter et al.
FALSE

Clinical predictors of survival in advanced epithelial ovarian cancer: Can we foresee the long-term survivors and develop a personalized treatment approach?
Shachar et al.
FALSE

Development of a microbead based immunoassay to detect circulating soluble HLA-E: Application in cancer immunobiology.
Kanangat et al.
FALSE

Multivariate index assay (MIA3G) to reduce preventive surgery for ovarian cancer.
Ghosh et al.
FALSE

Serial monitoring of ovarian cancer risk in women with adnexal mass.
Pappas et al.
FALSE

Multivariate index assay MIA3G vs other assessment tools for the ovarian cancer risk assessment of indeterminate masses.
Ghosh et al.
FALSE

The predictive value of CA-125 for radiologic evidence of metastatic disease in type 2 endometrial cancers.
Miller et al.
FALSE

The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.
Chang et al.
FALSE

Real-world characteristics and treatment pattern of patients with newly diagnosed endometrial cancer in China.
Yin et al.
FALSE

Molecular classification of endometrial carcinoma: Analysis of a multicentre Portuguese cohort.
Moreira et al.
FALSE

Targeting HE4 for treatment of endometrial cancer using a novel small molecule inhibitor.
Morell et al.
FALSE

Development and validation of prediction models for coexisting adnexa malignancy in patients with endometrial cancer using machine learning algorithm: A population-based cohort study.
Wang et al.
FALSE

Comparing sentinel lymphadenectomy and complete lymphadenectomy among obese patients (BMI >30) undergoing minimally invasive hysterectomy for early-stage endometrial cancer: An ACS-NSQIP database study.
Hollingsworth et al.
FALSE

Lynch screening and genetic testing in endometrial cancer in a diverse population.
Kim et al.
FALSE

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for human uterine sarcoma cells.
Omran et al.
FALSE

Study of endometrial carcinoma on correlation between molecular typing and lymph node metastasis and construction of prediction model.
Jiang et al.
FALSE

A novel prognostic model for high-grade endometrial cancer using combined neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR).
Zhang et al.
FALSE

Real world evidence on long-term survival of patients with endometrial cancer in Germany: Analysis of population-based cancer registry data on 49808 women.
Chinczewski et al.
FALSE

3D genomics identify alternate mechanisms of homologous recombination deficiency in uterine sarcoma.
Chiang et al.
FALSE

Clinical utility of plasma ctDNA sequencing monitoring and tumor molecular profile exploration in endometrial carcinoma: A Caribbean prospective cohort from Martinique.
Marlin et al.
FALSE

Immunohistochemical expression of ER and p53 as predictive biomarkers of immunotherapy in endometrial cancer.
Liontos et al.
FALSE

The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer.
Barbi et al.
FALSE

Risk reclassification of endometrial cancer according to molecular profiling: UK single centre experience.
Kebaier Ep Chaabouni et al.
FALSE

A pilot study evaluating somatic mutational burden and signatures among endometrial cancer patients: Is there prognostic benefit to whole genome sequencing?
Kulkarni et al.
FALSE

Survey of carboplatin desensitization therapy: JCOG Gynecologic Cancer Study Group multicenter retrospective study.
Komatsu et al.
FALSE

Uterine sarcoma patients who underwent morcellation: Who are they? Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA- NOGGO RU1).
Roser et al.
FALSE

Genomic characterization of vulvar squamous cell carcinoma to reveal differential gene expression based on clinical outcome.
Gordinier et al.
FALSE

Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.
Vandenberg et al.
FALSE

The distribution of HPV subtype in vulvar intraepithelial neoplasia and the association with recurrent VIN and vulva cancer in Taiwan.
Liao et al.
FALSE

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
Tang et al.
TRUE

Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.
Chen et al.
TRUE

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
Fayette et al.
TRUE

Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
Hanna et al.
TRUE

Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD).
Thomson et al.
TRUE

Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.
Rosenberg et al.
TRUE

Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
Ferrarotto et al.
TRUE

Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Mai et al.
TRUE

NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).
Hui et al.
TRUE

Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.
Rodriguez et al.
TRUE

Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).
Price et al.
TRUE

A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Chung et al.
TRUE

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.
Skinner et al.
TRUE

Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
Oppelt et al.
TRUE

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.
Cohen et al.
TRUE

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.
Swiecicki et al.
TRUE

Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
Ferris et al.
TRUE

Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).
Wong et al.
TRUE

The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer.
Posner et al.
TRUE

Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).
Park et al.
TRUE

Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.
Puram et al.
TRUE

Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
Cohen et al.
TRUE

Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
Kong et al.
TRUE

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
Desilets et al.
TRUE

A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
Mai et al.
TRUE

Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models.
Yeung et al.
TRUE

Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.
Kong et al.
TRUE

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
Doger de Spéville et al.
TRUE

Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.
Chen et al.
TRUE

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.
Lu et al.
TRUE

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
Koyama et al.
TRUE

To test, or not to test, that is the question: A real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Black et al.
TRUE

Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Galot et al.
TRUE

Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus–positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
Colevas et al.
TRUE

Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Ferris et al.
TRUE

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
Xue et al.
TRUE

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
Shen et al.
TRUE

Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).
Sun et al.
TRUE

Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
Kang et al.
TRUE

Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).
Chakravarthy et al.
TRUE

Evaluation of small extracellular vesicles as biomarkers of efficacy with anti-PD-1 mAb therapy in patients with recurrent/metastatic HNSCC.
Zandberg et al.
TRUE

A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity.
Rischin et al.
TRUE

Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
Fayette et al.
TRUE

Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.
Thyparambil et al.
TRUE

Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
Zamulko et al.
TRUE

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.
Jia et al.
TRUE

A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
Mohamadpour et al.
TRUE

Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.
Feng et al.
TRUE

Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
Bahig et al.
TRUE

Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in patients with head and neck cancer (HNSCC).
Sarfraz et al.
TRUE

Association of pretreatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation.
Yu et al.
TRUE

Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).
Chung et al.
TRUE

Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).
Guan et al.
TRUE

A proteomic signature associated with prognosis in HPV-related locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
Liu et al.
TRUE

Single-cell RNA and T cell receptor (TCR) sequencing in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) after induction CTLA4 and PD-1 immune checkpoint blockade (ICB).
Jiang et al.
TRUE

Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC.
Garb et al.
TRUE

Association of HPV genotype and phylogenic clade with oropharyngeal cancer outcomes.
Wotman et al.
TRUE

Spatial genomics to reveal an immunosuppressive tumor microenvironment after chemoradiation in head and neck cancer patients.
Choe et al.
TRUE

Clinical validity of TTMV-HPV DNA liquid biopsies for the diagnosis and surveillance of HPV-associated oropharyngeal carcinoma.
Roof et al.
TRUE

Spatial relationships and immune subsets in the tumor immune microenvironment of head and neck cancers.
Henry et al.
TRUE

Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).
Sehgal et al.
TRUE

The impact of genetic predisposition to depression on quality of life in patients with head and neck cancer immediately post-treatment: A longitudinal study.
Henry et al.
TRUE

Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.
Kong et al.
TRUE

Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Sanz Garcia et al.
TRUE

One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.
Allen et al.
TRUE

Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial.
Fangzheng et al.
TRUE

Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.
Ou et al.
TRUE

A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.
Wu et al.
TRUE

Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
Bai et al.
TRUE

Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.
Lv et al.
TRUE

Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.
Tang et al.
TRUE

CT radiomic signature to predict overall survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma.
Song et al.
TRUE

Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.
Biswas et al.
TRUE

Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis.
Kim et al.
TRUE

Development of CT-based radiomic model to predict 5-year progression-free survival (PFS) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with definitive chemoradiation.
Bruixola et al.
TRUE

Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.
Chen et al.
TRUE

Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.
Liu et al.
TRUE

Impact of acute kidney injury on overall survival in postoperative patients with head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of a phase II/III trial of JCOG1008.
Imamura et al.
TRUE

Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.
Yan et al.
TRUE

Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.
Bila et al.
TRUE

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.
Ottensmeier et al.
TRUE

Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.
De Los Santos et al.
TRUE

Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?
Misiukiewicz et al.
TRUE

10-year outcomes of technically unresectable oral cancers with neoadjuvant chemotherapy: Real-world data and implications for clinical practice.
Dhanawat et al.
TRUE

Use of machine learning derived features from CT and H&E whole-slide images to predict overall survival in head and neck squamous cell carcinoma.
Song et al.
TRUE

Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.
Gui et al.
TRUE

A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
Ji et al.
TRUE

Phase II prospective trial of induction chemotherapy for advanced sinonasal squamous cell or poorly differentiated carcinoma.
Contrera et al.
TRUE

Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
Cabanillas et al.
TRUE

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
Nagatani et al.
TRUE

Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
Okano et al.
TRUE

Clinical and genomic characterisation of adenoid cystic carcinoma of the head and neck, lung, and breast.
Heathcote et al.
TRUE

Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.
Srour et al.
TRUE

Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
Hoff et al.
TRUE

Monitoring epithelial, epithelial-mesenchymal, and mesenchymal circulating tumor cells on papillary thyroid cancer following thyroidectomy: A prospective cohort study.
Park et al.
TRUE

Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center.
Weijers et al.
TRUE

177Lu-PSMA radioligand therapy for patients with recurrent/metastatic (R/M) salivary gland cancer (SGC): A phase II pilot study.
Van Herpen et al.
TRUE

Artificial intelligence (AI) analysis of tumor-infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) slides to explore immune phenotypes in papillary thyroid cancer.
Nam et al.
TRUE

XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Ferris et al.
TRUE

A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
Colevas et al.
TRUE

Palbociclib + cetuximab versus cetuximab in patients with CDKN2A-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial.
Ley et al.
TRUE

Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
Cohen et al.
TRUE

A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.
Abdelhamid Ahmed et al.
TRUE

A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
Harrington et al.
TRUE

A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Ho et al.
TRUE

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
Adkins et al.
TRUE

Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A*0201 positive patients with HPV16+ OPSCC.
Zaretsky et al.
TRUE

A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.
Park et al.
TRUE

A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
Oliveira et al.
TRUE

Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.
Hu et al.
TRUE

KEVLAR: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. standard of care in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).
Reid et al.
TRUE

CCTG HN11: SPECT-CT guided elective contralateral neck treatment (SELECT) for patients with lateralized oropharyngeal cancer—A phase III randomized controlled trial.
de Almeida et al.
TRUE

Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).
Rosenberg et al.
TRUE

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma.
Bracken-Clarke et al.
TRUE

IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC.
Cabanillas et al.
TRUE

Oral capecitabine or tegafur/gimeracil/oteracil as induction and adjuvant/maintenance chemotherapy in the management of stage III-IVb nasopharyngeal carcinoma: A systematic-review and meta-analysis.
Polintan et al.
FALSE

Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Vugmeyster et al.
FALSE

Nominating molecular/immunologic drivers of central nervous system (CNS) metastases in squamous cell carcinoma of the head/neck (SCCHN).
Kacew et al.
FALSE

Mechanisms of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.
Burkitt
FALSE

The changes of HER3 expression in head and neck cancer patients treated with induction chemotherapy.
Kim et al.
FALSE

Nimotuzumab in combination with intensity modulated radiotherapy improve survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multicenter-based real-world study.
Yi et al.
FALSE

Social determinants of survival in head and neck cancer.
Kennedy et al.
FALSE

Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
Algazi et al.
FALSE

Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.
Yang et al.
FALSE

Comparison of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma based on phase 3 randomized clinical trials.
Xiong et al.
FALSE

A phase II study cohort of penpulimab plus anlotinib in patients with recurrent or metastatic non-squamous cell carcinomas of head and neck.
Zhang et al.
FALSE

Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses.
Zhang et al.
FALSE

Patterns and outcomes of palliative radiation therapy with immunotherapy in locally recurrent head and neck squamous cell carcinoma.
Roof et al.
FALSE

Chronotherapy in head and neck cancer (HNC): A systematic review.
Abu-Samak et al.
FALSE

Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).
Buriolla et al.
FALSE

A retrospective study evaluating the efficacy of pembrolizumab for metastatic or locally recurrent head and neck cancer: A real-world experience.
Pirruccello et al.
FALSE

Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.
Jiang et al.
FALSE

Impact of EBV positivity on clinical outcomes in nasopharyngeal cancer.
Ghimire et al.
FALSE

Long term disease-free survival in locoregional, metastatic and/or recurrent UCNT.
Hadji
FALSE

Adenocarcinoma in villous adenoma: Demographics analysis.
Sinai et al.
FALSE

Hypoalbuminemia, body mass index, and weight loss as predictors of outcomes in head and neck cancer.
Kennedy et al.
FALSE

Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced head and neck squamous cell carcinoma.
Liu
FALSE

Metastases harbored in the maxillofacial region: Patient and cancer related characteristics and outcomes.
Turgeman et al.
FALSE

Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.
Soulieres et al.
FALSE

Induction and concomitant chemoradiotherapy (CCRT) using modified TPF (docetaxel, cisplatin and 5-FU) for the patients with stage IVB advanced head and neck cancer.
Shiga et al.
FALSE

Atypical new metastatic sites after immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M H&NSCC).
Deeken et al.
FALSE

Patients characteristics, treatment patterns and clinical outcomes in patients with head and neck squamous cell carcinoma (aHNSCC) receiving immunotherapy in advanced setting: Retrospective cohort analysis of real-world data in Spain.
Ortega Granados et al.
FALSE

PORTO-001 study: Changes in the oral microbiome and matrix metalloproteinases in patients with oropharyngeal squamous cell carcinoma undergoing definitive chemoradiotherapy.
Boavida Ferreira et al.
FALSE

Effect of GNA13 on the alteration of tumor microenvironmental components through exosomes to promote the development of head and neck tumors.
Zhu et al.
FALSE

Association of molecular profiles of head and neck squamous cell carcinoma with heterogeneity across racial/ethnic groups in the United States.
Bhayani et al.
FALSE

The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.
Krause et al.
FALSE

Lactate metabolism as a dictator of patient outcomes and immune microenvironment in head and neck squamous carcinoma.
Chen et al.
FALSE

Clinical and pathological correlation of p53 expression in oral cancers.
Bellala et al.
FALSE

Radiation-sensitive genetic prognostic model to identify individuals at risk for radiation resistance in head and neck squamous cell carcinoma.
You et al.
FALSE

Rapid establishment of patient-derived organoids from treatment-naive head and neck cancer patients for drug and radiosensitivity screening.
Tinhofer et al.
FALSE

Whole exome sequencing of sinonasal cancers.
Bhateja et al.
FALSE

Prognosis-related molecular subtyping of nasopharyngeal carcinoma.
Ding et al.
FALSE

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck.
Schokrpur et al.
FALSE

Distribution pattern of metastatic lymph nodes in 870 cases of nasopharyngeal carcinoma: A clue for individualized elective prophylactic neck irradiation.
Wang et al.
FALSE

Efficacy and safety of nab-paclitaxel+cisplatin/nedaplatin + S-1 as an induction chemotherapy regimen for locally advanced hypopharyngeal cancer.
Jiang et al.
FALSE

Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients.
Lasonde et al.
FALSE

Positive margin and advanced depth of invasion as the indicators for assessing the necessity of adjuvant chemoradiotherapy in early-stage oral cavity squamous cell carcinoma.
Lu et al.
FALSE

Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC).
Hsieh et al.
FALSE

Comparing the role of different treatment modalities in locoregionally advanced olfactory neuroblastoma: The 20-year clinical experience of a single institution.
Chai et al.
FALSE

Efficacy and safety of immunonutrition in preventing oral mucositis during concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
Qin et al.
FALSE

Neoadjuvant camrelizumab plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
Gao et al.
FALSE

Efficacy and safety of induction chemotherapy with docetaxel + cisplatin in selected groups of patients with HNSCC.
Kutukova et al.
FALSE

A retrospective analysis of tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy plus nimotuzumab in patients with high-risk nasopharyngeal carcinoma.
Zhang et al.
FALSE

The association of body mass index with overall survival, progression free survival and locoregional control in head and neck cancer treated with curative-intent definitive chemoradiation.
Chatterjee et al.
FALSE

Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy.
Huang et al.
FALSE

Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19.
Wu et al.
FALSE

Radiation induced lymphopenia in unilateral versus bilateral radiochemotherapy in treatment of head and neck cancer: A retrospective case-control study.
Bendavid et al.
FALSE

Occult lymph node metastasis in cN0 tongue squamous cell carcinoma: A prospective observational study.
Huang et al.
FALSE

Adjuvant capecitabine in advanced nasopharyngeal carcinoma following concurrent chemoradiotherapy: A meta-analysis and systematic review.
Velasco et al.
FALSE

Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
Wu et al.
FALSE

Hearing loss related outcomes post-lateral temporal bone resection and other oncologic treatment.
Jivani et al.
FALSE

Incidence and survival of oropharyngeal carcinoma patients and the development of HPV-testing prevalence in North Rhine-Westphalia: A Cancer Registry analysis from 2008-2018.
Teichler et al.
FALSE

Real-world survival of older adults with LA SCCHN using SEER-Medicare.
Zhou et al.
FALSE

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: A single-arm, phase II trial.
Wu et al.
FALSE

Neoadjuvant chemotherapy followed by definitive chemoradiation in technically unresectable oral cavity squamous cancers.
Trikha et al.
FALSE

Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.
Wu et al.
FALSE

Treatment patterns and clinical outcomes of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): A retrospective cohort analysis of national real-world data in England.
Black et al.
FALSE

Recurrence free survival in patients with HPV+ head and neck cancer treated with TORS and neck dissection.
Melachuri et al.
FALSE

Re-irradiation for recurrent head and neck cancer: Freedom from cancer recurrence rate.
Mohamad et al.
FALSE

Malignant glomus tumor of the head and neck: A National Cancer Database analysis.
Anderson et al.
FALSE

Impact of pre-treatment anemia on survival in locally advanced head neck squamous cell carcinomas treated with radiation with or without concurrent chemotherapy.
Shah et al.
FALSE

The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan.
Chen et al.
FALSE

tRNA-derived fragments (tRFs) as regulators of oncogenes and tumor suppressor genes in head and neck squamous cell carcinoma.
Uzelac et al.
FALSE

Ceruminous adenocarcinoma: A National Cancer Database study of demographic characteristics.
Hsia et al.
FALSE

Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.
Li et al.
FALSE

Tumour mutational burden as a predictive and prognostic biomarker in locally advanced and recurrent/metastatic adenoid cystic carcinoma.
Patel et al.
FALSE

Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.
Ilerhunmwuwa et al.
FALSE

Real world outcomes of next generation sequencing (NGS) of progressive RAI resistant metastatic thyroid cancer and treatment of these patients with redifferentiation protocol.
Wheeley et al.
FALSE

Mixed medullary-follicular carcinoma: A national analysis and the demographic features.
Tade et al.
FALSE

Risk factors predictive of cervical lymph node metastasis in papillary thyroid microcarcinoma.
Jie et al.
FALSE

Association between hyperthyroidism and thyroid cancer in the Congolese hospital setting.
Bukasa-Kakamba et al.
FALSE

Factors associated with positive margins in major salivary gland cancer: An NCDB analysis.
Keirns et al.
FALSE

Comprehensive genomic analysis of salivary gland carcinomas in a Chinese population.
Lu et al.
FALSE

The effect of radioactive iodine (RAI) on disease-specific survival in differentiated thyroid cancer (DTC): A study of 96,557 patients.
Alshwayyat et al.
FALSE

Retrospective analysis of NUT carcinoma: The Northwestern experience.
Serritella et al.
FALSE

Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.
Inampudi et al.
FALSE

Thyroid carcinoma showing thymus-like element: A national analysis of demographic features.
Bitar et al.
FALSE

The influence of grade on mortality risk in salivary gland malignancy.
Bastien et al.
FALSE

Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.
Filogonio et al.
FALSE

The efficacy and safety of sequential use of anlotinib and 131I for locally advanced or metastatic differentiated thyroid cancer: A single-arm phase II clinical trial.
Song et al.
FALSE

Demographic and socioeconomic factors of patients with nonencapsulated sclerosing carcinoma: An NCDB analysis.
Stewart et al.
FALSE

Clinical outcomes in patients with radioiodine refractory thyroid carcinoma treated with dose-reduced lenvatinib.
Au et al.
FALSE

Overall survival trends of papillary thyroid cancer: A Surveillance, Epidemiology, and End Results (SEER) population-based data (2002-2016).
Balozian et al.
FALSE

An audit of neoadjuvant chemotherapy in sinonasal teratocarcinosarcoma from an academic tertiary care centre in India.
Peelay et al.
FALSE

A comparison of thyroid cancer survival managed with different surgical subtypes: A SEER database analysis.
Cogua et al.
FALSE

Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.
Knight et al.
TRUE

Evaluation of potential socioeconomic and racial/ethnic disparities in all-cause mortality in adolescent and young adult patients with cancer.
Henderson et al.
TRUE

Disparities in outcomes among hospitalized unhoused patients with cancer in the US.
Shah et al.
TRUE

Risk of early mortality in patients with cancer experiencing adverse financial events.
Khan et al.
TRUE

Health insurance continuity and survival among children, adolescents, and young adults with blood cancer: An analysis based on SEER-Medicaid data.
Ji et al.
TRUE

Association of medical debt and cancer mortality in the US.
Hu et al.
TRUE

The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.
Nesline et al.
TRUE

Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).
Stricker et al.
TRUE

Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.
Vidal et al.
TRUE

Strategies to increase accrual of underrepresented populations in Alliance NCTN trials.
Paskett et al.
TRUE

How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.
Ackbarali et al.
TRUE

Mediators of racial/ethnic inequities in clinical trial participation among US patients with cancer, 2011-2022.
Guadamuz et al.
TRUE

Comparison of incident breast cancer cases in the largest national US tumor registries.
Plichta et al.
TRUE

Big data in oncology: Challenges and solutions.
Shah et al.
TRUE

Enhancement in line of therapy (LoT) derivation from real-world data (RWD) from electronic health records (EHR) via integration of medical claims data.
Agrawal et al.
TRUE

End-of-life spending analysis of randomized trial of machine learning nudges to prompt serious illness communication among patients with cancer.
Parikh et al.
TRUE

Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.
Chang et al.
TRUE

The impact of adverse financial events on healthcare utilization and treatment costs at the end of life.
Kwendakwema et al.
TRUE

A multi-level system quality improvement project to reduce disparities in lung cancer screening: The Sylvester Lung Screening Project.
Gay et al.
TRUE

Guideline-concordant use of olanzapine as part of a 4-drug antiemetic regimen for high emetic risk chemotherapy across the state of Michigan.
Bowen et al.
TRUE

Impact of a web-based decision aid on socioeconomically disadvantaged patients’ engagement in decision making (Alliance A231701CD).
Schumacher et al.
TRUE

Curating clinical trials: Helping patients find hope by exploring clinical trial opportunities.
Abdel-Nabi et al.
TRUE

The Man Van: Mobile targeted case finding for prostate cancer.
Moghul et al.
TRUE

Association of social vulnerability with delays in starting guideline-adherent adjuvant therapy among patients with head and neck cancer.
Cagle et al.
TRUE

Analysis and optimization of equitable US cancer clinical trial center access by travel time.
Lee et al.
TRUE

Are enrollment criteria for phase II and III clinical trials in acute myeloid leukemia arbitrarily restrictive?
Hantel et al.
TRUE

Evaluating social vulnerability impact on care and prognosis of head & neck-nervous system cancers in the US.
Lutfallah et al.
TRUE

Association of measures of socioeconomic deprivation with healthcare utilization in elderly patients enrolled in SWOG cancer clinical trials.
Hershman et al.
TRUE

Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.
Martei et al.
TRUE

Healthcare coverage, access, and affordability among adult immigrant cancer survivors in the United States.
Santos et al.
TRUE

Impact of free hospital-provided rideshare service on radiation therapy completion rates: A matched cohort analysis.
Chen et al.
TRUE

Associations of loneliness and mortality risk among cancer survivors in the United States.
Zhao et al.
TRUE

Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.
Sayegh et al.
TRUE

Selection biases in the systematic collection of breast biobank specimens.
Bar et al.
TRUE

Beyond transportation: Financial hardship, food insecurity, and care access barriers among US cancer survivors with transportation barriers to care.
Jiang et al.
TRUE

County-level jail incarceration and cancer mortality in the US.
Zhao et al.
TRUE

An intersectional approach to cervical cancer screening disparities by race/ethnicity and immigrant status.
Chen et al.
TRUE

Associations of cancer history, food insecurity, and nonmedical financial worry and mortality risk in the US.
Zheng et al.
TRUE

The association between continuity of Medicaid enrollment and cancer survival in young adults diagnosed with cancer.
Johnson et al.
TRUE

Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer.
Shi et al.
TRUE

Disparities in uptake of novel therapies for acute myeloid leukemia.
Hantel et al.
TRUE

Talk, test, and take one click to curb prostate cancer mortality.
Cautha et al.
TRUE

Racial and ethnic disparities in employment of patients and caregivers following breast cancer diagnosis.
Weiss et al.
TRUE

Depression, systemic inflammation, and exposure to discrimination among sexual and gender minority (SGM) cancer survivors.
Kamen et al.
TRUE

Association of major adverse financial events and later stage cancer diagnosis in the US.
Yabroff et al.
TRUE

Racial disparities in cancer mortality in patients with gastrointestinal malignancies following Medicaid expansion.
Manisundaram et al.
TRUE

What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants.
Idossa et al.
TRUE

Sexual orientation and gender identity data collection among NCI community oncology research program (NCORP) practices: A 5-year landscape update.
Cathcart-Rake et al.
TRUE

Patient-level interventions to increase guideline concordant treatment among Black breast cancer patients: Can they close the racial gap in survival after diagnosis?
Yanguela et al.
TRUE

Disparities in clinical trial enrolment at a Canadian comprehensive cancer centre: A 15-year retrospective study.
Shapiro et al.
TRUE

The intersection of neighborhood-level disadvantage and overall lung cancer survival.
Kennedy et al.
TRUE

Impact of the COVID-19 pandemic on insurance transitions among commercially insured cancer patients in Washington state.
Ramsey et al.
TRUE

Translated consent documents (CDs) and use in non-industry sponsored studies (NISS).
Velez et al.
TRUE

Examining clinical trial eligibility for oncology patients with human immunodeficiency virus (HIV): A global cross-sectional analysis.
Abdullahi et al.
TRUE

Disparities in lung cancer screening in a diverse urban population and the impact of a community-based navigational program.
Khan et al.
TRUE

Racial disparity in dose intensity of early-stage breast cancer chemotherapy.
Rosenzweig et al.
TRUE

A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older women in breast cancer trials.
Islam et al.
TRUE

Disparities in intensity of care at the end-of-life for patients with gastrointestinal cancer.
Rodriguez et al.
TRUE

Source of funding and enrollment disparity in cancer clinical trials.
Riaz et al.
TRUE

CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials.
Pal et al.
TRUE

The patient experience of prior authorization for cancer care: Anxiety, delays, and the erosion of trust.
Chino et al.
TRUE

Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan et al.
TRUE

Use of direct oral anticoagulants (DOACs) in oncology: A phase IV study on impact of edoxaban treatment in Italian patients with cancer with venous thromboembolism during antineoplastic therapy (EDOI trial, GOIRC 05-2018).
Giovanardi et al.
TRUE

The IMPACT of an interdisciplinary goals-of-care program on readmission rates at a comprehensive care center.
Leung et al.
TRUE

Trends of using immune checkpoint inhibitors near end of life in limited resources setting: Experience of single cancer center in the MENA region.
Al-Rabi et al.
TRUE

Reducing infusion center wait times in a resource-limited setting.
Jones et al.
TRUE

The effects of social determinants of health on colorectal cancer screening.
Franklin et al.
TRUE

Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.
Bossi et al.
TRUE

Multimodal interventions targeting identified barriers to improve lung cancer screening in northeast Georgia.
Kanakamedala et al.
TRUE

Just ASK: A quality improvement project to enhance smoking assessment and treatment.
Warren et al.
TRUE

Use of germline testing in patients with prostate, pancreatic, or ovarian cancer in Washington (WA) state.
Sun et al.
TRUE

Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts).
Palmeri et al.
TRUE

Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.
Padmaraju et al.
TRUE

Machine learning and postoperative complications: Determining risk before surgery in patients with cancer.
Hernandez et al.
TRUE

Data driven insights from multiple OCM practices to optimize care for managing high-risk cancer patients across multiple cancer types.
Achuthan et al.
TRUE

Palliative care consultation and end-of-life outcomes in a retrospective cohort of patients treated with immune checkpoint inhibitors.
Bloomer et al.
TRUE

Mortality among oncology patients with multiple unplanned hospital admissions.
Roberts et al.
TRUE

Use of statistical process control charts to identify impactful implementation strategies for an ePRO-based symptom management program across the SIMPRO Consortium.
Doolin et al.
TRUE

The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
Canavan et al.
TRUE

Real-world program-based lung cancer care.
Liao et al.
TRUE

Proportion of patients in phase I solid tumor oncology trials receiving treatments that are clinically efficacious.
Muzlera et al.
TRUE

The association of HIV and other risk factors with triple-negative breast cancer in South African women.
Dubner et al.
TRUE

Breast cancer staging for patients with “low risk” disease: Are they all the same?
Plichta et al.
TRUE

Trends in the use of maintenance therapy in ovarian cancer.
Adjei et al.
TRUE

Survival of patients with solid tumors and sepsis admitted to intensive care in a tertiary oncology center: A retrospective analysis.
Smith et al.
TRUE

Real-world analysis of cardiac, gastrointestinal, and hematologic toxicities between commonly used antiemetics in everyday oncology clinical practice.
Beedupalli et al.
TRUE

Multicenter, retrospective population-based study on the incidence of medication-related osteonecrosis of the jaw in patients with breast cancer with bone metastases.
Brunner et al.
TRUE

Real-world evidence to inform clinical insights on tissue-agnostic approvals of therapies.
Sledge et al.
TRUE

Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts.
George et al.
TRUE

Malnutrition risk at diagnosis and influence on survival in patients with solid tumors at a large academic cancer center.
Kadakia et al.
TRUE

Real-world behavioral restrictional practices of cancer patients (pts).
Shachar et al.
TRUE

Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation.
Boyle et al.
TRUE

Tumor lysis syndrome in solid tumors: A retrospective cohort study of the National Inpatient Sample from 2016 to 2019.
Chitkara et al.
TRUE

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.
McKelvey et al.
TRUE

Molecular testing utilization in patients with advanced non-small cell lung cancer (NSCLC) in Washington (WA) state.
Shih et al.
TRUE

Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
Sathe et al.
TRUE

Decomposing racial differences in financial hardship among older cancer survivors.
Davis et al.
TRUE

Commercial vs. Medicaid insurance and use of high-priced anticancer treatments.
Mitchell et al.
TRUE

The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: Results of a retrospective cohort study.
Bhimani et al.
TRUE

Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.
Hyams et al.
TRUE

Evaluating depth of disparities in relation to relative survival rates: Analysis of SEER data.
Habib et al.
TRUE

Demographic disparities in lung cancer mortality and trends in the United States between 1999 and 2020: A population-based CDC database analysis.
Didier et al.
TRUE

Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
Naidoo et al.
TRUE

Intrathecal drug delivery systems for cancer pain control: Insights on current contemporary practices in the US.
Goel et al.
TRUE

The safety of seasonal influenza vaccination among patients prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
Grima et al.
TRUE

Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale.
Agrawal et al.
TRUE

A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.
Brooks et al.
TRUE

Assessment of patient reported outcomes (PROs) completion patterns in patients with cancer: Examining real-world data.
Al-Antary et al.
TRUE

Molecular diagnostic classification for cancers of unknown primary (CUP): Post-testing diagnosis and treatment impact analysis from real-world claims data.
Rivers et al.
TRUE

Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label.
Zong et al.
TRUE

Patient reported outcomes (PROs) collection modalities among patients diagnosed with cancer: Online vs in-person.
Adjei Boakye et al.
TRUE

An assessment of the provider financial risk impacts of adoption of biosimilars in the Medicare Oncology Care Model.
Roth et al.
TRUE

An application of extrapolating clinical data from single-arm trials to assess comparative effectiveness.
Suh et al.
TRUE

Racial disparities in survival and stage at diagnosis among adolescent and young adult patients with cancer.
Taparra et al.
TRUE

Real world utilization and disparities in outcome in the use of novel anti-androgen agents for metastatic prostate cancer.
Hirani et al.
TRUE

Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.
Singh et al.
TRUE

An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).
Costa et al.
TRUE

Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
El Saadany et al.
TRUE

The impact of using Elsevier ClinicalPath oncology treatment pathways on survival and cost of care.
Schmidt et al.
TRUE

Rates of emergency department visits and acute-care hospital admissions after starting chemotherapy or having surgery across six community-based cancer centers.
Hassett et al.
TRUE

Improved outcomes from reflex comprehensive genomic profiling-guided precision therapeutic selection across a major US healthcare system.
Piening et al.
TRUE

Financial toxicity, quality of life, symptom burden, and access to resources in early-phase clinical trial (EP-CT) participants.
Durbin et al.
TRUE

Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma.
Demetriou et al.
TRUE

Efficacy-effectiveness gap with immune checkpoint inhibitors in solid cancers: A population based cohort study.
Niraula
TRUE

Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC).
Pisano et al.
TRUE

Endoscopist volume and the quality of colonoscopy of the Korean National Cancer Screening Program.
Kim et al.
TRUE

An ehealth intervention during radical radiotherapy: Patient-Reported Outcome Side effects (PROSE) study—An emerging approach from sub-Saharan Africa.
Salako et al.
TRUE

Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.
Spira et al.
TRUE

Evaluation of studies with commonly used real world data sources submitted to ASCO journals: Initial steps toward furthering transparent reporting.
Bates et al.
TRUE

Racial disparities in hospitalization outcomes among patients with cholangiocarcinoma.
Jackson et al.
TRUE

Cancer survival (SURVCANCER BRAZIL): Analysis of 132,621 cases from 19 hospital-based registries in southernmost Brazilian state comparing public and private insurance.
Giacomazzi et al.
TRUE

Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.
DaCosta Byfield et al.
TRUE

Prognosis and risk of suicide after cancer diagnosis.
Kinslow et al.
TRUE

A comparison of the Optum Clinicogenomics Solid Tumor Database and the SEER Population-Based Cancer Registry.
Woodward et al.
TRUE

Disparity in regional recruitment across global cancer trials: A meta-analysis.
Asghar et al.
TRUE

Real world data for venous thromboembolisms (VTEs) in patients with active cancer: Thromboprophylaxis pooled analysis from GMaT and ACT4CAT studies.
Tsoukalas et al.
TRUE

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).
Bestvina et al.
TRUE

Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.
Mitchell et al.
TRUE

Palliative care as a component of high-value and cost-saving care during hospitalization for metastatic cancer.
Lu et al.
TRUE

The role of private insurance characteristics in the out-of-pocket costs of patients with multiple myeloma.
Gasoyan et al.
TRUE

Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations.
Fendrick et al.
TRUE

Unnecessary thrombophilia testing reduction: Quality improvement project.
Golubykh et al.
TRUE

Association between targeted cancer drug net health benefit and uptake, patient out-of-pocket spending, and total spending.
Lau-Min et al.
TRUE

Association of early completion of portable medical orders with inpatient costs at end-of-life for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
LoCastro et al.
TRUE

Maxed out: Reaching the annual maximum out-of-pocket limit among insured patients diagnosed with cancer.
Banegas et al.
TRUE

National survey of financial burdens and experience among patients with cancer receiving charitable co-pay assistance.
Peppercorn et al.
TRUE

A health economic model to assess the impact of prehabilitation on hospital cost savings in gastrointestinal cancer, modelled on English National Health Service tariff.
Zamora Talaya et al.
TRUE

Value-driven colorectal cancer survivorship through partnership with primary care.
Chan et al.
TRUE

Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: A cost consequence analysis using linked administrative data.
Hernando-Calvo et al.
TRUE

The impact of a cancer-specific novel therapy adjustment (NTA) in Medicare value-based care programs: A simulation exercise.
Feinberg et al.
TRUE

Assessment of price variation in colorectal cancer screening procedures at US hospitals.
Paranjpe et al.
TRUE

The FOR ME (Fostering Opportunities in Research through Messaging and Education) study: Developing a culturally sensitive narrative intervention to promote equity in clinical trials.
Hippalgaonkar et al.
TRUE

Understanding patient acceptance and compliance of a blood-based colorectal cancer screening test.
Kim et al.
TRUE

Association between social determinants of health and outcomes among young patients with prostate cancer.
Akinyemi et al.
FALSE

Navigator utilization rates in breast cancer patients by race in a comprehensive cancer center.
Onyewadume et al.
FALSE

Racioethnic differences in missing data in the national cancer database: A window into inequities in cancer care.
Raman et al.
FALSE

Geographic distribution of clinical trials for common advanced-stage cancers in the United States.
Swenson et al.
FALSE

Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic.
Iqbal et al.
FALSE

Socioeconomic and demographic barriers associated with delays in pancreatic cancer germline genetic testing.
Zou et al.
FALSE

Disparities in accessing open notes at a comprehensive cancer center.
Cutting et al.
FALSE

Tick tock on the stomach clock: Factors affecting time to diagnosis of gastric adenocarcinoma at an urban cancer center with a large East Asian patient population.
Choi et al.
FALSE

Disparities in the recommendation, acceptance, and performance of surgery as treatment modality for patients with stage 0-III breast cancer.
Cruz Pico et al.
FALSE

Community resilience and its impact on chemotherapy availability: An ecological analysis.
Shour et al.
FALSE

Real-world associations among patient-physician sex concordance, treatment practices, and cancer outcomes.
Ding et al.
FALSE

UK cancer healthcare professionals collaborating with colleagues in low- and middle-income counties: Mapping the extent and nature of partnerships.
Diprose et al.
FALSE

Assessing the translation capabilities of NCI-designated cancer websites with a focus on lung, breast, prostate and ovarian cancers.
Smith et al.
FALSE

Racial disparities and inequity in clinical trials of chimeric antigen receptor T-cell therapy.
Thakur et al.
FALSE

Lack of organization to access cancer treatment in southeast Brazil: Urgent need to change.
Aleixo et al.
FALSE

Older adults (OA) in clinical trials: Where are they? Representation of OA in clinical trials conducted at the national cancer institute (NCI) clinical center.
Iannantuono et al.
FALSE

Making sense of the dollars: Evaluation of financial toxicity in patients of breast medicine receiving oral chemotherapy at Roswell Park.
Liu et al.
FALSE

Medication acquisition program: Successful access to innovative treatment options.
Doctor et al.
FALSE

Demographic comparison of survival outcomes after bone marrow transplantation in adolescent and young adult patients: A single institution cohort study.
Seymour et al.
FALSE

Associations between micro-geographic social vulnerability and disparities in cancer incidence.
Aijazuddin et al.
FALSE

Validation of the Tagalog and Ilokano translations of the Functional Assessment of Cancer Therapy-General (FACT-G) scale for adult cancer center patients in a state-funded tertiary hospital.
Dela Cruz
FALSE

Expanding rural access to phase I clinical trials.
Powell et al.
FALSE

Cancer risk factors and screening tests in the Pantanal population, a rural area in Brazil.
Figueiredo et al.
FALSE

Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration.
Yang et al.
FALSE

The UC san diego health suspicion of cancer clinic.
Vaidya et al.
FALSE

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials.
Figueroa-Moseley et al.
FALSE

Point-of-care isoenzyme type M2 pyruvate kinase quick stool test for the detection of gastric cancer in Rwanda: A pilot study.
Riano et al.
FALSE

Breast cancer brain metastases: The graded prognostic assessment index (GPA) in a real-world low- and middle-income (LMIC) population.
Carvalho et al.
FALSE

Anticoagulation prescribing practices in high-risk, under-represented patients with malignancy and venous thromboembolism (VTE).
Berardi et al.
FALSE

Evidence-based cost estimation of essential medicines for pediatric cancer care in Peru.
Shrivastava et al.
FALSE

Readability and understandability of instruments for collecting patient-generated data (PGD).
Chiodi et al.
FALSE

A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 global oncology survey.
Garton et al.
FALSE

Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC.
Lee et al.
FALSE

Engine failures: A critical analysis of current clinical trial websites' search engines.
Paunic et al.
FALSE

Impact of ethnicity and insurance on adverse effects and treatment outcomes related to immune checkpoint inhibitors at a safety net hospital.
Mahadevia et al.
FALSE

Is physician-patient language discordance a barrier for clinical trial enrollment in patients with cancer? A real-life study.
Urueta Portillo et al.
FALSE

Racial differences in patterns of clinical trial discussion and participation among breast cancer patients at the University of Chicago.
Freeman et al.
FALSE

Palliative medicine referral trends by demographics for patients with stage IV cancer at an urban safety net hospital.
Sharma et al.
FALSE

Dedicated overseas consultation for patients evacuated from the south Pacific: Report of experience after six months of existence.
Epaillard et al.
FALSE

Time to colonoscopy and insurance status at an FQHC.
Dand et al.
FALSE

Racial disparity in cancer clinical trials: An analysis of clinicaltrials.gov protocols for race-related language and description.
Raghupathy et al.
FALSE

Demographic factors associated with time to treatment initiation in hepatocellular carcinoma.
Bettag et al.
FALSE

Use of molecular NGS vs single gene testing differs by clinical setting and physician’s specialty in mNSCLC management.
Keating et al.
FALSE

Unmasking ethnic disparities in Asian representation in U.S. oncology training programs.
Santos et al.
FALSE

Health disparities among patients with Ewing sarcoma in Florida.
Pham et al.
FALSE

Representativeness in cancer treatment trials in community and academic settings.
Altomare et al.
FALSE

Clinical trial enrollment in a Hispanic-majority NCI-designated cancer center: The Mays Cancer Center experience over 10 years.
Garza Morales et al.
FALSE

Racial disparities in DLBCL: Analysis of SEER data from 2010-2019.
Lee et al.
FALSE

Disparities in minority patients with breast cancer under 40 years of age: A single center experience.
Patel et al.
FALSE

Key difference-making conditions distinguishing ASCO members’ institutions that collect sexual orientation and gender identity (SOGI) data from those that do not.
Pratt-Chapman et al.
FALSE

Sociodemographic factors affecting survival in stage IIIA NSCLC treated with surgery-based treatment or definitive chemoradiation with immunotherapy consolidation: An NCDB analysis.
Sekkath Veedu et al.
FALSE

Association of ethnicity with overall survival in patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
Neupane et al.
FALSE

Disparities in screening, diagnosis, treatment, and survivorship care among urban and rural patients with colorectal cancer in the United States: A systematic review and meta-analysis.
Sepassi et al.
FALSE

The implementation of a diverse clinical trial program at a rural community cancer center over a 10-year period.
Hrom et al.
FALSE

Defining the patient population with HER2-low breast cancer in Hawaii.
Beaman et al.
FALSE

Clinical outcomes and national information of patients with multiple myeloma (MM) covered under the largest national health insurance in a low-middle-income country.
Lombana Quinonez et al.
FALSE

A comprehensive assessment of social determinants of health for metastatic breast cancer.
Abu-Khalaf et al.
FALSE

Next generation sequencing (NGS) testing for cancer patients at a safety NET hospital.
Azimzade et al.
FALSE

The roles of race and social determinants of health in pancreatic adenocarcinoma diagnosis and treatment.
Ajilore et al.
FALSE

Rural cancer care delivery during the COVID-19 pandemic for patients with early-stage cancer.
Okado et al.
FALSE

Quality dashboards: Uncovering potential health disparities.
Zhang et al.
FALSE

Racial disparities and clinical outcomes among cancer patients admitted with SARS-CoV-2 infection: A nationwide analysis.
Deenadayalan et al.
FALSE

Clinical outcomes of patients with cancer before the SARS COV2 pandemic vs during the pandemic: A nationwide analysis.
Swarna et al.
FALSE

Factors associated with readmission to the same hospital within 30 days of discharge in patients who received surgical treatment for head and neck cancer: An NCDB analysis.
Verplancke et al.
FALSE

Characterizing the digital divide in a diverse cohort of African American (AA) patients (pts) with prostate cancer (PCa).
Kilbridge et al.
FALSE

Identification of healthcare vulnerabilities associated with unplanned hospital care in Black patients with pancreas cancer.
John et al.
FALSE

Racial and ethnic disparities in presentation and outcomes of patients with gastrointestinal stromal tumors (GIST) in the era of targeted therapy.
Barreto Coelho et al.
FALSE

Transnational utilization of diagnostic studies across the US-Mexico border.
Diaz et al.
FALSE

Pursuing cancer treatment across the US-Mexico border: Motivations and barriers.
LaPelusa et al.
FALSE

Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?
Verduzco-Aguirre et al.
FALSE

The FOR US (Fostering Opportunities in Research Using Marketing Strategies) study.
Nguyen et al.
FALSE

Assessment of the utilization of immunotherapy in Sub-Saharan Africa.
Olatunji et al.
FALSE

CAR-T therapy access with Louisiana Medicaid: A single institution retrospective analysis.
Chennapragada et al.
FALSE

Impact of pandemic on accrual of minority participants to interventional cancer clinical trials.
Wingard et al.
FALSE

Disparities in molecular tumor board recommendations and treatment implementation.
Hensien et al.
FALSE

Implementation of a rapid access multidisciplinary pathway to reduce health disparities in veterans with thoracic malignancies.
Wilcox et al.
FALSE

Assessing changes in cancer-related financial support needs across three waves of the COVID-19 pandemic.
Thom et al.
FALSE

Barriers to diversity in cancer therapy: Uncovering disparities in knowledge and interpretation of genetic testing among African Americans, and their direct implications for access to mutation-based therapies.
Lapidot et al.
FALSE

Barriers and facilitators to discussion of cancer clinical trials: A qualitative study.
Castillo et al.
FALSE

Disparities in rectal cancer initial staging evaluation for distant metastasis.
Le et al.
FALSE

Disparities in African American oncology care in the US: A socioeconomic and geographic outlook.
Jasaraj et al.
FALSE

Patient navigation educational curriculum for cancer care in Mexico.
Chavarri Guerra et al.
FALSE

Breaking down the divide: An analysis of male breast cancer demographics and survival by race.
Yadukumar et al.
FALSE

Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center.
Davidson et al.
FALSE

Association of inability to secure timely medical appointment and medication non-adherence among cancer survivors in the US.
Chido-Amajuoyi et al.
FALSE

Effect of the large waves of COVID-19 on false-positive results in annual lung cancer screening.
Kimura et al.
FALSE

Evaluating differences in cancer survivorship care plans experienced by cancer survivors with disabilities.
Poghosyan et al.
FALSE

Is access to adjuvant treatments prioritized over therapies for metastatic cancer? The Israeli experience.
Siegelmann-Danieli et al.
FALSE

Effects of socio-economic status and gender on non-relapse mortality after allogeneic stem cell transplant.
Varshavsky Yanovsky et al.
FALSE

Implementation of a housing insecurity screening tool in patients with lung cancer.
Burns et al.
FALSE

Ethnically diverse communities and their priorities for cancer research.
Winter et al.
FALSE

Impact of neighborhood disadvantage on stage at diagnosis and outcomes in women diagnosed with breast cancer.
Harris et al.
FALSE

Real-world treatment patterns of non-small cell lung cancer in an Indian hospital.
Miyasato et al.
FALSE

Immediate inpatient toxicities associated with CAR T-cell therapy: Real world data from a national inpatient sample.
Singh et al.
FALSE

Oncology financial advocacy services guidelines: Results of a Delphi study.
Boehmer et al.
FALSE

Care cascade of anal dysplasia screening among MSM living with HIV from a single-center outpatient clinic.
Thirugnanasambandam
FALSE

Understanding disparities in who gets offered a virtual visit in oncology care.
Lafata et al.
FALSE

Association of food insecurity with reduced cancer screening rates.
Shah et al.
FALSE

Patterns of unmet needs of adolescents and young adults (AYA) in the developing world: Beyond the walls.
Papyan et al.
FALSE

Ethnic disparity in hospitalization among veterans with COVID-19 and cancer.
Gogtay et al.
FALSE

The impact of neighborhood socioeconomic deprivation on clinical trial enrollment at an NCI-designated cancer center.
Dhahri et al.
FALSE

Impact of area deprivation index on clinical outcomes of adults with acute myeloid leukemia at a rural academic medical center.
Edgren et al.
FALSE

Who is getting screened? Estimating uninsured and underinsured women utilizing NBCCEDP screening program in a high insurance state.
Haynes et al.
FALSE

Does community size impact survival with breast cancer? Data from a large population-based cohort in British Columbia.
Jackson et al.
FALSE

Distribution of non-Hodgkin lymphomas across US: Are Hispanics any different from non-Hispanics?
Urueta Portillo et al.
FALSE

Addressing the clinical trial selection process to improve representation by African American patients with breast cancer in cancer clinical trials.
Kim et al.
FALSE

Examining experiences of African American patients with breast cancer in a multidisciplinary survivorship clinic.
Uelk et al.
FALSE

Patients with breast cancer and the threat of septicemia.
Taneja et al.
FALSE

Real world evidence for continuing HER2-directed therapy for metastatic breast cancer.
Jackson et al.
FALSE

Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.
Kent et al.
FALSE

Supporting a climate of belonging: Justice, equity, diversity, and inclusion (B-JEDI) at the Sidney Kimmel Cancer Center (NCI-designated).
Lopez et al.
FALSE

Rates of surgical site infections and length of stay following major gynecologic oncology surgery for patients on federally funded insurance: A 6-month retrospective cohort.
Malone et al.
FALSE

Participation in phase I oncology trials by minorities: Survival and compliance data.
Bastos et al.
FALSE

Patient access to precision medicine: Correlation of immune checkpoint inhibitor (ICI) usage in non-small cell lung cancer (NSCLC) with patient household income levels across multiple Asian markets.
De Richter et al.
FALSE

Patterns of diversity in cancer clinical trial enrollment at a New York City academic health system, 2018-2022.
Rodriguez-Russo et al.
FALSE

Implementation of a comprehensive companion program for patients undergoing systemic cancer treatment.
Rioja et al.
FALSE

Barriers to implementing expanded access programs in oncology: A multidisciplinary perspective.
Fu et al.
FALSE

Rural communities and health professional shortage areas (HPSA) and access to immune effector cellular therapy and lymphoma/myeloma clinical trials.
Ahmed et al.
FALSE

Impact of COVID-19 pandemic on lung cancer diagnosis in a community hospital.
Arun Kumar et al.
FALSE

The impact of novel therapies on disparities in survival outcomes for metastatic cancers.
Degeling et al.
FALSE

How to close the care gap: Factors hindering the use of BRCA mutation profiling of patients with breast cancer and ovarian cancer in a real world setting.
A. et al.
FALSE

Barriers to and facilitators of prostate cancer screening among men in Uganda prisons: Findings from a survey of 2565 prisoners.
Orem et al.
FALSE

Repetitive presentations of phase II and III trials involving systemic therapies in gastrointestinal (GI) malignancies at international meetings in the past few years.
Barbosa et al.
FALSE

Impact of state health disparity on lung, breast, and prostate cancer incidence and mortality in the United States.
Muthusamy Kumarasamy et al.
FALSE

Impact of primary language on health inequities in multiple myeloma.
Conic et al.
FALSE

Barriers and facilitators to enrolling in a cancer clinical trial financial reimbursement program.
Nguyen et al.
FALSE

Advancing digital innovation to improve equity and reduce financial toxicity in cancer treatment.
Sheehan et al.
FALSE

Access to National Cancer Institute (NCI)–designated cancer centers among Native American patients with cancer.
Li et al.
FALSE

Opportunities and challenges to implementing a coordinated social care network for patients with cancer: Perspectives of local community based organizations.
Hassan et al.
FALSE

Faith-based communities’ preferred interventions to improve the participation of black/African-American persons in medical research and clinical trials: A focus group study.
Hurwitz et al.
FALSE

Using key stakeholder interviews to inform implementation of a cancer center collaborative intervention to improve clinical trial accruals.
Goel et al.
FALSE

Area deprivation index and breast cancer subtypes in young patients.
Chung et al.
FALSE

Awareness of symptoms, risk factors, and barriers to seeking help related to breast cancer among university students in Mexico City.
Cruz Ramos et al.
FALSE

Medical terminology and interpretation of results in plain language summaries published by oncology journals.
Wissing et al.
FALSE

Differences in racial and sex at birth representativeness between randomized controlled trial (RCT) and real-world evidence (RWE) or Surveillance, Epidemiology, and End Results (SEER) datasets in advanced non-small cell lung cancer (aNSCLC).
Savill et al.
FALSE

A real-world study of ALK fusion detection, treatment patterns, and survival outcomes of patients with advanced non–small-cell lung cancer (aNSCLC) in Brazil.
Montella et al.
FALSE

Oncologist perceptions of health inequity.
Balanean et al.
FALSE

Evaluating disparities in pancreatic cancer outcomes in African Americans.
Shrotriya et al.
FALSE

Making decisions about clinical trial enrollment: What’s important to the patient?
Meyer et al.
FALSE

Social determinants of health as a primary driver in outcomes in acute myeloid leukemia: An urban academic center experience.
Bouligny et al.
FALSE

Demographic factors impacting time to diagnosis of diffuse large B-cell lymphoma.
McAlarney et al.
FALSE

Examination of current status of cross-provincial border access for clinical trials for patients with cancer.
Rim et al.
FALSE

Risk of financial stressors in patients diagnosed with cancer: Lessons from a nationwide financial navigation program.
Incudine et al.
FALSE

Evaluating access to brentuximab in elderly patients with Hodgkin lymphoma.
Mobley et al.
FALSE

Evaluating root causes contributing to real-world disparities in ovarian cancer care: Insights from an implementation science initiative utilizing tethered patient-provider surveys and chart reviews.
McKinnon et al.
FALSE

Role of social disparity in 30-day readmissions and healthcare utilization in patients with history of sickle cell crisis in United States: Cross-sectional analysis from US national database.
Nagadia et al.
FALSE

The effect of formal education on ovarian cancer, clinical trial access, and clinical trial awareness among Black and Latino US women.
Equils et al.
FALSE

Identifying and overcoming racial disparities in triple-negative breast cancer care: Insights from an equity-focused quality improvement initiative.
Dooyema et al.
FALSE

The COVID-19 pandemic's impact on diagnosis of cancers detectable through screening.
Guerra et al.
FALSE

Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.
Gentile et al.
FALSE

Disparities in medical oncology visit adherence among African American (AA) men with prostate cancer (pCa).
Nelson et al.
FALSE

Representation of age, race and ethnicity in real-world evidence (RWE), randomized clinical trial (RCT), and Surveillance, Epidemiology, and End Results (SEER) cancer patient registry data in advanced renal cell carcinoma (aRCC).
Garretson et al.
FALSE

Factors associated with health information technology use in adults recently diagnosed with cancer: NHIS 2012-2017.
Monestime et al.
FALSE

Understanding barriers to LGBTQ+ cancer clinical trial participation: A qualitative inquiry.
Andac-Jones et al.
FALSE

The human connection: Oncologist characteristics that facilitate therapeutic bonding among Latino patients with advanced cancer.
Tergas et al.
FALSE

Cancer deaths in the state of Sao Paulo, Brazil: Is there a solution for disparities among private and public services?
Preto et al.
FALSE

Comparison of lung cancer clinical trials treatment options and standard practice in Brazilian national health system over the last decade.
Melo et al.
FALSE

Location-based cancer survival in Philadelphia chromosome-negative acute lymphoblastic leukemia: An urban center retrospective analysis.
Gor et al.
FALSE

Black voices on gynecologic cancer: Understanding experiences.
Richardson et al.
FALSE

The Onc Docs: Partnering with Black cancer patients for cancer education.
Balogun et al.
FALSE

The impact of hispanic ethnicity in presentation and outcomes of patients with synovial sarcoma.
Barreto Coelho et al.
FALSE

Evaluation of a risk-sharing agreement for atezolizumab treatment in second- and third-line NSCLC patients: A strategy in order to improve access in low income countries.
Arrieta et al.
FALSE

National Coalition for Cancer Survivorship State of Survivorship Survey.
Fuld Nasso et al.
FALSE

Identifying and addressing barriers to screening mammography in a medically underserved community.
Zeballos Torres et al.
FALSE

Breast cancer disparities: A literature review of the last five years.
Anamika et al.
FALSE

Presenting symptoms, screening and diagnosis in asian and white patients with stage IV lung cancer.
Hu et al.
FALSE

Analysis of sarcoma outcomes at a metropolitan area safety net hospital.
Haji et al.
FALSE

Risk of treatment refusal in male patients with advanced-stage cancers.
Akpoviroro et al.
FALSE

Use of positron emission tomography-computed tomography (PET-CT) scan in cancer patients: A single Canadian academic oncology center experience.
Melendez-Pena et al.
FALSE

Quality-of-life measurement in high-risk patients with uveal melanoma receiving adjuvant sunitinib or valproic acid.
Nshimiyimana Maniraho et al.
FALSE

Use of antibiotics and outcomes of patients presenting to emergency department with non-neutropenic fever and/or suspected infection.
Siddiqui et al.
FALSE

Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study.
Li et al.
FALSE

Rural healthcare: A retrospective review of lung carcinoma demographics and screening in the northern Arizona healthcare system.
Schmoyer et al.
FALSE

Oncology provider perceptions about quality care.
Amaefule et al.
FALSE

False positive PET scan in patients with treated malignancy following COVID-19 vaccination.
Slota et al.
FALSE

Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.
Maseeh et al.
FALSE

The quality of advance care planning at a comprehensive cancer center.
Goyco Vera et al.
FALSE

Implementation of a secure mobile application to improve care of patients with breast cancer: Experience from a medically underserved area.
Adhikari et al.
FALSE

Standardization of pregnancy screening prior to chemotherapy: A quality improvement project.
Shah et al.
FALSE

The impact of 4R oncology model on patient self management and satisfaction in lung versus breast cancer.
Trosman et al.
FALSE

Improving guideline-concordant biomarker testing through implementation of a precision cancer medicine steward.
Kajdic Hodzic et al.
FALSE

Turnaround time of tissue next generation sequencing in cancer patients at a safety net hospital: A quality improvement project.
Bhatt et al.
FALSE

Defining and implementing meaningful advance care planning.
Hannan et al.
FALSE

Integration of breast-oncology clinical pathways in Providence Southern California clinical research network.
Peddi et al.
FALSE

Physical therapy and rehabilitation for improvement of quality of life of breast cancer patients.
Abuladze et al.
FALSE

DelPHI: A novel program to accelerate access to precision oncology in the community oncology setting.
Magliocco et al.
FALSE

Increasing COVID-19 vaccine adherence within an immunocompromised patient population in a community practice.
Tolkinen et al.
FALSE

Do external factors such as weather affect patient reported outcomes of patients with malignant diseases?
Salm et al.
FALSE

Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital.
Bowers et al.
FALSE

Primary concerns and goals of care identified by people receiving hematopoietic stem cell transplantation (HSCT).
D'cruze et al.
FALSE

The impact of the COVID-19 pandemic on the diagnosis and treatment of breast cancer at a community hospital.
McGee et al.
FALSE

Impact of vaccine hesitancy on antibody response after SARS-CoV-2 vaccination in patients with cancer.
Overheu et al.
FALSE

The impact on hospice quality after initiation of an internal palliative care program by a community oncology practice.
Foster et al.
FALSE

A national survey of current scenario and future perspectives of cancer research in Brazil.
Resende et al.
FALSE

New concept infusion pump with an anticancer drug exposure prevention function.
Tsuji
FALSE

Assessment of how differences in efficacy and toxicity change healthcare professionals’ views on presentation of treatment options.
Santos Teles et al.
FALSE

How does the war affect breast cancer quality of care? The Syrian experience.
Nahhat et al.
FALSE

A self-assessment survey to identify the risk of screen failure in phase I clinical trials (SCITEP score).
Ouali et al.
FALSE

Indian oncologists’ perception of the benefit of antiestrogen therapy in premenopausal women with hormone receptor positive non-metastatic breast cancer: An implementation science study.
Davichan et al.
FALSE

Barriers to HIV-associated lymphoma diagnosis in Soweto, South Africa: A nurse's perspective.
Tshabalala et al.
FALSE

Are we missing the beat in cancer end-of-life care: Prevalence and end-of-life monitoring of implantable cardioverter defibrillators in a population-based sample of older adults diagnosed with breast, colorectal, or pancreatic cancer.
Mullins et al.
FALSE

Cancer centers as potential knowledge hubs for emergency preparedness efforts.
Espinel et al.
FALSE

Improving the care of patients with lung cancer hospitalized with immune checkpoint inhibitor-related pneumonitis: Implementation of a clinical pathway algorithm.
Manzano et al.
FALSE

Telemonitoring program for genito-urinary cancer patients treated with oral anticancer agents.
Seguin et al.
FALSE

Addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma.
Guare et al.
FALSE

Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows.
Fugere et al.
FALSE

Quality improvement interventions targeting vaccine uptake in cancer patients: A systematic review.
Kazi et al.
FALSE

Quality of life during medical oncological treatment in a real-world study in a single-institution of Peru.
Rioja et al.
FALSE

Preventable emergency department visits and admissions for patients on chemotherapy including oral chemotherapy.
Tehranchi et al.
FALSE

Promoting adherence to germline genetic testing for pancreatic cancer.
Hannon
FALSE

COVID-19 pandemic impact on the oncology care using a virtual survey in Peru.
Valencia et al.
FALSE

A novel program to address acute food insecurity among patients with cancer in Philadelphia.
Rowe et al.
FALSE

Women cancer early detection and linkage to care (navigation) in Rwandan community.
Maniragaba
FALSE

New insights on oncologist use of genomic testing.
Smith et al.
FALSE

Implementation and assessment of a provincial early palliative care initiative for patients with pancreatic cancer.
Kim et al.
FALSE

Study of practice patterns in NGS vs single gene testing, provider-identified barriers to biomarker testing and utilization of liquid biopsy across multiple hospital-based cancer centers.
Simpson et al.
FALSE

Safety and feasibility of implementation of ERAS in CRS and HIPEC: Enhancing recovery or complications.
Somashekhar et al.
FALSE

The impact of patient demographics on involvement in cancer care decisions in the US.
Brierly et al.
FALSE

Differences in oncofertility beliefs, knowledge, and practice between medical oncologists and advanced practice providers: Identifying quality improvement targets.
Baclig et al.
FALSE

Molecular technique for precise antibiotics administration in patients with cancer.
Sabu et al.
FALSE

Timeliness of care for breast cancer patients with a single day multidisciplinary clinic.
Farmer et al.
FALSE

Failure rates of mutation-based ctDNA assays in lung cancer treatment monitoring.
Phallen et al.
FALSE

Dynamics of multidisciplinary teams in the Arab world.
AbdelAziz et al.
FALSE

Uptake of MRI in patients without a personal history of breast cancer (PHBC) classified as “high risk”.
Boccuzzi et al.
FALSE

Clinician-patient insights and alignment on urothelial carcinoma care.
Ackbarali et al.
FALSE

Quality care of patients with HR+/HER2- breast cancer: Insights from an implementation science program.
McKinnon et al.
FALSE

Oncology patients through the eyes of their physicians.
AbdelAziz et al.
FALSE

The impact of COVID-19 on patient involvement in treatment decisions in the US and EU4+UK.
Ng et al.
FALSE

Enhancing patient clinical streamlining (EPACS) pilot in the breast medicine service at memorial sloan kettering cancer center.
Amel Riazat-Kesh et al.
FALSE

Qualitative analysis of barriers to precision oncology within the VHA.
Becker et al.
FALSE

Evaluating knowledge, attitudes, and practices toward breast cancer and breast cancer screening among females in Arab countries of the Middle East: A systematic literature review.
Theeb et al.
FALSE

Advancing TNBC care in the community oncology practice: Insights from a quality improvement initiative.
Force et al.
FALSE

Unmasking the MASCC score: A retrospective study.
Arun Kumar et al.
FALSE

Disparities in fertility preservation in rural adolescent and young adult patients with hematologic malignancies.
Thomas et al.
FALSE

NO BUGS: Nosocomial operative best-practices for unplanned infections in gynecologic surgery: A 6-month retrospective.
Aliabadi et al.
FALSE

Understanding the motives to seek additional care at non-governmental organizations.
Villarreal-Garza et al.
FALSE

Breast cancer early diagnosis detection of breast cancer through education of primary healthcare providers in Côte D'Ivoire.
Homian et al.
FALSE

Assessment of outpatient chemotherapy and unplanned emergency department visits in a large community hospital system.
Dvorak et al.
FALSE

Barriers, facilitators, and strategies for improving breast cancer screening in Ukraine.
Dzhemiliev et al.
FALSE

Functional status and therapy receipt among older adults with multiple myeloma.
Jensen et al.
FALSE

A contemporary national population-based analysis of demographics and outcomes of Hispanics with adult T-cell leukemia/lymphoma in the US.
Velez-Mejia et al.
FALSE

National population-based analysis of demographics and outcomes of patients diagnosed with extranodal NK/T-cell nasal type lymphoma in the US: Does ethnicity play a role?
Velez-Mejia et al.
FALSE

Peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma: Are the outcomes any different in Hispanics?
Velez et al.
FALSE

Real world data evidence (RWDE) on cancer patients' (pts) awareness and knowledge of cancer associated thrombosis (CAT) events.
Duek et al.
FALSE

Prognostic stratification and outcome of metastatic NSCLC based on activating mutation profile and PD-L1 status.
Chan et al.
FALSE

Agranulocytosis secondary to cancer chemotherapy and association with higher in-hospital mortality in patients with central line insertion during hospital stay.
Mohamed Jiffry et al.
FALSE

Risk factors for in-hospital mortality in cancer patients hospitalized for COVID-19.
Abuhelwa et al.
FALSE

Immunocompetent and immunocompromised cancer populations: Post-vaccination humoral and cellular immune responses against SARS-CoV-2.
Titova et al.
FALSE

Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey.
Kubilay et al.
FALSE

The impact of Covid-19 pandemic on breast cancer multidisciplinary management at the Vall d'Hebron University Hospital.
Pimentel et al.
FALSE

Chronic leukemias and COVID-19: An analysis of mortality and morbidity outcomes in the United States.
Abuhelwa et al.
FALSE

Nutrition and head-neck cancer: A prospective observational study in patients with head neck cancer receiving adjuvant/definitive radiotherapy/chemoradiotherapy.
Deshmukh et al.
FALSE

Real world data on immunotherapeutic outcomes in solid tumours.
Srinivasalu et al.
FALSE

COVID-19 vaccination, infection, and symptoms among cancer survivors in the United States during 2021.
Yang et al.
FALSE

Real-world healthcare resource utilization (HCRU) and costs among patients with hematologic or solid tumor malignancy (STM) with COVID-19 in a commercially insured or Medicare Advantage population.
Cunningham et al.
FALSE

Experience of a stem cell transplant in multiple myeloma: The patient and care partner perspective.
Hansen et al.
FALSE

The utilization of cryopreserved sperm in males with cancer.
Reynolds et al.
FALSE

Real-world utilization pattern of pexidartinib in patients with tenosynovial giant cell tumor (TGCT).
Lin et al.
FALSE

Durvalumab outcomes for patients with PD-L1 positive and negative stage III unresectable non-small cell lung cancer treated at veterans health administration facilities.
Burton et al.
FALSE

Real-world experience with liposomal doxorubicin in metastatic and locally advanced sarcoma.
Hodge et al.
FALSE

Robotic CT guided biopsy to aid histological confirmation of recurrent lymphoma in cases where tissue sample is challenging to obtain through conventional percutaneous methods.
Bamania et al.
FALSE

Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status.
Cumaraswamy et al.
FALSE

Did COVID-19 impact national trends of hospitalization and outcomes for neutropenic fever in adults with cancer?
Bhardwaj et al.
FALSE

Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.
Crump et al.
FALSE

Under-screened: COVID-19 lockout measures and the reduction of early-stage cancer patients’ consultations in Argentina.
Gil Deza et al.
FALSE

Survival in patients with cancer of unknown primary site (CUP): Mayo Clinic experience.
Suleiman et al.
FALSE

Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience.
Algarin Perneth et al.
FALSE

Correlation between step count and clinical outcomes for patients with cancer during treatment: A feasibility study.
Oakley-Girvan et al.
FALSE

Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting.
Cosgrove et al.
FALSE

Characteristics of SARSCOV2 infection in vaccinated patients with cancer in one Latin American country: Real world evidence from ACHOCC19-VAC study.
Ospina Serrano et al.
FALSE

Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience.
Duran et al.
FALSE

Outcome differences by sex in oncology clinical trials.
Kammula et al.
FALSE

Cancer in the time of COVID: Trends in presentation, staging, and demographic disparities in breast, uterus, and gynecologic cancers at an NCORP site.
Myers et al.
FALSE

Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy.
Kolodziej et al.
FALSE

Effect of pandemic-related reductions in cancer care delivery on different US health systems.
Janczewski et al.
FALSE

Exploring the association between medical marijuana cardholder status and antiemetic overuse.
Baltz et al.
FALSE

Cost savings and clinical outcomes in cancer patients enrolled in clinical trials from a national public health system perspective.
Garcia-Garro et al.
FALSE

Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.
Ferrari et al.
FALSE

The incidence and risk factors predictive of bone metastases at initial diagnosis of malignancy.
Knapp et al.
FALSE

Risk of inpatient and emergency department visits among lung cancer patients receiving immunotherapies as first line treatment: Findings from a linked population dataset.
Tay et al.
FALSE

A national analysis of Burkitt lymphoma in the Hispanic community.
Alhaj et al.
FALSE

Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.
Kosmidis et al.
FALSE

Adjuvant therapy for HR+/HER2– early-stage breast cancer (EBC): Changes in practice patterns among community oncologists in Brazil.
Goncalves et al.
FALSE

Analysis of hospitalizations of patients with Kaposi sarcoma: A national population-based study.
Kanemo et al.
FALSE

Retrospective analysis of the effect of COVID-19 in hospitalized cancer patients.
Shah et al.
FALSE

Outcomes of venous thromboembolism among cancer patients admitted with COVID-19: A nationwide inpatient sample analysis.
Ibrahim et al.
FALSE

Utility of Brock model for risk stratification in patients with high-risk pulmonary nodules: A single center study.
Iqbal et al.
FALSE

Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.
Guillaume et al.
FALSE

Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.
Goyal et al.
FALSE

Patterns, perceptions, and experience with cannabidiol (CBD) after cancer diagnosis.
Lapen et al.
FALSE

Real-world data of early-onset colorectal cancer (EOCRC) in private health system in Brazil.
Mathias et al.
FALSE

Etiology and outcomes of neutropenic fever in Malawi: A prospective, observational cohort.
Puranam et al.
FALSE

Health care provider and hospital decision-maker perceptions and beliefs on global environmental sustainability in the operating room.
Gorgun et al.
FALSE

Tolerability of capecitabine in difference racial/ethnic groups.
Dower et al.
FALSE

Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.
Michaeli et al.
FALSE

Outcomes among Hispanic metastatic breast cancer patients treated with alpelisib and fulvestrant: Single institution retrospective study.
Chamorro et al.
FALSE

Male breast cancer survival data and clinicopathological characteristics: A single-centre experience.
Tzouda et al.
FALSE

Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.
Reis Neto et al.
FALSE

COVID-19 and prevalence of venous thromboembolism among cancer patients: A nationwide inpatient sample analysis.
Ibrahim et al.
FALSE

Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in patients with non-small cell lung cancer receiving first-line treatment.
Khabbaha et al.
FALSE

A single-centre experience of immune checkpoint inhibitors in patients with cancer in the Top End of the Northern Territory, Australia from 2016 to 2021.
Miller et al.
FALSE

Impact of the COVID pandemic on reporting of breast cancer cases and mortality.
Khorfan et al.
FALSE

Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer.
Naser et al.
FALSE

Utilization and dispensing patterns of medical cannabis products in a state with legalized medical cannabis.
Olson et al.
FALSE

Clinical characterization of patients with recurrent glioblastoma in trials involving CED and non-CED treatment.
Ensign et al.
FALSE

Association of cannabis use with real-world time to treatment discontinuation (rwTTD) in patients with advanced cancer initiating immune checkpoint inhibition (ICI).
Zylla et al.
FALSE

Real-world efficacy of nivolumab in Peruvian patients with advanced melanoma.
Roque et al.
FALSE

Safety of same day administration of pegfilgrastim in breast cancer patients.
Reynolds et al.
FALSE

Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.
Saidi et al.
FALSE

Real world outcomes of veterans 18-45 years old with acute lymphocytic leukemia.
McKinnell et al.
FALSE

Real world assessment of clinical benefit with consolidation durvalumab following chemoradiotherapy in stage III unresectable non-small cell lung cancer.
Marur et al.
FALSE

Trends in breast cancer death by stage at diagnoses in 2000-2018.
Kahn et al.
FALSE

Evaluating patient adherence and persistence to first-line tyrosine-kinase inhibitors for metastatic renal cell carcinoma.
Arter et al.
FALSE

Real world data on off-label use of consolidation durvalumab in newly diagnosed stage II and recurrent non-small cell lung cancer patients treated with definitive chemoradiotherapy.
Wise et al.
FALSE

Characterizing of adverse events across 30,000 peer reviewed case report publications.
Khabbaha et al.
FALSE

Outcomes of stage IV non-small cell lung cancer patients after failure of platinum-based chemotherapy in clinical trials and real-world settings: A literature review.
Soon et al.
FALSE

Cancer ontology understanding among community oncologists: Insights from a survey linked to implementation of mCODE-informed electronic health record (EHR).
Dienstmann et al.
FALSE

Correlation of survival in colorectal cancer with tumor mutational burden and mutations identified by next-generation sequencing.
Taflin et al.
FALSE

Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.
Goyal et al.
FALSE

A population-level analysis of survival in patients with ALK+ anaplastic large cell lymphoma (ALCL) in the era of novel therapies.
Mishra et al.
FALSE

Development of a multiphase patient-reported outcomes dashboard to support population health and drive quality improvement in ambulatory oncology.
Zhang et al.
FALSE

Association of weight loss with risk of myelodysplastic syndromes (MDS) in adults with obesity: Insights from the SPLENDID cohort.
Mishra et al.
FALSE

The same outcome of cancer patients treated with radiotherapy or chemoradiotherapy regardless COVID-19 status.
Zhang et al.
FALSE

The impact of COVID-19 on national trends of hospitalization and outcomes for acute leukemias.
Bhardwaj et al.
FALSE

Impact of early mammography screening on time to diagnosis.
Rutter et al.
FALSE

Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).
Tolaney et al.
FALSE

Pan-cancer analysis of tumor mutation burden and other key ICI biomarkers in the Indian cohort.
Vaid et al.
FALSE

Real world challenges in defining oligometastatic disease in clinical practice.
Navarro-Domenech et al.
FALSE

Assessing gender disparities in young patients with lung cancer among a diverse urban population.
Edwards et al.
FALSE

Impact of COVID-19 pandemic on breast cancer screening rates.
Rutter et al.
FALSE

Navigating how to choose an oncologist as part of the cancer journey.
Francis et al.
FALSE

Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer.
Kobe et al.
FALSE

Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+ in the United States (US).
Kalinsky et al.
FALSE

Factors that determine selection of a cancer treatment location.
Francis et al.
FALSE

The broader impact of specialized outpatient cancer rehabilitation on health and quality of life among breast cancer survivors.
Pergolotti et al.
FALSE

Utilization and barriers to genomic profiling in breast cancer treatment among oncologists.
Miller et al.
FALSE

Return to work in breast cancer patients with and without pre-diagnosis psychological distress.
Pai et al.
FALSE

Understanding the information needs of lymphoma and CLL patients: A comparison of Asia-Pacific and Europe.
Bates et al.
FALSE

Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.
Salah et al.
FALSE

Identification of predictive, treatment-specific Charlson comorbidity score thresholds in acute myeloid leukemia.
Bouligny et al.
FALSE

Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.
Yadukumar et al.
FALSE

Healthcare resource utilization (HCRU) and costs among adult patients with lung cancer with broad panel genomic testing and clinically relevant or non-clinically relevant genomic variants.
Moore et al.
FALSE

Antidepressant adherence trajectory before cancer diagnosis and risk of antidepressant discontinuation after cancer diagnosis among middle-aged US adults.
Onasanya et al.
FALSE

Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.
Kish et al.
FALSE

Using real-world evidence to evaluate broad panel vs. sequential single and narrow panel sequencing in members with non-small cell lung cancer (NSCLC).
Byrd et al.
FALSE

Incidence of skin cancer among patients with Waldenström macroglobulinemia: Analysis of the SEER database (2000-2019).
Taneja et al.
FALSE

Difference in persistence between tablets and capsules.
Zaidi et al.
FALSE

Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.
Kish et al.
FALSE

COVID-19 vaccination in patients with cancer: Results from survey based observational study.
Polimera et al.
FALSE

A powerful random forest-based pipeline for accurately identifying the structural variants on panel sequencing data.
Zhuang et al.
FALSE

Assessing the willingness to participate in future clinical trials.
Shaver et al.
FALSE

Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).
Taneja et al.
FALSE

Effect of COVID-19 on mortality in patients admitted for DVT/PE with pre-existing cancer diagnosis at the beginning of the COVID-19 pandemic: A national inpatient sample study.
Campbell et al.
FALSE

Patient preferences for use of archived biospecimens in Turkey.
Kubilay Tolunay et al.
FALSE

Financial toxicity of hematologic malignancy therapies: Subjective experience of patients and impact on access to care.
Fedorov et al.
FALSE

Estimated value-based pricing for blood-based colorectal cancer screening test versus multi-target stool DNA test.
Kisiel et al.
FALSE

Receipt of financial drug assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer (NSCLC).
Kumar et al.
FALSE

Cost of breast cancer screening in the USA: Comparison of current practice, advocated guidelines, and a personalized risk-based approach.
Badal et al.
FALSE

Financial toxicity and quality of life among people with chronic myeloid leukemia on tyrosine kinase inhibitors.
Burns et al.
FALSE

Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma.
Meyer et al.
FALSE

Impact of economic inequality on Kaposi sarcoma of the lung: A retrospective cohort.
Guevara et al.
FALSE

Breaking down cancer costs: Hospital charges for patients with melanoma.
Hundal et al.
FALSE

Excess testing after diagnosis of incidental pulmonary nodules (IPNs) in the Medicare population.
Osarogiagbon et al.
FALSE

The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson et al.
FALSE

Cost-effectiveness of novel systemic therapies for advanced breast cancer: Global representativeness and influence of funding.
Lazar Neto et al.
FALSE

Multi-cancer early detection screening tools: A dream come true or a nightmare in the offing.
Fleck et al.
FALSE

Cost effectiveness of a personalized approach for lung cancer screening with LDCT based on the use of blood-based biomarker test.
Irajizad et al.
FALSE

Cost-utility analyses of later-line treatments for metastatic colorectal cancer (mCRC) by network meta-analysis (NMA) approach: Conventional constant hazard ratio vs novel survival curves methodologies.
Obeng-Kusi et al.
FALSE

Cost-effectiveness analysis of a circulating tumor DNA-based molecular residual disease assay to guide adjuvant chemotherapy decisions in patients with resectable early stage colorectal cancer.
Schneider et al.
FALSE

Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
Roddie et al.
TRUE

Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
Roloff et al.
TRUE

Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.
Hill et al.
TRUE

Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
Garcia-Manero et al.
TRUE

IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
Zeidan et al.
TRUE

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Stein et al.
TRUE

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
Wieduwilt et al.
TRUE

A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).
Kopmar et al.
TRUE

Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.
Muffly et al.
TRUE

Adherence and satisfaction with remote cognitive training in blood or marrow transplant (BMT) survivors: The cognitive training and attitudes towards genetics (cTAG) study.
Sharafeldin et al.
TRUE

Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.
Kuzmanovic et al.
TRUE

Association of Agent Orange and myeloproliferative neoplasms, thrombosis, and bleeding among veterans.
Tiu et al.
TRUE

Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
De Botton et al.
TRUE

Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis.
Martinelli et al.
TRUE

Outcomes of 3- versus 5-day administration schedule of consolidation cytarabine in adults with acute myeloid leukemia (AML).
Diebold et al.
TRUE

A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
Zhang et al.
TRUE

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
Gerds et al.
TRUE

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
Bose et al.
TRUE

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Ajufo et al.
TRUE

Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.
Passamonti et al.
TRUE

Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.
Aguirre et al.
TRUE

Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study.
Scott et al.
TRUE

Outcomes of 10-day decitabine with venetoclax for AML.
Coltoff et al.
TRUE

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
Shah et al.
TRUE

UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
Gaut et al.
TRUE

Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.
You et al.
TRUE

Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
Yang et al.
TRUE

Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
Ritchie et al.
TRUE

First-in-human trial of tocilizumab in combination with a standard induction chemotherapy in newly diagnosed acute myeloid leukemia patients: The phase 1 TOCILAM study.
Peterlin et al.
TRUE

Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.
Mitchell et al.
TRUE

BOS-371, a monoclonal antibody against IL1RAP: Characterization in preclinical models of AML.
West et al.
TRUE

Identification of factors to predict low risk febrile neutropenia admissions in patients with acute myeloid leukemia (AML) following intensive chemotherapy.
Pal et al.
TRUE

Shattering myths regarding Hispanic ethnicity and survival in acute myeloid leukemia: Insights from the National Cancer Database.
Premnath et al.
TRUE

Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.
Nittur et al.
TRUE

Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML).
Amaya et al.
TRUE

Clinical outcomes of patients with newly diagnosed acute myeloid leukemia receiving treatment in a safety-net hospital system.
Lu et al.
TRUE

Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
Watts et al.
TRUE

A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
Elsebaie et al.
TRUE

Evaluation of cardiac failure and recovery in acute myelogenous leukemia.
Wu et al.
TRUE

Analysis of short-term efficacy and safety of mitoxantrone hydrochloride liposome regimen therapy in adult acute myeloid leukemia.
Ma et al.
TRUE

Association of intensive chemotherapy with the rate of pathogenic driver mutation clearance in acute myeloid leukemia.
Maini et al.
TRUE

Predictors of early port infection in adult patients with acute myeloid leukemia.
Kandala et al.
TRUE

Comparison of characteristics and prognostic impact of FUS-ERG and AML1-MTG16 fusion genes in adult AML patients: A retrospective study from 1988 to 2022 with a medical database.
Zhou et al.
TRUE

An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).
Al Malki et al.
TRUE

Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
Zeidan et al.
TRUE

Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.
Garciaz et al.
TRUE

Capped F10, a novel DNA directed fluoropyrimidine, in TP53 mutated acute myeloid leukemia (AML).
Pardee et al.
TRUE

Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).
Senapati et al.
TRUE

Treatment outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: A comparison between pediatric-inspired regimens and HyperCVAD at a Hispanic-serving cancer center.
Griffin et al.
TRUE

Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).
Rojek et al.
TRUE

Early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with post-transplant cyclophosphamide: Updated results of a monocentric phase 1 study.
Jullien et al.
TRUE

Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
Popat et al.
TRUE

Financial toxicity and quality of life in patients undergoing bone marrow transplant evaluation: A single center analysis.
Hussaini et al.
TRUE

Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.
Moslehi et al.
TRUE

Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
Othieno-Abinya et al.
TRUE

Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
Varughese et al.
TRUE

External validation of the Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes.
Chernak et al.
TRUE

Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting.
Mukherjee et al.
TRUE

Methylation-based prediction of myelodysplastic syndrome survival outcomes.
Shi et al.
TRUE

Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.
Shah et al.
TRUE

Defining the immune microenvironment in myelodysplastic syndrome and acute myeloid leukemia using machine learning.
Albitar et al.
TRUE

Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.
Zhang et al.
TRUE

Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.
Jin et al.
TRUE

Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
Ali et al.
TRUE

Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
Rinaldi et al.
TRUE

Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).
Masarova et al.
TRUE

Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).
Mesa et al.
TRUE

Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging.
Azoulay et al.
TRUE

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.
Bose et al.
TRUE

Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
Watts et al.
TRUE

Outcomes of patients with a myeloproliferative neoplasm and atrial fibrillation.
Leiva et al.
TRUE

Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).
Makinde et al.
TRUE

Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.
Chien et al.
TRUE

A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML).
Daver et al.
TRUE

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.
Jamy et al.
TRUE

Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.
Fathi et al.
TRUE

A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.
Short et al.
TRUE

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).
Smith et al.
TRUE

Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Lin et al.
TRUE

Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.
Zeidan et al.
TRUE

A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
Ponce et al.
TRUE

A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML).
Li et al.
TRUE

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).
Atallah et al.
TRUE

A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS).
Garcia-Manero et al.
TRUE

A phase I study of MEK inhibitor selumetinib in combination with azacitidine in patients with higher-risk chronic myeloid neoplasia.
Roloff et al.
TRUE

Phase 1b clinical study of IRAK 1/4 inhibition for low-risk myelodysplastic syndromes refractory/resistant to prior therapies.
Garcia-Manero et al.
TRUE

A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Bewersdorf et al.
TRUE

Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib.
Masarova et al.
TRUE

EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
Masarova et al.
TRUE

Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.
McCullough et al.
TRUE

Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience.
Almanza-Huante et al.
FALSE

Novel RNA epigenetics-driven technologies for rapid prediction of cancer drug resistance.
Wood et al.
FALSE

Work absenteeism and disability days after diagnosis among patients with AML and caregivers.
LeBlanc et al.
FALSE

Association of FLT3 and NPM1 mutations in patients with acute myeloid leukemia with metabolomic patterns determined by mass spectrometry.
Toprak et al.
FALSE

Molecular and cytogenetics abnormalities in acute myeloid leukemia at Puerto Rico.
Marrero-León et al.
FALSE

A real-world evaluation of treatment (Tx) patterns and outcomes of acute myeloid leukemia (AML) induction therapies in the community setting.
Maher et al.
FALSE

Effect of change in ECOG performance status at diagnosis and relapse in patients with acute myeloid leukemia.
Zhang et al.
FALSE

Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study.
Nasr et al.
FALSE

Defining risk of central nervous system relapse in acute myeloid leukemia following allogeneic stem cell transplantation.
Nicchi et al.
FALSE

Responses in patients with AML and treated with entospletinib monotherapy.
Lin et al.
FALSE

Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.
Fleming et al.
FALSE

Early death (ED) in elderly acute promyelocytic leukemia (APL) patients treated with lower induction doses of all-trans retinoic acid (ATRA).
Dalgetty et al.
FALSE

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Short et al.
FALSE

Effect of upfront HSCT on patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at high risk of relapse: Single center retrospective observational study on minority rich population.
Neupane et al.
FALSE

Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.
Maher et al.
FALSE

Optical genome mapping for cytogenomic analysis of hematological neoplasms.
Tang et al.
FALSE

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).
Short et al.
FALSE

Clinical-grade natural killer cells expanded from donor peripheral blood and anti-leukemia effect against myeloid leukemia.
Zhao et al.
FALSE

Identification of a novel NPM1 mutation in acute myeloid leukemia.
Yao et al.
FALSE

Clinical spectrum and outcomes of carbapenem resistant infections in patients with acute leukaemia: A clinical study from a tertiary oncology centre in India.
Hari et al.
FALSE

A retrospective analysis of the outcomes among hospitalized patients with myeloid leukemia undergoing leukapheresis: Insight from the National Inpatient Sample.
Arya et al.
FALSE

10-year real-world data on acute myeloid leukemia: The paradigm of a public health center in Brazil.
Campos et al.
FALSE

A demographic study of acute megakaryoblastic leukemia using the national cancer database.
Juang et al.
FALSE

Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia.
Chen et al.
FALSE

Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial.
Nasnas et al.
FALSE

Biomarker subpanel customization for different use cases in acute myeloid leukemia research.
Li et al.
FALSE

Demographic factors affecting patients with AML with myelodysplasia-related changes.
Stewart et al.
FALSE

Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.
Nasr et al.
FALSE

Use of daunorubicin and cytarabine in adults with acute myeloid leukemia and associated risk factors for inpatient mortality: National inpatient sample review.
Pagidipally et al.
FALSE

Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy.
Abedin et al.
FALSE

Survival outcomes of acute erythroid leukemia in the United States: A 20-year population-based study.
Gera et al.
FALSE

Busulfan versus treosulfan conditioning for acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis.
Rehman et al.
FALSE

Intracranial hemorrhage (ICH) in acute leukemia (AL): A single-center study from a general hospital with two cases managed with middle meningeal artery (MMA) embolization.
Yohannan et al.
FALSE

Comparison of time of onset of leukemia with patients receiving adalimumab vs other TNF α inhibitors.
Devarkonda et al.
FALSE

Why adult patients with acute leukemias are dying in the developing world: The other side of the coin.
Voskanyan et al.
FALSE

Outcomes of different therapies in acute myeloid leukemia patients with core-binding factor.
Zhou et al.
FALSE

Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Nasnas et al.
FALSE

Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase.
Zoghbi et al.
FALSE

Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.
Zoghbi et al.
FALSE

Trajectories of physical well-being among adults with acute myeloid leukemia.
Jensen-Battaglia et al.
FALSE

Olutasidenib in post-venetoclax patients with mIDH1 AML.
Cortes et al.
FALSE

Venetoclax pharmacokinetics in subjects with end-stage renal disease undergoing hemodialysis.
Noorani et al.
FALSE

IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia.
Murray et al.
FALSE

A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML).
Senapati et al.
FALSE

Massively multiplex blocker displacement amplification (BDA) for the detection of measurable residual disease in acute myeloid leukemia.
Li et al.
FALSE

Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia.
Murray et al.
FALSE

FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia.
Tran et al.
FALSE

The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.
Doyel et al.
FALSE

A National Cancer database study on the demographic factors associated with mast cell leukemia.
Voth et al.
FALSE

Acute lymphocytic leukemia incidence and survivability trends in the United States over the last two decades: SEER data set from 2000-2019.
Ghosh et al.
FALSE

Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia.
Zacholski et al.
FALSE

Age-standardized incidence, mortality rates, mortality-to-incidence ratios, and disability-adjusted life years for acute lymphoblastic leukemia in the European Union 15 + countries, Australia, and United States of America.
Jain et al.
FALSE

Acute myeloid leukemia (AML) outcomes in the era of novel therapies: A 9-year single-institution experience.
Gera et al.
FALSE

Clinical outcomes of core binding factor acute myeloid leukemia in the modern era.
Hang et al.
FALSE

Treatment phase stratified outcomes of core binding factor acute myeloid leukemia.
Gor et al.
FALSE

Outcomes of hematological malignancy patients who underwent myeloablative haploidentical transplant with PTCy and ATG.
Hameed et al.
FALSE

Impact of body mass index (BMI) and weight changes on hematopoietic stem cell transplant (HSCT) outcomes in the elderly population.
Hemrajani et al.
FALSE

Trends in hematopoietic stem cell transplantation for leukemia, lymphoma and multiple myeloma in the United States: 2016 to 2020.
Amadife et al.
FALSE

Racial disparities in the outcomes of allogeneic bone marrow transplant: A 5-year nationwide inpatient study.
Vikash et al.
FALSE

Diagnostic performance of natural language processing in detection of acute cancer VTE.
Subramanian et al.
FALSE

Treatment patterns and outcomes of diffuse alveolar hemorrhage: Findings from a single-center retrospective study.
Butler et al.
FALSE

Comparison of outcomes of Clostridium difficile infection in autologous stem cell transplant recipients compared to allogenic stem cell transplant recipients.
Bains et al.
FALSE

Absolute lymphocyte counts (ALC) recovery and risk of viral reactivation in the setting of haploidentical hematopoietic stem cell transplant.
Chu et al.
FALSE

Efficacy and safety of ponatinib in management of chronic myeloid leukaemia: Experience from Kenya.
Othieno-Abinya et al.
FALSE

Treatment failure with first line imatinib for patients with chronic myeloid leukaemia in Kenya vs high-income countries.
Mcligeyo et al.
FALSE

Stopping study in chronic myeloid leukemia: Defining a new paradigm for Ontario CML1.
Ravipati et al.
FALSE

Incidence of drug-induced myelosuppression and associated adverse events (AEs), quality of life (QOL), and medical resource use (MRU) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Vutcovici Nicolae et al.
FALSE

The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.
Zhang et al.
FALSE

Incidence of cardiac events in patients with MDS or AML receiving azacitidine or decitabine within a large community health system.
Naffakh et al.
FALSE

Characteristics and survival of secondary acute myeloid leukemia arising from myelodysplastic syndrome (MDS-sAML).
Adrianzen Herrera et al.
FALSE

Effect of hypomethylating agent (HMA) exposure on survival of secondary acute myeloid leukemia (sAML) from myelodysplastic syndrome (MDS).
Adrianzen Herrera et al.
FALSE

Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).
Komrokji et al.
FALSE

Predictors of survival outcomes in patients with MECOM EVI1 rearrangement aberrations in AML or MDS.
Kusne et al.
FALSE

Expression of CD47 and CALR in myeloproliferative neoplasms: Potential new therapeutical targets.
Rinaldi et al.
FALSE

Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.
Chojecki et al.
FALSE

Juvenile myelomonocytic leukemia: A national analysis of demographic features.
Whooley et al.
FALSE

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
Woyach et al.
TRUE

Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.
Siddiqi et al.
TRUE

Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.
Frustaci et al.
TRUE

Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).
Cai et al.
TRUE

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.
Choi et al.
TRUE

Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
Merryman et al.
TRUE

Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
Kambhampati et al.
TRUE

Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
Sarkozy et al.
TRUE

Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Jacobson et al.
TRUE

Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang et al.
TRUE

SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.
Crombie et al.
TRUE

Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.
Coombs et al.
TRUE

Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Shah et al.
TRUE

Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
Harker-Murray et al.
TRUE

Circulating tumor DNA of classical Hodgkin lymphoma.
Pirosa et al.
TRUE

Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.
McDonald et al.
TRUE

Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
Hu et al.
TRUE

Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
Falchi et al.
TRUE

Impact of imaging frequency on progression free survival in Alliance clinical trials enrolling patients with untreated follicular lymphoma.
Rutherford et al.
TRUE

Effectiveness and safety outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.
Choquet et al.
TRUE

A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Yoon et al.
TRUE

Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.
Herrera et al.
TRUE

High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study.
Nair et al.
TRUE

Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
Karimi et al.
TRUE

Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.
Nastoupil et al.
TRUE

Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
Yang et al.
TRUE

Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).
Frigault et al.
TRUE

AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.
Khanal et al.
TRUE

Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.
Bennani et al.
TRUE

Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Ozcan et al.
TRUE

Efficacy of COVID vaccinations in patients with chronic lymphocytic leukemia.
Annunzio et al.
TRUE

Analysis of racial disparities accounting for treatment received in chronic lymphocytic leukemia: A real-world cohort analysis.
Kittai et al.
TRUE

Patient perspectives on CLL treatment side effects: A sub-analysis of the VOICE survey.
Tam et al.
TRUE

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
Barr et al.
TRUE

Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the informCLL registry.
Barrientos et al.
TRUE

Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).
Rogers et al.
TRUE

Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.
Stephens et al.
TRUE

A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL).
Kittai et al.
TRUE

Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.
Basher et al.
TRUE

Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.
Bowers et al.
TRUE

Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory and early relapsing diffuse large B-cell lymphoma (DLBCL).
Bock et al.
TRUE

Identifying racial and ethnic disparities in patients diagnosed with mycosis fungoides/Sezary syndrome in the United States: A contemporary SEER analysis.
Fierro et al.
TRUE

Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
Flowers et al.
TRUE

Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.
Phillips et al.
TRUE

Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).
Miles et al.
TRUE

Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Asai et al.
TRUE

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
Dickinson et al.
TRUE

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.
Falchi et al.
TRUE

A phase 1a/b study of BR101801, a PI3Kγδ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.
Kim et al.
TRUE

Real-world outcomes with novel therapies in R/R DLBCL.
Crombie et al.
TRUE

Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
Li et al.
TRUE

Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).
Shah et al.
TRUE

Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.
Dreyling et al.
TRUE

Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.
Nguyen et al.
TRUE

First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Zhang et al.
TRUE

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies.
Li et al.
TRUE

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
Ho et al.
TRUE

Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Chen et al.
TRUE

A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant.
Foley et al.
TRUE

Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.
Burkart et al.
TRUE

Treatments and outcomes of patients with localized extranodal NK/T-cell lymphoma (ENKL) diagnosed between 2014 and 2021: A cooperative study in Japan.
Miyazaki et al.
TRUE

Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
Alcantara et al.
TRUE

Racial and ethnic disparities in risk of second primary malignancies among diffuse large B-cell lymphoma survivors.
Advani et al.
TRUE

Uncertainty and coping in patients with newly diagnosed indolent non-Hodgkin’s lymphoma (iNHL).
Newcomb et al.
TRUE

Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
Ailawadhi et al.
TRUE

Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the US.
Hansen et al.
TRUE

Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Samples et al.
TRUE

Unveiling the prognostic significance of BCL6+/CD10+ mantle cell lymphoma: A systematic analysis.
Castillo et al.
TRUE

Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis.
Niyogusaba et al.
TRUE

A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.
Cao et al.
TRUE

Clinical characteristics, survival outcomes, and prognostic factors in extranodal natural killer/T-cell lymphoma, nasal type: The National Cancer Database study (2004-2019).
Baidoun et al.
TRUE

Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.
Mcshinsky et al.
TRUE

Risk of incident melanoma among individuals with low-count monoclonal B-cell lymphocytosis (MBL).
Vallejo et al.
TRUE

ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
Westin et al.
TRUE

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
Flinn et al.
TRUE

The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
Patel et al.
TRUE

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).
Hess et al.
TRUE

BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Follows et al.
TRUE

BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Eyre et al.
TRUE

BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Woyach et al.
TRUE

KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Lavie et al.
TRUE

SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Westin et al.
TRUE

BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.
Wang et al.
TRUE

A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
Olszewski et al.
TRUE

waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
Lavie et al.
TRUE

MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
Nastoupil et al.
TRUE

A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.
Patel et al.
TRUE

Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
Sehn et al.
TRUE

BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.
Perini et al.
TRUE

BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Sevindik et al.
TRUE

waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
Zinzani et al.
TRUE

Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Kunz et al.
FALSE

Translational development of BAFF-R-specific chimeric antigen receptor T-cell therapy targeting B-cell lymphoid malignancies.
Luo et al.
FALSE

Comprehensive myeloid-derived suppressor cell (MDSC) immunophenotyping and functional assessment in chimeric antigen receptor (CAR) T therapy.
Wang et al.
FALSE

Single center experience of using Anakinra prophylactically at Day 0 to reduce CD19 CART toxicities.
Nain et al.
FALSE

Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience.
Zhuang et al.
FALSE

Chronic lymphocytic leukemia/small lymphocytic lymphoma nationwide analysis: Comparing sociodemographic and survival outcomes among Hispanics and non-Hispanics in the United States.
Toro-Vélez et al.
FALSE

Association of congestive heart failure with hospital outcomes among patients with chronic lymphocytic leukemia in the United States: Analysis of nationwide inpatient sample.
Olusoji et al.
FALSE

Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy.
Kosydar et al.
FALSE

Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.
Wang et al.
FALSE

Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.
Lin et al.
FALSE

Do Hispanic individuals have similar overall survival of nodular lymphocyte-predominant Hodgkin’s lymphoma? A national analysis.
Mines et al.
FALSE

Incidence and outcomes of immune-related adverse events after immune checkpoint inhibitors in patients with Hodgkin lymphoma.
Lin et al.
FALSE

Classical Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results (SEER) Database analysis comparing racial and ethnic disparities with emphasis on Hispanics.
Toro-Vélez et al.
FALSE

Hodgkin lymphoma mortality trends in age subgroups from 1999 to 2020 in the United States.
Varughese et al.
FALSE

Anthracycline-related cardiotoxicity among patients with lymphoma: Systematic review and meta-analysis.
Abu Rmilah et al.
FALSE

Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma.
Rozental et al.
FALSE

Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell et al.
FALSE

Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL): Proposal for intensive therapy.
Wei et al.
FALSE

Real-world treatment patterns of bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US).
Shah et al.
FALSE

Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): Matching-adjusted indirect comparison (MAIC).
Thieblemont et al.
FALSE

Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL).
Thieblemont et al.
FALSE

CAR-T cells targeting CD38 and LMP1 and anti-tumor activity against NK/T cell lymphoma.
Li et al.
FALSE

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases.
Munoz et al.
FALSE

Risk reduction of CNS relapse in diffuse large B cell lymphoma with intrathecal methotrexate prophylaxis: A single institution retrospective study.
Hino et al.
FALSE

Phase I clinical study of orally-dosed HBW-3220 in patients with relapsed/refractory B-cell lymphoma.
Li et al.
FALSE

Health-related quality of life and economic burden in Chinese patients with cutaneous T-cell lymphoma.
Wang et al.
FALSE

Diffuse large B-cell lymphoma in HHV8+ multicentric castleman disease: A national analysis of demographic features.
Whooley et al.
FALSE

Cryptococcosis in non-HIV/non-transplant hematological patients: A 12-year retrospective clinical analysis in a Peruvian referral cancer center.
Meza et al.
FALSE

Does low-grade follicular lymphoma with high proliferation index require a different treatment strategy? A single center experience.
Vusqa et al.
FALSE

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for the treatment of peripheral T cell lymphoma.
Huang et al.
FALSE

High dose methotrexate (MTX) treatment: Value of post treatment MTX level monitoring and risk factors for acute kidney injury.
Snyder et al.
FALSE

Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma.
Chong et al.
FALSE

What differences in outcomes exist in Hispanic patients being treated for lymphoplasmacytic lymphoma and waldenstrom macroglobulinemia?
Huston-Cravens et al.
FALSE

COVID-19 infection in patients on anti-CD20 monoclonal antibodies: Changes in clinical outcomes and management over time.
Ali et al.
FALSE

Systematic review determining the characteristics of primary bone lymphoma.
Benkhadra et al.
FALSE

Epidemiology and prognostic factors of hepatosplenic T-cell lymphoma (HSTL): An analysis of NCDB (National Cancer Database).
Albagoush et al.
FALSE

Serum IL-6 levels following siltuximab administration in castleman disease.
Mango et al.
FALSE

Outcomes of intravenous and subcutaneous cladribine administration in patients with hairy cell leukemia: A systematic review and meta-analysis.
Basit et al.
FALSE

Evaluating the effectiveness and tolerability of chemotherapy in hairy cell leukemia: A comprehensive systematic review and meta-analysis.
Basit et al.
FALSE

Clinical characteristics, survival outcomes, and prognostic factors in subcutaneous panniculitis like T-cell lymphoma: National Cancer Database analysis (2004-2018).
Baidoun et al.
FALSE

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
Knop et al.
TRUE

Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.
Nooka et al.
TRUE

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Cohen et al.
TRUE

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
Dholaria et al.
TRUE

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Sperling et al.
TRUE

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
Du et al.
TRUE

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Lee et al.
TRUE

A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
Weisel et al.
TRUE

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
Nooka et al.
TRUE

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Lin et al.
TRUE

Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
Mi et al.
TRUE

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk et al.
TRUE

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Hansen et al.
TRUE

Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
Afrough et al.
TRUE

Plasma cell leukemia: A multicenter retrospective study of 150 patients.
Chineke et al.
TRUE

Disparities in multiple myeloma: A global perspective on drug toxicity trends.
Jaberi-Douraki et al.
TRUE

Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.
Potluri et al.
TRUE

Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma.
Khan et al.
TRUE

A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
Usmani et al.
TRUE

Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
Janardan et al.
TRUE

Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Rodríguez-Otero et al.
TRUE

Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.
Norton et al.
TRUE

Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies.
Zanwar et al.
TRUE

Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.
Shah et al.
TRUE

Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.
Bansal et al.
TRUE

CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).
Li et al.
TRUE

Updated OS of patients with AL amyloidosis after CAEL-101.
Hughes et al.
TRUE

Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
Shearer et al.
TRUE

Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
Martinez-Lopez et al.
TRUE

Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.
Facon et al.
TRUE

Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Shalaby et al.
TRUE

Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
Piasecki et al.
TRUE

Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
Delforge et al.
TRUE

Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
van de Donk et al.
TRUE

Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
Usmani et al.
TRUE

Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).
Stong et al.
TRUE

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
Schinke et al.
TRUE

Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data.
Durie et al.
TRUE

Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Sun et al.
TRUE

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty et al.
TRUE

Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
Raje et al.
TRUE

Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
Ma et al.
TRUE

Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
Vogl et al.
TRUE

Clinical characteristics, markers of adverse prognosis, and predictors of development of extramedullary multiple myeloma.
Zanwar et al.
TRUE

Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.
Quach et al.
TRUE

Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.
Bahlis et al.
TRUE

ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).
Manasanch et al.
TRUE

Patient-derived MicroOrganoSpheres (MOS) and precision clinical decision-making for patients with multiple myeloma.
Xi et al.
TRUE

Retrospective analysis of the relationship between time to anti-resorptive therapy and incidence of skeletal related events in patients with multiple myeloma.
Binder et al.
TRUE

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
Firestone et al.
TRUE

Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.
Terpos et al.
TRUE

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampous et al.
TRUE

Determinants of overall survival of young adults with multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017.
Chaulagain et al.
TRUE

Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
Touzeau et al.
TRUE

Lenalidomide-based monotherapy versus augmented therapy for maintenance in standard risk multiple myeloma patients with no complete response post autologous hematopoietic cell transplantation.
Awada et al.
TRUE

Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma.
Kumar et al.
TRUE

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.
Harvey et al.
TRUE

Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database.
Mejia Saldarriaga et al.
TRUE

Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.
Al Hadidi et al.
TRUE

T cell exhaustion markers in multiple myeloma patients before and after physical activity intervention.
Joseph et al.
TRUE

Utilizing a two-step frailty assessment strategy in older adults with multiple myeloma (MM): A decision curve analysis.
Gahagan et al.
TRUE

Presence of hyperdiploidy and history of tobacco use in African American patients with SMM.
Parikh et al.
TRUE

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Berdeja et al.
TRUE

CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
Kumar et al.
TRUE

MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
Grosicki et al.
TRUE

MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma.
Mateos Manteca et al.
TRUE

MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Touzeau et al.
TRUE

OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
Hess et al.
TRUE

EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial et al.
TRUE

A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
Richardson et al.
TRUE

Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.
Liedtke et al.
TRUE

Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy.
Subramanian et al.
FALSE

Effect on hospital outcomes of hematopoietic stem cell transplant recipients with Clostridium difficile infection.
Dhaliwal et al.
FALSE

Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).
Mashadi-Hossein et al.
FALSE

Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).
White et al.
FALSE

Bortezomib-induced cardiotoxicity: Real-world data from a single-center.
Chennapragada et al.
FALSE

Racial bias in multiple myeloma clinical trials: Racial minorities continue to miss out on treatment advances.
Jasaraj et al.
FALSE

A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients—A nationwide cross-sectional study.
Lakhanpal et al.
FALSE

Outcomes of patients with multiple myeloma refractory to different administration schedules of bortezomib.
Goel et al.
FALSE

Longitudinal changes in echocardiographic variables and endothelial function to predict cardiovascular toxicities in patients with multiple myeloma receiving carfilzomib.
Johnston et al.
FALSE

Demographic and socioeconomic determinants to the access to hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM): A National Cancer Database (NCDB) analysis of years 2004-2017.
Saba et al.
FALSE

Racial differences in outcomes of patients with relapsed/refractory multiple myeloma treated with selinexor.
Cole et al.
FALSE

Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.
Larson et al.
FALSE

Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
Tomasson et al.
FALSE

Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients.
Hydren et al.
FALSE

External validation of venous thromboembolism risk prediction models in patients with multiple myeloma in a community setting: A retrospective cohort study.
Ramasamy et al.
FALSE

Trends in presentation, treatment, and survival in young multiple myeloma patients age 50 and under from 2000-2021.
Kumar et al.
FALSE

Patterns and risk factors of infection and its impact in outcomes of newly diagnosed multiple myeloma.
Gonzalez Amaya et al.
FALSE

Role of PETCT in multiple myeloma: A 3 year data analysis of tertiary care center.
Gupta et al.
FALSE

Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.
Terpos et al.
FALSE

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous et al.
FALSE

Pitfalls with analyses of real-world data: A look at ASCO’s CancerLinQ Discovery Multiple Myeloma dataset.
Shou et al.
FALSE

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.
Baljevic et al.
FALSE

Determinants of overall survival (OS) of elderly patients with multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017.
Chaulagain et al.
FALSE

Socioeconomic factors associated with a late-stage multiple myeloma diagnosis: An analysis of the National Cancer Database.
Patel et al.
FALSE

Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma.
Lin et al.
FALSE

A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician’s choice of treatment.
Hlavacek et al.
FALSE

The efficacy of autologous hematopoietic cell transplantation in standard risk multiple myeloma refractory to multiple therapies.
Awada et al.
FALSE

Health-related quality of life among patients with multiple myeloma treated with CAR-T therapy.
Gagnon et al.
FALSE

Non-vitamin k oral antagonists versus aspirin for primary thromboprophylaxis in patients with multiple myeloma on outpatient chemotherapy: A systematic review and meta-analysis.
Costa et al.
FALSE

A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.
Biran et al.
FALSE

A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.
Biran et al.
FALSE

Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).
Venkatesh et al.
FALSE

Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update.
Hultcrantz et al.
FALSE

In hospital outcomes and mortality predictors of multiple myeloma on stroke hospitalizations: A multivariable logistic regression study on the National Inpatient Sample Database.
Shah et al.
FALSE

Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.
Patel et al.
FALSE

Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
Cerchione et al.
FALSE

Identifying associations between race and gender in the incidence and mortality of patients with multiple myeloma.
Ghosh et al.
FALSE

Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB.
Al Hadidi et al.
FALSE

Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.
Kirby et al.
FALSE

Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.
Ionescu et al.
FALSE

FISH abnormalities in Agent Orange–associated multiple myeloma.
Kort et al.
FALSE

Denosumab for smoldering multiple myeloma: Rates of osteoporosis and change in lowest T-score after 12 months of treatment.
Lipof et al.
FALSE

Management and outcomes of advanced stage cardiac AL amyloidosis in the daratumumab era.
Feuvrier-Rivera et al.
FALSE

Survival outcomes, clinical features and treatment patterns of solitary plasmacytoma in the United States: A National Cancer Database (NCDB) analysis of years 2004-2017.
Saba et al.
FALSE

Impact of time period of diagnosis, race, and military exposures on the survival of US military veterans with multiple myeloma and/or plasmacytoma.
Mahmood et al.
FALSE

Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES).
Joseph et al.
FALSE

Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.
Aigner et al.
TRUE

Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.
Lu et al.
TRUE

First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).
Wermke et al.
TRUE

Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.
Rudin et al.
TRUE

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
Abdel Karim et al.
TRUE

Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
Fennell et al.
TRUE

Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma.
Zhu et al.
TRUE

Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.
Aredo et al.
TRUE

Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
Aokage et al.
TRUE

Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS).
Shum et al.
TRUE

Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.
Krebs et al.
TRUE

Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).
Gronberg et al.
TRUE

CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.
Takamochi et al.
TRUE

The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.
Ganti et al.
TRUE

Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
Huang et al.
TRUE

Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT).
Taranova et al.
TRUE

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
Oselin et al.
TRUE

Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.
Spicer et al.
TRUE

IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.
Reck et al.
TRUE

Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
Rosner et al.
TRUE

Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.
Ikeda et al.
TRUE

Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.
Fan et al.
TRUE

Clinical and financial implications of ADUARA trial on a real-world population.
Muthusamy et al.
TRUE

A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.
Wang et al.
TRUE

Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.
Xia et al.
TRUE

Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
Pedraz et al.
TRUE

Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.
Saw et al.
TRUE

Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.
Soo et al.
TRUE

Examining ultrafine particle pollution and lung cancer risk in a large, diverse cohort.
Bookstein et al.
TRUE

Clinical validation of an activity-based enzyme assay for early stage lung cancer.
Dempsey et al.
TRUE

Multi-genomic analysis of compound and uncommon EGFR mutations in patients with non-small cell lung cancer.
Park et al.
TRUE

Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer.
Schuurbiers et al.
TRUE

Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.
Bylicki et al.
TRUE

Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
Hassan et al.
TRUE

Long-term outcomes of single and five fraction schedules of stereotactic body radiation therapy for early-stage central or peripheral NSCLC: Neither fractionation nor location matter?
Huang et al.
TRUE

EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma.
Goffinet et al.
TRUE

Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer (SACTION-01 study).
Zhao et al.
TRUE

The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations.
Gray et al.
TRUE

Two-year lung cancer survival between 2000 to 2020: Results from 3 French nationwide cohorts.
Debieuvre et al.
TRUE

Association of nuclear shape in the tumor epithelium with response to atezolizumab in NSCLC.
Leo et al.
TRUE

Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).
Hata et al.
TRUE

Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
Heymach et al.
TRUE

A systematic comparison of whole genome sequencing and targeted panel sequencing for precision oncology.
Park et al.
TRUE

SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
Mauti et al.
TRUE

Sequential intravenous chemotherapy with drug-eluting bead bronchial arterial chemoembolization for the treatment of stages III and IV lung squamous cell carcinoma: A retrospective controlled clinical study.
Tu et al.
TRUE

Prospective dynamic sampling and molecular residual disease monitoring to predict clinical outcomes for patients with unresectable, locally advanced non-small cell lung cancer undergoing radical radiotherapy.
Zhang et al.
TRUE

Association of circulating CD103+ T cells with major pathological response in a randomized phase 2 trial of neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer.
Walsh et al.
TRUE

Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).
Sierra-Rodero et al.
TRUE

Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).
Yegya-Raman et al.
TRUE

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
Minne et al.
TRUE

Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.
Schvartsman et al.
TRUE

Assessing the efficacy and safety of DEB-BACE combined with intravenous chemotherapy for the treatment of intermediate to advanced lung adenocarcinoma after progression of targeted drug resistance.
Lai et al.
TRUE

Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
Lee et al.
TRUE

Development of a novel blood-based RNA gene expression platform for early-stage lung cancer diagnosis.
Keiser et al.
TRUE

Benefit of post-operative radiation therapy for incompletely resected stage I-IIIA non-small cell lung cancer: An analysis of the National Cancer Database.
Iska et al.
TRUE

Large scale evaluation of pulmonary nodule workup: A real-world study of over 150,000 patients in New York State.
Velcheti et al.
TRUE

Mortality benefit of a blood-based biomarker panel for lung cancer and the PLCO cohort.
Fahrmann et al.
TRUE

Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.
Lim et al.
TRUE

Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.
Deenadayalan et al.
TRUE

Development and validation of a prediction model for the recurrence of stage 1 EGFR mutation positive NSCLC in patients using machine learning with WES-based gene sets.
Tateishi et al.
TRUE

Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).
Lin et al.
TRUE

Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
Wei et al.
TRUE

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
Nassar et al.
TRUE

A combinatorial model of plasma proteins and LDCT imaging and the diagnosis of pulmonary nodules.
Yang et al.
TRUE

Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.
Li et al.
TRUE

Optimal number of lymph node stations associated with improved survival among patients with non-small cell lung cancer (NSCLC).
Ray et al.
TRUE

Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.
Heiden et al.
TRUE

Acute hospitalizations after proton beam therapy (PBT) versus intensity-modulated radiotherapy (IMRT) for locally advanced non–small-cell lung cancer (LA-NSCLC) in the era of immune checkpoint inhibitor (ICI) consolidation: A retrospective propensity score weighted study.
Iocolano et al.
TRUE

Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.
Hiremath et al.
TRUE

A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.
Tendler et al.
TRUE

Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
Torasawa et al.
TRUE

Analysis of tumor- and circulating-free DNA methylation to identify clinically relevant small cell lung cancer subtypes.
Heeke et al.
TRUE

Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.
Sato et al.
TRUE

Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).
Cheng et al.
TRUE

Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
Chen et al.
TRUE

Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system.
Godbole et al.
TRUE

Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis.
Champiat et al.
TRUE

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Falchero et al.
TRUE

IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).
Girard et al.
TRUE

Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment.
Zhang et al.
TRUE

Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.
Shirasawa et al.
TRUE

Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial.
Yu et al.
TRUE

The effect of various social determinants of health on overall survival in the SCLC population.
Mirsky et al.
TRUE

Assessing inpatient outcomes for patients with small cell lung cancer presenting with superior vena cava thrombosis.
Vakil et al.
TRUE

A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.
Zhou et al.
TRUE

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
Cousin et al.
TRUE

Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes.
Rinaldi et al.
TRUE

Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
Azuma et al.
TRUE

Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
Peressini et al.
TRUE

Role of consolidative thoracic and prophylactic cranial radiation in extensive stage small cell lung cancer in chemo-immunotherapy era.
Khatri et al.
TRUE

Brain metastasis burden and management in small cell lung cancer: An analysis of 8705 patients.
Gaebe et al.
TRUE

Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.
Chiang et al.
TRUE

Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.
Ardeshir-Larijani et al.
TRUE

Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
Forde et al.
TRUE

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.
Griffiths et al.
TRUE

Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.
Shah et al.
TRUE

Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).
Mansfield et al.
TRUE

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
Mansfield et al.
TRUE

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
Guisier et al.
TRUE

A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).
Paz-Ares et al.
TRUE

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
Zhu et al.
TRUE

Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515).
Robinson et al.
TRUE

A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.
Solomon et al.
TRUE

Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
Özgüroğlu et al.
TRUE

Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
Barlesi et al.
TRUE

Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
Paz-Ares et al.
TRUE

A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.
Kato et al.
TRUE

A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).
Besse et al.
TRUE

Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients (EORTC-1901: PRIMALung).
Levy et al.
TRUE

Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
Juloori et al.
TRUE

Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies.
Rimner et al.
TRUE

FGR methylation in blood as a potential marker for the pre-clinical detection of early lung cancer: A case-control study.
Yang et al.
FALSE

Estimating the impact of adjuvant atezolizumab in preventing recurrences and reducing costs in resectable early PD-L1 high non-small cell lung cancer in Europe.
Arnold et al.
FALSE

A survey on the detection of HPD-related genes by liquid biopsy in patients with lung cancer in China.
Zhang et al.
FALSE

Peripheral pre-existing cancer-antigen specific T-cell immunity as predictive biomarker for immunotherapy in NSCLC patients.
Xagara et al.
FALSE

Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.
Bharde et al.
FALSE

Clinical and molecular Characterization of NSCLCs with MET exon 14 skipping mutation coexist MET amplification.
Tian et al.
FALSE

Value of Patlak-Ki from ultra-high sensitivity dynamic total body [18F]FDG PET/CT for evaluation of treatment response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer (LA-NSCLC) patients.
Wang et al.
FALSE

Comparing the prognostic implications of spread through airspaces versus lymphovascular invasion in non-small cell lung cancer.
Epstein et al.
FALSE

Tumor immune microenvironment (TIME) analysis of stage I lung adenocarcinoma with micropapillary pattern.
Han et al.
FALSE

Comparison of gene alterations detected with tumor tissue and plasma in a Chinese population with advanced lung adenocarcinoma.
Zhang et al.
FALSE

Association of CAR-T cell secreting CD47 blocking protein with an enhanced antitumor activity in small cell lung cancer.
Guo et al.
FALSE

Circulating tumor DNA (ctDNA) methylation-based linkage regions to predict recurrence in early-stage lung cancer.
Yue et al.
FALSE

High frequency of germline mutations in DDR associated genes SLX4, MSH6, CDK4, TSC2, and BRCA2 might contribute to the occurrence of MPLC.
Gu et al.
FALSE

Multicenter evaluation of AI-based CT radiomics for EGFR mutation prediction in NSCLC.
Liu et al.
FALSE

Using next-generation sequencing for RET fusion detection in Chinese cancer patients.
Dang et al.
FALSE

Impact of CLEC3B mRNA expression on genetic landscape and immune tumor-microenvironment in NSCLC.
Zimmer et al.
FALSE

Comparative analysis of the mutation detection using malignant pleural effusion and blood cell-free DNA samples in lung cancer.
Lin et al.
FALSE

Computational recognition of lncRNA signature of tumor-infiltrating activated CD4+ memory T cells with potential implications in prognosis and immunotherapy of lung adenocarcinoma.
Liu et al.
FALSE

Artificial intelligence (AI) –powered H&E whole-slide image (WSI) analysis of tertiary lymphoid structure (TLS) correlates with immune phenotype and related molecular signatures in non–small-cell lung cancer.
Song et al.
FALSE

Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.
Wong et al.
FALSE

Effects of concomitant chronic obstructive pulmonary disease on immune microenvironment in non-small cell lung cancer patients.
Lin et al.
FALSE

Clinical characteristics of patients with non-small cell lung cancer eligible for biology-guided radiotherapy.
Olaechea et al.
FALSE

CD73/adenosine pathway-related gene signature for intratumor heterogeneity and immune infiltration in prognosis of lung adenocarcinoma.
Luo et al.
FALSE

Tumor immune infiltrates and overall survival in non-small cell lung cancer are associated with an unsupervised radiomic signature.
Oh et al.
FALSE

Use of immune checkpoint gene (ICG) signatures to identify selective enrichment of FGL1 and CEACAM1 in histologic subtypes of lung cancer.
Puthanmadhom Narayanan et al.
FALSE

Postoperative prognosis in patients with NSCLC with different EGFR mutation sites.
Dong et al.
FALSE

Association of TP53 mutations with the expression of PD-L1 expression and TMB, and R175H could be the predictor of neoantigen.
Wang et al.
FALSE

Clinical outcomes of patients with early-stage epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who underwent reflex molecular testing.
Kieser et al.
FALSE

Perioperative IDO-1 dynamic changes in NSCLC patients.
Sun et al.
FALSE

Influence of increase in hospital costs on mortality for pleural mesothelioma in teaching hospitals: A nationwide analysis.
Guevara et al.
FALSE

A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.
Fennell et al.
FALSE

Incidence of additional primary malignancies in patients with malignant peritoneal mesothelioma.
Pandav et al.
FALSE

Granular analysis of individual immune-related gene expression in a randomized phase I/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed/cisplatin (P/C) in patients (pts) with unresectable malignant pleural mesothelioma (MPM).
Hansen et al.
FALSE

Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience.
Ogbue et al.
FALSE

Trends and survival of malignant mesothelioma across racial groups between 2000-2019: A real-world study.
Al Armashi et al.
FALSE

Survival trends among patients with mesothelioma: Impact of initial therapy at academic centers.
Mooradian et al.
FALSE

Incidence of immune checkpoint inhibitor induced myocarditis in patients with mesothelioma from a regional tertiary cancer centre covering a patient population of 2.6 million.
Johnson et al.
FALSE

Management of tumor treating fields (TTFields) therapy-related skin adverse events in pleural mesothelioma: A single center experience of TTFields therapy concomitant with chemotherapy.
Grosso et al.
FALSE

Demographic and racial characteristics, and survival trends in pleural mesothelioma: A population based study.
Patel et al.
FALSE

Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.
Guo et al.
FALSE

Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma.
Homicsko et al.
FALSE

Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non–small-cell lung cancer after stereotactic body radiation therapy.
Huang et al.
FALSE

Tumor immune microenvironment of different lesions in patients with multiple primary lung cancer.
Li et al.
FALSE

Radiomics to predict checkpoint inhibitor pneumonitis based on chest CT scans in patients with advanced cancer.
Vos et al.
FALSE

Blood-based DNA methylation panel for the early diagnosis of lung cancer.
Yang et al.
FALSE

ctDNA for clonal evolution surveillance and therapeutic efficacy prediction in unresectable locally advanced non-small cell lung cancer under radiotherapy.
Bi et al.
FALSE

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: A retrospective study.
Yin et al.
FALSE

Respiratory toxicities after concurrent chemoradiotherapy and subsequent consolidation immune checkpoint inhibitors in locally advanced non-small cell lung cancer: Infectious and non-infectious subtypes by pathogen NGS testing.
Qiu et al.
FALSE

Clinical and molecular characteristics of multiple primaries identified by whole-exome sequencing-based genetic divergence in non-small-cell lung cancer.
Liu et al.
FALSE

The association between body mass index and distribution intensity of tumor treating fields (TTFields) in the lungs.
Mooney et al.
FALSE

Racial disparities in the treatment of unresectable, stage III non-small cell lung cancer: An analysis of the National Cancer Database.
Mohanna et al.
FALSE

The impact of portability of wearable monitoring device on study retention and participant experience in patients with unresectable stage III NSCLC treated with standard-of-care durvalumab: Learnings from the ON TRAX pilot study.
Cotarla et al.
FALSE

The association of race and curative-intent treatment with mortality outcomes among early-stage NSCLC.
Liu et al.
FALSE

Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer: A real-world study.
Zhang et al.
FALSE

The cardiac outcomes of radiation therapy to thoracic malignancies: Nationwide analysis.
Turk et al.
FALSE

A real-world analysis of nonmetastatic non–small-cell lung cancer in Italy.
Esposito et al.
FALSE

Association of lymph node examination during resection with overall survival (OS) and healthcare costs in patients with early non–small-cell lung cancer (eNSCLC).
Lee et al.
FALSE

The role of immunotherapy in stage III large cell neuroendocrine carcinoma of the lung (LCNEC): A retrospective NCDB analysis.
Findakly et al.
FALSE

A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy.
Liu et al.
FALSE

Surgical outcomes and patient-reported outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy.
Wang et al.
FALSE

Transcriptomic subtype, TP53 mutation status, and APOBEC mutation signature in early-stage EGFR-mutant non-small-cell lung cancer.
Jung et al.
FALSE

Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer.
Swarna et al.
FALSE

Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimen or chemotherapy: A study based on the SEER database and multicentric real-world settings.
Peng et al.
FALSE

Pathological response and tumor immune microenvironment remodeling of neoadjuvant ALK-TKIs in NSCLC with ALK.
Li et al.
FALSE

A robust and accurate method to detect MET Exon 14–skipping mutation in pan-cancer samples using an NGS-based RNAseq approach.
Wang et al.
FALSE

Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.
Teng et al.
FALSE

Deep learning algorithm for automatic prediction of visceral pleural invasion of lung cancer based on surgical video.
Xu et al.
FALSE

A 9-gene signature in circulating tumor DNA based on molecular residual disease detection to predict recurrence of resectable non–small-cell lung cancer.
Lu et al.
FALSE

Detection effectiveness of immune-related gene mutations in lung adenocarcinoma by circulating tumor DNA.
Qin et al.
FALSE

Multi-omics analysis to reveal the change of peripheral blood TCR repertoire and tumor burden during neoadjuvant chemotherapy combined with sequential PD-1 blockade for patients with non-small cell lung cancers: A single-center, single-arm phase 2 trial.
Yang et al.
FALSE

NK cell expansion after primary multimodal treatment to predict progression free survival in inoperable stage III NSCLC.
Hofer et al.
FALSE

Prevalence of EGFR and PDL1 testing in a population-based lung cancer surgical resection cohort from 2018-2022.
Smeltzer et al.
FALSE

Management and treatment of patients with stage III unresected NSCLC at UPMC: A quality initiative by Integra Connect Precision Q.
Petro et al.
FALSE

Patients’ epidemiology in stage III, unresectable non-small-cell lung carcinoma: A real-world analysis in Brazil.
Amaral Duarte et al.
FALSE

Correlation analysis of MRD positivity after non-small cell lung cancer surgery.
Dong et al.
FALSE

Exploration of biomarkers in potentially resectable stage IIIB NSCLC patients receiving neoadjuvant chemoimmunotherapy.
Ma et al.
FALSE

Characteristics of lung cancer in renal transplant recipients.
Sridhar et al.
FALSE

Real world early experience of precision neoadjuvant systemic therapy in patients with resectable NSCLC: Single institution experiences and perspectives.
Park et al.
FALSE

Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.
Zhou et al.
FALSE

Establishment of a nomogram predictive model for survival and prognosis of 97 patients with different subtypes of lung adenocarcinoma after radical resection.
Aosiman et al.
FALSE

Comprehensive genetic characteristics of multiple primary lung cancer in patients in China.
Pei et al.
FALSE

Comprehensive plasma genotyping of patients with EGFR positive NSCLC as a monitoring tool for therapy response and disease progression.
Shafi et al.
FALSE

CT based radiomics signature for phenotyping histopathological subtype in patients with non-small cell lung cancer.
Liu et al.
FALSE

Somatic aberrations detected in tumor tissue and plasma in Chinese patients with stage I single-lesion and multi-lesions lung cancer.
Pei et al.
FALSE

Importance of DICER1 pathogenic variants in non-small cell lung cancer.
Wu et al.
FALSE

Treatment of newly developed metastases after definitive chemoradiotherapy +/- ICI for unresectable stage III NSCLC.
Taugner et al.
FALSE

Demographics of the tumor formerly known as bronchiolo-alveolar carcinoma.
Luker et al.
FALSE

Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva).
Sharp et al.
FALSE

Spread through air spaces in non-small cell lung cancer: Experience of a tertiary hospital.
Calvo et al.
FALSE

Differentiating ensartinib from lorlatinib and alectinib for first line use in an ALK+ non-small cell lung cancer preclinical model (ResCu).
Gadde et al.
FALSE

Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non–small-cell lung cancer (NSCLC).
Smeltzer et al.
FALSE

Survival for patients of stage III non-small cell lung cancer after radiotherapy in different periods.
Wang et al.
FALSE

Molecular profiling in a Peruvian population with advanced non-small cell lung cancer assessed by NGS.
Galvez-Nino et al.
FALSE

Radiation fractionation effect on IDO1 through NF-kB/COX2 axis in non-small cell lung cancer.
Lan et al.
FALSE

Early detection of lung cancer using a panel of circulating cell-free DNA methylation biomarkers.
Hu et al.
FALSE

Role of adjuvant chemotherapy (CT) in node negative 4-5 cm non-small cell lung cancer in elderly population.
Gaire et al.
FALSE

Surgery with adjuvant chemotherapy versus chemoradiation for early-stage large cell neuroendocrine cancer (LCNEC) of the lung: A SEER plus based analysis.
Shah et al.
FALSE

Prevalence of delta-like ligand 3 expression in small cell lung cancer.
Pundole et al.
FALSE

Outcomes of patients with small cell lung cancer admitted to the intensive care unit.
Huang et al.
FALSE

Real-world analysis of ICI efficacy in ES-SCLC patients with and without brain metastases: A call for inclusion in clinical trials.
Cao et al.
FALSE

Correlations between overall response rate, progression-free survival and overall survival in refractory small cell lung cancer treated with lurbinectedin.
Wasifuddin et al.
FALSE

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases.
Wang et al.
FALSE

Impact of systemic immune-inflammation index in patients with limited-stage small cell lung cancer.
Zhang et al.
FALSE

The combination therapy of anlotinib and penpulimab for the treatment of small cell lung cancer after platinum-based chemotherapy: Results of a phase II exploratory study.
Yang et al.
FALSE

Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm, phase Ⅱ study.
Zhang et al.
FALSE

Racial disparities in the prevalence of extrathoracic metastases in lung cancer patients and survival: A SEER database study (2010–2019).
Al Armashi et al.
FALSE

Safety analysis of lurbinectedin versus topotecan in elderly patients.
Subbiah et al.
FALSE

Combinatorial analysis of CD4+Tregs and CD8+Teff to predict response to ICI in patients with ES-SCLC.
Tsapakidis et al.
FALSE

The changing landscape of small-cell lung cancer.
Cittolin Santos et al.
FALSE

Treatment of extensive stage small cell lung cancer (ES-SCLC) in geriatric patients before the advent of immunotherapy: Real-life experience from one centre.
Medina et al.
FALSE

Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis.
Gaebe et al.
FALSE

Real world outcomes of trilaciclib in ES-SCLC.
Elijah et al.
FALSE

Survival outcomes of stage I small cell lung cancer (SCLC) treated with stereotactic body radiation therapy (SBRT) versus external beam radiation therapy (EBRT): An NCDB analysis.
Heckman et al.
FALSE

Real world outcomes of patients treated with first line chemo-immunotherapy (IO) for small cell lung cancer (SCLC): Impact of brain metastases and patterns of subsequent therapy.
Farid et al.
FALSE

Temporal trends in small cell lung cancer: Analysis of the U.S. Surveillance, Epidemiology and End Results (SEER) database.
Cohen et al.
FALSE

A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.
Watanabe et al.
FALSE

The role of adjuvant chemotherapy (CT) for early stage resectable node negative small cell lung cancer with size of ≤ 2 cm post-surgical resection: A SEER plus based statistical analysis.
Budhathoki et al.
FALSE

Application of a contralateral esophageal-sparing technique to reduce radiation esophagitis in limited-stage small cell lung cancer treated with twice-daily radiotherapy and concurrent chemotherapy.
Hu et al.
FALSE

Carcinoid tumor of the bronchus and lung: A nationwide cross-sectional study.
Perez et al.
FALSE

Investigation of the prognostic significance of CD5, CD117, EZH2, POU2F3, MTAP and BAP1 in thymic carcinoma.
Naso et al.
FALSE

Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs).
McAdams et al.
FALSE

Immunological signature of patients with thymic epithelial tumors and Good syndrome: Correlation with clinical outcome.
Morra et al.
FALSE

Racial and ethnic differences in thymic epithelial tumors: A single-institution retrospective analysis.
Wuthrich et al.
FALSE

An evaluation of cisplatin, doxorubicin, and cyclophosphamide (PAC) compared to other regimens for patients with unresectable or metastatic thymic carcinoma: A single-institution retrospective analysis.
Wuthrich et al.
FALSE

Effect of SARS-CoV-2 mRNA vaccine booster in serologically negative patients with thymic epithelial tumors.
Pietroluongo et al.
FALSE

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Wu et al.
TRUE

Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.
Wang et al.
TRUE

Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Wang et al.
TRUE

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
Goto et al.
TRUE

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
Sakata et al.
TRUE

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
Cassier et al.
TRUE

Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).
Skoulidis et al.
TRUE

BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.
Elamin et al.
TRUE

First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).
Uematsu et al.
TRUE

Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
Besse et al.
TRUE

Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations.
Duan et al.
TRUE

FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.
Ma et al.
TRUE

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
Lin et al.
TRUE

Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Riely et al.
TRUE

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
Swalduz et al.
TRUE

Large-scale transcriptomic profiling of the tumor immune microenvironment in ALK+ lung cancer.
Lam et al.
TRUE

Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.
Tan et al.
TRUE

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
Vokes et al.
TRUE

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.
He et al.
TRUE

SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
Zhao et al.
TRUE

Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).
Kagawa et al.
TRUE

The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
Tan et al.
TRUE

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.
Murray et al.
TRUE

Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
Parikh et al.
TRUE

Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.
Scott et al.
TRUE

MSH3 and MSH6 gene polymorphisms: Association with lung cancer susceptibility and prognostic value in patients with NSCLC undergoing platinum-based chemotherapy.
Singh et al.
TRUE

Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC).
Camidge et al.
TRUE

Analytical and clinical validation of oncomine Dx target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02).
Li et al.
TRUE

Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
Kardos et al.
TRUE

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.
Mack et al.
TRUE

Efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.
Shi et al.
TRUE

Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
Desai et al.
TRUE

Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
Khan et al.
TRUE

Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
Herzberg et al.
TRUE

TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
Italiano et al.
TRUE

Pre-treatment plasma-informed circulating tumor DNA detection as an early identification of therapeutic benefit for patients with untreated advanced lung squamous cell carcinoma.
Jiang et al.
TRUE

Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?
Burns et al.
TRUE

Factors impacting outcomes in individuals ≥80 years with non-small cell lung cancer (NSCLC): A national cancer database (NCDB) analysis.
Burns et al.
TRUE

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non–small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B.
Fukuhara et al.
TRUE

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
Okuma et al.
TRUE

Role of immunotherapy in stage IV non-small cell lung cancer with liver metastasis: A NCDB analysis.
Komiya et al.
TRUE

Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).
Cho et al.
TRUE

Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT carcinoma registry.
Luo et al.
TRUE

Thoracic SMARCA4-deficient cancer descriptors and clinicopathologic determinants of survival: Analysis of a pooled database.
Powell et al.
TRUE

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
Rohrberg et al.
TRUE

Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
Yang et al.
TRUE

Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).
Liu et al.
TRUE

Safety and efficacy of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease: A systematic review and meta-analysis in non-small cell lung cancer.
Aung et al.
TRUE

Phase II trial of lazertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
Hong et al.
TRUE

Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE.
Liu et al.
TRUE

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Lin et al.
TRUE

The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.
Choi et al.
TRUE

Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of patients with non-small cell lung cancer with brain metastases at diagnosis.
Nigen et al.
TRUE

Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.
Bosch-Barrera et al.
TRUE

Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.
Paik et al.
TRUE

Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.
Cantor et al.
TRUE

Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.
Wang et al.
TRUE

Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.
Bauer et al.
TRUE

Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
Nguyen et al.
TRUE

First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Cooper et al.
TRUE

Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lung.
Mu et al.
TRUE

Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.
Kwon et al.
TRUE

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
Zalcman et al.
TRUE

Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.
Reuss et al.
TRUE

Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
Le et al.
TRUE

Sexual dysfunction in women with lung cancer: Updates from the SHAWL study.
Florez et al.
TRUE

Outcomes of patients with advanced EGFR mutant lung cancer treated with first line (1L) osimertinib (osi) who would not have met eligibility criteria for the FLAURA trial.
Wells et al.
TRUE

Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.
Xu et al.
TRUE

Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.
Yu et al.
TRUE

Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).
Pellini et al.
TRUE

Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
Rolfo et al.
TRUE

Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.
Liu et al.
TRUE

Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
Camidge et al.
TRUE

A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.
Watanabe et al.
TRUE

Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.
Huang et al.
TRUE

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
Shi et al.
TRUE

Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
Neal et al.
TRUE

Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.
Arbour et al.
TRUE

Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.
Watson et al.
TRUE

Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.
Fan et al.
TRUE

Immune checkpoint inhibitors use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
Hong et al.
TRUE

Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
Zhang et al.
TRUE

First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark et al.
TRUE

Safety, efficacy and biomarker data in patients with non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet.
Paz-Ares et al.
TRUE

The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
Christopoulos et al.
TRUE

RET testing and treatment patterns among patients with aNSCLC in US clinical practice.
Kim et al.
TRUE

Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019).
Swalduz et al.
TRUE

A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
Shanshal et al.
TRUE

Characterization of diverse targetable alterations in ERBB2 and ERBB3 in 93,465 non-small cell lung cancers (NSCLC).
Liu et al.
TRUE

Updated molecular analysis of MET exon 14skippingmutations (METex14) in non-small cell lung cancer (NSCLC).
Marks et al.
TRUE

Long-term outcome for patients with advanced non‒small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002.
Liu et al.
TRUE

A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
Izumi et al.
TRUE

Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).
Feng et al.
TRUE

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
Reck et al.
TRUE

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
Reuss et al.
TRUE

Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
Sun et al.
TRUE

The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.
Puri et al.
TRUE

Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.
Yang et al.
TRUE

Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.
Stockhammer et al.
TRUE

Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.
Fang et al.
TRUE

Dacomitinib for patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations: Do mutation patterns matter?
Li et al.
TRUE

Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.
Thummalapalli et al.
TRUE

Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.
Piotrowska et al.
TRUE

Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
Evangelist et al.
TRUE

Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.
Shi et al.
TRUE

A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
Zhou et al.
TRUE

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
Zhang et al.
TRUE

First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
Zhao et al.
TRUE

SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
Fang et al.
TRUE

Implementation strategies for monitoring adherence in real time (iSMART): A pilot randomized trial.
Rendle et al.
TRUE

Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).
Marmarelis et al.
TRUE

Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States.
Levy et al.
TRUE

Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer.
Ricciuti et al.
TRUE

FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.
Liu et al.
TRUE

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).
Hadfield et al.
TRUE

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
Gettinger et al.
TRUE

Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC).
Gandhi et al.
TRUE

Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.
Sako et al.
TRUE

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.
Saltos et al.
TRUE

Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.
Minchom et al.
TRUE

Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer.
Di Federico et al.
TRUE

Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).
Clarke et al.
TRUE

Clinical and genomic landscape of EGFR-mutant lung cancers (LCs) with squamous and adenosquamous differentiation.
Elkrief et al.
TRUE

Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials.
Orcutt et al.
TRUE

A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
Wu et al.
TRUE

Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.
Rakaee et al.
TRUE

Investigating racial inequities of circulating tumor DNA (ctDNA) use in patients with non-small cell lung cancer: A real world analysis.
D'Aiello et al.
TRUE

Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
Lee et al.
TRUE

Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Frascati et al.
TRUE

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
Aggarwal et al.
TRUE

Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
Girard et al.
TRUE

A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1–negative advanced or metastatic non–small-cell lung cancer (NSCLC).
Zhang et al.
TRUE

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.
Goldberg et al.
TRUE

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.
Rodriguez-Abreu et al.
TRUE

A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
Subbiah et al.
TRUE

ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
Padda et al.
TRUE

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
Cappuzzo et al.
TRUE

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
Seckl et al.
TRUE

PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.
Socinski et al.
TRUE

Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.
Spira et al.
TRUE

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
Chouaid et al.
TRUE

Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC).
Horinouchi et al.
TRUE

Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).
Fang et al.
TRUE

LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.
Nguyen et al.
TRUE

A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non–small-cell lung cancer.
Reuss et al.
TRUE

Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
Johnson et al.
TRUE

Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
Veluswamy et al.
TRUE

VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).
Spira et al.
TRUE

A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
Johnson et al.
TRUE

A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
Lindsay et al.
TRUE

A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.
Spira et al.
TRUE

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
Breadner et al.
TRUE

LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
Besse et al.
TRUE

CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
Aggarwal et al.
TRUE

Characterization of URST1 as a prognostic marker and therapeutic target for lung cancer.
Takano et al.
FALSE

Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC.
Rubio et al.
FALSE

Tumor immune microenvironment in BRAF V600E mutant lung adenocarcinoma.
Liu et al.
FALSE

Genomic biomarker testing and treatment in advanced NSCLC: Practice patterns and barriers in a global survey of oncology point-of-care mobile app users.
Jacobson et al.
FALSE

Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.
Jiang et al.
FALSE

An exploratory analysis of lung cancer survival using NGS genetic predictors and partial least squares.
Sequero-Lopez et al.
FALSE

Revealing distinct immune landscape in EGFR mutant and EGFR wild type lung adenocarcinoma by using single-cell RNA sequencing.
Yin et al.
FALSE

Single cell RNA sequencing to reveal immune microenvironment in primary and brain metastatic lesion of non-small cell lung cancer.
Teng et al.
FALSE

Impacts of androgen pathway manipulation on patients with lung cancer.
Lee et al.
FALSE

Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries.
Bahl et al.
FALSE

A differential analysis of TCR repertoire between patients with EGFR-mutant and KRAS-mutant non–small-cell lung cancer.
Xie et al.
FALSE

Frequency and patterns of TP53 mutations in lung cancer.
Yang et al.
FALSE

Comparison of mutation detection rate between cell pellet DNA and cell-free DNA from cerebrospinal fluid in patients with advanced lung cancer.
Hu et al.
FALSE

Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.
Provencio-Pulla et al.
FALSE

Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC).
McAdams et al.
FALSE

Mechanism-based peripheral blood biomarkers to evaluate anticancer effects of the plinabulin/docetaxel combination (plin/doc) vs. doc alone in second/third line EGFR wild-type (WT) NSCLC.
Feinstein et al.
FALSE

Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination.
Feinstein et al.
FALSE

RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer.
Yun et al.
FALSE

Effect of bevacizumab plus double dose icotinib on advanced non-small cell lung cancer with EGFR L858R mutation.
Jiang et al.
FALSE

A comparative analysis of next-generation sequencing based on plasma cfDNA and tumor tissue DNA in patients with advanced lung cancer.
Li et al.
FALSE

Preclinical evidence for synergistic effects of autophagy inhibitor and alpelisib in PI3KCA mutated non-small cell lung cancer: Implications for future clinical trials.
Shim et al.
FALSE

A series of nine newly developed techniques in CT-guided percutaneous lung biopsyPreliminary results from a prospective study.
Zhang et al.
FALSE

Mutational profiling of true single circulating tumor cells (sCTC) in metastatic lung cancer to determine genomic heterogeneity and drug-resistance signatures.
Khandare et al.
FALSE

Identification and characterization of karyopherin a-2, a nuclear export protein in lung adenocarcinoma.
Kim et al.
FALSE

Effects of different immune microenvironment characteristics on predictive efficacy of PTCH1 mutations in immune checkpoint inhibitor therapy of solid tumors.
Zhu
FALSE

Effects of different immune microenvironment characteristics on effect of immune checkpoint inhibitors in solid tumors with TGFBR2 mutation.
Yao
FALSE

Genomic mechanisms of RET inhibitor sensitivity and resistance in RET-fusion positive cancer cells.
Heymach et al.
FALSE

Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy.
Qin et al.
FALSE

Sex- and co-mutation-dependent prognosis of patients with SMARCA4-mutated malignancies.
Pan et al.
FALSE

Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting.
Yang et al.
FALSE

Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer.
Mathiot et al.
FALSE

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.
Gu et al.
FALSE

Clinical characteristics, response to poly (adenosine phosphate-ribose) polymerase inhibitors and platinum chemotherapy in patients with lung cancer harboring BRCA mutations.
Arnon et al.
FALSE

Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.
Besse et al.
FALSE

Cerebrospinal fluid circulating tumor DNA for the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
Miao et al.
FALSE

Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the types of EGFR mutations and agents in non-small cell lung cancer (NSCLC): A real-world study.
Choi et al.
FALSE

Artificial neural network model analysis in T790M detection after failure of first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Pluzanski et al.
FALSE

Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer.
Goktas Aydin et al.
FALSE

Comparison between liquid biopsy and tissue NGS in two cohorts of advanced NSCLC.
Bote et al.
FALSE

Efficacy and safety analysis of immune checkpoint inhibitors plus angiogenesis inhibitors for treatment of advanced driver-negative NSCLC in elderly patients: A retrospective study.
Zhang et al.
FALSE

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.
Yang et al.
FALSE

Whole-course management of traditional Chinese medicine in the treatment of EGFRIs related skin toxicity in lung cancer: A series of clinical studies.
Lu et al.
FALSE

Effect of intrathecal pemetrexed on survival in patients with lung adenocarcinoma with leptomeningeal metastasis: A propensity score matching analysis.
Hong et al.
FALSE

Epidemiology and survival trends of lung carcinoids in the veteran population.
Tehzeeb et al.
FALSE

Gut microbiota profiling and clinical response in patients with metastatic non-small cell lung cancer receiving endothelial growth factor-tyrosine kinase inhibitors (EGFR-TKI).
Zhao et al.
FALSE

Outcome analysis of immunotherapy and possible prognostic role of pretreatment neutrophil-lymphocyte ratio in lung cancer: An Appalachian study.
Yadala et al.
FALSE

Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression.
Friedes et al.
FALSE

Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer.
Karaboué et al.
FALSE

Treatment outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver.
Ryder et al.
FALSE

Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification.
Ryder et al.
FALSE

Efficacy and safety of immune checkpoint inhibitor without pemetrexed for first-line maintenance therapy in advanced lung adenocarcinoma.
Gao et al.
FALSE

Gaps and factors in patient awareness of biomarker test timing and purpose in non-small cell lung cancer (NSCLC): Baseline assessment for implementation of 4R Oncology model.
Mohindra et al.
FALSE

Pretreatment radiomic biomarker for immunotherapy responder prediction in IB-IV stage NSCLC: A multi-center retrospective study.
Wu et al.
FALSE

Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer.
Lee et al.
FALSE

A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC).
Wells et al.
FALSE

Clinical efficacy of frontline immunotherapy (IO) in ethnic-minority patients (pts) with metastatic NSCLC.
Lee et al.
FALSE

Real world EGFR testing practices for non-small cell lung cancer by thoracic pathology laboratories across Europe.
Hofman et al.
FALSE

Prognostic effects of TP53 variants co-occuring in patients with HER2-mutated non-small cell lung cancer (NSCLC).
Feng et al.
FALSE

Therapeutic effects of combination with EGFR-TKIs and radiotherapy on the prognosis of stage IV lung adenocarcinomas harboring 19-Del or 21-L858R: A retrospective study.
Liang et al.
FALSE

Predicting non-small cell lung cancer response to immune checkpoint inhibitors with machine learning based on heterogeneous biomarkers.
Schmutz et al.
FALSE

Safety and efficacy of stereotactic body radiotherapy (SBRT) to oligoresidual sites combine with osimertinib in stage IV EGFR mutant NSCLC patients: A prospective pilot study.
Chen et al.
FALSE

Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial.
Heeke et al.
FALSE

Anaplastic lymphoma kinase (ALK) and ROS 1– positive advanced NSCLC: A real-world institutional experience.
Bala et al.
FALSE

Serum tumor biomarkers as a surrogate for radiographic assessment of non-small cell lung cancer.
Strum et al.
FALSE

Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.
Bertolini et al.
FALSE

The impact of cationic amphiphilic antihistamines on patients with lung cancer receiving immunotherapy.
Chiang et al.
FALSE

Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib.
Cheung et al.
FALSE

Analysis of different color unmixing methods for cMET-PDL1-EGFR multiplex assay.
MUKHERJEE et al.
FALSE

Prevention of amivantamab infusion related reactions with extended pre-infusion day oral steroid therapy.
Chan
FALSE

Clinical efficacy analysis of furmonertinib and structural insights into sensitivity to diverse TKIs for NSCLC with EGFR exon 20 insertion.
Zhang et al.
FALSE

Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Yang et al.
FALSE

Phase 1b/2 study of surufatinib in combination with docetaxel as second-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer (NSCLC).
Jiang et al.
FALSE

Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non–small-cell lung cancer (NSCLC) in the United States.
Oksen et al.
FALSE

Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC.
Marin-Acevedo et al.
FALSE

Plasma cell-free RNA PD-L1 expression and survival with immune checkpoint inhibitor-based treatment in advanced non-small-cell lung cancer.
Walker et al.
FALSE

Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience.
Bose et al.
FALSE

Real world prognostic utility of body mass index and platelet lymphocyte ratio in first-line immunotherapy response in stage IV non-small cell lung cancer.
MacDonald et al.
FALSE

Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).
Li et al.
FALSE

Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases.
Hua et al.
FALSE

Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in adults aged older than 75 years.
Yamanaka et al.
FALSE

First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC.
Wang et al.
FALSE

A prospective, non-interventional study among patients diagnosed with locally advanced or metastatic non–small-cell lung cancer to assess the adherence to oral antineoplastic therapy from data collected through patient-reported questionnaires and tablets count in Spain: LOADH study.
Mangues Bafalluy et al.
FALSE

Washing solution of tissue biopsy compared with paraffin-embedded tissue for NSCLC gene test.
Wu et al.
FALSE

Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens.
Ansell et al.
FALSE

TIGIT expression and outcomes in pembrolizumab treated patients with NSCLC.
Senosain et al.
FALSE

Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14).
Furqan et al.
FALSE

LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.
Seager et al.
FALSE

Clinical trial versus standard of care in EGFR-wild type and ALK- negative lung adenocarcinoma: A propensity-matched analysis.
Jung et al.
FALSE

An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.
Bian et al.
FALSE

Molecular characterization of nectin-4 in non-small cell lung cancer subtypes.
Hsu et al.
FALSE

Correlation of homologous recombination deficiency (HRD) score with response to the first-line treatment of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
Li et al.
FALSE

Yttrium-90 radioembolization for lung cancer metastases: Small institutional experience.
Kovalenko et al.
FALSE

Comparative proteomic profiling of plasma exosomes in patients with lung cancer with brain metastasis and liver metastasis.
Li et al.
FALSE

Circulating tumour DNA (ctDNA) as a predictor of clinical outcome in non-small cell lung cancer undergoing targeted therapies: A systematic review and meta-analysis.
Zaman et al.
FALSE

Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.
Osataphan et al.
FALSE

Predictors of benefit to radiation for oligoprogressive disease in EGFR-mutant metastatic non-small cell lung cancer patients treated with osimertinib.
Chen et al.
FALSE

Real-world clinical outcomes in a U.S. Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype.
Liu et al.
FALSE

Differential therapeutic benefit of platinum-doublet chemotherapies with ICIs based on the classification by combined with smoking status and PD-L1 expression in patients with advanced NSCLC.
Fukuda et al.
FALSE

Effect and safety of combining bevacizumab and fractionated stereotactic radiotherapy for brain metastases in patients with non-small cell lung cancer: A phase II trial.
Zhou et al.
FALSE

Immunotherapy combined with rh-endostatin improved clinical outcomes over ICIs plus chemotherapy for second-line treatment of advanced NSCLC.
Huang et al.
FALSE

Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced non-small cell lung cancer (NSCLC) harboring EGFR mutation.
Dong et al.
FALSE

Association between body mass index and survival outcomes for patients with advanced non–small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Sun et al.
FALSE

Role of synthetic lethal mutations for the immune response: Exploratory studies of two non-small cell lung cancer cohorts and two pan-cancer cohorts.
Wang et al.
FALSE

Analysis of significant weight gain in patients using alectinib for ALK-positive lung cancer.
Sikkema et al.
FALSE

Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.
Scharpenseel et al.
FALSE

PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy.
Wong Zhun Hong et al.
FALSE

Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
Yang et al.
FALSE

First-line pembrolizumab plus platinum-pemetrexed in metastatic non-small cell lung cancer: Clinical experience in a Spanish tertiary hospital.
Lombardero et al.
FALSE

Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: Incidence, pattern of failure and clinical value of local consolidative therapy.
Zhang et al.
FALSE

Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.
Giommoni et al.
FALSE

Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets).
Sui et al.
FALSE

ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study.
Lee et al.
FALSE

Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.
Grohé et al.
FALSE

Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation.
Samblás et al.
FALSE

How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.
Zhao et al.
FALSE

Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer.
Fernández Madrigal et al.
FALSE

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.
Sposito et al.
FALSE

Prevalence of KRAS p.G12C mutation in patients with metastatic non-small cell lung cancer in Argentina.
Mendoza Bertelli et al.
FALSE

Effect of immunotherapy cessation without disease progression on outcomes in patients with metastatic non-small cell lung cancer.
McKinley et al.
FALSE

Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.
Li et al.
FALSE

Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis.
Michelon et al.
FALSE

Impact of next generation sequencing on a clinicians’ first line treatment decision in patients with stage IV non-small cell lung cancer.
Megahed et al.
FALSE

Restaging scans frequency heterogeneity in patients being treated for stage IV non-small cell lung cancer (NSCLC).
Sacchi de Camargo Correia et al.
FALSE

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet et al.
FALSE

Prevention of chemotherapy-induced neutropenia (CIN) with plinabulin (Plin) vs placebo (Plac) in patients (pts) with non-small cell lung cancer (NSCLC) treated with docetaxel (Doc): A pooled analysis from 3 randomized trials.
Blayney et al.
FALSE

Models including pathological and radiomic features vs clinical models in predicting outcome of patients with metastatic non-small cell lung cancer treated with immunotherapy.
Captier et al.
FALSE

UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer.
Goldman et al.
FALSE

Safety, tolerability, and quality of life (QoL) of single-agent plinabulin (Plin) for the prevention of docetaxel (Doc) chemotherapy (chemo)-induced neutropenia (CIN) in non-small cell lung cancer (NSCLC) patients (pts) from two randomized trials.
Blayney et al.
FALSE

Prediction of brain metastases progression and overall survival in patients with metastatic non-small cell lung cancer treated by immune checkpoint inhibitors using a radiomic model.
Henon et al.
FALSE

Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial.
Ni et al.
FALSE

Update on real-world efficacy of anlotinib in non-small cell lung cancer.
Gao et al.
FALSE

Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.
Jun et al.
FALSE

Correlation of drug susceptibility testing on short term cultures of CTCs positively with clinical outcomes in non-small cell lung cancer.
Kumar et al.
FALSE

Nivolumab treatment of NSCLC patients in clinical practice in Greater Poland: Long term survival analysis.
Bryl et al.
FALSE

Immune phenotype-driven treatment outcome of IO-only versus chemo-IO in PD-L1-high, first-line, advanced non-small cell lung cancer (NSCLC).
Park et al.
FALSE

Auranofin and the efficacy of anti-PD1 immunotherapy.
Zhang
FALSE

Long-term survival following adrenalectomy for secondary adrenal tumor (SATs): A systematic literature review and meta-analysis.
Alhajahjeh et al.
FALSE

Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutated NSCLC with brain metastasis instructed by dynamic monitoring circulating tumor DNA of paired cerebrospinal fluid and plasma.
Wei et al.
FALSE

Patients harboring uncommon EGFR exon 19delins variants of advanced non-small-cell lung cancer and response to osimertinib: A multi-center retrospective study.
Lu et al.
FALSE

Sensitive detection of CSF-derived cell-free DNA at the CNV level by shallow whole-genome sequencing for diagnosis and characterization of CNS metastases.
Yubin et al.
FALSE

Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer.
Dabbous et al.
FALSE

Real-world healthcare costs amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC).
Iams et al.
FALSE

Systemic inflammation markers ratio in heavily pretreated NSCLC patients treated with nivolumab.
Bitar et al.
FALSE

CD57+CD8+ T cells and response to PD-1/PD-L1 blockade in patients with NSCLC.
Zhou et al.
FALSE

Implementation of a knowledge-based mechanistic model of EGFR-mutant lung adenocarcinoma that considers tumor heterogeneity and metastases to reproduce disease progression upon EGFR-TKI administration.
Darré et al.
FALSE

Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers.
Lopes et al.
FALSE

Retreatment with nivolumab and ipilimumab with or without chemotherapy in patients with metastatic non-small cell lung cancer after progression on immune checkpoint inhibitor therapy.
Mederos et al.
FALSE

Combining plasma and tissue next-generation sequencing provides optimal treatment selection for metastatic NSCLC: A comparative study.
Samol et al.
FALSE

Comparison of response from RECIST1.1 and abstraction in real-world patients with lung cancer.
Chen et al.
FALSE

A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer.
Menon et al.
FALSE

Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients.
Uy et al.
FALSE

Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy.
Garitaonaindia et al.
FALSE

Using cell-free DNA to predict response to immunotherapy in non-small cell lung cancer pre- and post-treatment.
Rao et al.
FALSE

Time to treatment initiation in a retrospective cohort of patients with advanced lung cancer treated with an immune checkpoint inhibitor.
Quattlebaum et al.
FALSE

The impact of COVID-19 on the survival outcome of lung cancer at a Canadian academic centre: A real-world data analysis.
Agulnik et al.
FALSE

Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer.
Rohatgi et al.
FALSE

Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.
Limaye et al.
FALSE

Immune therapy related adverse events in metastatic non-small cell lung carcinoma patients at a rural academic center.
Pasli et al.
FALSE

Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.
Rasokat et al.
FALSE

Clinical outcomes of chemotherapy rechallenge in patients with metastatic non-small cell lung (NSCLC) who progressed on immunotherapy maintenance after front line platinum doublets and immunotherapy.
Wang et al.
FALSE

Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US).
Oskar et al.
FALSE

High-confidence AI-based biomarker profiling for H&E slides to optimize pathology workflow in lung cancer.
Ofek et al.
FALSE

Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancer.
Li et al.
FALSE

Real-world healthcare resource utilization amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC).
Iams et al.
FALSE

Patterns of actionable biomarker testing in lung cancer patients: Disparity or an opportunity for improvement.
Horn et al.
FALSE

Comparing survival and clinical characteristics of patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy less than and more than 2 years.
Rose et al.
FALSE

Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.
Khorasanchi et al.
FALSE

Ethnic disparities in biomarker testing and targeted therapy use in metastatic lung adenocarcinoma: A 2014-2021 analysis.
Pereslete et al.
FALSE

Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).
Yu et al.
FALSE

Oncomine Dx Express CE-IVD liquid biopsy assay for non-small cell lung cancer: Performance review and analytical validation.
Schageman
FALSE

Association of immune-related adverse events and improved treatment outcomes across race/ethnicity in a diverse patient population.
Jani et al.
FALSE

Reality check for precision oncology in squamous cell lung cancer.
Bakhtyar et al.
FALSE

Clinical outcomes for immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
Jia et al.
FALSE

piRNA-14633 underexpression as an independent prognostic marker in non-small cell lung cancer.
Peng et al.
FALSE

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.
Hamid et al.
TRUE

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
Tawbi et al.
TRUE

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
Long et al.
TRUE

Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358).
Bhatia et al.
TRUE

Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial.
Zuur et al.
TRUE

Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.
Lian et al.
TRUE

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.
Chmielowski et al.
TRUE

Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Si et al.
TRUE

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).
Eroglu et al.
TRUE

Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.
Patel et al.
TRUE

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
Mao et al.
TRUE

Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
Lucas et al.
TRUE

Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).
Smithy et al.
TRUE

Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
Grover et al.
TRUE

Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.
Hanna et al.
TRUE

Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
Maloney et al.
TRUE

Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib.
Eroglu et al.
TRUE

Subsets of interferon signaling and response to immune checkpoint blockade.
Lee et al.
TRUE

The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.
Fa'ak et al.
TRUE

Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.
Li et al.
TRUE

CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
Lau et al.
TRUE

Leveraging longitudinal clinical annotations and panel sequencing to characterize dynamics of organotropism in metastatic melanoma.
Aprati et al.
TRUE

Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
Sacco et al.
TRUE

Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
Zimmer et al.
TRUE

Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.
Deng et al.
TRUE

Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.
Guo et al.
TRUE

Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
Schadendorf et al.
TRUE

A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin et al.
TRUE

A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).
Olofsson Bagge et al.
TRUE

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma.
Brohl et al.
TRUE

Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
Niu et al.
TRUE

Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
Chapman et al.
TRUE

Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.
Blom Fily et al.
TRUE

Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.
Smith et al.
TRUE

Economic evaluation for the US of relatlimab and nivolumab (RELA+NIVO) versus nivolumab (NIVO) monotherapy in untreated advanced melanoma.
Aqel et al.
TRUE

Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
Jin et al.
TRUE

Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.
Bai et al.
TRUE

Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
Hodi et al.
TRUE

The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
Shoushtari et al.
TRUE

Breaking primary checkpoint inhibitor resistance: Interim analysis of a multicenter phase II study by intermittent application of an alkylating agent among patients with metastatic melanoma.
Heinzerling et al.
TRUE

Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.
Shah et al.
TRUE

Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
Zijlker et al.
TRUE

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.
Ayala de Miguel et al.
TRUE

A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.
Mehmi et al.
TRUE

Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.
Ibrahim et al.
TRUE

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.
Mao et al.
TRUE

Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
Mørk et al.
TRUE

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
Schadendorf et al.
TRUE

Melanomas lacking HLA class I expression and response to checkpoint inhibitor.
Chapman et al.
TRUE

Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).
Glitza et al.
TRUE

High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.
Williamson et al.
TRUE

The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.
Reijers et al.
TRUE

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
Shaheen et al.
TRUE

Machine learning (ML)-based quantification of tumor-infiltrating lymphocytes (TIL) and clinical outcomes of patients with melanoma treated with immune-checkpoint inhibitors (ICI).
Adib et al.
TRUE

Correlation of DNA methylation signatures with response to immune checkpoint inhibitors in metastatic melanoma.
Ressler et al.
TRUE

Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
Gebhardt et al.
TRUE

Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
Gibney et al.
TRUE

Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of orienX010 in stage IV melanoma with liver metastases.
Cui et al.
TRUE

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum: Outcomes for patients with melanoma.
Karapetyan et al.
TRUE

Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
Asher et al.
TRUE

Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma.
Rapoport et al.
TRUE

De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
Williams et al.
TRUE

Overall survival after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry based study.
Helgadottir et al.
TRUE

Population-based validation of the melanoma institute australia (MIA) and the memorial sloan-kettering cancer center (MSKCC) predictive tool for sentinel node status in patients with melanoma.
Mikiver et al.
TRUE

Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
Rhea et al.
TRUE

Discovery and validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma.
Lovat et al.
TRUE

Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.
DePalo et al.
TRUE

Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.
Woodford et al.
TRUE

NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.
Ascierto et al.
TRUE

Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.
Syeda et al.
TRUE

Melanoma disparities in urban vs rural communities in the era of immunotherapy: An NCDB analysis.
Akers et al.
TRUE

A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.
Petrella et al.
TRUE

Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.
Knight et al.
TRUE

Intralesional oncolytic virotherapy with talimogene laherparepvec in patients with cutaneous lymphomas and non-melanoma skin cancers.
Ramelyte et al.
TRUE

Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.
Kollipara et al.
TRUE

Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.
Hennegan et al.
TRUE

[18F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.
Breukers et al.
TRUE

FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
De Barros E Silva et al.
TRUE

Successful management of Australian patients with locally advanced keratinocyte cancer (KC) and/or extensive skin field cancerization (ESFC), using widefield volumetric arc radiation therapy (VMAT): Report with 24-month follow-up.
Potter et al.
TRUE

Comprehensive genomic profiling (CGP) of clinically advanced and metastatic cutaneous adnexal carcinomas (CAs; MCADCA): A genomic landscape study.
Bou Zerdan et al.
TRUE

A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
Phillips et al.
TRUE

Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.
Feng et al.
TRUE

Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.
Caplan et al.
TRUE

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.
Goodman et al.
TRUE

ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.
Weber et al.
TRUE

Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study.
Wu
TRUE

A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Davar et al.
TRUE

Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.
Jacob et al.
TRUE

Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation/alteration.
Kim
TRUE

Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).
Henry et al.
TRUE

A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
Panella et al.
TRUE

OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
Ascierto et al.
TRUE

NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.
Wong et al.
TRUE

Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.
Van Akkooi et al.
TRUE

A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
Baramidze et al.
TRUE

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
Eroglu et al.
TRUE

A pilot, open study to assess efficacy and safety of ON-01910 (rigosertib) in patients with recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma.
Banner et al.
TRUE

Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).
Phillips et al.
TRUE

A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.
Betof Warner et al.
TRUE

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
Olson et al.
TRUE

The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB).
Farias et al.
TRUE

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.
Gonzalez et al.
TRUE

KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.
Long et al.
TRUE

NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).
O'day et al.
TRUE

PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
Rodrigues et al.
TRUE

CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting.
Park et al.
TRUE

Key factors associated with response in the treatment of liver metastatic melanoma by cryoablation combined with PD-1 blockade therapy: The Cryo-Fire-001 study.
Shen et al.
FALSE

Socioeconomic and demographic factors on academic center accessibility in sebaceous adenocarcinoma: An NCDB analysis.
Wu et al.
FALSE

Preapproval medical products in patients with the diagnosis of metastatic uveal melanoma.
Nshimiyimana Maniraho et al.
FALSE

Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy.
Bleiberg et al.
FALSE

Survival in patients with unresectable melanoma: To infinity and beyond?
van Not et al.
FALSE

CAROLINE study: Incidence and characterization of melanoma in French Polynesia.
Epaillard et al.
FALSE

Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.
Mesana et al.
FALSE

Immunotherapy and radiotherapy in metastatic uveal melanoma: Results from a single institute study.
Guan et al.
FALSE

Trends in overall survival in 133 cases of balloon cell melanoma: An NCDB analysis.
Wu et al.
FALSE

Adjuvant polypeptide vaccines for high-risk uveal melanoma.
Gaughan et al.
FALSE

Patterns of care delivery and outcomes in patients with melanoma brain metastases treated with ipilimumab/nivolumab.
Haykal et al.
FALSE

Relationship of adverse events after combined immunotherapy and treatment outcomes in patients with advanced melanoma: A multicenter experience in Poland.
Pacholczak-Madej et al.
FALSE

Predicting immunotherapy outcomes of melanoma patients before treatment by intestinal microbiota.
Wang et al.
FALSE

Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.
Wang et al.
FALSE

A dual institution real-world study of avelumab for advanced Merkel cell carcinoma.
Miller et al.
FALSE

Intrathecal anti-PD-1 treatment in patients with metastatic melanoma (MM) with leptomeningeal disease (LMD): Real-world data and evidence.
Zhen et al.
FALSE

Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary to in-transit and distant metastasis in acral melanoma.
Tarantino et al.
FALSE

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world evidence.
Koch Hein et al.
FALSE

Meta-analysis of efficacy outcome measures across immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) in melanoma to guide future clinical trial design.
Ousey et al.
FALSE

Low dose anti-PD(L)-1: A potentially effective alternative for greater accessibility in solid malignancies.
Souza et al.
FALSE

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.
Gupta et al.
FALSE

Trends, predictors and impact of atrial fibrillation on inpatient outcomes among malignant melanoma patients: A 5-year National Inpatient Sample (NIS) study.
Olafimihan et al.
FALSE

Trends, sociodemographic and hospital-level factors associated with inpatient palliative care utilization among malignant melanoma patients: A 5-year National Inpatient Sample (NIS) study.
Olafimihan et al.
FALSE

Eosinophilia in patients with melanoma under treatment with immune checkpoint inhibitor-based regimens.
Diamantopoulos et al.
FALSE

Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: A systematic review of clinical trials.
Anwar et al.
FALSE

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.
Wen et al.
FALSE

Cemiplimab in first line treatment for locally advanced and metastatic skin squamous cell carcinoma in Slovenia.
Ocvirk et al.
FALSE

Investigating the patterns of treatment failure in patients with advanced stage III and IV melanoma receiving adjuvant therapy.
Alimohamed et al.
FALSE

Efficacy of nivolumab and relatlimab-rmbw in patients with advanced melanoma who were previously treated with PD-1 inhibitor: Real world experience.
Jang et al.
FALSE

Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.
Connell et al.
FALSE

Efficacy and safety of BRAF/MEK inhibitor rechallenge in patients with advanced melanoma: Systematic review and meta-analysis.
Priantti et al.
FALSE

Prognostic significance of pseudoprogression defined with lowered threshold iRECIST criteria in advanced melanoma treated with immune checkpoint inhibitor therapy.
Park et al.
FALSE

Multi-omics analysis of atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma.
Dai et al.
FALSE

Long-term outcomes of melanoma oligoprogressive metastases treated with radiotherapy combined with locoregional hyperthermia.
Borkowska et al.
FALSE

Survival outcomes of metastasectomy and primary site resection in melanoma patients with isolated brain metastasis: A SEER analysis.
Fahmawi et al.
FALSE

Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.
Madeira et al.
FALSE

Impact of antibiotics on survival outcomes and risk of gastritis/colitis in patients with advanced-stage melanoma receiving anti-PD-1 therapy.
Bailey et al.
FALSE

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) therapy.
Si et al.
FALSE

The phase 1 clinical trial of anti–PD-1 (pucotenlimab) plus intrahepatic injection of oncolytic virus (OH2) combined with radiotherapy of liver metastasis in stage IV melanoma.
Cui et al.
FALSE

“Interchangeability” of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM).
Kravchuk et al.
FALSE

Targeted inhibition of IRAK-4 with emavusertib on immune remodeling in metastatic brain melanoma.
Von Roemeling et al.
FALSE

Factors associated with overall survival in patients with melanoma leptomeningeal disease (M-LMD): A single institution retrospective review.
Nyman et al.
FALSE

Long-term efficacy of BRAFi/MEKi rechallenge in metastatic melanoma: Report of 9 years of clinical practice.
Czarnecka et al.
FALSE

Long-term outcomes of PD-1 blockade in metastatic or unresectable cutaneous squamous cell cancer.
Ali et al.
FALSE

Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab.
Kozak et al.
FALSE

Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A retrospective analysis.
Ben Haj Frej et al.
FALSE

Real-world experience of tebentafusp for uveal melanoma via an Australian access program.
Inderjeeth et al.
FALSE

Distant stage melanoma incidence among US adult women.
Johnson et al.
FALSE

Correlation of low B7-H6 expression with efficacy of immunotherapy inpatients with melanoma.
Chen et al.
FALSE

A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma.
Obermayer et al.
FALSE

Influence of follow-up time on outcome of children and adolescents with atypical Spitz tumor/Spitz melanoma (AST/SM): Results from the MACMEL registry.
Kacar et al.
FALSE

Detection of ctDNA in patients with stage III cutaneous melanoma with satellite/in-transit or nodal metastases.
Al-Mondhiry et al.
FALSE

A cilia-related marker predicting suitability for immunotherapy in melanoma.
Zhu et al.
FALSE

Elucidating the connection between pneumonia and melanoma: Risk factors and outcomes for patients with melanoma.
Hundal et al.
FALSE

An immunogenomic signature for molecular classification in melanoma.
Liu et al.
FALSE

Utility of circulating tumor DNA as a tool to detect minimal residual disease in patients with metastatic cancer and durable response following treatment with immune checkpoint inhibitors.
Afzal et al.
FALSE

Targeting Exportin 1 as treatment for cutaneous squamous cell carcinoma.
Rana et al.
FALSE

Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience.
Sevillano Tripero et al.
FALSE

EGFR expression and relapse in patients with melanoma receiving adjuvant PD-1-based immunotherapy.
Amaral et al.
FALSE

Prognostic value of BRAF and RAS mutations in radically resected patients (pts) with stage I-III melanoma: Preliminary results from a retrospective study.
Brugnara et al.
FALSE

The current state and future of neoadjuvants in resectable melanoma: Review of phase II/III studies conducted between 2018-2022.
Lee et al.
FALSE

Effect of lymph node dissection and adjuvant therapy in patients with sentinel node+ melanoma: An observational multicenter study.
Ogata et al.
FALSE

Distinct genetic and phenotypic characteristics of not otherwise specified (NOS) melanoma.
Goldberger et al.
FALSE

Epidemiology and outcomes of anorectal melanomas: A national database analysis.
Wang et al.
FALSE

Multicenter analysis of melanoma recurrence pattern and management after adjuvant immunotherapy.
Martínez Recio et al.
FALSE

Long-term outcomes in a population-based cohort of 2,967 uveal melanoma patients clinically tested with the 15-gene expression profile: A collaborative study with the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Registries.
Cook et al.
FALSE

Sun exposure and associated risks: Insight from an international survey with a focus on the population with past medical history of skin cancers.
Dreno et al.
FALSE

Prognostic biomarkers for survival in mucosal melanoma.
Thierauf et al.
FALSE

HLA discordance between blood and tumor: A treatment conundrum?
Seedor et al.
FALSE

Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.
Kerob et al.
FALSE

Real-world efficacy of chemotherapy in patients with advanced extramammary Paget's disease: A retrospective, multicenter study of 204 Japanese patients.
Miyashita et al.
FALSE

Investigating the clinical relevance of RNA editing events and their derived neoantigens in patients with melanoma treated with immunotherapy.
Zhang et al.
FALSE

Impact of disadvantaged socioeconomic and demographic status on survival in Kaposi sarcoma.
Swedek et al.
FALSE

Academic medical center access and outcomes in Kaposi sarcoma.
Swedek et al.
FALSE

Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).
Piperno-Neumann et al.
FALSE

Effectiveness and safety of conventional systemic treatments in classical and endemic Kaposi sarcoma: A multicentric retrospective study of 110 patients.
Grolleau et al.
FALSE

Genome-wide CRISPR-Cas9 screening to identify CDS2 as an essential gene in uveal melanoma.
Chan et al.
FALSE

A retrospective study of Merkel cell carcinoma treated at The Ohio State University (OSU) in the last 20 years.
Li et al.
FALSE

Community outreach in vulnerable populations: Skin cancer screening for firefighters.
Fay et al.
FALSE

Immunohistochemical analysis of the tumor microenvironment in acral lentiginous melanoma (ALM).
McGillivray et al.
FALSE

Interim analysis of MelaRisk, a biomarker assay validation study in stage IB/IIA melanoma tissue.
Forchhammer et al.
FALSE

Immuno-embolization plus PD1 antibody in metastatic uveal melanoma.
Javed et al.
FALSE

Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas.
Maubec et al.
FALSE

Demographic and socioeconomic risk factors in treatment of malignant eccrine spiradenoma.
Shin et al.
FALSE

Dissecting the relationship between ethnicity and response to checkpoint inhibitors in patients with acral melanoma.
Kreidieh et al.
FALSE

A national analysis of demographic trends in gynecological cases of basosquamous carcinoma.
Tuman et al.
FALSE

Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study.
Sohn et al.
FALSE

Association between the primary site of disease and the stage at diagnosis for merkel cell carcinoma: A population-based analysis.
Gor et al.
FALSE

High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.
Ladenstein et al.
TRUE

Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.
Corbacioglu et al.
TRUE

A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.
Henderson et al.
TRUE

Biological medicines for diffuse intrinsic pontine glioma (DIPG) eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG.
Grill et al.
TRUE

Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
Kilburn et al.
TRUE

Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies.
Armstrong et al.
TRUE

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).
Macy et al.
TRUE

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).
Lee et al.
TRUE

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
Laetsch et al.
TRUE

Feasibility of the Poverty-Targeted Pediatric Cancer Resource Equity (PediCARE) intervention.
Newman et al.
TRUE

Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.
Jones et al.
TRUE

Medicaid enrollment changes among U.S. adult survivors of childhood cancer following medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).
Ji et al.
TRUE

Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.
Chow et al.
TRUE

Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.
Armenian et al.
TRUE

Clonal hematopoiesis in survivors of childhood cancer.
Friedman et al.
TRUE

Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.
Chang et al.
TRUE

A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.
O'Brien et al.
TRUE

Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).
Pennesi et al.
TRUE

Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.
Lin et al.
TRUE

Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.
Berlanga et al.
TRUE

Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.
Carceller et al.
TRUE

Intensity at the end of life in pediatric neuro-oncology patients: The case for pediatric palliative care.
Udemgba et al.
TRUE

Identifying osteosarcoma signatures in cell free DNA using 5-hydroxymethylcytosine profiling.
Neczypor et al.
TRUE

A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
Hu et al.
TRUE

A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.
Cash et al.
TRUE

Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.
Balsamo et al.
TRUE

Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.
Hall et al.
TRUE

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.
Vinti et al.
TRUE

Accelerated brain age and associated neurocognitive impairments in adult survivors of childhood cancer.
Phillips et al.
TRUE

Genetic study of type 2 diabetes risk in diverse populations of survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).
Im et al.
TRUE

Adherence to mercaptopurine (6-MP) and habit strength in pediatric acute lymphoblastic leukemia (ALL).
Yang et al.
TRUE

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
Bender et al.
TRUE

Outcomes in pediatric relapsed/refractory anaplastic large cell lymphoma: A multi-institutional retrospective analysis.
Marks et al.
TRUE

Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.
Lipak et al.
TRUE

Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
Lode et al.
TRUE

Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.
Slaby et al.
TRUE

A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
Schellekens et al.
TRUE

Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.
Kushner et al.
TRUE

Healthcare resource use for pediatric low-grade glioma care: A cohort of linked electronic health records and claims data.
Cooney et al.
TRUE

Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
Lassaletta et al.
TRUE

Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.
Doz et al.
TRUE

Clinical application of ctDNA detection in Chinese pediatric patients with soft tissue sarcoma (STS).
Zhu et al.
TRUE

Reduction in curie score in neuroblastoma patients treated with naxitamab.
Mora et al.
TRUE

Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
Pinto et al.
TRUE

Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies.
Simon et al.
TRUE

Quality of cancer family history taking in pediatric solid tumor patients.
Hu et al.
TRUE

18F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBG.
Modak et al.
TRUE

Adherence to surveillance guidelines in survivors of hodgkin lymphoma: A report from the Childhood Cancer Survivor Study (CCSS).
Shoag et al.
TRUE

Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) report.
Ohlsen et al.
TRUE

Associations between psychosocial and lifestyle factors and biological age acceleration among long-term survivors of childhood cancer: A prospective study from the St. Jude Lifetime Cohort.
Streck et al.
TRUE

Demographic predictors of successful transition to adult survivorship care for survivors of pediatric cancer.
Gilbert et al.
TRUE

Treatment and treatment-related toxicity following subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Im et al.
TRUE

Mortality and the burden of subsequent malignant neoplasms in survivors of childhood cancer beyond age 50: A report from the Childhood Cancer Survivor Study (CCSS).
Bhandari et al.
TRUE

Longitudinal associations between peripheral neuropathy and neurocognitive decline in long-term survivors of pediatric cancer treated without central nervous system (CNS) directed therapy.
Williams et al.
TRUE

Predictors of cancer center-based follow-up among pediatric and adolescent/young adult cancer survivors.
Pang et al.
TRUE

Outcomes of childhood, adolescent, and young adult cancer survivors (CAYACS) with solid organ transplants: A population-based study.
Gupta et al.
TRUE

Outcomes among survivors of childhood cancer in low- and middle-income countries: A systematic review.
Denburg et al.
TRUE

Subsequent meningiomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Cooney et al.
TRUE

Leveraging a community-academic partnership to evaluate the needs of Latinx AYA cancer survivors.
Smith et al.
TRUE

Influence of genetic predisposition and lifestyle on modifiable cardiovascular risk factors among survivors of childhood cancer.
Wilson et al.
TRUE

Racial disparities in treatment and outcomes of pediatric hepatoblastoma.
Billion et al.
TRUE

Clinical course and native antibody development after COVID-19 infection in 50 pediatric oncology patients.
Smart et al.
TRUE

Expansion of the fertility preservation program to all newly diagnosed prepubertal oncology patients at a pediatric hospital.
Leavitt et al.
TRUE

Self-reported sleep difficulties and association with cognitive function in pediatric cancer survivors.
Stavinoha et al.
TRUE

Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.
Wedekind et al.
TRUE

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg et al.
TRUE

Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).
Greengard et al.
TRUE

Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
Laetsch et al.
TRUE

Phase 1/2, first-in-child study of sonodynamic therapy (SDT) using low intensity focused ultrasound and 5-aminolevulinic acid (ALA) for patients with diffuse intrinsic pontine glioma.
Syed et al.
TRUE

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.
Parsons et al.
TRUE

A multicenter, phase II trial of maintenance sirolimus in combination with metronomic chemotherapy in children and adolescents with high-risk solid tumors.
Sutton et al.
TRUE

A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.
Bacha et al.
TRUE

Outcomes among children with hearing loss admitted with acute lymphocytic leukemia.
Ramphul et al.
FALSE

Protective effect of the dexrazoxane against cardiotoxicity of the anthracycline in the treatment of the childhood cancers.
Tacyildiz et al.
FALSE

Synergistic activity of JAK2 and BCL-2 inhibition against B-cell acute lymphoblastic leukemia.
Rinella et al.
FALSE

Novel biomarkers to predict chronic kidney disease and hypertension at 3 and 12 months post-cisplatin.
Huang et al.
FALSE

Pediatric cancer registry in Turkey 2002-2022: 21 years of achievement (TPOG & TPHD).
Kutluk et al.
FALSE

Recursive partitioning analysis to identify risk stratification for pediatric rhabdomyosarcoma: A real-world data retrospective cohort study based on the SEER database.
Lin et al.
FALSE

Deep multi-omic analyses to identify targetable pathways in desmoplastic small round cell tumor (DSRCT) with opportunities for clinical intervention.
Zhu et al.
FALSE

Event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance treatment based on a retrospective, blinded independent central review (BICR) of imaging during long-term follow-up.
Oesterheld et al.
FALSE

Clinical trends of children with primary cardiac tumors: 15-year experience from a single center.
Patel et al.
FALSE

Pelvic Ewing sarcoma in children: Multimodal treatment, long term outcome and prognostic factors.
Kebudi et al.
FALSE

Clinical features and outcomes of pediatric nasopharyngeal carcinoma: A SEER database study.
Nirmal et al.
FALSE

Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease.
Kushner et al.
FALSE

The spectrum of RAF1 fusion positive solid tumors in children and young adults.
Chen et al.
FALSE

Molecular pathways involved in hepatoblastoma tumorigenesis in trisomy 18.
Schepers et al.
FALSE

Outcome of nasopharyngeal carcinoma (epithelial undifferentiated NOS) in children and adolescents: SEER database analysis.
Pendharkar et al.
FALSE

Pediatric carcinoid tumors of the lungs: A descriptive analysis.
Lee et al.
FALSE

Impact of occupational therapy on comprehensive care in pediatric oncology.
Hsueh
FALSE

Primary care utilization and cardiovascular screening in adult-aged survivors of childhood cancer: A report from the childhood cancer survivor study (CCSS).
Ohlsen et al.
FALSE

Congenital anomalies and health outcomes among survivors of childhood cancer: A report from the childhood cancer survivor study.
Janitz et al.
FALSE

Cardiac iron overload in pediatric oncology and bone marrow transplant survivors.
Hans et al.
FALSE

SARS-CoV2 vaccination response in pediatric oncology patients.
D'Souza et al.
FALSE

Germline genetic testing use and results after a cancer diagnosis.
Kurian et al.
TRUE

Breast cancer risk associated with missense variants in BRCA2.
Yadav et al.
TRUE

Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141).
Kuhl et al.
TRUE

Second primary breast cancer in young breast cancer survivors.
Brantley et al.
TRUE

Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes.
Joseph et al.
TRUE

Polygenic risk score calibration and association with breast cancer in diverse ancestries.
Kucera et al.
TRUE

Integrating polygenic risk scores into clinical breast cancer models: Influence on prediction in diverse cohorts.
Busby et al.
TRUE

Whole exome sequencing and machine learning germline analysis of individuals presenting with phenotypes of extreme high and low risk of developing tobacco-induced lung adenocarcinoma.
Perez-Gracia et al.
TRUE

Lung cancer metabolomics: A pooled analysis in the cancer prevention studies.
Tang et al.
TRUE

Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers.
Arafa et al.
TRUE

Redefining early-onset cancer and risk of hereditary cancer predisposition.
Stadler et al.
TRUE

POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.
Walsh et al.
TRUE

Germline alterations in patients with lung cancer.
Govindan et al.
TRUE

Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: A single-center exploratory study.
Ge et al.
TRUE

Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study.
Hüneburg et al.
TRUE

Real-world outcomes and safety in patients with VHL associated tumors receiving belzutifan.
Chidharla et al.
TRUE

Neoplasia detection via colonoscopic surveillance among young patients with MSH6 and PMS2-associated Lynch syndrome.
Latham et al.
TRUE

Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS).
Harrold et al.
TRUE

High-risk constitutional MLH1 methylation as a cause of early-onset colorectal and endometrial cancers displaying mismatch repair deficiency and MLH1 methylation.
Hitchins et al.
TRUE

Early real-world (RW) experience with a multi-cancer early detection (MCED) test.
Westgate et al.
TRUE

Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.
Klein et al.
TRUE

Real-world performance of a multi-cancer early detection test based on integrative analysis of cell-free DNA whole-methylome sequencing.
LI et al.
TRUE

Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
Marshall et al.
TRUE

Prevalence of unexpected actionable germline pathogenic variants identified on broad-based multi-gene panel testing in a cohort of cancer patients.
Landry et al.
TRUE

CDH1 incidental findings in patients with personal or family history of breast cancer.
Abdel-Salam et al.
TRUE

The impact of climate change on cancer incidence in U.S. women: Who is most affected?
Johnson et al.
TRUE

Twenty-year patterns in area deprivation index and risk of metastatic prostate cancer at initial diagnosis among men in Ohio.
Cullen et al.
TRUE

Trends in diagnosis of de novo metastatic hormone sensitive prostate cancer in US Veterans, 2002-2021.
Al masalmeh et al.
TRUE

Breast cancer: Global patterns of incidence, mortality, and trends.
Sedeta et al.
TRUE

Comparison of 5- and 10-year breast cancer risk predictions.
Hopper et al.
TRUE

Epidemiologic effectors on the breast tumor microenvironment: Results from the Cancer Prevention Study-II and -3 cohorts.
Elsebaie et al.
TRUE

Clinical characteristics of interval breast cancer within 12 months and 13-24 months in Utah.
Wei et al.
TRUE

Trends in mortality caused by neoplasms of the heart in the United States between 2000 and 2019: An observational analysis of disparities by gender and race.
Shahapurkar et al.
TRUE

Epidemiological and clinicopathological features of patients (pts) with early- (EOPC) and late-onset pancreatic cancer (LOPC): A mono-institutional retrospective analysis.
Bensi et al.
TRUE

Cardiorespiratory fitness and BMI in youth and site-specific cancer mortality in men: A population-based cohort study with register linkage.
Onerup et al.
TRUE

Examining the potential for lead-time bias by estimating stage-specific proportions of deaths due to diagnosed cancer.
Chang et al.
TRUE

Obesity and breast cancer in women under age 40.
Cattie et al.
TRUE

The impact of high body mass index on hepatocellular carcinoma in viral hepatitis and cirrhosis.
Kim et al.
TRUE

Association between excess body mass index trajectory and change in monoclonal protein level in patients diagnosed with monoclonal gammopathy of undetermined significance.
Liu et al.
TRUE

County-level food insecurity to predict cancer incidence and mortality in the United States, 2015-2020.
Chen et al.
TRUE

The role of metabolic perturbations in mediating the effects of ambient air pollution on lung cancer in the cancer prevention studies.
Liang et al.
TRUE

Global burden and economic impact of vaccine-preventable cancer mortality.
Bencina et al.
TRUE

Impact of social media messages on perceived risk and severity of adverse effects and regret of HPV vaccination: The moderating role of decision-making preference.
Villegas et al.
TRUE

The impact of HPV vaccination in Florida compared to New York.
Neerukonda et al.
TRUE

Barriers to cervical cancer screening in a developing Middle Eastern country: A nationwide survey.
Abdulelah et al.
TRUE

Incomplete HPV vaccination among individuals aged 27-45 years in the United States: A mixed effect analysis of individual and contextual factors.
Adekanmbi et al.
TRUE

Sex differences in cancer incidence rates by race and ethnicity: Results from the surveillance, epidemiology, and end results (SEER) Registry (2000-2019).
Tosakoon et al.
TRUE

Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations.
Trendowski et al.
TRUE

Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems.
Shevach et al.
TRUE

Disparities in germline genetic testing results from a cohort of 493,515 black and white patients.
Wyatt et al.
TRUE

Characterizing medical mistrust (MM) in a socio-demographically diverse sample of patients with cancer.
Park et al.
TRUE

Training oncologists (Oncs) to conduct better informed discussions with African American (AA) cancer (CA) patients (pts) about tumor genomic profiling (TGP): Results of a randomized pilot trial of gene pilot pro (GPP).
Hall et al.
TRUE

Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.
Koehler et al.
TRUE

African American women who carry the BRCA1/2 mutation: Clinical characteristics and prevention strategies.
Karki et al.
TRUE

Racial disparities in aging-related comorbidity among breast cancer survivors.
Nguyen et al.
TRUE

Sleep health and quality of life in African American cancer survivors: The Detroit ROCS Cohort.
Beebe-Dimmer et al.
TRUE

Prevalence of and racial/ethnic distribution of full-body skin examination among sexual and gender minority patients.
Freeman et al.
TRUE

Melanoma literacy and predictors for skin self-examination in three western U.S. states: A population-based survey.
Nelson et al.
TRUE

Vitamin D deficiency as a risk factor for breast cancer development.
Mackey et al.
TRUE

A nationwide population based primary CNS lymphoma (PCNSL) analysis: Do Hispanics have better outcomes?
Orellana et al.
TRUE

Elevated cancer risk among individuals with combinations of cancer-related risk factors: A large claims database analysis.
Cong et al.
TRUE

Modeling genetic testing (GT) attitudes in a socio-demographically diverse cohort of patients (pts) with cancer: The importance of race/ethnicity and medical mistrust (MM).
Hall et al.
TRUE

Assessing disparities in lung cancer screening eligibility among high-risk individuals.
Gudina et al.
TRUE

Patient-level factors associated with the use of active surveillance: The talking about prostate cancer cohort.
Mukand et al.
TRUE

Colorectal cancer and digital/live screening navigation: Promoting prevention through personalized recommendations and access.
Newcomer et al.
TRUE

The impact of extending CRC screening to the older population: Results from CRC-AIM microsimulation model.
Ebner et al.
TRUE

Navigation program for LDCT lung cancer screening implementation: A quality initiative.
Shrestha et al.
TRUE

The probability of lung cancer in patients with incidentally detected pulmonary nodules detected via low-dose computed tomography screening in China.
Lan-Wei et al.
TRUE

LungFlag, a machine-learning (ML) personalized tool for assessing lung cancer risk in a community setting, to evaluate performance in flagging non-small cell lung cancer (NSCLC) regardless of sex or race.
Morgenstern et al.
TRUE

Assessing the risk of gastrointestinal cancers among cannabis users compared to nicotine users.
Waris et al.
TRUE

Rates of routine cancer screening compared with pre-pandemic levels.
Oakes et al.
TRUE

Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.
Chung et al.
TRUE

Enhancing lung cancer screening through ‘Saved by the Scan’: Lessons from a multipronged public service advertising program.
Bellur et al.
TRUE

A multivariate analysis of low-dose CT lung cancer screening in a Michigan community hospital network.
Law et al.
TRUE

Patient navigation for lung cancer screening in an urban safety-net system: A pragmatic randomized clinical trial.
Bhalla et al.
TRUE

Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.
Zaheed et al.
TRUE

Effect of colorectal cancer screening on 1-year mortality and medical costs: Real-world evidence from the largest commercial medical claims database in the US.
Nguyen et al.
TRUE

Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.
Fendrick et al.
TRUE

The role of molecular biomarker CDKN-2A in early diagnosis of colorectal cancer.
Ten et al.
TRUE

Does adherence to cancer prevention guidelines before diagnosis associate with improved cancer survival?
Davis et al.
TRUE

Genetic testing into survivorship after diagnosis of breast cancer.
Katz et al.
TRUE

Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?
Casasanta et al.
TRUE

Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.
Shah et al.
TRUE

Analysis of ATM germline mutations in solid tumors from Chinese patients.
Fu et al.
TRUE

Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.
Akkoc Mustafayev et al.
TRUE

Comprehensive analysis of patients with cancer with a positive CHEK2 test: Are we getting closer to a genotype/phenotype correlation?
Fragoso et al.
TRUE

Investigation of cancer predisposition in Fanconi anemia heterozygotes: A DiscovEHR cohort population study.
Deng et al.
TRUE

Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.
Nielsen et al.
TRUE

Implementation of universal pan-cancer germline genetic testing in an Arab population: The jordanian exploratory cancer fenetics (Jo-ECAG) study.
Abdel-Razeq et al.
TRUE

Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
Incorvaia et al.
TRUE

A pan-cancer statistical study of microsatellite instability and Lynch syndrome–associated mismatch repair genes germline mutations.
Cao et al.
TRUE

Hereditary breast and ovarian cancer syndrome: A misnomer?
Weiss et al.
TRUE

Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.
Harrold et al.
TRUE

Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States.
Guo et al.
TRUE

A randomized controlled trial evaluating pretest cancer genetics educational video or in-person genetic counseling.
Chavarri Guerra et al.
TRUE

Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Giri et al.
TRUE

Evaluating interventions to increase the uptake of NCCN genetic counseling recommendations.
Stempel et al.
TRUE

Scalable new model of genomic care delivery: Assessing psychological outcomes.
Gray et al.
TRUE

Genetic testing outcomes and pathogenic germline mutation prevalence in renal cell carcinoma.
Nguyen et al.
TRUE

Clinical utility of reporting research genetic predisposition testing results to Total Cancer Care participants.
Hutchcraft et al.
TRUE

Healthcare utilization among individuals diagnosed with lynch syndrome through a universal germline genetic testing program.
Hampel et al.
TRUE

Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.
Gray et al.
TRUE

Validation of a guidelines-based brief patient-administered digital tool to assess the need for germline genetic testing.
Russell et al.
TRUE

A comprehensive analysis of clinical characterization in 149 Chinese patients with Lynch syndrome.
Lin et al.
TRUE

Using patient-reported outcomes to assess the impact of germline genetic testing on prostate cancer patients.
Nielsen et al.
TRUE

Somatic profiling guides germline genetic testing in patients with mutations in cancer predisposition genes.
Darabi et al.
TRUE

Prospective prevalence estimation of BRCA1, BRCA2, and other germline mutations associated with hereditary pancreatic cancer (HPC) using a comprehensive gene panel in an unselected cohort of Mexican patients with pancreatic ductal adenocarcinoma (PDAC).
Rosas Camargo et al.
TRUE

Cancer risk and characteristics in older female BRCA1/2 mutation carriers.
Ghimire et al.
TRUE

Beyond the standards: The impact of provider collaboration on referrals to genetic counseling.
Fowler et al.
TRUE

Digital cancer genetic risk assessment in a gynecologic oncology clinic.
Webster et al.
TRUE

Impact of early testing and analysis of germline genetic mutation patterns in patients with breast cancer: A single institution experience.
Reddy et al.
TRUE

Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.
Cheo et al.
TRUE

Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.
Kuwata et al.
TRUE

A population-based study of BRCA breast cancer incidence and prognosis in the Italian Emilia Romagna region: The MUTina study.
Cortesi et al.
TRUE

Eliminating barriers to uptake of germline genetic testing for patients with advanced cancer: The GTAC study.
Landry et al.
TRUE

Geographical impact on prostate cancer genetic testing eligibility: A preliminary study from an academic cancer center.
Beck et al.
TRUE

Perceived mental and physical health in patients with common cancers: A study using the PROMIS framework in All of Us database.
Mohamed Salih et al.
TRUE

Spectrum of germline pathogenic variants among patients with cancer in Mexico.
Rodriguez Olivares et al.
TRUE

Clinical and social importance of follow-up assessment of family members of patients with BRCA mutations.
Nascimento et al.
TRUE

A scalable approach to democratizing cancer risk stratification: One healthcare system’s approach using a patient-facing digital platform.
Fecteau et al.
TRUE

Impact of risk-reducing mastectomy on quality of life of women with Li-Fraumeni syndrome.
Polidorio et al.
TRUE

Newly diagnosed lung cancer in hospitalized patients during the COVID-19 pandemic: How well are LDCTs utilized?
Assis et al.
TRUE

Risk of death among lung cancer patients before and during the COVID-19 pandemic.
Lee et al.
TRUE

Immunogenicity after COVID-19 vaccination in patients with solid tumor and hospital staff: A prospective single-center observational study.
Katsuya et al.
TRUE

AI to characterize patients with lung or ovarian cancer and those with cachexia for discovery of undiagnosed, misdiagnosed, and miscoded patients at scale in a privacy-preserving manner.
Guo et al.
TRUE

Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry.
Paller et al.
TRUE

Inverse association of post-transplant malignancy and graft failure on survival outcome following double lung transplantation.
Lee et al.
TRUE

Prevalence of pathogenic germline variants in a cohort of patients with early onset non-small cell lung cancer (EOLUNG).
Jove et al.
TRUE

Validation of a breast cancer polygenic risk score in 15,490 Brazilians using exome sequencing.
Eichemberger Rius et al.
TRUE

Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings.
Walsh et al.
TRUE

Overall and non-lung cancer incidence in the national lung screening trial (NLST) as indicators of potential for multi-cancer screening.
Chang et al.
TRUE

Correlation of unobserved incidence of cancer in earlier stages with the observed incidence.
Chhatwal et al.
TRUE

Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort.
Parikh et al.
TRUE

Metformin for chemoprevention of lung cancer in high-risk overweight or obese individuals.
Nour et al.
TRUE

Characterization of pre-malignant lesions in patients with pediatric neurofibromatosis type 1 using a novel whole-body magnetic resonance imaging technique.
Baca et al.
TRUE

Connecting Black families in Houston, Texas, to hereditary cancer genetic counseling, genetic testing, and cascade testing by using a simple cancer genetic risk assessment and telegenetics.
Kizub et al.
TRUE

A multi-component educational intervention for oncologists to improve tobacco cessation treatment among patients with cancer who smoke.
Jose et al.
FALSE

The impact of minority health social vulnerability on population-based cancer incidence.
Onitilo et al.
FALSE

Patient perception and adherence to lung cancer screening in those who meet eligibility criteria.
Menakuru et al.
FALSE

Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?
Menakuru et al.
FALSE

Skin cancer screening and sun safety education program for high school students in southern California.
Savage et al.
FALSE

The effect of an ultraviolet photography educational exercise on sunscreen application.
Young et al.
FALSE

A CBTH intervention for reducing stress in women with high risk in a DCE-MRI breast cancer screening study.
Liu et al.
FALSE

A flexible quantitative framework to assess the potential contribution of early cancer detection to improved cancer survival.
Yu et al.
FALSE

Mammography in women with sickle cell disease.
Farooqui et al.
FALSE

Inclusive healthcare for persons with disabilities (PWDs) in advocacy and partnership in breast and cervical cancer screening through the EMPOWER Program.
Nyongo et al.
FALSE

Breast malignancy after radioactive iodine ablation for thyroid pathology: A systematic review of the literature.
Yellamaty et al.
FALSE

Inclusive innovation: World health organization (WHO) task-shifting principles in community health workers living with disabilities through women’s cancer screening in the EMPOWER Program.
Kanari et al.
FALSE

Obesity and triple negative breast cancer diagnosis among premenopausal women.
Taylor et al.
FALSE

Patient-provider communication factors associated with mt-sDNA screening for colorectal cancer.
Alam et al.
FALSE

Cervical cancer risk factors, knowledge and attitudes towards HPV vaccine among coastal Kenyan women: A prospective cross-sectional survey.
Omar et al.
FALSE

Lung cancer screening status and acceptability of a personalized approach in Texas.
Resong et al.
FALSE

Barriers to breast cancer screening in a developing middle eastern country: A nationwide survey.
Abdulelah et al.
FALSE

Prevalence of risk factors for liver fibrosis and associations of serum biomarkers with liver fibrosis in a Houston community clinic.
Hwang et al.
FALSE

The impact of food insecurity on county-level colorectal cancer screening rates.
Jafri et al.
FALSE

Hospital length of stay in patients with cancer who undergo systemic or ultrasound-catheter-directed thrombolysis for pulmonary embolism.
Ostos et al.
FALSE

A case-control study of 10,757 individuals to assess potentially modifiable risk factors, including stress, for breast cancer among Chinese patients in Hong Kong.
Yeo et al.
FALSE

An epidemiological profile of colorectal cancer patients diagnosed at a single cancer center in Costa Rica from 2018 to 2022.
Garita et al.
FALSE

Impact of the Covid-19 pandemic on the treatment of resectable liver neoplasms: A cross-sectional study from Brazil.
Marangoni Roschel et al.
FALSE

Prevalence of cancer-related risk factors and associated cancer burden: A targeted literature review.
Jazieh et al.
FALSE

Independent prognostic value of method of detection in lung cancer: Analysis of the PLCO lung screening trial.
Long et al.
FALSE

Mediation of race/ethnicity (R/E) disparities in mental health patient reported outcomes (PROS) among elderly female patients with breast cancer (BC) in the Surveillance, Epidemiology, and end results-medicare health outcomes survey (SEER-MHOS) database.
Champion et al.
FALSE

Real-world data on survival outcomes and characteristics of lung cancer patients in northern serbia.
Bokan et al.
FALSE

Further insights on social determinants of health: Investigating racial disparities and estimated household income in relation to staging of newly diagnosed breast cancer.
Ghorpade et al.
FALSE

Post pandemic reality in breast cancer in Brazil.
Aleixo et al.
FALSE

Opinions and usage of cancer-associated thrombosis scoring systems among hematologists and oncologists: An international survey.
Agrawal et al.
FALSE

Time trend on breast cancer mortality: How are we allocating physicians to deal with the disease in men and women in Brazil?
Schoueri et al.
FALSE

Genetic evaluations and testing rates for hereditary breast and ovarian cancer syndrome in a community oncology setting.
Bunnell et al.
FALSE

Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.
Martin et al.
FALSE

Clinical implications of universal germline testing in breast cancer patients in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study.
Abdel-Razeq et al.
FALSE

Clinical synergy of universal paired tumor genomic and germline sequencing in an unselected, pan-cancer cohort of patients: Greater than the sum of the parts.
Heald et al.
FALSE

Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2.
Previs et al.
FALSE

Frequency and spectrum of CHEK2 variants in a large Brazilian set of germline-tested patients.
Santana et al.
FALSE

Aligning NCCN criteria with testing workflows using a novel database application (Criterion).
Sharma et al.
FALSE

Measuring real-world concordance with evidence-based guidelines for genetic testing in patients with breast cancer: A retrospective quality review.
Ezratty et al.
FALSE

BRCA mutations in triple negative breast cancer patients in Guatemala: A descriptive study.
Kihn-Alarcón et al.
FALSE

Modifiable risk factors and risk of colorectal and endometrial cancer in Lynch syndrome: A systematic review and meta-analysis.
Power et al.
FALSE

Energetics and lifestyle in inherited syndromes (ELLIES Project): Feasibility of remote specimen collection for biomarker analysis.
Venkatesh et al.
FALSE

Survival outcomes of BRCA1/BRCA2 mutated breast cancers: Study from a tertiary care cancer centre in India.
S G et al.
FALSE

Prevalence and clinical correlations of Lynch syndrome (LS) in northeast Brazil.
Sant'Ana et al.
FALSE

Outcomes for patients with Lynch Syndrome in Manitoba.
Jia et al.
FALSE

Breast cancer in patients with Lynch syndrome: A single institution retrospective analysis.
Miano et al.
FALSE

A basket-platform trial for neurofibromatosis type 1: A potential model for rare cancer predisposition syndromes.
Bakker et al.
FALSE

Malignancy in patients with sickle cell disease: A single center experience.
Sharma et al.
FALSE

Intervening factors for participation and non-participation in colorectal cancer screening in Spain.
Amador
FALSE

Differential burnout by race, sex, and sexual orientation in academic oncology.
Odei et al.
TRUE

The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.
MacDuffie et al.
TRUE

Diversity, equity, and inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.
Ansari et al.
TRUE

Workplace sexual harassment in academic oncology.
Yerramilli et al.
TRUE

Should I stay, or should I go? Factors associated with intent to leave academic oncology.
Velazquez Manana et al.
TRUE

Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.
Velazquez Manana et al.
TRUE

A multifaceted approach to wellness in a hematology/oncology fellowship program.
Srikumar et al.
TRUE

Remote delivery of a mindfulness-based intervention to decrease stress levels and promote coping among health-care workers during the COVID-19 pandemic.
Helou et al.
TRUE

Tumor board tuesday and awareness of novel therapies and toxicities in solid tumor oncology.
Ebben et al.
TRUE

Assessment of YouTube as an information source for immune checkpoint inhibitors (ICIs).
Garg et al.
TRUE

Quality and accessibility of liquid biopsy information: An analysis of online content.
Litt et al.
TRUE

Defining the educational needs for a community-based hematology/oncology career: A national needs assessment.
Agrawal et al.
TRUE

Integration of clinical trial development in hematology and oncology fellowship training: Washington university school of medicine experience.
Auberle et al.
TRUE

Novel curriculum for training in medical cannabis in oncologic populations for oncology trainees.
Patell et al.
TRUE

Innovating the hematology/oncology (H/O) curriculum for internal medicine (IM) residents: A modified flipped classroom (FC) approach.
Bhatt et al.
TRUE

Creating an infrastructure to address physician and advanced practice provider burnout at a complex community cancer care delivery system.
Tray et al.
TRUE

Addressing resiliency and burnout: A quantitative needs assessment of oncology physician assistants (PAs).
Tetzlaff et al.
TRUE

The implementation of a self-care tool for patients that may reduce clinician burden.
Wei et al.
TRUE

Characterizing imposter syndrome among oncologists on social media.
Teplinsky et al.
TRUE

Impact and engagement of a virtual platform to provide equitable oncology education globally.
Leyfman et al.
TRUE

Reliability of audiovisual information on lung cancer from cancer organizations.
Dand et al.
TRUE

How reliable are post-mastectomy breast reconstruction videos on YouTube?
Morena et al.
TRUE

The impact of physician gender on patient satisfaction in an academic hematology/oncology practice.
Turchi et al.
TRUE

A review of diversity, equity, and inclusion (DEI) efforts by medical oncology journals.
Abuali et al.
TRUE

Bringing the teaching close to home: Implementation of a near-peer model for an introductory hematology-oncology fellowship lecture series.
Berry et al.
TRUE

Fellow-led didactics in a hematology/oncology fellowship program.
Thawani et al.
TRUE

Utility of a novel trainee-level hematology/oncology podcast in graduate medical education.
Mistry et al.
TRUE

Teaching how to navigate difficult conversations: A combined palliative care–oncology didactic simulation intervention for hematology/oncology fellows.
Dupuis et al.
TRUE

Hematology and oncology fellow education about sexual and reproductive health: A survey of program directors in the United States.
Reese et al.
TRUE

Recommendations for medical cannabis use in cancer patients by US oncology fellows and the impact of receiving prior training.
Tehranchi et al.
TRUE

The brown university cancer prevention and survivorship curriculum: A case study on program development in an internal medicine residency.
Francis et al.
TRUE

Mapping objectives of a new interprofessional morbidity and mortality conference to ACGME core competencies in hematology/oncology.
Sharma et al.
TRUE

The cognitive load of inpatient consults involving immune-related adverse events.
Brondfield et al.
TRUE

The impact of oncology hospitalist utilization on resident education.
Bhatt et al.
TRUE

Multimodality, online oncology learning resources: Meeting residents where they are—A pilot to create a new oncology curriculum.
King et al.
TRUE

Efficacy of a hematology/oncology podcast curriculum at a community-based internal medicine program.
Fitzpatrick et al.
TRUE

Effects of a focused one-day interactive session on oncology research on medical students’ interest in and understanding of oncology research.
Alrawabdeh et al.
TRUE

Early introduction to clinical radiation oncology through a self-directed competency-based medical student curriculum.
Claunch et al.
TRUE

A pilot curriculum to transition from 2D to 3D image-guided brachytherapy: A preliminary needs assessment.
Ogunmuyiwa et al.
TRUE

Web-based patient educational material on chimeric antigen receptor T-cell therapy: Quantitative assessment of readability.
Thakur et al.
TRUE

Empowering self-advocacy for breast health: A successful educational campaign on breast cancer risk and screening recommendations.
Culbert et al.
TRUE

Clinicians’ experiences with patients with cancer or their families who endorse medical misinformation.
Palmer et al.
TRUE

Burnout in oncology nurses.
Sharma et al.
FALSE

Incorporation of fellow-driven, interactive case-based discussions to improve fellowship education in a new fellowship program.
Sridhar et al.
FALSE

The power of writing: Impact of writing for health professionals working with oncology patients.
Chagas et al.
FALSE

Real-world impact of oncology education on clinical practices at five community cancer care centers.
Johnson et al.
FALSE

Trends in application and match outcomes for hematology and oncology fellowship: An analysis of charting outcomes from 2008 to 2022.
Ojo et al.
FALSE

Global impact of a video education platform on oncology education amongst healthcare professionals.
Leyfman et al.
FALSE

Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.
Khosla et al.
FALSE

From abstract to publication: Factors predictive of publication success in the field of breast and gynecological malignancy.
Kapoor et al.
FALSE

The impact of large oncology meetings (
Dizon et al.
FALSE

Website and social media presence for National Cancer Institute Community Oncology Research Program (NCORP) sites.
Steinmetz et al.
FALSE

Trends of female representation in ASCO leadership and abstracts authorship: A detailed review.
Aljaras et al.
FALSE

Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).
Reichardt et al.
TRUE

A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.
Wilky et al.
TRUE

ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.
Martin Broto et al.
TRUE

A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Grilley-Olson et al.
TRUE

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.
Agulnik et al.
TRUE

A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.
Palassini et al.
TRUE

Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).
Cote et al.
TRUE

Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.
Movva et al.
TRUE

Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).
Salawu et al.
TRUE

The clinical value of tumor-informed minimal residual disease detection in sarcoma.
Fu et al.
TRUE

Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.
Pasquali et al.
TRUE

Deep learning with whole slides images to predict histological response to neoadjuvant chemotherapy in patients with resectable high grade soft-tissue sarcomas: A multicenter study.
Adjadj et al.
TRUE

Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study.
Fiore et al.
TRUE

Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.
Alcindor et al.
TRUE

RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.
Gounder et al.
TRUE

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
Chae et al.
TRUE

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
Movva et al.
TRUE

Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).
Rosenbaum et al.
TRUE

SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).
Grohar et al.
TRUE

SELISARC: A Spanish Sarcoma Group (GEIS) phase I/II trial of selinexor plus gemcitabine in selected sarcoma subtypes—Results of the phase I part.
Martin Broto et al.
TRUE

A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
Cranmer et al.
TRUE

Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.
Trent et al.
TRUE

Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.
Heinrich et al.
TRUE

Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
Jones et al.
TRUE

Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
Xu
TRUE

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.
Tang et al.
TRUE

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children’s oncology group pediatric early-phase clinical Trial Network study.
Reed et al.
TRUE

Variations in the approach to lung metastases in osteosarcoma among pediatric and adult patients.
Wytiaz et al.
TRUE

Evaluation of local control strategies on patterns of treatment failure in patients with localized ewing sarcoma treated on AEWS1031: A report from the children’s oncology group.
Ahmed et al.
TRUE

ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.
Shen et al.
TRUE

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Lacuna et al.
TRUE

Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.
Tap et al.
TRUE

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.
Salkeni et al.
TRUE

Prolonged 14-day continuous infusion of high-dose ifosfamide (14IFO) for relapsed/refractory high-grade osteosarcoma (R/R HOS): A retrospective multicenter cohort study.
Tirtei et al.
TRUE

Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.
Reiter et al.
TRUE

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
Trent et al.
TRUE

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.
Tap et al.
TRUE

Combination targeted therapy with avapritinib and sunitinib in patients with refractory gastrointestinal stromal tumors after failure of standard treatments: A small prospective pilot study.
Xia et al.
TRUE

Fluorine-18 fluorodeoxyglucose (18FDG)-uptake assessment of PDGFRA mutant gastrointestinal stromal tumors (GIST): A retrospective multicenter Italian study.
Nigro et al.
TRUE

Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).
Qiu et al.
TRUE

Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST).
Hildebrand et al.
TRUE

Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST.
Dagalakis et al.
TRUE

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.
Li et al.
TRUE

Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).
Koyama et al.
TRUE

Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.
Brahmi et al.
TRUE

Alternative splicing (AS) regulation as a novel therapeutic target in soft-tissue sarcoma (STS).
Moura et al.
TRUE

Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.
Zhuk et al.
TRUE

Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.
Dorand et al.
TRUE

Loss of the DNA repair gene RNase H2 and a unique subset of DDR-deficient leiomyosarcomas.
Nakazawa et al.
TRUE

Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS).
Chen et al.
TRUE

Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS).
Zaidi et al.
TRUE

Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.
Liu et al.
TRUE

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
LoRusso et al.
TRUE

Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.
Omelchenko et al.
TRUE

Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.
Chawla et al.
TRUE

Metronomic dosing of selinexor in select soft tissue sarcomas (STS).
Alshibany et al.
TRUE

Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.
Kawai et al.
TRUE

Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update.
Yao et al.
TRUE

Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials.
Alshibany et al.
TRUE

Novel MRI scoring system to assess osseous malignancy in patients with soft tissue sarcoma following radiotherapy.
Vijayakumar et al.
TRUE

HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
Fan et al.
TRUE

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.
Van Tine et al.
TRUE

Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.
Van Der Graaf et al.
TRUE

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
Bose et al.
TRUE

A phase II clinical trial of chidamide in combination with toripalimab in patients with advanced soft tissue sarcoma.
Zhang et al.
TRUE

Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.
Salawu et al.
TRUE

Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
Meyer et al.
TRUE

Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.
Zhou et al.
TRUE

A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.
Kelly et al.
TRUE

Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).
Stacchiotti et al.
TRUE

Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
Guo et al.
TRUE

Trabectedin failure-free survival (TFFS) after resuming trabectedin (T) in advanced myxoid liposarcoma (MLPS) patients.
Fabbroni et al.
TRUE

Outcome of patients (PTS) with advanced epithelioid hemangioendothelioma (EHE) after failure on sirolimus (S).
Giani et al.
TRUE

Risk stratification tools to help decide on adjuvant chemotherapy usage in resected soft tissue sarcomas: A 10 year review of an Irish sarcoma centre experience.
Weadick et al.
TRUE

Clinical implications of recurring mutations in myxoid liposarcoma (MLS).
Thirasastr et al.
TRUE

DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma.
Liebner et al.
TRUE

AOST2031: An in-progress COG phase 3 randomized controlled trial comparing open vs thoracoscopic management of pulmonary metastases in patients with osteosarcoma.
Doski
TRUE

A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
VAN HAL et al.
TRUE

ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma.
Albert et al.
TRUE

INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.
George et al.
TRUE

ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
Riedel et al.
TRUE

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
Lacuna et al.
TRUE

A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor.
Gelderblom et al.
TRUE

PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.
Sellan-Albert et al.
TRUE

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Dickson et al.
TRUE

Engagement of patient participation in genomics research by the Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network.
George et al.
TRUE

Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
Cote et al.
TRUE

A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
D'Angelo et al.
TRUE

Distinguishing enchondroma from low-grade chondrosarcoma using a multi-stage deep learning model for patient radiographs and histopathology.
Nye et al.
FALSE

Effect of dual properties of regorafenib in osteosarcoma on tumor progression and bone parameters in mouse preclinical models.
Munoz Garcia et al.
FALSE

The impact of demographic factors on patients with intraosseous well-differentiated osteosarcoma.
Cook et al.
FALSE

Clear cell chondrosarcoma: A national analysis exploring the demographic features.
Tade et al.
FALSE

Chondrosarcoma: The OSU experience.
Husain et al.
FALSE

Comprehensive genomic and transcriptomic profiling analysis of the recurrent gastrointestinal stromal tumor (GIST).
Sun et al.
FALSE

Racial differences in prognostic role of white blood cell ratios in gastrointestinal stromal tumors.
Chintapally et al.
FALSE

Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
George et al.
FALSE

Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: A retrospective single-centre case-controlled study.
Zhang et al.
FALSE

MSI analysis in patients with GIST with lynch syndrome.
Gasperoni et al.
FALSE

Sex differences in localized gastrointestinal stromal tumor.
Boye et al.
FALSE

Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.
Liu et al.
FALSE

Comparing GIST outcomes between geriatric and non-geriatric patients: A population-based analysis.
Singh et al.
FALSE

Ripretinib therapy in treating advanced gastrointestinal stromal tumors: A single-center analysis in a real-world setting.
Guan et al.
FALSE

National overview of gastrointestinal stromal tumors: Experience from middle income setting.
Mkhitaryan et al.
FALSE

Gastric gastrointestinal stromal tumors and overall survival in elderly patients.
Spitzer et al.
FALSE

B7H3 expression in sarcoma.
Lynch et al.
FALSE

Microsatellite instability in sarcomas: Which tests are ideal for diagnosis, and a systematic review.
Fernandes et al.
FALSE

Identification of novel actionable SNVs using targeted comprehensive genome profiling in patients with sarcoma.
Bhonde et al.
FALSE

Treatment response prediction with circulating tumor cell-derived organoids for soft tissue sarcoma.
Liu et al.
FALSE

Methylation classifier array and classification of solitary fibrous tumors.
Chelsky et al.
FALSE

Genomic analysis in patients with soft tissue sarcoma to examine gene mutations involved in chromosome segregation, mitotic spindle assembly, and degradation.
Takahashi et al.
FALSE

Preliminary survival outcomes and toxicities in patients with retroperitoneal sarcoma treated with radiotherapy.
Cheng et al.
FALSE

Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study.
Ye et al.
FALSE

Efficacy and safety of pazopanib in the treatment of pediatric sarcoma: Retrospective cohort study.
Unal et al.
FALSE

Diverse genomic characterization of Chinese patients with osteosarcoma and soft tissue sarcoma.
Sun et al.
FALSE

Publication trends in sarcoma research: A bibliometric analysis.
Fanfan et al.
FALSE

Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.
Zhang et al.
FALSE

Clinicopathological features and treatment profile of patients referred to a sarcoma medical oncology centre in India: Challenges and insights from the developing world.
Tansir et al.
FALSE

Comorbidities in patients with sarcoma: Insights from the National In-Patient Database from 2006 to 2014.
Cuartas Mesa et al.
FALSE

Epidemiology, survival, and treatment of liposarcoma subtypes: An analysis of the national cancer database.
Kennard et al.
FALSE

Genitourinary embryonal rhabdomyosarcoma clinicopathologic determinants of clinical outcomes: Analysis of a pooled database.
Graham et al.
FALSE

Head and neck embryonal rhabdomyosarcoma clinical outcomes determinates: A pooled database analysis.
lakra et al.
FALSE

Phase I study of anlotinib in pediatric patients with high-risk, recurrent, or refractory sarcomas.
Lu et al.
FALSE

Factors associated with overall and cancer specific mortality in primary cardiac sarcoma.
Bangolo et al.
FALSE

A phase II study of surufatinib in patients with osteosarcoma and soft tissue sarcoma who have experienced treatment failure with standard chemotherapy.
Zhang et al.
FALSE

Italian report of expanded access for nab-sirolimus in patients with malignant perivascular epithelioid cell tumor (PEComa).
Sanfilippo et al.
FALSE

A phase ll study on the neoadjuvant treatment of resectable high-risk soft tissue sarcoma with anlotinib and doxorubicin.
Weitao et al.
FALSE

Study of microwave ablation in patients with unresectable soft tissue sarcoma.
Weitao et al.
FALSE

Demographic analysis of diagnostic patterns in head and neck fibromyxosarcoma.
Wang et al.
FALSE

A phase II study of fruquintinib in the first- (1L) or second-line (2L) treatment of unresectable metastatic soft tissue sarcoma.
Luo et al.
FALSE

SPRINT trial: Preoperative chemotherapy and IMRT SIB in locally advanced sarcoma.
Greto et al.
FALSE

Clinical outcomes of soft tissue sarcoma in the Philippines: A single-center experience.
Maaño et al.
FALSE

Comparative analysis between the 8th and 7th AJCC as a prognostic tool for patients diagnosed with nonmetastatic head and neck soft-tissue sarcoma.
Brito et al.
FALSE

Presentation of congenital soft-tissue sarcomas: A single institution experience.
Parra Del Riego et al.
FALSE

Dendritic/histiocytic cell sarcoma: The OSU experience.
Tinoco et al.
FALSE

Concordance between orthotopic-patient derived xenograft models and patient treatment responses.
Nakashima et al.
FALSE

Clear cell sarcoma: The OSU experience.
Tinoco et al.
FALSE

Analysis of demographic characteristics of malignant peripheral nerve sheath tumor in adults: A National Cancer Database study.
Voth et al.
FALSE

Differential overall survival and treatment for non-dedifferentiated liposarcoma in academic and non-academic facilities: An NCDB analysis.
Czaplicki et al.
FALSE

Income level as a prognostic factor in non-dedifferentiated liposarcoma.
Bine et al.
FALSE

A multicenter randomized controlled trial (RCT) for the effectiveness of comprehensive geriatric assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.
Kenis et al.
TRUE

Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
Ligibel et al.
TRUE

Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The CARE for CAYA multicenter, randomized clinical trial.
Elmers et al.
TRUE

Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.
Trivedi et al.
TRUE

Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116).
Rapp et al.
TRUE

Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.
Santhosh et al.
TRUE

Reduced symptom burden after implementation of an electronic symptom management program.
Bian et al.
TRUE

Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.
Forst et al.
TRUE

Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer.
Michael et al.
TRUE

Frailty status determined by an electronic health record embedded frailty index and hospitalization risk among older adults following the initiation of cancer chemotherapy.
Klepin et al.
TRUE

Web-based patient-reported outcome measures (PROMs) in elderly cancer patients: A French multicentric prospective feasibility trial (the FASTOCH study).
Cancel et al.
TRUE

Cost-utility of geriatric assessment in older adults with cancer: Results from the 5C trial.
Sahakyan et al.
TRUE

Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.
Buchbinder et al.
TRUE

Fertility post immune checkpoint blockade.
Ogle et al.
TRUE

Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy.
Goldfarb et al.
TRUE

Long-term outcomes of adolescents and young adults with testicular germ cell tumors: A population-based retrospective matched cohort study.
Ajaj et al.
TRUE

Social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival.
Rodriguez et al.
TRUE

Predicting therapy-induced cardiomyopathy in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).
Petrykey et al.
TRUE

Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.
Mersiades et al.
TRUE

Safety and efficacy of cannabidiol in the management of chemotherapy-induced peripheral neuropathy.
Weiss et al.
TRUE

Long term efficacy of psilocybin in patients with cancer and major depressive disorder (MDD).
Agrawal et al.
TRUE

Neurocognitive function outcomes in NRG/RTOG 0534, the SPPORT trial.
Wefel et al.
TRUE

Yoga vs. behavioral placebo for fatigue and quality of life among older cancer survivors.
Arana et al.
TRUE

The menopause after cancer study: A multimodal technology assisted intervention for the management of menopausal symptoms after cancer.
Donohoe et al.
TRUE

A meta-analysis studying the utility of cryotherapy in the prevention of peripheral neuropathy in breast cancer patients receiving paclitaxel and nab-paclitaxel.
Ashok Kumar et al.
TRUE

Interventions to improve outcomes for caregivers of patients with advanced cancer: A systematic review and meta-analysis.
Chow et al.
TRUE

Use of clinical pathways to identify patients with cancer who may benefit from serious illness conversations.
Cotner et al.
TRUE

Quality for all: Clinical trial enrollment and end-of-life care in solid and hematologic malignancies.
Rosen et al.
TRUE

Trends in place of death in adolescents and young adults dying from cancer in the US, 2003-2019.
Hussaini et al.
TRUE

End-of-life outcomes of patients with advanced cancer enrolled in palliative care.
Lynch et al.
TRUE

Patient characteristics associated with psychosocial distress about end-of-life.
Tergas et al.
TRUE

Psychosocial health of patients engaging in medical aid in dying and their family members: A prospective descriptive analysis.
Turner et al.
TRUE

Risk of malnutrition and predisposing factors among Mexican patients with advanced cancer.
Contreras et al.
TRUE

The impact of patient age on palliative care utilization and end-of-life outcomes among patients with metastatic breast cancer.
Mitchell et al.
TRUE

Falls and hospitalization during chemotherapy in older women with early breast cancer.
Ji et al.
TRUE

The association of the comorbidity polypharmacy score (CPS) with functional limitations, frailty, and mortality in older adults with gastrointestinal malignancies.
Westbrook et al.
TRUE

Biologic profile to predict overall survival in non-metastatic breast cancer: A latent class analysis on aging biomarkers.
Falandry et al.
TRUE

Association of sarcopenia and treatment tolerability in older adults with advanced cancer: Secondary analysis of a nationwide NCI Community Oncology Research Program (NCORP) randomized clinical trial.
Dunne et al.
TRUE

Defining an abnormal geriatric assessment for older adults with cancer: Which deficits matter most?
Carrozzi et al.
TRUE

Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.
Lee et al.
TRUE

Satisfaction in older patients by geriatric assessment using a novel tablet-based questionnaire system: A cluster-randomized, phase III trial of patients with non–small-cell lung cancer (ENSURE-GA study; NEJ041/CS-Lung001).
Soda et al.
TRUE

Exploring decisional control preferences in older patients with cancer and their caregivers.
Hryniv et al.
TRUE

Association of nutrition with psychological health and quality of life among older adults with advanced cancer.
Singhal et al.
TRUE

Racial differences in muscle measures and survival among older adults with GI malignancies.
Aleixo et al.
TRUE

Peaceful acceptance of illness among older adults with cancer.
Gilbride et al.
TRUE

Association between food insecurity and frailty among older adults with gastrointestinal malignancies: The CARE Registry.
Fowler et al.
TRUE

Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.
Badri et al.
TRUE

An evaluation of the financial toxicity amongst older patients with cancer in India.
Ramaswamy et al.
TRUE

Overall survival outcomes in older patients with metastatic breast cancer: A National Cancer Database analysis.
Patel et al.
TRUE

Association of emotional support with quality of life, mental health, and survival among older adults with gastrointestinal (GI) malignancies.
Clausing et al.
TRUE

Toxicity and outcomes of ipilimumab plus nivolumab in patients 80 years and older.
Meyer et al.
TRUE

Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.
Modi et al.
TRUE

The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.
Faour et al.
TRUE

Understanding treatment toxicity patterns through remote symptom monitoring and examining the effect of frailty in older men with metastatic prostate cancer.
Parthipan et al.
TRUE

Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.
Feng et al.
TRUE

Associations between sarcopenia and clinical outcomes in men with metastatic castrate-resistant prostate cancer.
Papadopoulos et al.
TRUE

A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).
Tsang et al.
TRUE

Sedentary lifestyle as a predictor of early death in older adults with cancer: A prospective cohort study with 2692 patients.
Telles O Lima et al.
TRUE

Safety of checkpoint inhibitors in older patients with genitourinary cancers.
Ramnaraign et al.
TRUE

Demographic stratification, evaluation of symptoms burden on basis of gender, and implications of G8 questionnaires in elderly patients with cancer in Bangladesh.
Islam et al.
TRUE

Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy.
Faucheux et al.
TRUE

Frailty IO: Frailty parameters and incidence of immune related adverse events in older patients treated with immune checkpoint blockers (ICB).
Baldini et al.
TRUE

Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience.
Zhi et al.
TRUE

Frailty and pre-frailty associated with physical functional performance and quality of life in breast cancer and bone marrow transplant survivors.
Wang et al.
TRUE

Geriatric-assessment-guided interventions for older adults with multiple myeloma: A feasibility study.
Jensen et al.
TRUE

Dissecting the prognostic role of baseline body mass index (BMI) in early breast cancer (BC): Individual patient-level analysis from five mammella interGruppo (MIG) and gruppo italiano mammella (GIM) randomized clinical trials (RCTs).
Soldato et al.
TRUE

A pilot study of intraneural facilitation versus standard physical therapy for prevention of chemotherapy-induced peripheral neuropathy.
Castillo et al.
TRUE

The effect of exercise on physical function and medication adherence in women receiving endocrine therapy for breast cancer: The breast cancer endocrine therapy fitness (BE-FIT) randomized controlled trial.
Myers et al.
TRUE

Evaluation of a mobile behavior change program for weight loss in breast cancer survivors: A prospective single-arm pilot study.
Shen et al.
TRUE

Preliminary outcomes of a financial navigation program among lower socioeconomic patients with cancer.
Tan et al.
TRUE

Nutritional program among patients with prostate cancer receiving androgen deprivation therapy (ADT).
Lages et al.
TRUE

Dietary and lifestyle profiles between patients with and without cancer in the national health interview survey.
Gong et al.
TRUE

Associations between body mass index with cancer recurrence and all-cause mortality among survivors of breast cancer.
Chen et al.
TRUE

Survivorship care and breast and cervical cancer screening.
Santos Teles et al.
TRUE

Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the wake forest nCI community oncology research program (NCORP) research base REMEMBER trial (WF97116).
Ernster et al.
TRUE

Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer.
Saint et al.
TRUE

Cardiac dysfunction (CD) among breast cancer survivors (BCS): Role of cardiotoxic therapy and cardiovascular risk factors.
Bostany et al.
TRUE

Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.
Livi et al.
TRUE

Serum cytokines and autoantibodies to GM-CSF and immune-related colitis in ipilimumab-treated patients with cancer.
Gonzalez-Kozlova et al.
TRUE

Long-term longitudinal patterns of patient-reported quality of life (QOL) after breast cancer (BC) to inform the implementation of personalized pathways of care.
Franzoi et al.
TRUE

Estimating burden of cardiovascular disease among survivors of breast, colorectal, lung, and prostate cancer in the detroit research on cancer survivors (ROCS) cohort.
Nair et al.
TRUE

Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.
Yu et al.
TRUE

Social determinants of health and neurocognitive and psychosocial outcomes in adult childhood cancer survivors: A report from the childhood cancer survivor study (CCSS).
Bai et al.
TRUE

A prospective study evaluating the association of patient-reported outcomes with activity level and sleep patterns in sarcoma survivors.
Davis et al.
TRUE

Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).
Pagliuca et al.
TRUE

A genome-wide association study for doxorubicin-induced cardiomyopathy in childhood cancer survivors from the St. Jude lifetime cohort (SJLIFE) and the childhood cancer survivor (CCSS) studies.
Petrykey et al.
TRUE

Burden of chronic health conditions (CHCs) among people with HIV (PWH) and non-AIDS defining cancers (NADC): A report from the center for AIDS research (CFAR) network of integrated clinical systems (CNICS).
Goyal et al.
TRUE

Polygenic risk of anthracycline-related cardiomyopathy in childhood cancer survivors: Report from children’s oncology group and childhood cancer survivor study.
Sharafeldin et al.
TRUE

Long-term prospective data on correlation between overall mortality and HADS (Hospital Anxiety and Depression Scale) assessed psychological distress in prostate cancer patients (11 year follow-up data).
Sundar et al.
TRUE

The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).
Nakshatri et al.
TRUE

Racial and ethnic disparities in survival among persons with subsequent primary cancer.
Sung et al.
TRUE

Sexual dysfunction in patients with cancer: Results from the CLARIFY project.
Ospina Serrano et al.
TRUE

Associations among anesthesia-induced brain biomarkers during surgery, preoperative exposure to cancer therapeutics, and clinical outcomes.
Stone et al.
TRUE

Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.
Yuan et al.
TRUE

Associations of employment disruptions and financial hardship among individuals diagnosed with cancer in the US.
Halpern et al.
TRUE

Patient-reported symptom monitoring linked to an alert algorithm: Effects on progression-free and overall survival in the SYMPRO-Lung trial.
Billingy et al.
TRUE

Patient- versus clinician-reported symptoms in the POLARIX study.
Thompson et al.
TRUE

Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial.
Mao et al.
TRUE

Early palliative care for patients with metastatic upper gastrointestinal cancers: A survival analysis of the EPIC randomized trial.
Adenis et al.
TRUE

Prospective evaluation of factors associated with acceptance of feeding tube (FT) placement and clinical outcomes during radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinoma (HNSCC).
Clatot et al.
TRUE

A risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer who receive chemoradiotherapy: A supplement analysis of a phase II/III trial of JCOG1008.
Imamura et al.
TRUE

Out-of-pocket costs burden for cancer treatment toxicities and symptoms management in Italy: A prospective, multicenter pilot study.
Raffaele et al.
TRUE

Quality of pain management in patients with cancer in the outpatient setting.
Adhikari et al.
TRUE

The efficacy of hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: A phase 3 randomized self-controlled study, J-SUPPORT 1701 APRON trial.
Takashima et al.
TRUE

Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia.
Goldfarb et al.
TRUE

Patient-reported hope, prognostic understanding, quality of life, symptom burden, coping mechanisms, and financial wellbeing in early phase clinical trial participants.
Lundquist et al.
TRUE

Self-reported overall wellbeing and physical function among chemotherapy and surgery patients completing symptom questionnaires across six health systems.
Hassett et al.
TRUE

Effects of yoga vs placebo on inflammation among cancer survivors: A nationwide multicenter phase III randomized controlled trial (RCT).
Lin et al.
TRUE

Phase 3 RCT of dexamethasone versus placebo for chemotherapy induced fatigue in patients with advanced solid malignancies.
Radhakrishnan et al.
TRUE

Apixaban versus rivaroxaban for treatment of acute deep venous thrombosis in patients with cancer.
Miles et al.
TRUE

Rose geranium in sesame oil nasal spray to improve symptoms of nasal vestibulitis: A phase III double blinded randomized controlled trial.
Cathcart-Rake et al.
TRUE

Feasibility and acceptability of implementing electronic patient reported outcomes (ePRO) collection in Zambia: Findings from a patient needs assessment.
Peterson et al.
TRUE

Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).
Janelsins et al.
TRUE

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.
George et al.
TRUE

Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabis.
Salz et al.
TRUE

Opioid use, gabapentinoid use, and pain-related emergency department visits for patients living with advanced cancer.
Jairam et al.
TRUE

Unveiling inequities in palliative care and clinical trial participation among patients with metastatic breast cancer in the state of Florida.
Oladeru et al.
TRUE

End-of-life outcomes after implementation of an embedded, criteria-based palliative care consultation service in inpatient oncology.
Norman et al.
TRUE

A supervised remote exercising program for patients receiving immunotherapy alone or in combination with chemotherapy in Brazil: ExIO.
Bergerot et al.
TRUE

Risk of severe toxicity from topical fluoropyrimidine treatment in patients carrying DPYD variant alleles.
Granados et al.
TRUE

Patient-controlled subcutaneous analgesia with hydromorphone versus oral oxycodone for opioid titration of cancer pain: A prospective multicenter randomized trial.
Xiao et al.
TRUE

Concurrent hospice healthcare utilization in the hematology/oncology patient population at veterans affairs.
Hemrajani et al.
TRUE

Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.
Zhao et al.
TRUE

A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
Radhakrishnan et al.
TRUE

Utilization of early integrated palliative medicine among patients with metastatic solid tumor cancers: Findings from a safety net medical center treating a majority African American population.
Ananthula et al.
TRUE

Palliative care in hematopoietic stem cell transplant recipients and impact on survival: A nationwide analysis.
Premnath et al.
TRUE

Key components of goals of care conversations on determining end-of-life care for advanced cancer patients.
An et al.
TRUE

Adjuvant endocrine therapy adherence changes among patients after a virtual behavioral intervention.
Jacobs et al.
TRUE

Facilitating the transition to posttreatment survivorship for adolescent and young adults: A randomized waitlist control trial of a virtual mind-body intervention.
Perez et al.
TRUE

Will we have a match? Observations from decision making conversations between hematologists and White and Black patients considering allogeneic stem cell transplant.
Thordardottir et al.
TRUE

Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.
Derry-Vick et al.
TRUE

Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.
Gupta et al.
TRUE

Analysis of delivery of cancer survivorship education to community healthcare professionals.
Pariser et al.
TRUE

The FARGO study: Frailty assessment for risk prediction in gynecologic oncology.
Nguyen et al.
TRUE

Comprehensive geriatric assessment based multidisciplinary team intervention for hospitalized frail patients in oncology: COMPASS-ONCO/KCSG AL21-13.
Lee et al.
TRUE

Digital voice analysis as a measure of frailty and distress: A feasibility study (DIVAN).
Vetter et al.
TRUE

Evaluating the impact of exercise in women living with indolent metastatic breast cancer: The EMBody trial.
Cancilla et al.
TRUE

Comprehensive 0utcomes for After Cancer Health: COACH.
Lally et al.
TRUE

The CROWN study (CaRdiac outcomes with near complete estrogen deprivation): A multicenter, prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor.
Douglas et al.
TRUE

A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.
Saint et al.
TRUE

A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy in survivors of cancer.
Lopez-Nieves et al.
TRUE

Objective assessment of fatigue, sleep and insomnia in breast cancer survivors on estrogen deprivation therapy.
Fowler et al.
TRUE

Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain.
Matsuoka et al.
TRUE

Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.
Crawford et al.
TRUE

Prospective observational study to evaluate lemborexant utility in insomnia among women with breast cancer (WJOG14921B, LUNAR study).
Ozaki et al.
TRUE

Study for the prevention of oral mucositis.
Oganesyan et al.
TRUE

Effects of virtual reality on pain and anxiety in patients with cancer undergoing bone marrow biopsy.
Pinski et al.
TRUE

Exploratory study investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20).
Satomi et al.
TRUE

Empathic communication skills training: Randomized controlled trial to reduce lung cancer stigma in lung cancer care.
Ostroff et al.
TRUE

Affecting burden and cost of care for the caregiver of dependent patients with advanced stage of cancer who had an arrangement for expected death at home.
Palanupap
FALSE

Integrating ayurveda rasayana therapy with standard of care therapies in patients with glioblastoma multiforme improves caregivers' quality of life: A prospective study.
Bendale et al.
FALSE

Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.
Daum et al.
FALSE

Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes.
Lavecchia et al.
FALSE

Do future innovations in development influence oncologists’ treatment recommendations today? A survey of U.S. oncologists.
Li et al.
FALSE

One way to provide effective healthcare services for patients with advanced cancer to improve their quality of life and survival: Prediction modeling using machine learning techniques and causal relationship between self-management strategy, health-related quality of life, and survival.
Jung et al.
FALSE

End of life care: Preferences of patients with advanced urologic and dermatologic malignancies.
Heers et al.
FALSE

The financial toxicity of chemotherapy in Belize.
Wong et al.
FALSE

Outcomes of pancreatic malignancy in octogenarians: A single tertiary center experience.
Al-Jumayli et al.
FALSE

Leg and walking self-exercise (LAWS) program for older adults with cancer during treatment.
Nishijima et al.
FALSE

Clinical benefit (rate) of geriatric assessment in a Veterans Affairs (VA)-based oncology clinic according to the Geriatric 5Ms framework.
Gregorio et al.
FALSE

Effects of comprehensive geriatric assessment (CGA) guided care versus usual care on overall survival (OS) and health-related quality of life (HRQL) for older adults with cancer: A systematic review of randomized trials (RCTs).
Ng et al.
FALSE

Evaluating embedded geriatric care in gastrointestinal (GI) oncology program for older adults (OA): Feasibility and key learnings.
McCleary et al.
FALSE

A retrospective single-centre analysis of the prevalence of statin use in geriatric oncology: Is there a role for cessation?
O'Sullivan et al.
FALSE

Limited and uneven geriatric cancer drug trials worldwide.
Hui-Yao et al.
FALSE

The role of Chinese acupuncture plus herbal decoction for chemotherapy induced cognitive impairment in elderly cancer patients.
Lv et al.
FALSE

Identifying sources and mechanisms for missed opportunities in discussing cognition and capacity among older adults with advanced cancer, their caregivers, and physicians.
Kyi et al.
FALSE

Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients.
Donisi et al.
FALSE

Pilot trial of the feasibility, acceptability, and potential efficacy of a pain management intervention adapted for older adults with cancer in rural settings.
Shen et al.
FALSE

Toxicity profile, palliative care and hospice utilization of geriatric patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the veteran health administration.
Lucero et al.
FALSE

Association of frailty index of laboratory tests (FI-LAB) and COVID-19 clinical outcomes in veterans with cancer.
Melo Resendes et al.
FALSE

Feasibility of integrating geriatric oncology and palliative care assessment into the routine care of older adults in a community setting.
Sedhom et al.
FALSE

Comparison of glomerular filtration rate estimating equations in Indian geriatric patients with cancer.
Gota et al.
FALSE

Examination of real-world data from geriatric assessments in a comprehensive cancer center to explore predominant and cancer-specific domains for intervention.
Pelletier et al.
FALSE

Vulnerability assessment and decision-making in older patients with head and neck squamous cell carcinomas planned for chemoradiation: Experience from a tertiary care cancer centre in India.
Sarkar et al.
FALSE

Learning what matters in allogeneic transplant: Insights into older patient preferences in an age-friendly multidisciplinary clinic.
Braun et al.
FALSE

Validation of the distress thermometer score in a geriatric oncology population.
Zuber et al.
FALSE

Dual language interview guide to improve understanding of risk perception among newly diagnosed breast cancer patients who are limited English proficient (LEP).
Schiaffino
FALSE

Risk factors for falls and fear of falling among older patients with cancer.
Gomaa et al.
FALSE

Predictive factors of early death in older women with gynecological cancer: A prospective cohort study.
Telles O. Lima et al.
FALSE

Is Karnofsky performance scale a proxy measure of frailty phenotype in older adults with cancer?
Parala-Metz et al.
FALSE

The SMILE scale: A pilot study among patients with cancer.
Vater et al.
FALSE

Efficacy of BNT162b2 vaccine and its correlation with serum vitamin D in staff at the national comprehensive cancer center in slovakia.
Slopovsky et al.
FALSE

Exploring the benefits of therapeutic horticulture in patients in gynecologic oncology: A pilot study.
Jhaveri et al.
FALSE

Clinical trial knowledge among cancer survivors in the United States: The role of health information technology.
Adewunmi et al.
FALSE

Strategies to support primary care involvement in the care of patients with a history of breast cancer: A Delphi study.
Mikesell et al.
FALSE

First integrative oncology clinic in the Veteran Affairs (VA) Pittsburgh healthcare system.
Tan et al.
FALSE

Role of ketogenic diet in the management of cancer: A systematic review.
Chelikam et al.
FALSE

A new model of cancer survivorship: Feasibility and findings of a survivorship-based primary care clinic led by a medical oncologist.
Yurkiewicz et al.
FALSE

Clinical use of quality of life data for treatment and survivorship in oncology.
Beutter et al.
FALSE

Safety and feasibility of a randomized controlled trial testing a personalized exercise program in patients with cancer: The CHOiCE trial.
Pilotto et al.
FALSE

Patient understanding of immunotherapy and its side effects for women with triple negative breast cancer.
Canning et al.
FALSE

Early integration of exercise into breast cancer care: The MSK healthy living program.
Rowed et al.
FALSE

Healthy lifestyle behaviors among a diverse population of early posttreatment adolescent and young adult (AYA) survivors participating in a virtual stress management program.
Venkataraman et al.
FALSE

Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: A systematic review and meta-analysis.
Marin Comini et al.
FALSE

Analysis of the applicability of the mHealth ALIBIRD platform and its impact on the follow-up of patients with lung cancer.
Sereno et al.
FALSE

Statin use for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in breast cancer (BC) patients (pts).
Melson et al.
FALSE

PAVING the path to wellness: Lifestyle medicine to improve outcomes in breast cancer survivors.
Lee et al.
FALSE

Feasibility of nutrition counseling for breast cancer survivors: Results from the force trial.
Teplinsky et al.
FALSE

Perspectives about healthy eating and exercise among patients and providers at the safety-net Lyndon B. Johnson (LBJ) hospital oncology clinic.
Kizub et al.
FALSE

Effect of insulin resistance on CAC scores in cancer survivors.
Jacobi et al.
FALSE

Factors associated with long-term gastrointestinal toxicity in colorectal cancer survivors in the women’s health initiatives (WHI) study.
Han et al.
FALSE

The sit to stand test in cancer patients and survivors.
Cristian
FALSE

Subjective and objective hearing loss among US adult cancer survivors: A national cross-sectional study.
Wang et al.
FALSE

The impact of 4R Care Delivery Model on timing and sequence of bone density screening among breast cancer patients.
Brookhart et al.
FALSE

Association of surgery and radiotherapy with risk of thoracic soft tissue sarcoma among older survivors of breast cancer.
Whelan et al.
FALSE

The safety, tolerability and efficacy of LP-10 in subjects with refractory moderate to severe hemorrhagic cystitis: Phase 2a multicenter dose escalation clinical trial.
Chancellor et al.
FALSE

Adherence to statins and risk of cardiovascular disease in patients with breast cancer.
Kwan et al.
FALSE

Outcome of deep venous thrombosis and pulmonary embolism in COVID-19 cancer patients vs non-cancer patients.
Jones et al.
FALSE

Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.
Chan et al.
FALSE

Survivorship in patients with cardiac metastases defined by cardiac magnetic resonance imaging in relation to lesion hypoperfusion.
Jain et al.
FALSE

Fear of cancer recurrence inventory scores and their correlation with quality of life and stress levels in breast cancer survivors.
Morrissey et al.
FALSE

Comparison among three predictive models for cancer-associated thromboembolism in a Hispanic population.
Ramos-Esquivel et al.
FALSE

The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis.
Bonomi et al.
FALSE

Understanding cancer treatment decision making among cancer survivors.
Streck et al.
FALSE

External validation of biomechanical computed tomography for fracture risk classification in metastatic hormone sensitive prostate cancer.
Lin et al.
FALSE

Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.
Mian et al.
FALSE

Risk factors and early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs.
Grechukhina et al.
FALSE

NGAL and KIM-1 as early biomarkers of cisplatin-associated nephrotoxicity.
Chebotareva et al.
FALSE

A novel risk assessment metric for antimyeloma therapies and drug interactions.
Xu et al.
FALSE

Immune checkpoint inhibitors (ICIs) with or without anti-angiogenic agents (AAAs) and cardiovascular toxicity: A meta-analysis.
Madonia et al.
FALSE

Association between symptoms and health-related quality of life in patients with cancer with prior or ongoing immune checkpoint inhibitor therapy exposure.
Jones et al.
FALSE

Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors.
Jovaisaite et al.
FALSE

Barriers to offering female fertility preservation to pediatric and young adult oncology patients: A national survey of pediatric hematology oncology providers in the United States and Canada.
Walker et al.
FALSE

Risk and protective factors for dementia in cancer survivors vary by cancer type.
Neth et al.
FALSE

Adverse events with the use of radiotherapy in patients with inflammatory arthritides and cancer: A systematic review and meta-analysis.
Lopez-Olivo et al.
FALSE

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
Jacob et al.
FALSE

A systematic review with meta-analysis of radiotherapy adverse events in patients with cancer and lupus erythematosus.
Lopez-Olivo et al.
FALSE

Toxicities associated with sacituzumab govitecan: Data from clinical trials and real-word pharmacovigilance database.
Mei et al.
FALSE

Non-hematopoietic cell transplant-related veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in solid tumor and hematologic malignancies: A systematic review.
Stewart et al.
FALSE

Trends and factors related to pregnancy after breast cancer treatment in young patients.
Lee et al.
FALSE

Quality of life in patients diagnosed and treated for breast cancer in Uruguay.
Camejo et al.
FALSE

Obesity and toxic habits as avoidable determinants of chronic peripheral neuropathy induced by chemotherapy (NPCIQ): NeuroPredict project.
Vargas et al.
FALSE

Chronic disease outcomes among South Asian cancer survivors.
Gowda et al.
FALSE

Building epigenetic clocks for estimating accelerating aging in patients with testicular cancer treated with cisplatin-based chemotherapy.
Wojewodzic et al.
FALSE

Trastuzumab-induced cardiotoxicity in breast cancer patients: A meta-analysis and review of the literature (2012-2022).
Anamika et al.
FALSE

Relative and functioning sleep disturbance and fatigue: Impact on patients with ovarian cancer.
Andac-Jones et al.
FALSE

Assessing the acceptability and feasibility of using a computerized food frequency questionnaire (FFQ) to determine dietary patterns in survivors of head and neck cancer (HNC).
Senchak et al.
FALSE

Assessing the frequency of anemia evaluations in patients who are transfusion-dependent in an academic hematology and oncology practice.
Li et al.
FALSE

Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer.
Westvold et al.
FALSE

Hypertriglyceridemia associated with the use of capecitabine in a Mexican cohort.
Luna Palencia et al.
FALSE

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium, BB-12 and Lactobacillus rhamnosus, LGG in colorectal cancer patients: The Probio SK 006-Slovak cooperative oncology group trial.
Mego et al.
FALSE

Clinical research policy for oral mucositis associated with cancer treatment (J-SUPPORT).
Yokota et al.
FALSE

Change in quality of life of metastatic breast cancer patients seeking treatment at Komfo Anokye Teaching Hospital, Ghana.
Agbeko et al.
FALSE

Development of a palliative care lecture series for hematology-oncology fellows.
Rodenbach et al.
FALSE

Transitions of care with a community-based palliative care program: Results from a pilot project for advanced solid tumor oncology patients.
Garcia et al.
FALSE

Nationwide utilization of palliative care in patients admitted for GI malignancies.
Litvin et al.
FALSE

Dermocosmetics in management of cancer-related skin toxicities: International expert consensus.
Dreno et al.
FALSE

Morbidity of single-fraction spine radiosurgery for metastatic disease.
Gardner et al.
FALSE

Symptom burden and end of life care in patients with acute myeloid leukemia undergoing intensive induction chemotherapy in a rural setting.
O'Neil et al.
FALSE

A pilot study to determine the effects of early palliative care integration on patients with newly diagnosed multiple myeloma.
Samala et al.
FALSE

Interactive music therapy for chronic pain management in people with advanced cancer: A mechanistic study.
Bradt et al.
FALSE

Patients with endometrial cancer: Expectations and preferences towards therapy and quality of life—First results of an international survey (NOGGO, ENGOT, GCIG - IMPROVE/EXPRESSION XI).
Chinczewski et al.
FALSE

Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.
Wright et al.
FALSE

Home parenteral nutrition (HPN) using individually compounded PN administered via multi-chamber Eurotubes versus PN administered via 2/3-chamber bags in patients with metastatic or localized solid tumors requiring HPN: The randomized IKF-010 PEKANNUSS trial of AIO.
Al-Batran et al.
FALSE

The impact of music therapy on opioid use in cancer survivors with chronic pain.
Bradt et al.
FALSE

Availability of palliative specialty care for adults in community oncology: Results from the 2022 NCORP landscape assessment.
Statler et al.
FALSE

Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.
Cole et al.
FALSE

Symptom severity, specialty palliative care, and subsequent symptom control among adolescents and young adults with cancer: A population-based study.
Coburn et al.
FALSE

Sexuality as a prognostic factor: Results of an individual participant data NOGGO-meta-analysis of 1,041 recurrent ovarian cancer patients before starting chemotherapy.
Balint et al.
FALSE

Awareness, preferences, and experiences of thrombosis and thromboprophylaxis in adults commencing systemic anticancer therapies: TARGET-TP trial.
Alexander et al.
FALSE

“It’s been a long journey:” A qualitative study of patient and caregiver experiences during multimodality treatment for locally advanced rectal cancer.
Lau-Min et al.
FALSE

The effect of touch on pain, anxiety, and the patient experience during bone marrow biopsies.
Dhawan et al.
FALSE

Opiate use after total hip arthroplasty for metastatic bone disease.
Vijayakumar et al.
FALSE

Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN): A proof-of-concept, placebo-controlled, randomized clinical trial (RCT).
Gewandter et al.
FALSE

Effect of multimodal intervention care on cachexia in patients with advanced cancer compared to conventional management (MIRACLE): An open-label, parallel, randomized, phase 2 trial.
Kim et al.
FALSE

Use of Myeloma Patient Outcome Scale (MyPOS) to gauge the effectiveness of palliative management in patients with multiple myeloma: Experience from a large tertiary academic center in India.
Koolwal Kapoor et al.
FALSE

Mobile-based multimodal rehabilitation including exercise, nutritional, and psychological interventions in patients with abdominal cancer receiving concurrent chemoradiotherapy: Prospective, multicenter, randomized trial.
Yang et al.
FALSE

Phase II study about efficacy and safety of the continuous intravenous infusion of ketamine as adjuvant to opioids in terminally ill cancer patients with refractory cancer pain.
Park et al.
FALSE

Effectiveness of NEPA, an oral fixed-dose combination of netupitant and palonosetron in the prevention of chemotherapy induce nausea (CIN): A post-hoc analysis.
Pednekar et al.
FALSE

Nutrition assessment reports in oncology clinical trials.
Aung et al.
FALSE

Cancer-related fatigue and functional impairment: Retrospective study in patients with newly diagnosed solid-tumor cancer.
Beeler et al.
FALSE

Adverse health effects of opioids in survivors of breast cancer after active cancer treatment.
Haque et al.
FALSE

Factors affecting administration of palliative care in primary central nervous system tumors: An NCDB analysis.
Spalinski et al.
FALSE

Feasibility of cryocompression for bortezomib-induced peripheral neuropathy (BIPN) among patients with multiple myeloma (MM).
Statler et al.
FALSE

D-CRSE: Diminishing chemotherapy related side effects through patient education.
Dailey et al.
FALSE

The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.
Karkash et al.
FALSE

Symptom burdens in long-term survivors of gynecologic cancer receiving acupuncture care.
Daugherty et al.
FALSE

Therapeutic evaluation on Chinese calycosin decoction for chemoradiotherapy induced thrombocytopenia.
Lv et al.
FALSE

METASNCore: A new tool for palliative whole brain radiotherapy (WBRT) assessment in the era of targeted therapies.
Flores Paco et al.
FALSE

Incidence patterns and clinical implications of venous thromboembolisms (VTE) in patients (p) with neuroendocrine tumors (NET).
Hernando et al.
FALSE

Extracranial palliative radiotherapy for metastatic renal cell carcinoma.
Kwon et al.
FALSE

Introduction and validation of the RONIN open assessment framework: A modular system for assessing patient-reported outcomes (PRO) in clinical practice and research.
Sidey-Gibbons et al.
FALSE

Factors associated with utilization of palliative care among hospitalized patients with cholangiocarcinoma.
Ibodeng et al.
FALSE

A whole-food, plant-based dietary intervention and cognitive function in women with metastatic breast cancer.
McGuire et al.
FALSE

Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.
Chumsri et al.
FALSE

Recruitment lessons learned from a cross-sectional study of quality of life experienced by people receiving treatments for hepatocellular carcinoma.
Woodrell et al.
FALSE

Cannabis use among recently treated cancer patients: Perceptions and experiences.
Salz et al.
FALSE

A retrospective chart review of palliative care consultation during curative-intent chemoradiation for head and neck cancer.
Rizwan et al.
FALSE

Racial disparities in utilization of palliative care among inpatients admitted for lung cancer.
Bharathidasan et al.
FALSE

Cancer pain in the emergency department: An EMR-based opioid dosing intervention and the effects on patient outcomes.
Coyne et al.
FALSE

Timing of specialized palliative care integration and its impact on quality of end-of-life care indicators among Latin American cancer patients.
Dias e Silva et al.
FALSE

Patient and clinician perspectives about cannabis use while receiving cancer treatment at a comprehensive cancer center (CCC).
Lee et al.
FALSE

Use of medical cannabis in cancer-related symptons: A systematic review.
Sette et al.
FALSE

Platelet decline rate as the indication of using recombinant human thrombopoietin to prevent chemotherapy induced thrombocytopenia: A prospective, randomized, controlled study.
Wang et al.
FALSE

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II study.
Fan et al.
FALSE

Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions.
Wytiaz et al.
FALSE

Exploring the reproductive and sexual health concerns of young adults with cancer.
Menon et al.
FALSE

Information and decisional needs of patients (pts) with newly diagnosed advanced cancer in the hospital: A multi-level, mixed-methods study.
Reyes et al.
FALSE

The impact of COVID-19 on anxiety among breast cancer survivors before, during and after the pandemic.
Tsui et al.
FALSE

Types of work young adults perform to adjust to a cancer diagnosis and treatment.
Ghazal et al.
FALSE

The voice of the breast cancer survivor: Implementation of survivorship needs assessment in an integrated health system.
Tahir et al.
FALSE

Differential efficacy of antidepressants in the treatment of hormone mediated depression in patients with ER+ breast cancer.
Kato et al.
FALSE

Implementation study of a novel brief clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 Implementation Study).
Liu et al.
FALSE

Patient resilience and distress level prior to chemotherapy based on time estimation.
Kraleva et al.
FALSE

Ask Questions (ASQ): Implementation of a question prompt list communication intervention in a network of outpatient medical oncology clinics.
Hamel et al.
FALSE

Gynecologic oncology patients’ perception of physician empathy in the age of COVID-19.
Cohn et al.
FALSE

Patient expectations and understanding of treatment intent in Belize.
Dickerson et al.
FALSE

Transplant teeter-totter: How hematologists communicate the high risk, high reward nature of allogeneic hematopoietic cell transplant with patients.
Rodenbach et al.
FALSE

Willingness of women at increased genetic and non-genetic risk of breast cancer to participate in intervention trials to prevent cancer.
Mastrogiacomo et al.
FALSE

A phase III randomized controlled trial of a stepped collaborative care intervention versus standard of care.
Steel et al.
FALSE

How did the COVID-19 pandemic affect the management of patients with cancer? What is the impact of anti-cancer medications on the immune response to the COVID-19 vaccinations?.
Abdelsalam et al.
FALSE

Effectiveness of a video-based educational training program to enhance primary care providers confidence and self-efficacy in the management of cancer survivors.
Gilmore et al.
FALSE

Do Chinese/Chinese-American patients prefer indirect communication methods?
Galkin et al.
FALSE

Feasibility trial of child care as a therapeutic intervention.
Singh et al.
FALSE

Factors associated with admissions for suicidal ideation in two cancers: A national database analysis.
Sharma et al.
FALSE

Creating patient-friendly informed consent form (ICF): Insights from global oncology patient insights panels (GOPIPs).
Aubel et al.
FALSE

Effects of the coronavirus disease 2019 pandemic on anxiety and spirituality in patients with cancer undergoing chemotherapy: A cross-sectional study.
Barbosa Oliveira et al.
FALSE

Evaluation of the psychological state of patients suspected of Lynch syndrome after the germline genetic testing result.
Barbosa Oliveira et al.
FALSE

Cancer survivorship: Patient experiences on early phase trials during the COVID-19 pandemic—Qualitative study from an Australian Phase 1 unit.
Zdanska et al.
FALSE

The impact of COVID-19 on a stand-alone cancer support community.
Mitchell et al.
FALSE

Therapy preferences of patients with cancer.
Dhakal et al.
FALSE

Psychological impact of COVID-19 vaccination in patients with cancer: The VACCINATE study.
Tregnago et al.
FALSE

Oncology literacy: Educational book for children, families and health professionals.
Mozzilli et al.
FALSE

Understanding and preparing for life on immunotherapy (UPLIFT): A feasibility randomized controlled trial among adults with advanced cancer.
Petrillo et al.
FALSE

Impact of death anxiety (DA) on the psychological well-being and survival of patients with advanced cancer (ACP) in phase I trials and their spousal caregivers (SC).
Hlubocky et al.
FALSE

Association of albumin and neutrophil-to-lymphocyte ratio with hormone-mediated depression in prostate cancer.
Kato et al.
FALSE

Delivering written peer support as a patient resource during hematopoietic stem cell transplant: Pros, cons, and clinician feedback on a new website.
Rini et al.
FALSE

The semantics of cancer: An experimental study in the meaning and use of cancer-related terms among surgical professionals.
Raghunathan et al.
FALSE

The emotional experience of treatment for locally advanced cervical cancer: Qualitative research findings from Brazil, China, Germany and the US.
Szamreta et al.
FALSE

Impact of breast cancer on employment in Mexico.
Villarreal-Garza et al.
FALSE

The accuracy of the Psychological Distress Inventory – Revised (PDI-R) in identifying distress in oncological outpatients: A pilot study using a machine learning approach.
Rossi et al.
FALSE

Exploring the unmet needs of Mexican women living with metastatic breast cancer: A patient survey.
Enriquez et al.
FALSE

Sexual health among cancer patients on active chemotherapy: A cross-sectional study from tertiary care cancer center in India.
Chaudhary et al.
FALSE

Interpersonal concerns of young adult surgical oncology patients with advanced cancer diagnoses: A mixed methods study.
Sun et al.
FALSE

